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Abstract 
Extracellular nucleotides are signalling molecules whose purinergic receptor-mediated 
effects are known to be key regulators of inflammatory and other immune responses, and they are 
considered archetypal activators of the innate immune system. It has been shown by our group 
that infective larvae of Trichinella spiralis secrete enzymes which catalyze the degradation of 
extracellular nucleotides, and thus potentially interfere with host cell purinergic receptor 
signalling. Murine bone marrow-derived macrophages (BMMΦ) of various activation states and 
CD4+ T cells were used to examine the effects of T. spiralis secreted proteins on immune cell 
purinergic signalling. This study showed, by PCR and pharmacological analyses, that these cell 
types possess functional purinergic receptors and the sub-types of receptors responsible for the 
signalling events were identified. It was shown that the ecto-nucleotidases, CD39 and CD73, 
were functionally expressed on BMMΦ and CD4+ T cells. The signalling events which were 
triggered following purinergic receptor stimulation were inhibited by T.spiralis secreted enzymes 
due to metabolism of nucleotides to adenosine. It was shown that the action of T.spiralis secreted 
proteins enhanced anti-inflammatory processes, such as IL-10 release and arginase I activity in 
BMMΦ, while NO, TNF-α and IL-6 release were inhibited. In CD4+ T cells, proliferation and 
cytokine release were all inhibited by adenosine generation. Pharmacological characterisation of 
adenosine-induced effects on these cells showed that they were predominantly due to A2R 
activation. In addition to the interference with purinergic signalling, T.spiralis secreted products 
were shown to have direct effects on BMMΦ and T cell effector functions and this was shown to 
be due to the glycan component of the secreted proteins. In BMMΦ, T.spiralis glycans appeared 
to activate C-type lectins, and in particular, the Macrophage Galactose Lectin (MGL). Thus the 
parasite, via its secreted proteins, appears to interfere with host purinergic signalling as well as 
having direct effects on immune cells by activation of C-type lectins. 
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1.1 Purinergic signalling  
Extracellular nucleotides are perceived as danger signals and they can act as signalling 
molecules in host-pathogen interactions (Gallucci and Matzinger, 2001). Under conditions of cell 
damage, hypoxia, inflammation or mechanical stress, nucleotides can be released either as a 
result of cell lysis or via plasma membrane channels or transporters (Communi et al, 2000; 
Lazarowski et al, 2003). Adenosine 5`-triphosphate (ATP) and adenosine 5`-diphosphate (ADP) 
released by apoptotic cells also promote clearance of these cells by recruiting phagocytes (Elliot 
et al, 2009). Furthermore, these nucleotides, which can reach concentrations higher than 50μM 
locally, control inflammatory responses, release of tumour necrosis factor-α (TNF-α) and 
interleukin-1β (IL-1β) by macrophages and are involved in hemostasis and platelet aggregation 
(Trautmann, 2009). On the other hand, the breakdown product of ATP and ADP, adenosine, has 
opposite effects that suppress immune responses and is considered an endogenous regulator of 
innate immunity (Hasko and Cronstein, 2004). The effects triggered by nucleotides once in the 
extracellular milieu are mediated by selective plasma membrane receptors, namely, the purinergic 
receptors. Purinergic receptors are known to be present on all circulating hematopoietic cells, 
hence, nucleotides can potentially act as regulators of inflammation (Hasko et al, 2008). In 
addition to purinergic receptors, hematopoietic and epithelial cells also express surface proteins 
that can degrade extracellular nucleotides, called ecto-nucleotidases. These ecto-nucleotidases 
can alter the type and local concentration of nucleotides and act together with purinergic 
receptors in controlling responses triggered by nucleotides (Hasko et al, 2007). Specifically, 
adenosine is released in the extracellular milieu by neutrophils and endothelial cells at sites of 
inflammation and infection and is important in achieving a balance in purinergic receptor 
stimulation, as it triggers opposite responses to adenine nucleotides. The concentration of 
adenosine at its receptors is regulated by extracellular and intracellular breakdown of adenine 
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nucleotides catalyzed by nucleotidases as well as by release and re-uptake from cells via 
nucleoside transporters (summarised in Diagram 1). There are four equilibrative nucleoside 
transporters (ENT1–4) and three concentrative nucleoside transporters (CNT1–3) that are 
involved in recycling adenosine and the ENTs are inhibited by compounds such as dipyridamole, 
which is used in this study to prevent re-uptake of adenosine and prolong P1 receptor activation 
(Junger, 2011). In addition to adenosine removal by these transporters, adenosine-induced 
responses can be eliminated by catabolism of adenosine to inosine by adenosine deaminase 
(Bours et al, 2006). 
Ecto-nucleotidases  
 Ecto-enzymes that are capable of catalyzing nucleotide hydrolysis are found on cell 
surfaces as well as in the interstitial medium following proteolytic cleavage. There are four 
known families of ecto-nucleotidases with similar expression patterns and substrate specificity: 
the ectonucleoside triphosphate diphosphohydrolase (E-NTPDase) family, the ectonucleotide 
pyrophosphatase/phosphodiesterase (E-NPP) family, the alkaline phosphatases, and the ecto-5′-
nucleotidase (CD73) (Bours et al, 2006). The E-NTPDases have apyrase activity catalysing the 
hydrolysis of nucleotide triphosphates and diphosphates such as ATP and ADP to ADP and AMP 
(adenosine 5`-monphosphate), respectively. CD39, which is a member of this family of enzymes, 
is expressed on vascular endothelial cells and is important in degrading ATP and ADP released 
from platelets. The E-NPP family includes enzymes with catalyze the hydrolysis of cAMP (cyclic 
AMP) to AMP and ATP to AMP and pyrophosphate. The GPI-anchored alkaline phosphatases 
release inorganic phosphate from nucleotide tri-, di- and monophosphates while the ecto-
5′nucleotidase, CD73, specifically catalyzes the hydrolysis of AMP to adenosine (Communi et al, 
2000). The accumulation of adenosine resulting from the above enzymes is regulated by the 
balance between activation of adenosine deaminase (ADA) and adenosine kinase. Ecto-ADA is 
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responsible for catalysing adenosine deamination to inosine which is irreversible due to further 
degradation to the stable end product, uric acid. Adenosine kinase is an intracellular enzyme 
which catalyzes the phosphorylation of adenosine to AMP, effectively removing adenosine and 
producing a concentration gradient which regulates entry of adenosine into cells (Kowaluk and 
Jarvis, 2000).  
 
 
Diagram 1: The fate of extracellular nucleotides. Nucleotides can bind purinergic receptors to trigger 
intracellular signal transduction cascades. They can be metabolized by ecto-enzymes to adenosine which 
can be taken up by transporters on immune cell surfaces. (Diagram taken from Roman and Fitz, 1999).  
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Purinergic receptors 
Purinergic signalling was first described in terms of the adenosine-mediated regulation of 
cell function following activation of specific surface receptors (Sattin and Rall, 1970). Since then 
purinergic receptors with different substrate specificities and intracellular signalling properties 
have been characterised (Di Virgilio et al, 2001). Purinergic receptor-mediated responses depend 
on receptor expression and density which differs according to cell type and activation state. For 
example, expression of certain purinergic receptor subtypes has been shown to be regulated by 
lipopolysaccharide (LPS), TNF-α and IFNγ (Xaus et al, 1999; Khoa et al, 2001; Nemeth et al, 
2003).  
Purinergic receptors belong to either the P1 or the P2 receptor families. The P1R family 
consists of four seven transmembrane-spanning G-protein coupled receptors, A1, A2A, A2B, A3, 
which respond to adenosine with differing affinity, and all except A2B, also respond to inosine. 
This means that, under conditions of metabolic stress when extracellular adenosine is abundant, 
the low affinity A2B receptors are activated while the high affinity A1, A2A, and A3 receptors are 
only activated when adenosine levels are low in the extracellular milieu, allowing cells to monitor 
extracellular adenosine levels (Hasko et al, 2007). These receptors differ in the type and efficacy 
of coupling to G-proteins thus the intracellular signalling pathways they trigger depend on 
activatory G-protein (Gq) or inhibitory G-protein (Gi) coupling (Fredholm et al, 2001). Gq 
coupling results in phospholipase C-  (PLC- ) activation with the concomitant generation of 
second messengers, inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG), that ultimately 
cause release of calcium ions from intracellular stores leading to activation of protein kinase C 
(PKC). Gi coupling results in inhibition of adenylyl cyclase and a subsequent decrease in cyclic 
AMP (cAMP). Conversely, GS coupling involves activation of adenylyl cyclase leading to 
increase in cAMP levels (Bours et al, 2006; Communi et al, 2000). The A1 receptors signal 
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through activation of PLC with G protein βγ-subunits, which also activate K+ channels, and 
negatively couple to adenylyl cyclase through their G α-subunits. The low affinity A3 receptors 
couple to Gi and their activation results in signalling similar to that triggered by the A1 receptors. 
Both A2A and A2B receptors are positively coupled to adenylyl cyclase via Gs which leads to 
cAMP formation, while A2B receptor activation has been shown to couple to PLC via Gq 
resulting in mobilization of intracellular calcium (Linden, 2001; Sitkovsky et al, 2008). A 
summary of the above is presented in Table 1.1A. The mitogen activated protein kinases 
(MAPK) are activated following G-protein coupling of purinergic receptors and consist of the 
extracellular regulated kinases (ERK) and the stress activated protein kinases (SAPK), such as 
the p38 and the jun-N-terminal kinase (JNK). Coupling to Gq leads to activation of MAPK via 
MEK and Ras while A2A receptor activation was also shown to increase MAPK activity. ERK1/2 
was shown to be activated in a time- and dose-dependent manner by A1 receptor coupling to Gi, 
whereas the A2B receptor has also been shown to activate ERK1/2 in addition to p38 and JNK 
(Fredholm et al, 2000).  
Cells usually express more than one adenosine receptor subtype, therefore their 
responsiveness to extracellular adenosine may not be pharmacologically typical of one specific 
receptor subtype.  This is complicated further by the fact that, G protein-coupled receptors can 
dimerise to form oligomers, which, along with cross-talk of intracellular signalling pathways, can 
lead to diverse purinergic signalling outcomes (Linden, 2001). In order to control the type of P1 
receptor activated as well as to prevent sustained activation, the presence of these receptors on 
the cell surface is down-modulated following ligation with their respective agonists. Specifically, 
it has been reported for A2A, A2B and A3 receptors that they are desensitised by G protein-coupled 
receptor kinase (GRK) – mediated phosphorylation which targets them for internalisation via 
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lipid rafts or clathrin-coated pits to dampen GPCR signalling (Klaasse et al, 2008; Zezula and 
Freissmuth, 2008).  
The P2 receptor family is subcategorised into the metabotropic P2Y and the ionotropic 
P2X, as a consequence of differences in molecular structure and signal transduction mechanisms 
(Di Virgilio et al, 2001; Burnstock et al, 2009). The P2Y family consists of eight receptors, 
P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, P2Y14, that have subtype-specific responsiveness 
to both purines (ATP, ADP) and pyrimidines (UTP, UDP) and these are also G-protein coupled.  
P2Y1, P2Y2, P2Y4 and P2Y6 receptors couple to Gq proteins signalling via increases in IP3 and 
cytosolic calcium while activation of the P2Y11 leads to elevation of both cAMP and IP3. The 
P2Y13 receptor, which routinely couples to Gi, can also couple to Gs at high ADP concentrations 
(Linden, 2001). P2Y14 is also a Gi-coupled receptor which is activated by UDP-glucose. 
(Summarised in Table 1.1B). The P2X family, comprised of seven members P2X1-7, differs from 
the two families described so far in that it consists of ligand-gated ion channels that respond 
mainly to extracellular ATP and mediate fast permeability changes in monovalent and divalent 
cations such as Na
+
, K
+
 and Ca
2+ 
 (Ralevic and Burnstock, 1998). The P2X receptors will not be 
discussed further because this study focused on P1 and P2Y receptor activation due to their 
coupling to G-proteins that produce responses that could be measured in vitro by techniques used 
in our lab. 
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Receptor Ligand G-protein coupling 
A1 Adenosine, Inosine Gi 
A2A Adenosine, Inosine GS 
A2B Adenosine GS, Gq 
A3 Adenosine, Inosine Gi, Gq 
Table 1.1A: P1 receptors, their natural agonists and their coupling to G-proteins. 
 
 
Table 1.1B: P2Y receptors, their natural agonists and their coupling to G-proteins. 
 
 
Receptor Ligand G-protein coupling 
P2Y1 ADP Gq 
P2Y2 ATP, UTP Gq 
P2Y4 UTP Gq 
P2Y6 UDP Gq 
P2Y11 ATP Gq, GS 
P2Y12 ADP Gi 
P2Y13 ADP Gi 
P2Y14 UDP-glucose Gi 
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Purinergic signalling and immune cells 
The purinergic receptor repertoire of immune cells varies according to their maturation 
and activation state and, as a result, the function of these cells in immunity is tightly regulated by 
purinergic signalling (Di Virgilio et al, 2001; Junger, 2011). For example, extracellular ATP is 
known to control chemotactic responses in dendritic cells, macrophages and neutrophils while 
macrophages exposed to ATP tend to exhibit a pro-inflammatory cytokine profile (Bours et al, 
2006; Junger, 2011). The presence of ecto-nucleotidases (such as CD39 and CD73) on immune 
cells ensures that ATP-induced responses are not long-lived as they catalyze the hydrolysis of 
ATP to adenosine and exposure of these cells to adenosine leads to anti-inflammatory responses. 
Interestingly, it has been observed that the activity of CD39 and CD73 is up-regulated during 
macrophage differentiation thus these cells become more specialized in forming adenosine 
(Hasko et al, 2007). Activation of A2A receptors by adenosine has been shown to inhibit the 
secretion of TNF-α and IL-12 and enhance IL-10 secretion by macrophages which also adopt an 
angiogenic phenotype (Hasko et al, 1996; Pinhal-Enfield et al, 2003). In neutrophils and 
leukocytes, activation of A2A receptors leads to inhibition of chemokine and TNF-α release as 
well as degranulation, production of oxygen free radicals and transmigration across vascular 
endothelia (Hasko et al, 1996).  An unusual role of P1 receptors has been shown whereby DC-
expressed P1R act to anchor adenosine deaminase which binds CD26 on T cells providing an 
additional co-stimulatory signal, leading to Th1 expansion and pro-inflammatory cytokine 
production (Pacheco et al, 2005).  
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1.2 Macrophages  
Immune responses require a tightly regulated balance of pro- and anti-inflammatory 
mediators released from immune cells. Macrophages are important immune effector cells which 
are involved in both innate and adaptive immune responses providing a link between the two and, 
in doing so, maintaining immune homeostasis. Macrophage populations arise from myeloid 
progenitors in the bone marrow or differentiate from monocytes in the bloodstream in response to 
immunoglobulins, cytokines and chemokines. Macrophages differentiated from murine bone 
marrow using macrophage colony-stimulating factor (M-CSF) are a good culture model as cells 
are generated in a state that has not been previously activated and can thus respond to any 
cytokine stimulus (Valledor et al, 1998). The effector functions of activated macrophages range 
from phagocytosis to release of pro-inflammatory mediators that promote killing, and anti-
inflammatory mediators that enable repair. For example, interleukin-10 (IL-10) and transforming 
growth factor-β (TGF-β) are important cytokines involved in dampening vigorous inflammatory 
responses triggered by the release of nitric oxide (NO) and TNF-α.  
Macrophages and Pattern Recognition Receptors (PRRs) 
Antigen presenting cells (APCs) perform their function in innate immunity by recognising 
antigens, and in particular pathogen associated molecular patterns (PAMPs), by means of their 
expression of pattern recognition receptors (PRRs). The most common PRRs are the Toll-like 
receptors (TLRs) which are important in handling microbial infections. TLRs are members of the 
Toll/IL-1 receptor (TIR) family, contain cytoplasmic TIR domains, and are capable of 
recognizing structurally diverse microbial ligands (Krishnan et al, 2007). TLR4 is the most 
studied because of its specificity for binding LPS, a major component of gram-negative bacterial 
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walls. Ligation of TLR4 by LPS is preceded by engagement to CD14 which enables LPS to be 
brought into direct contact with TLR4 and MD-2 (Beutler et al, 2003). CD14, which is expressed 
on myeloid cells, acts as an accessory molecule to TLR2 and TLR4 as is does not contain a 
transmembrane domain to link it with intracellular signal transduction (Taylor et al, 2005). 
Signalling via TLRs, which is dependent on other surface molecules such as CD14/MD-2 for 
ligand recognition, leads to cytokine production against the foreign antigen as well as inducing 
maturation of immune cells. Downstream signalling from TLR activation requires recruitment of 
adaptor proteins, the major one being MyD88 (Myeloid differentiation primary response gene 
88), which is recruited by all TLRs except TLR3. Other adaptor proteins include MAL (MyD88 
adapter like), TRIF (TIR domain-containing adapter protein inducing IFN-β) and TRAM (TRIF-
related adapter molecule) which are recruited by different TLRs leading to variations in 
signalling specificity. Following LPS ligation and MyD88 recruitment, TRAM appears to act as 
an adaptor for TLR4 and TRIF. IRAKs (MyD88/interleukin-l receptor associated kinase) are next 
in the signalling cascade downstream of MyD88 which, when phosphorylated, dissociate from 
MyD88 resulting in activation of TRAF6 (TNF receptor associated factor), which is a member of 
the E3 ubiquitin ligase family (Chen, 2005). TRAF6 then activates the canonical NF-κB pathway 
which is where all TLR pathways converge. In the case of TLR3 and TLR4, downstream 
signalling can follow a MyD88-independent route that involves activation of IRF3. MyD88-
independent signalling events downstream of TLR3 require TRIF while TLR4 recruits 
TRIF/TRAM in order to induce IRF3-dependent type I interferon production. In general, TLR 
engagement leads to signalling involving IκB kinase (IKK), MAPK (JNK/p38) and PI3K/Akt 
pathways, which ultimately lead to AP-1 and NF-κB activation and production of inflammatory 
cytokines and chemokines (Kawai and Akira, 2006).  
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TLRs are known to collaborate with other PRRs in PAMP recognition improving their 
affinity and effectively coupling innate and adaptive immune responses. Specifically, Dectin-1 
which has a cytoplasmic immunoreceptor tyrosine-based activation motif (ITAM)-like sequence, 
cooperates with TLR2 in production of pro-inflammatory cytokines following recognition of β-
glucan particles. Dectin-1 is a phagocytic receptor that also recognizes endogenous ligands on T 
cells and can act as a co-stimulatory molecule for T cell proliferation (Taylor et al, 2005). CLRs 
(C-type lectin receptors) are another group of PRRs that can collaborate with TLRs and they are 
known to act as antigen uptake receptors. CLRs bind a specific glycan repertoire via their 
carbohydrate recognition domains (CRDs) whose structural integrity is dependent on the 
presence of Ca
2+
 ions. Their binding properties are also influenced by positioning of 
carbohydrates on their ligands as well as by the proximity of CRDs often achieved by 
oligomerisation (Taylor and Drickamer, 2003). CLRs have roles in cell-cell or cell-matrix 
adhesion and glycoprotein turnover, while their function in immature DCs is antigen capture for 
presentation by MHC class I and II molecules to induce CD4+ and CD8+ T-cell responses. 
Therefore, they are important in pathogen recognition and promote cellular interactions that are 
required for pathogen internalisation and elimination. Examples of these CLRs capable of 
glycosylated antigen internalization are DC-SIGN, MGL, Dectin-1 and Mincle (Van Vliet, 
Garcia-Vallejo et al, 2008). The macrophage galactose lectin, MGL, (CD301) exists as a homo-
oligomer and is found on myeloid APCs, especially on tolerogenic or alternatively activated 
subsets. Humans are known to express one MGL while mice express two closely related MGLs, 
MGL1 and MGL2, with unique carbohydrate specificities for Lewis X sugars as well as galactose 
and N-acetylgalactosamine (GalNAc). Human MGL specifically recognizes GalNAc sugars thus 
bearing more similarity to mMGL2, while mMGL1 binds Lewis X structures similar to rMGL 
(Sakakura et al, 2008; Singh et al, 2009). MGL shares a common internalisation motif to the 
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asialoglycoprotein receptor (ASGP-R) and DC-SIGN and can endocytose antigens which are 
directed to the endosomal-lysomal pathway for presentation via MHC II. No signalling properties 
have been attributed to MGL so far. MGL functions in controlling granulation of murine tissues 
as well as in distinguishing between healthy and tumour tissue (Van Vliet et al, 2008). In 
addition, MGL has been recently shown to bind terminal GalNAc moieties on T cell-expressed 
CD45 which affects T cell proliferation (Van Vliet et al, 2006). Finally, MGL1 and MGL2 were 
shown to be expressed in alveolar macrophages in an IL-4-dependent manner during asthma, 
suggesting that MGL can act as a marker of alternative activation (Raes et al, 2005).  
 
The link between alternative activation of macrophages and lectins is also supported by 
the fact that, IL-4 stimulates a galectin-3 feedback loop leading to sustained PI3K activation via 
CD98 and is a requirement for alternative activation of macrophages. Galectin-3 is a 
carbohydrate-binding lectin which binds macrophage CD98 that triggers PI3K pathway 
activation. Its secretion is enhanced by IL-4 which provides a positive feedback loop resulting in 
sustained PI3K activation. Inhibition of galectin-3 suppresses the IL4-induced alternative 
activation in macrophages without affecting IFN-γ/LPS-induced classical activation or IL-10-
induced deactivation (Mackinnon et al, 2008). Similarly, another PRR influenced by IL-4 
stimulation is the macrophage mannose receptor. The MR (CD206) is an endocytic receptor 
involved in clearance of endogenous glycoproteins that recognizes mannose, fucose, and N-
acetylglucosamine (Mukhopadhyay et al, 2009). Other PRRs such as the collectins and selectins 
are involved in both innate and adaptive immune responses. The collectins are soluble proteins, 
an example of which is MBP (mannose binding protein), are involved in the innate response by 
fixation of complement. The selectins are involved in adaptive immune responses by mediating 
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transient interactions between leukocytes and the endothelium for leukocyte trafficking (Weis et 
al, 1998).  
Macrophages are known to express all cytokine receptors and PRRs in all their activation 
states allowing them to adjust to a changing local environment, as polarised macrophages can 
respond to both classical and alternative activation stimuli (Gratchev et al, 2006). For example, in 
parasite infections macrophages are able to respond to signals such as cytokines from other 
immune cells and PAMPs, which are recognized directly by macrophage PRRs. In fact, MGL as 
well as scavenger receptor and Dectin-1 are up-regulated in parasite infections.  
Macrophage activation 
The activation state of macrophages is important in determining the outcome of an 
inflammatory response. Distinct macrophage subsets with different expression profiles have been 
characterised in the presence of foreign antigens and T cells (Noel et al, 2004). Macrophages 
were originally considered as pro-inflammatory effector cells involved in cytotoxicity induced by 
T helper 1(Th1) cytokines [interferon-γ (IFN-γ) and TNF-a]. However, Stein and colleagues 
found that the T helper 2 (Th2) cytokine interleukin-4 (IL-4) activated murine macrophages in an 
alternative mode characterised by mannose receptor (MR) expression, suggesting the existence of 
an alternative activation state (Stein et al, 1992). Furthermore, Doyle and colleagues reported that 
the human macrophage MR was up-regulated by IL-4 which enhanced macrophage fusion, while 
interleukin-13 (IL-13), another Th2 cytokine, was found to produce a response that was between 
IFN-γ activation and IL-10 deactivation (Doyle et al, 1994). Deactivation of certain cell types, 
including macrophages, by IL-10 has been reported to involve inhibition of pro-inflammatory 
responses by reducing inflammatory cytokine production such as interleukin-6 (IL-6) and TNF-α 
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(Bogdan et al, 1991; Moore et al, 1993). In addition, enhancement of IL-10 production was 
shown to promote the anti-inflammatory phenotype of macrophages following expression and 
activation of AMP-activated kinases (Sag et al, 2008). 
The most common macrophage activation phenotype, that arises in the presence of 
microbial stimuli, such as lipopolysaccharide (LPS), or IFN-γ, is known as the classically 
activated macrophage (CAMΦ) phenotype, and is involved in pro-inflammatory reactions by 
production of TNF-α, interleukin-1β and interleukin-12 and promotion of Th1 responses. CAMΦ 
are inhibited by Th2 cytokines and thus the macrophages generated in the presence of IL-4/IL-13 
are termed alternatively activated macrophages (AAMΦ). Glucocorticoids have also been shown 
to induce an anti-inflammatory phenotype in macrophages that is very similar to IL-4 - stimulated 
AAMΦ (Edwards et al, 2006; Martinez et al, 2008). However, macrophage heterogeneity under 
different in vivo settings results in inaccurate classification of macrophage activation phenotypes 
(Naito et al, 1996). Despite the fact that certain macrophage features are shared by more than one 
phenotype, they are generally considered as either wound healing, regulatory or acting in host 
defence (Mosser and Edwards, 2008). In general, CAMΦ are aimed at dealing with threats by 
exhibiting aggressive action, which may lead to tissue destruction, whereas AAMΦ are 
responsible for tissue restoration. This AAMΦ characteristic is a result of preferential use of 
arginase I for processing L-arginine instead of inducible nitric oxide synthase (iNOS). This is the 
main distinguishing feature between the two modes of activation. These differences are 
summarised in Diagram 2.  
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Diagram 2: Summary of macrophage activation. Microbial triggers (such as LPS) and Th1 cytokines 
(such as IFN-γ) lead to classical activation (CAMΦ) while Th2 cytokines (IL-4/IL-13) alternatively 
activate macrophages (AAMΦ). CAMΦ are considered pro-inflammatory while AAMΦ are anti-
inflammatory. (iNOS = inducible nitric oxide synthase). 
 
 
The balance between the activity of arginase I and iNOS is important in determining the 
state of macrophage activation and, specifically, arginase I induction is accompanied by 
suppression of iNOS (Corraliza et al, 1995). There are two known isoforms of arginase: arginase 
I is cytosolic and arginase II is mitochondrial. Both these enzymes convert L-arginine to L-
ornithine which is essential for the production of polyamines for cell growth, and prolines which 
are major components of collagen (Hesse et al, 2001).  
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The process of L-arginine metabolism (summarised in Diagram 3) is regulated by its 
transporter, cationic amino acid transporter (CAT2), and macrophage activation results in a 
higher rate of L-arginine transport (Yeramian et al, 2006). In addition to controlling macrophage 
activation directly, arginase I, and the depletion of L-arginine, also regulates proliferation of T 
cells indirectly by interfering with formation of the T cell receptor (TCR) complex (Bronte and 
Zanovello, 2005).  
 
Diagram 3: Schematic representation of L-arginine metabolism. iNOS and arginase I are responsible 
for L-arginine metabolism. The products of the former include the pro-inflammatory nitric oxide (NO) 
while the latter provides products used in proliferation processes.  
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Classically activated macrophages (CAMΦ) 
Classically activated macrophages have a major role in pro-inflammatory responses and 
are involved in the resolution of intracellular infections. This is achieved by the synthesis and 
release of cytotoxic reactive oxygen intermediates (ROI) and nitric oxide (NO) (Martinez et al, 
2008). In addition, CAMΦ produce high levels of pro-inflammatory cytokines such as IL-6, 
TNF-α and IL-1 which also aid in eliminating pathogens by recruitment of additional effector 
cells. Furthermore, CAMΦ have increased antigen presenting capacity, as a result of the high 
levels of major histocompatibility complex II (MHCII) and CD86 they express, and this points to 
an important role in the establishment of adaptive immunity (Noel et al, 2004).  
Classical activation is initiated during cell-mediated immune responses by IFN-γ 
produced by natural killer (NK) cells, responding to stress and infections, and then by Th1 cells. 
In addition, LPS-derived from the cell walls of Gram-negative bacteria also triggers classical 
activation following ligation of toll-like receptors (TLR) on macrophages (Mantovani et al, 
2004). TLR ligation acts via MyD88 to induce TNF-α expression which provides sustained 
autocrine activation of CAMΦ as a result of cooperation with IFN-γ. In fact, lack of IFN-γ 
expression leads to increased susceptibility to various bacterial, protozoal and viral infections. 
Furthermore, certain pathogens can interfere with macrophage activation by preventing IFN-γ 
signalling (Mosser and Edwards, 2008). Activation of the IFN-γ receptor leads to expression of 
target genes via signal transducer and activator of transcription (STAT) molecules, while TLR 
and TNF receptor ligation activates nuclear factor-κB (NF-κB) and mitogen activated protein 
kinases (MAPKs). Gene expression downstream of these signal transducers involves, among 
others, the production of IL-1, IL-6 and IL-23 by CAMΦ which aids in the development of Th17 
cells. In turn these cells produce IL-17, a cytokine that has been implicated in the development of 
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inflammatory autoimmune pathologies by recruitment of polymorphonuclear leukocytes (PMN) 
(O‟Shea and Murray, 2008). Despite the beneficial role of CAMΦ in fighting infection, excessive 
responses are generally damaging to the host and it is at this stage that macrophages with 
remodelling and repair characteristics must be recruited to dampen CAMΦ effects. 
 Alternatively activated macrophages (AAMΦ) 
Macrophages become alternatively activated following stimulation with IL-4 or IL-13 and 
are characterised by anti-inflammatory properties, although they are still able to respond to 
microbes by cytokine secretion (Varin et al, 2010). AAMΦ are distinguished from CAMΦ by the 
expression of certain markers. The MR, arginase I, Ym1 and Fizz1 are established markers of 
alternative activation although some discrepancies have been reported (Gordon, 2002). For 
example, arginase I expression has also been reported following activation of macrophages with 
TLR ligands (Huber et al, 2010). Human alternatively activated myeloid cells were not found to 
express arginase I and Ym1 (Raes et al, 2005). Finally, the MR is not always up-regulated in 
AAMΦ and the fact that this marker is also expressed by un-stimulated differentiating 
macrophages may suggest that the distinguishing feature of AAMΦ is an up-regulation of MR 
expression levels (Rouleux-Bonnin et al, 1998). The roles of these markers in AAMΦ are not 
clear but certain observations have been reported that implicate these markers in AAMΦ effector 
functions. Up-regulation of MR expression and activity by IL-4 has been shown to enhance 
macrophage ability to fuse (McNally et al, 1996). Ym1 is an inducible lectin synthesised and 
secreted by activated macrophages, which is homologous to mammalian chitinases. However, it 
has no known chitinase activity as its natural substrates are glucosamine (GlcN) oligomers and 
heparin (Chang et al, 2001). Fizz1 (Found in the inflammatory zone) is also known as RELM-α 
as it is a resistin-like secreted protein and it is up-regulated during allergic reactions and 
pulmonary inflammation in epithelial and alveolar cells (Raes et al, 2002). Fizz1 is an anti-
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inflammatory molecule and its expression by AAMΦ in the lung has been shown to reduce 
pathogenesis resulting from type 2 inflammation (Nair et al, 2009).  
Expression of markers of alternative activation is activated at the molecular level as a 
result of STAT6 and IRS-1 signalling recruited following IL-4Rα activation (Nelms et al, 1999). 
The IL-4Rα chain is shared by IL-4 and IL-13 mediated signalling as it is a major component of 
functional IL-4 and IL-13 receptor heterodimers (Zurawski et al, 1993). Association of the IL-
4Rα chain with the common γ chain forms an IL-4R or type I receptor, while association with the 
IL-13Rα1 binding chain forms a type II, IL-13 receptor. Despite the fact that both IL-4Rs and IL-
13Rs share a common chain, downstream signalling potencies are not the same suggesting that 
extracellular receptor interactions may vary (LaPorte et al, 2008). The IL-4R is a hematopoietic 
receptor that is associated with kinases, such as Src kinases, that allow signal transduction via 
STAT6 leading to activation of phosphatidylinositol 3-kinase (PI3K) and Ras-MAPK signalling 
(Varin and Gordon, 2009). IL-4Rs are also known to activate IRS2 for induction of target gene 
expression in macrophages (Heller et al, 2008).  
IL-14 and IL-13 are known as Th2 cytokines and are produced by CD4+ T cells, 
basophils and mast cells. They activate and maintain Th2 responses by stimulating the production 
of IL-10 and IL-1R antagonist and inhibiting the expression of IL-1, TNF-a, IL-6, IL-12, 
macrophage inflammatory protein-1a (MIP-1a) thus providing protection from excessive 
inflammation (Fenton et al, 1992). In addition, they suppress NO production and increase 
scavenger receptor and MR for clearance by endocytosis while AAMΦ-derived TGF-β induces 
IL-2 production from T helper cells (Goerdt and Orfanos, 1999; Varin and Gordon, 2009). The 
specificity of these two Th2 cytokines to induce alternative activation is emphasised by the fact 
that, although IL-10 is also a type 2 cytokine, only IL-4 and IL-13 were found to induce arginase 
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I activity (Herbert et al, 2004). Furthermore, arginase I expression is down-regulated by IFN-γ 
and TNF-α. Recently, Huber and colleagues have reported that PD-L2 (Programmed Death-1 
ligand 2) is up-regulated in AAMΦ and the authors suggest that it may be a more specific marker 
of alternative activation because of its STAT6-dependent expression (Huber et al, 2010). PPARγ 
(peroxisome proliferator activated receptor) was also shown to be induced in IL-4 stimulated 
macrophages, and is considered important in AAMΦ maturation and maintenance, by negative 
regulation of LPS and IFN-γ induced gene expression and enhancement of arginase I expression 
and activity (Odegaard et al, 2007). 
Naturally occurring AAMΦ are found in the lung and the placenta where their role is to 
prevent unnecessary immune reactions, such as allergic reactions. In disease, AAMΦ are 
generally associated with the repair phase of acute inflammation or chronic inflammation such as 
rheumatoid arthritis (Martinez et al, 2009). Furthermore, AAMΦ down-regulate inflammation, 
cause angiogenesis and eliminate tissue debris which are important for restoration of damaged 
tissue (Goerdt and Orfanos, 1999).  The recruitment of AAMΦ to wounds is critical for healing 
as they have enhanced expression of fibronectin, which is an extracellular matrix (ECM) 
glycoprotein, as well as collagen which is a product of their increased arginase I activity (Lucas, 
2010). Excessive arginase-induced deposition of collagen has been suggested to promote fibrosis, 
however, Pesce and colleagues have shown that arginase I producing macrophages are beneficial 
for suppression of Th2-driven fibrosis (Pesce et al, 2009). However, the fact that wound 
macrophages also express TNF-α and IL-6 along with the fact that IL-4/IL-13 have not been 
found in wounds, has led to the suggestion that these macrophages are not purely AAMΦ (Daley 
et al, 2010). Alternatively, this may be due to the fact that the role of macrophages in wound 
healing is not continuous and that they are recruited at different stages to perform specialised 
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functions. AAMΦ have a protective role in Crohn‟s disease and inflammatory bowel disease 
(IBD), which are due to an excessive Th1 response, and Fizz1 and arginase I have been shown to 
be up-regulated when colon inflammation is reduced. In allergic asthma, the presence of AAMΦ, 
confirmed by detection of elevated levels of Fizz1 and Ym1, is not beneficial as IL-4 and IL-13 
are associated with increased severity of this condition (Locksley, 2010). Tumour associated 
macrophages (TAMs) which promote tumour progression, have also been described as AAMΦ 
which inhibit MyD88-dependent TNF-α and NO production and express IL-10, Dectin-1, MGL1, 
TGF-β. However, they also express IFN-γ-inducible chemokines and there is no clear connection 
between IL-4/IL-13 and tumour progression, which may suggest that the phenotype of these 
macrophages is regulated by a variety of cytokines (Martinez et al, 2008). 
Macrophages in nematode infections 
 The roles of macrophages in helminth infections are multifaceted owing to their 
involvement in many stages during the course of infection. Despite the fact that macrophages are 
typically associated with Th2-inducing infections, they can adopt different activation phenotypes 
in immune responses due to their versatile natureas. For example, nematode-elicited macrophages 
(NeMΦ) can be „re-programmed‟ to respond to Th1 stimuli (Mylonas et al, 2009; Varin et al, 
2010). Functional modulation of macrophages as well as APCs is thought to be a fundamental 
event involved in establishing immune regulation by parasites. In general, helminths are known 
to induce Th2 responses characterised by increased numbers of CD4+ Th2 cells, eosinophils, 
mast cells and basophils and the release of Th2 cytokines such as IL-4, IL-5, IL-9, IL-10, IL-13 
(Loke et al, 2007). Consequently, the phenotype of NeMΦ most closely resembles an alternative 
activation phenotype with characteristic elevation of Fizz1 and Ym1 expression and suppression 
of inflammatory cytokine production (Nair et al, 2003; Nair et al, 2005; Kreider et al, 2007).  
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F. hepatica secreted products were found to up-regulate alternative activation markers in 
macrophages both in in vitro and in vivo studies by inducing an IL-4-dependent Th2-type 
response (Donnelly et al, 2005; Flynn et al, 2007). In N.brasiliensis infection, all macrophages 
present after the first week of infection were AAMΦ aimed at reducing chronic pulmonary 
inflammation by Fizz1 and Ym1 expression, as they did not have a role in the expulsion of this 
parasite (Herbert et al, 2004; Marsland et al, 2008). AAMΦs, which are recruited to sites of 
infection in a variety of helminth infections (Schistosoma mansoni, Nippostrongylus brasiliensis, 
Trichinella spiralis, Fasciola hepatica and filarial parasites), orchestrate immune responses that 
lead to parasite expulsion, at the same time preventing any associated immune pathologies 
(Kreider et al, 2007). Pathology that may be associated with filarial infections is determined by 
the phenotype of macrophages as secreted products induce Th2 cytokine production and AAMΦ 
recruitment, while dying worms recruit CAMΦ as a result of endosymbiotic bacteria being 
released (Allen and Loke, 2001). Host survival is enhanced by AAMΦ as these cells protect the 
host by down-regulating the inflammation induced when parasite eggs are deposited, killing or 
promoting expulsion of adult worms, as well as repairing damaged tissue resulting from these 
processes. Additionally, AAMΦ may directly target chitin expressed by helminths as Fizz1 and 
Ym1 have been detected in sites of T.cruzi and H.polygyrus infection (Anthony et al, 2007). 
T.spiralis infection has also been shown to recruit macrophages with an alternative activation 
phenotype characterised by up-regulated Ym1 expression and secretion (Chang et al, 2001). 
Furthermore, IL-4/IL-13 was found to be necessary for expulsion of T.spiralis despite the fact 
that in the absence of IL-4R an effector response was still generated (Michels et al, 2009). This 
response is dependent on CD4+ T cells and IL-4 to generate AAMΦ which are involved in 
parasite clearance through arginase I activation.  
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The mode of action used by helminths to induce of alternative activation of macrophages 
is both direct modulation of macrophages as well as indirect through activation of other immune 
cells (Perrigoue et al, 2008). Specifically, the intestinal epithelium acts as a sensor of infection by 
gut parasites to which cells are recruited that can activate APCs indirectly (Artis and Grencis, 
2008). This is achieved by induction of regulatory T cell subsets which are either recruited 
directly or activated by APCs, such as dendritic cells. Furthermore, helminths are known to 
directly interfere with immune cell recruitment and proliferation by production of molecules like 
MIF (macrophage inhibitory factor) which prevents macrophage accumulation (Maizels et al, 
2004). Helminth secretory products contain glycan PAMPs that can be recognized by PRRs such 
as TLRs and C-type lectins (CTLs) on host APCs leading to innate immune responses. For 
example, LNFPIII (Lacto- N-fucopentaose III) which is a Lewis X sugar derived from S.mansoni, 
is recognized by TLR4 as is the ES-62 protein from A.viteae (Goodridge et al, 2005; Harn et al, 
2009). Activation of TLR4 by these parasite products did not resemble LPS-induced signalling 
due to the release of a mixture of pro- and anti- inflammatory cytokines. The β-linked GalNAc in 
LDN (LacdiNAc) and Lewis X motifs of S.mansoni glycans were shown to bind the C-type lectin 
DC-SIGN which also recognizes M.tuberculosis, L. mexicana and H. pylori epitopes (Hokke and 
Yazdanbakhsh, 2005). Glycans from T. canis are also recognized by DC-SIGN, an event that is 
associated with granuloma formation in vivo. Helminths can also modulate immune cells by 
lipids such phosphatidylserine (PS) and lyso-PS, which induce IL-4 and IL-10 secreting T cells 
via DC activation through TLR2 (Maizels and Yazdanbakhsh, 2003). On the other hand, T. canis 
secreted products appear to mimic mammalian CTLs, such as the mannose receptor, suggesting 
an alternative mode of manipulation (Hewitson et al, 2009). In addition, helminths interfere with 
PAMP-induced TLR activation in DCs by conditioning them through PRR signalling to produce 
46 
 
cytokines, such as IL-10 and TGF-β, which also promotes induction of regulatory T cells (Everts 
et al, 2010).  
The presence of AAMΦ during parasite infections is important in down-regulating 
effector cell pro-inflammatory functions by driving Th2 responses as well as repairing helminth-
induced damage (Maizels et al, 2004). In turn, NeMΦ maintain the anti-inflammatory response 
by activating naïve T cells towards a Th2 phenotype (Flynn et al, 2010). This enhances AAMΦ 
recruitment as Th2 cells are important for their activation and maintenance even in the presence 
of innate cell-derived IL-4/IL-13. However, nematodes are also known to achieve their survival 
by suppressing immune responses through the promotion of regulatory T cell induction (Anthony 
et al, 2007). In fact, Treg produce IL-10 and TGF-β which suppress T helper cell subsets. It has 
been suggested that AAMΦ are actually a result of Th2 cell induction and are not important in 
the early stages of infection but rather act to stabilise Th2 cells. In fact, B.malayi-induced AAMΦ 
promote Th2 differentiation by inhibition of IFN-γ producing T cells instead of inducing IL-4 
producing cells (Allen and Loke, 2001).  
Helminth-induced Th2 responses are beneficial to both the host and the parasite as they 
protect themselves from clearance and prevent severe pathology to the host as a result of 
excessive tissue damage. As a result of this, helminth responses are considered beneficial for 
resolution of chronic inflammation characteristic of autoimmune diseases, allergy and Crohn‟s 
disease and the role of AAMΦ is recognized as a potential means of therapeutic intervention in 
these diseases (Namangala et al, 2001).  
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1.3 T cells 
An important process in linking the innate and adaptive arms of the immune response is 
antigen presentation to T cells. APCs capture and process antigens which they present to T cells 
via MHCI and II. Therefore, T cell activation is dependent on the activation state of APCs such 
as macrophages, used in this study. T cells then mount a more specific response which cooperates 
with APCs to further eliminate pathogens (Hasko et al, 2007).  
Naïve T cells originate in the thymus and develop into effector T cells that can either be T  
helper (CD4+), cytotoxic (CD8+), memory (CD4+/CD8+), regulatory (CD4+) or natural killer 
cells. T helper (Th) cells are subdivided into Th1 and Th2 subsets which are counter-regulatory. 
Th1 cells induced by intracellular pathogens, produce IFN-γ, GM-CSF and TNF-α and are 
involved in cell-mediated immunity, while Th2 cells induced by extracellular pathogens, are 
involved in humoral immunity as they produce IL-4, IL-5, IL-13 and IL-10. In addition, NO 
which is a known pro-inflammatory mediator, enhances Th1 cell development via a cGMP-
induced mechanism of IL-12R up-regulation (Niedbala et al, 2006). Regulatory T cells (Treg) 
which are characterised by Foxp3 and CD25 expression (Foxp3+CD4+CD25+) and are 
constitutively expressed, develop in the thymus and regulate peripheral T cells, while „inducible‟ 
Treg (Tr1 or Th3 cells) develop from peripheral CD4+ T cells in response to antigen or 
deactivating cytokines. Treg expressing markers such as Foxp3, CD25, CD62L, OX40, 
Glucocorticoid induced tumor necrosis factor receptor family related gene (GITR), Cytotoxic T-
Lymphocyte Antigen 4 (CTLA-4) are known to produce IL-4, IL-10, TGF-β.  Foxp3 is 
considered the most reliable marker as it is responsible for their development and function. In 
fact, low levels of Foxp3 lead to a Th2 phenotype that produces IL-4 even under Th1 conditions 
(Wan and Flavell, 2007). This is because Foxp3 expression represses cytokines controlled by 
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TCR activation such as IL-4, IFN-γ, TNF-α as well as altering surface expression of molecules 
that determine Treg responses to environmental cues (Gavin et al, 2007).  
Naïve T cells are activated by APCs presenting antigen via MHC only in the presence of 
co-stimulatory molecules. T cells that encounter antigen without sufficient co-stimulation become 
anergic and their expansion is inhibited (Appleman and Boussiotis, 2003). T cell proliferation is 
also suppressed by Tregs and, although the mechanism is not entirely clear, different modes of 
suppression have been proposed. Antagonism either by competition with APCs for specific 
MHC:peptide complexes or by expression of inhibitory molecules is one possibility. Treg-
expressed CTLA-4 is one such molecule while cytokines such as IL-10 and TGF-β are also 
considered as potential candidates of suppression. CTLA-4 binds the co-stimulatory molecules 
B7.1 and B7.2 and has also been shown to induce indoleamine dioxygenase (IDO), an enzyme 
whose metabolic products have immunosuppressive effects (Fehervari and Sakaguchi, 2004). 
This could also lead to modulation of APC activation providing an indirect mechanism of 
inhibition of T cell activation. Furthermore, suppression may also be mediated by „metabolic 
disruption‟ which is achieved by two mechanisms. The presence of CD25 on Treg may result in 
uptake of IL-2 thus reducing the amount available for effector T cells in the vicinity. Ecto-
enzymes such as CD39 and CD73 (discussed in section 1.1 of this chapter), which are now 
considered to be more specific markers for Tregs than CD25, participate in generation of 
extracellular adenosine which is also a potent suppressor of T cell effector functions (Vignali, 
2008; Zarek et al, 2008).  
T cell receptor (TCR) activation by MHC leads to recruitment and activation of Src 
kinases such as Lck and Fyn to the CD3 complex where they phosphorylate immune receptor-
based activation motifs (ITAMs). Subsequently, the tandem Src homology 2 (SH2) domain-
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containing tyrosine kinase Zap-70 is recruited to the phosphorylated CD3-δ chain ITAMs 
resulting in an active TCR complex (Acuto et al, 2008). An important linker for signalling 
downstream of the TCR is the transmembrane adaptor protein linker for activation of T cells 
(LAT) which is phosphorylated by Zap-70/Syk producing a platform for the recruitment of PLCγ, 
and the p85 subunit of PI3K which initiate signalling events. These events ultimately result in 
binding of transcription factors such as NF-kB/NFAT, Ap-1 and CREB to initiate transcription of 
T cell activating genes (Torgersen et al, 2002). PKA (cAMP-dependent protein kinase) signalling 
is important for activation of several of these transcription factors as it can inhibit TCR-CD3 
complex activation through activation of Csk (C-Src tyrosine kinase) which reduces the ability of 
Lck to phosphorylate the CD3-δ chain (Vang et al, 2001). TCR signalling has also been shown to 
induce TLR2 and TLR4 expression which were proposed to act as co-receptors for T cell 
activation by antigens as well as enhancing Treg proliferation and immunosuppressive ability in 
response to LPS (Liu and Zhao, 2007). Furthermore, it has been reported that, NK cells produce 
IFN-γ in response to TLR activation, which they express constitutively, and that this leads to 
further recruitment of macrophages allowing for efficient resolution of microbial infections 
(Sawaki et al, 2007).  
As a result of the potent suppressor ability of Tregs, they are generally considered to play 
a critical role in controlling inflammation and promoting self-tolerance and recruitment of these 
cells by parasites is beneficial for generating conditions favoring their survival and persistence 
(Belkaid et al, 2006). In the case of parasite infections, Tregs are beneficial to the host as they 
control immunopathology resulting from excessive responses aimed at eliminating the parasites. 
On the other hand, host death can result from uncontrolled parasite growth which is promoted by 
Treg-induced tolerance. Chronic parasite infections support survival and function of Tregs by 
triggering the release of TGF-β by cells in the site of infection (Belkaid et al, 2006). In 
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schistosome-infected mice, Tregs isolated from hepatic granulomas and lymphoid tissues were 
shown to produce IL-10, which promotes parasite persistence by targeting IL-12 production by 
dendritic cells (Hesse et al, 2004). Recruitment of Tregs was also observed in lung draining 
lymph nodes in T.spiralis infection which was suggested to improve lung function and reduce 
allergic airway inflammation (Park et al, 2011).  
1.4 Trichinella spiralis 
Trichinella spiralis is a parasitic nematode that infects mammalian species via the 
gastrointestinal tract, through which it enters the systemic circulation to penetrate muscle tissue. 
The uniqueness of T.spiralis infection is emphasised by the fact that it can exist both 
intracellularly and extracellularly in its host (Despommier et al, 1983). Furthermore, its life cycle 
is completed in one host and consists of an enteral and parenteral phase (Summarised in Diagram 
4). Infective larvae are ingested in contaminated meat and enter the stomach where they are 
released during digestion. Larvae become activated in the stomach and by bile as they enter the 
small intestine where they penetrate mucosal epithelial cells and mature into adults. Adults are 
expelled once they have shed newborn larvae which then exit the intestine and migrate through 
the bloodstream to the striated muscle tissue (Patel et al, 2009). Following penetration of 
myofibres, larvae induce formation of a parasite-host cell complex. Infection by new-born larvae 
initiates muscle de-differentiation and is accompanied by increased angiogenesis as a result of 
subversion of host cell gene expression which also promotes expression of vascular endothelial 
growth factor (VEGF) (Shariati et al, 2009). In addition, parasite survival is enhanced by 
expression of IL-10 and TGF-β. Both these cytokines inhibit inflammation of infected muscle 
which protects larvae from the host immune response mounted against them (Beiting et al, 2007).  
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Diagram 4: The life cycle of T.spiralis. Parasites are released from contaminated meat into the stomach 
of the host. Larvae mature into adults in the small intestine and are expelled after newborn larvae are shed. 
Larvae migrate through the intestinal epithelium to the blood and lymphatics in search for striated muscle 
where they form a nurse cell complex (Taken from http://www.trichinella.org/bio_lifecycle.htm). 
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The gastrointestinal tract contains more immune cells than all the other immunological 
organs combined (Stokes and Bailey, 2000), therefore, products secreted by nematodes act in the 
parasite‟s advantage to ensure survival and prolong persistence until new larvae are released 
(Gibbs, 1982; Grencis, 1997). These secreted products consist of enzymes that are believed to 
down-regulate the host‟s immune system by generating mediators that serve to inhibit nucleotide 
induced activation of immune responses (Gounaris and Selkirk, 2005). A nucleotide metabolizing 
enzyme with dual apyrase and 5`-nucleotidase activity has been characterized that is capable of 
mimicking the endogenous ecto-enzymes, such as ecto-nucleotidases and ecto-NDPDases that are 
naturally expressed on cells of the immune system (Gounaris, 2002). This enzyme, known as 
5`NT, catalyzes the hydrolysis of nucleoside 5`-diphosphates (ADP and UDP) and the 5`-
monophosphate AMP at the same active site, thus limiting the availability of diphosphates and 
AMP (Gounaris et al, 2004). The importance of this potential evasion mechanism can be 
explained by the fact that, during parasite invasion the resulting tissue damage causes release of 
nucleotides such as ATP and ADP which act as warning signals to the immune system. 
Activation of purinergic signalling by these nucleotides leads to immediate inflammatory 
responses so the removal of these signals by T.spiralis enzymes, which is accompanied by 
generation of adenosine, could protect the parasite from host responses that would jeopardise its 
survival. The enzymatic cascade present in T.spiralis secreted proteins acting on extracellular 
nucleotides consists of nucleoside diphosphate kinases (NDPKs), adenosine deaminase and the 
5`-nucleotidase mentioned above (Diagram 5). Extracellular nucleotides such as ATP act on P2 
receptors expressed on immune cells leading to pro-inflammatory responses. The T.spiralis 
NDPK can convert these nucleotides to nucleoside diphosphates such as ADP which also 
activates P2 receptors. 5`NT is important in catalyzing the conversion of ADP to AMP and then 
to adenosine which acts on P1 receptors, also expressed on immune cells, to induce anti-
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inflammatory responses that protect T.spiralis from inflammation-induced killing. Furthermore, 
inosine which is the breakdown product of adenosine from the action of adenosine deaminase, 
also acts on P1 receptors ensuring a sustained anti-inflammatory response. Interestingly, a similar 
mechanism of manipulation of purinergic signalling has also been proposed for ATP 
metabolising enzymes found on schistosome surfaces as well as in hematophagus insects 
(Gounaris and Selkirk, 2005; Bhardwaj and Skelly, 2009). Specifically, nucleoside triphosphate 
dephosphorylases (apyrases), which hydrolyze ATP and ADP to AMP, and 5`-nucleotidases, 
which hydrolyze AMP to adenosine, and adenosine deaminase are used by haematophagous 
insects to suppress immediate inflammatory responses (Gounaris and Selkirk, 2005). In addition, 
alkaline phosphatase, phosphodiesterase and ATP diphosphohydrolase 1 have been shown to be 
expressed on the tegumental surface of S. mansoni (Bhardwaj and Skelly, 2009). 
. 
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Diagram 5:  Schematic representation of the enzymatic cascade catalyzed by T. spiralis secreted 
proteins. Extracellular nucleotides acting on P2 receptors are converted by nucleoside diphosphate  kinase 
(NDPK) to nucleoside diphosphates like ADP/UDP, which are still P2 receptor agonists. The apyrase 
activity of 5`NT converts nucleoside diphosphates to monophosphates which have no known purinergic 
receptors. The 5`-nucleotidase activity of 5`NT then catalyzes the conversion of AMP to adenosine which 
is deaminated by adenosine deaminase to inosine and both these products act on P1 receptors. 
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1.5 Aims 
Macrophages are involved in both innate and adaptive immune responses. Recently their role 
in nematode infection has also been established where they adopt a unique alternatively activated 
phenotype that promotes Th2 responses. The aims of this study were to investigate the effects of 
the parasitic nematode Trichinella spiralis on macrophage activation. In view of the parasite‟s 
potential to manipulate purinergic signalling of immune cells, the effects of T.spiralis secreted 
proteins on macrophage purinergic signalling were also investigated. Taking into account that 
macrophage activation can influence T cell responses either by antigen presentation or by release 
of soluble mediators, investigation of T.spiralis effects was also extended to T cells.  
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2.1 Chemical reagents  
Chemical reagents were purchased from Sigma-Aldrich (Dorset, UK), unless stated 
otherwise.  
 
2.2 Animal strains  
 Wild type BALB/c mice were obtained at 6-8 weeks of age (Harlan, UK) for schedule 1 
procedures to obtain bone marrow and spleens and Sprague-Dawley rats were obtained for 
maintenance of Trichinella spiralis and maintained at the Central Biological Services facility 
(CBS, Imperial College London).  
 
2.3 Generation and maturation of mouse bone marrow-derived macrophages (BMMΦ) 
Bone marrow was isolated from femurs and tibia of BALB/c mice sacrificed by cervical 
dislocation. Using forceps and scissors, fur was removed from the legs that were previously cut at 
the hip and placed in 15ml standard culture medium [RPMI-1640 (Lonza) supplemented with 
2mM L-glutamine (Gibco), 100Uml
-1
 penicillin/ 100 g ml
-1 
streptomycin (Gibco), 50 M 
mercaptoethanol, 1mM sodium pyruvate (Lonza), 10mM HEPES (Lonza) and 10% v/v FCS 
(Biosera)]. After cleaning the bones with tissue paper, they were collected in 10ml of standard 
culture medium. They were then transferred to a sterile dish with 70% v/v ethanol and washed for 
2 minutes, followed by a wash in culture medium. The ends were snipped with sterile scissors, 
and a hollow tube created with a fine needle (27GA1) attached to a 2ml syringe filled with 
culture medium to flush the bone marrow progenitor cells into a sterile dish containing standard 
58 
 
culture medium. After breaking up the cell clumps, the suspension was collected in a 50ml tube 
and centrifuged at 300 xg at 4
 o
C for 5 minutes. The red blood cells were lysed by resuspending 
the pellet in 0.83% ice cold ammonium chloride (1ml per leg) for 2 minutes at room temperature 
(RT). The cell suspension was made up to 50ml with standard culture medium and centrifuged at 
300 xg at 4
 o
C for 5 minutes. The cell pellet was then resuspendend in 10ml standard culture 
medium for counting and then 3.5 x 10
6
cells plated per Sterilin dish in 10ml of complete medium 
supplemented with 20% v/v M-CSF and incubated at 37
o
C, 5% CO2. L929 cell conditioned 
medium was used as a source of macrophage colony stimulating factor (M-CSF) obtained from 
NIMR, filtered and stored at -20
 o
C.  On day 4, 10ml of fresh medium was added and after 7 days 
macrophages were obtained as a homogeneous population of adherent cells which were harvested 
by incubating with ice cold PBS at 4
 o
C for 15 minutes. Macrophage suspensions were 
centrifuged at 300 xg at 4
 o
C for 5 minutes and then resuspended in 10ml of standard culture 
medium for counting. Macrophages were then cultured in standard culture medium in 96-well or 
6-well plates at 10
6cells/ml in 200μl and 2ml final volume per well, respectively.  
2.4 Macrophage culture  
Macrophages were seeded in plates as described above and allowed to adhere prior to 
exposure to the following treatments: LPS and interleukin-4 (IL-4) were used to activate 
macrophage populations at concentrations ranging from 0.1 to 50 ng/ml and 1 to 10 ng/ml, 
respectively (specified in the relevant text of Chapter 4). Ultrapure LPS and Pam3C were used at 
10 ng/ml. Adenosine, NECA, AMP, ADP, β-ADP, ATP, ATP-γ and UDP were used at 100μM 
unless otherwise stated in the relevant figure legends. NECA (5′-N-Ethylcarboxamido adenosine) 
is an analogue of adenosine that has high affinity for the A2 receptors and β-ADP and ATP-γ are 
slowly hydrolysable analogues of ADP and ATP, respectively. Purinergic receptor agonists CPA 
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(N
6
-Cyclopentyladenosine) (A1 receptor), CGS21680 (A2A receptor), IB-MECA (A3 receptor) 
were used at 100μM (purchased from Tocris Bioscience). P1R antagonists DPCPX (A1 receptor), 
ZM241385 (A2A receptor), MRS1754 (A2B receptor), MRS1523 (A3 receptor) were used at 10μM 
(purchased from Tocris Bioscience). Suramin (P2Y receptor) and PPADS (Pyridoxalphosphate-
6-azophenyl-2',4'-disulfonic acid) (P2Y receptor) were also used at 10μM. The following 
inhibitors of intracellular signalling pathways were used as indicated in the relevant text: cAMP 
inhibitor RP-cAMP (Adenosine- 3', 5'- cyclic monophosphorothioate, Rp- isomer), PLC inhibitor 
U73122 and its inactive analogue U73343, PI3 kinase inhibitor LY294002 (Calbiochem), NF-κB 
inhibitor Bay 11-7082, MEK1/2 inhibitor U0126. Cells were pre-incubated in 100μl medium 
with antagonists or inhibitors for 15 minutes at 37
o
C before the addition of 100μl medium with 
LPS/IL-4 and/or agonists to yield the final concentrations specified. Rp-cAMP was added to cells 
and incubated at 37
o
C for 1 hour prior to agonist addition. Elevators of cAMP (forskolin and 
rolipram) were used at concentrations indicated in the relevant text and were added to the cells 1 
hour prior to addition of any other stimulant. For IL-10 neutralisation experiments, macrophages 
were incubated for 15 minutes at 37
o
C with anti-IL-10 (R&D systems) to neutralise any IL-10 
secreted by the cells into the medium, before addition of any other stimulant. Carbohydrates used 
to block macrophage surface lectins [D-mannose, mannan, laminarin, GalNAc, EGTA (ethylene 
glycol tetraacetic acid)] were added to macrophages incubated at 37
o
C 45 minutes prior to 
T.spiralis ES addition in 100μl medium to yield final concentrations specified in the text. Cells 
were incubated in 200μl in triplicate for 20 hours at 37 oC, 5% CO2 and 150μl supernatant per 
well were collected for analysis or stored at -20
 o
C. 
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2.5 Fluorescence Activated Cell Sorting (FACS) analysis 
FACS analysis was carried out with 10
5
-10
6
 cells per FACS tube resuspended in FACS 
buffer (PBS + 1% w/v BSA + 0.1% v/v Sodium Azide). They were then washed twice with 0.5 or 
1ml FACS buffer and centrifuged at 500 xg at 4
o
C for 3 minutes. Pellets were resuspended by 
vortexing in 100μl FACS buffer per tube and 1μl of the relevant antibody (antibodies used are 
listed below) added to each tube, except for the negative controls which had FACS buffer only. 
Fc receptor block (anti-CD16/CD32, BD Biosiences) was added to the cell suspension 10 
minutes prior to specific antibody incubations. Then cells were incubated with the relevant 
antibodies for 45 mins in the dark, on ice. Cells were washed again twice with 1ml of FACS 
buffer after which they were resuspended in 150μl of FACS buffer and analysed on a FACS 
Calibur. Antibodies used: Phycoerythrin/PE - conjugated anti - CD11b (Caltag), CD73 (BD 
Biosciences), anti-mouse CD124 (IL-4Rα). Unconjugated anti – CD39 (Santa Cruz), CD73 (BD 
Biosciences) and Fluorescein isothiocyanate/FITC - conjugated anti – mouse secondary (Sigma). 
Allophycocyanin/APC – conjugated anti - F4/80 (Caltag).  
2.6 PCR analysis 
2.6.1 RNA isolation. Bone marrow derived macrophages were homogenized directly in the 
culture dish or 6-well plate by adding 1ml of Trizol per 10cm
2
. Cell lysates were passed several 
times through a pipette and then transferred to 1.5ml tubes at 1ml per tube. Samples were 
incubated for 5 mins at RT and then 0.2ml of chloroform was added per tube. The solutions were 
mixed vigorously by shaking for 15 seconds and incubated at RT for 2-3 mins. Samples were 
then centrifuged at 12000 xg for 15mins at 4 
o
C. The top aqueous phase of each sample was 
transferred to a fresh tube. 0.5ml of isopropyl alcohol was added per tube and mixed followed by 
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a 10 min incubation at RT. Samples were then centrifuged at 12000 xg for 10 min at 4
o
C in order 
to precipitate the RNA. The supernatant was removed and pellets washed with 1ml of 75% 
ethanol per tube. Samples were mixed by vortexing and centrifuged at 7500 xg for 5 mins at 4 
o
C. 
Supernatants were removed and samples pulsed once more to remove any remaining supernatant 
before air-drying pellets for 10 mins at RT. Pellets were dissolved in RNase free water and 
incubated at 55
o
C for 5 mins and cooled on ice before DNase digestion. To avoid any DNA 
contamination, samples were incubated with DNaseI (Qiagen) at RT for 45 mins. The RNeasy 
Kit (Qiagen) was then used to „clean up‟ the RNA according to the manufacturer‟s protocol. 
Briefly, RNA was applied to the RNeasy Mini column and centrifuged with several buffers 
provided by the manufacturer. The concentration of isolated RNA for each sample was then 
determined by measuring absorbance at 260nm. Purity of the sample was confirmed by obtaining 
the OD260/OD280  ratio.  
2.6.2 cDNA synthesis. First strand synthesis of cDNA from RNA was performed using Moloney 
Murine Leukemia Virus Reverse Transcriptase (M-MLV RT; Promega). 2-3 g RNA of each 
sample were mixed with mRNA primer, Oligo (dt) (40 gml
-1
; Biolabs) and an appropriate 
volume of RNase-free water to make a total volume of 13 l. Samples were incubated for 
5minutes at 70
o
C in a gradient cycler (MJ Peltier thermal cycler-200) followed by cooling on ice 
before the following were added to the annealed primer/template: M-MLV 5x reaction buffer 
(20% v/v; Promega) Ribonuclease Inhibitor (1μl of a 1.6U l-1 stock), dNTP (5 l of a 2.5mM 
stock; Fermentas) and M-MLV RT (1 l of a 8U l
-1 
stock). The samples at total volumes of 25 l 
were incubated in the gradient cycler for 1hour at 37
o
C and subsequently for 5minutes at 94 
o
C.  
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2.6.3 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR). RT-PCR was carried out 
to detect the presence of transcripts for markers of alternative activation, ecto-nucleotidases and 
purinergic receptors. The sequences of all the primers used in the RT-PCR are shown in Table 
2.1 with their corresponding base pair product sizes. RT-PCR reactions contained 1 l of each 
cDNA sample, sense and anti-sense primers (1 l of each), 2.5mM dNTP, 2.5mM MgCl2, 10x 
PCR buffer (10% v/v), water and Taq polymerase (0.06Uml
-1
) in 25 l final volume and carried 
out in the GeneAmp PCR system 2700.  The cycler conditions were as follows:  94
o
C for 
5minutes, followed by 35 cycles of 94
 o
C for 30sec, 54-57
 o
C for 30sec, 72
 o
C for 30sec and a 
final extension step of 72
 o
C for 10min. The annealing step varied according to the primer pair 
used; see Table 2.1 A, B, C and D.
 
 
Control -actin primers were used (55
 o
C annealing temperature). PCR products were resolved by 
electrophoresis in 1.5% w/v ethidium bromide stained agarose gels and visualised under UV 
illumination. 
2.6.4 Quantitative PCR analysis. RNA extracted as described above was serially diluted from 
2μg/ml – 0.03125μg/ml reverse transcribed to cDNA and a standard curve was generated with β-
actin in order to select an appropriate concentration of RNA to produce cDNA template in the 
linear range. 250ng of RNA was used in experiments to produce cDNA and primer-probes 
designed for each gene of interest used according to manufacturer‟s instructions (Applied 
Biosystems). Relative transcript levels were obtained by normalising against β-actin levels and 
then compared to controls as specified in the relative figure legends. 
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Table 2.1A: Sequences, annealing temperatures and sizes for primers of markers of alternative 
activation 
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Table 2.1B: Sequences, annealing temperatures and sizes for ecto-nucleotidase primers.  
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Table 2.1C: Sequences, annealing temperatures and sizes for P1 receptor primers. 
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Table 2.1D: Sequences, annealing temperatures and sizes for P2Y receptor primers. 
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2.7 Cloning for sequencing 
In order to sequence arginase I and A3 receptor PCR products, they were cloned into 
TOPO vectors. PCR products were generated as described in section 2.3 and purified from 
agarose gels using a DNA purification kit (Qiagen) according to the manufacturer‟s instructions. 
Briefly, the gel was dissolved at 52
o
C using the buffer provided and applied to a column to bind 
DNA which was washed by centrifuging several times with another buffer provided. The DNA 
was eluted with 30μl dH2O and quantified (OD260) before running 2μl of the sample on an 
agarose gel. Having confirmed that the correct bands for the PCR products were obtained on the 
gel, the DNA was concentrated to a volume of 8-10μl for use in the cloning reactions. These 
cloning reactions were carried out according to the TOPO-TA cloning kit (Invitrogen) protocol 
with 4μl of DNA, 1μl of salt solution and 1μl vector provided in the kit. This mixture was 
incubated on ice for 30 minutes prior to adding to competent DH5α-T1 and returning to ice for 
another 30 minutes. Cells were heat shocked for 30 seconds at 42
o
C and transferred to ice 
immediately. Room temperature S.O.C. (Super Optimal Broth) medium was then added and the 
tubes incubated at 37°C for 1 hour, with shaking. Two different volumes from each 
transformation were spread onto pre-warmed selective LB agar plates (1% w/v Tryptone, 0.5% 
w/v Yeast extract, 1% w/v NaCl, 1.5% w/v agar plus 75μg/ml Kanamycin spread with X-gal 
50mg/ml) and incubated overnight at 37°C. White colonies were selected to patch plate and 
colony PCR was carried out to confirm that the selected colonies contained PCR product inserts. 
The PCR reaction was carried out as described in Section 2.3 with a few changes outlined below. 
Colonies were diluted in 10μl of dH2O and placed at 94°C for 10 minutes to lyse bacteria prior to 
setting up the usual PCR reaction. Products were resolved using agarose gel electrophoresis. 
Colonies positive for the insert were selected from the patch plate and grown in falcon tubes with 
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10ml LB (1% w/v Tryptone, 0.5% w/v Yeast extract, 1% w/v NaCl plus 75μg/ml Kanamycin) 
overnight at 37°C, shaking. DNA was isolated from the overnight cultures using a Qiaspin Mini 
prep kit (Qiagen) according to the manufacturer‟s instructions. Briefly, cells were lysed and 
neutralized prior to collecting supernatants which were applied to Qiaspin columns. These were 
washed a couple of times and DNA was eluted with 30μl of dH2O. After DNA quantification, 
100ng/μl of each cloning reaction were sent for sequencing (Cogenics). 
 
2.8 Recombinant 5`-nucleotidase (5`NT) expression and purification  
2.8.1 Recombinant 5`NT expression. P.pastoris transformed with pPICZα containing a 6 x His 
and c-Myc tagged T.spiralis recombinant 5`NT was streaked onto YPD agar [1% (w/v) yeast 
extract, 2% (w/v) peptone, 2% (w/v) glucose, 2% (w/v) agar, 0.1 mg/ml zeocin] and incubated at 
30
o
C for 3 days. A single P.pastoris colony was used to inoculate 25ml of buffered glycerol 
complex medium [BMGY: 100mM potassium phosphate pH 6.0, 1% (w/v) yeast extract, 2% 
(w/v peptone 1.34% (w/v) yeast nitrogen base, YNB (with ammonium sulphate w/o amino acids) 
4x10
-5 
% (w/v) Biotin, 1% (v/v) glycerol] and incubated at 30
o
C with agitation until the culture 
reached an OD600 value between 2 and 6 units. The 25ml culture was then transferred into 400ml 
BMGY and incubated for a further 24 hours at 30
o
C with shaking. Subsequently, cells were 
harvested by centrifugation at 3000 xg for 10 minutes at RT and resuspended in 400ml buffered 
methanol complex medium [BMMY: 100mM potassium phosphate pH 6.0, 1% (w/v) yeast 
extract, 2% (w/v peptone 1.34% (w/v) yeast nitrogen base, YNB (with ammonium sulphate w/o 
amino acids) 4x10
-5 
% (w/v) Biotin, 0.5% (v/v) methanol]. To induce protein expression, 
methanol was added at a final concentration of 0.5% (v/v) every 24 hours to cultures incubated at 
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30
o
C with shaking for 48 hours. Cells were harvested again by centrifugation at 3000 xg for 10 
minutes at 4 
o
C. The supernatant was then filtered through glass Whattman paper and 0.2 μm 
filters (Schleicher and Schuell) and concentrated to a final volume of approximately 10ml in an 
Amicon concentrator using a 30 kDa cut off membrane. The concentrated supernatant was then 
dialysed against 4L of dialysis buffer containing 20mM NaH2PO4, pH8, 300mM NaCl and 1mM 
Imidazole for 16 hours at 4 
o
C.  
2.8.2 5`NT purification. Recombinant 5`NT was purified using nickel nitrilotriacetic acid (Ni-
NTA) affinity chromatography. Ni-NTA-agarose beads were equilibrated with dialysis buffer 
(containing 20mM NaH2PO4, pH8, 300mM NaCl and 1mM Imidazole) and added to the 
concentrated 5′-NT yeast supernatant. Beads were incubated overnight with rotation at 4 oC. The 
slurry was added to a chromatography column (Bio-Rad) and beads allowed to sediment before 
the flow-through solution containing unbound proteins was decanted. The column was washed 
with 10ml of dialysis buffer to remove unbound proteins and bound proteins were eluted with 3 x 
20ml washes of dialysis buffer with increasing Imidazole concentrations (10mM and 100mM). 
The eluted protein fractions were concentrated in a Centricon-YM10 micro-concentrator, 
according to the manufacturer‟s instructions to a final volume of ~1ml. Samples were then 
washed with 25mM HEPES pH7.5 and further concentrated to a volume of ~200μl. Aliquots 
were immediately stored at -20 
o
C. Proteins were analysed by SDS-PAGE and Western blotting 
using anti-c-myc antibody to confirm presence and purity. Protein concentration was determined 
using the BCA protein estimation assay (Bicinchoninic Acid protein assay, Pierce) according to 
the manufacturer‟s instructions.  
2.8.3 Confirmation of 5`NT expression: Western analysis. Samples (25μl) containing SDS-
PAGE loading buffer were loaded onto 12% polyacrylamide gels (recipes shown in appendix) 
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and electrophoresed  at 15 mA/250V in running buffer (2.5mM Tris pH8.3, 19.2mM glycine, 
0.01% w/v SDS) for an hour or until the tracking dye reached the bottom of the gel. The gels 
were either stained with Coomasie (40% v/v methanol, 10% v/v acetic acid, 01% w/v Coomasie 
Brilliant Blue) or transferred to nitrocellulose membranes (Appendix, Figure 1).  
Staining of polyacrylamide gels with Coomasie was carried out overnight with shaking at 
RT and then gels were washed in destain solution (40% v/v methanol, 10% v/v acetic acid in 
dH2O). Gels were set up for transfer onto nitrocellulose membranes, submerged in transfer buffer 
(2.5mM Tris pH8.3, 19.2mM glycine, 20% v/v methanol) and electrophoretic transfer was 
allowed for 2 hours at 10mA/500V at RT. Following transfer nitrocellulose membranes were 
placed in PBS and blocked with PBS/0.1% v/v Tween containing 1.25% w/v milk powder for an 
hour at RT on a shaker. Primary antibody (anti-His, mouse) diluted 1:1000 in PBS/0.1% v/v 
Tween 1.25% w/v milk powder was added and the membrane was incubated at RT on a shaker 
for 25 minutes. This is followed by 3 x 10 minute washes with PBS/0.1% v/v Tween at RT on a 
shaker before incubating with the secondary antibody (1:1000 goat anti-mouse IgG-HRP in 
PBS/0.1% v/v Tween) for 1 hour, shaking at RT. The membranes were washed as before 
followed by one wash with PBS for 10 minutes. Visualisation was achieved by a 
chemiluminescent detection system (ECL Western blotting analysis system, Amersham) 
following standard procedures.  
2.9 Bicinchoninic acid assay (BCA) 
The BCA assay was carried out in 96-well flat bottom plates according to the 
manufacturer‟s instructions (Pierce). Briefly, the protein concentration was estimated as follows: 
a standard curve was generated using BSA (2mg/ml) to produce samples of known 
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concentrations (dilutions shown in Table 2.2). 25μl of sample (standards/ blank-dH20/ unknown 
sample) was added per well and then 200μl of BCA reagent added before incubating the plate at 
37
o
C for 30 minutes, in the dark. The absorbance at 550nm was then measured using a FLUOstar 
OPTIMA plate reader (BMG).  
mg/ml BSA BSA dilutions 
1.5 115μl BSA stock + 35μl dH20 (A) 
1 100μl BSA stock + 100μl dH20 (B) 
0.75 100μl (A) + 100μl dH20 (C) 
0.5 100μl (B) + 100μl dH20 
0.25 100μl ( C ) + 100μl dH20 (D) 
0.125 100μl (D) + 100μl dH20 
0.025 10μl (D) + 90μl dH20 
Table 2.2: BSA dilutions for standard curve.  
 
2.10 Preparation of Trichinella spiralis excretory/secretory proteins 
2.10.1 Trichinella spiralis infection. In order to obtain muscle stage larvae of Trichinella 
spiralis, adult Sprague-Dawley rats were infected orally with 3500-4000 infective larvae. 
Infections were allowed to establish for 30 days before isolating muscle stage larvae. 
2.10.2 Parasite recovery and culture. Parasites were recovered from infected rats which were 
culled by cervical dislocation. Rats were skinned and eviscerated and striated muscle tissue 
removed and chopped. The tissue was then digested by incubation, with agitation, in a solution of 
1% (w/v) pepsin, 1% (v/v) HCl at 37
o
C for 1hour. The digested tissue was then filtered through 
two layers of muslin cloth attached to a Baerman funnel connected to a collection tube and larvae 
were allowed to settle for 45minutes to 1hour. They were then washed in sterile PBS followed by 
sterile parasite culture medium [RPMI supplemented with 1% (w/v) glucose, 100U/ml penicillin, 
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100μg/ml streptomycin, 20μg/ml gentamycin, 20U/ml nystatin and 2mM L-glutamine], pre-
warmed at 37 
o
C.  
2.10.3 Collection of parasite secreted proteins. Muscle stage larvae were cultured for 3 days 
and the medium containing parasite secreted proteins was collected daily and replaced with fresh 
sterile culture medium pre-warmed at 37 
o
C. Medium containing parasite secreted proteins was 
concentrated and washed with 25mM HEPES, pH 7.5 in Vivaspin microconcentrators 
(Millipore). The concentrated protein solution was then aliquoted and stored at -20
 o
C.  
2.11 Phosphate release Assay 
2.11.1 5`-Nucleotidase activity assay. The 5`-nucleotidase activity of T.spiralis secreted proteins 
(ES) was measured by calculating the amount of free inorganic phosphate released from different 
nucleotide substrates. NaH2PO4 ranging from 1-10nmoles was used as a standard to generate a 
calibration curve. 1 l of nucleotide (ADP, AMP) was added to 20 l buffer (50mM Hepes, 
300mM NaCl, 10mM MgCl2, and 5mM DTT) to give a final concentration of 2.5mM to which 
1 g of ES was added and the volume made up to 40 l with distilled water. Controls were 
included containing enzyme alone or nucleotides alone. Samples were incubated for 10 minutes 
at 37
o
C following which 200 l of the chromogenic substrate malachite-green-phosphomolybdate 
(1.25mM Malachite green, 1.7N HCl, 8.6mM ammonium molybdate) were added to both the 
enzyme reactions and the standards simultaneously to ensure an accurate readout. Measurement 
of absorbance at 660nm using FLUOstar OPTIMA microplate reader (BMG Labtech) was then 
carried out. Background (control) absorbance values were subtracted from the actual readout of 
the enzyme sample.  
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2.11.2 Phosphate Release Assay; modified for phosphate release by ecto-nucleotidases. 
         BMMΦ were plated in 96 well plates at 105 cells per well and incubated overnight with 
200μl of standard cell growth medium +/- stimuli. Cells were then washed twice with 200μl of 
assay buffer (10mM glucose, 20mM HEPES pH7.5, 5mM KCl, 120mM NaCl, 2mM CaCl2, 
5mM MgCl2). Cells were allowed to adjust prior to nucleotide addition by incubating at 37
o
C for 
15 minutes with 100μl of assay buffer. Nucleotides were made up in assay buffer at 2x the final 
concentration and 100μl added per well already containing 100μl assay buffer. Cells were 
returned to 37
o
C for 15-150 minutes. 40μl from each well was transferred to a new 96 well plate 
at the time points specified in the relevant figure legends and the standard curve was prepared as 
for the standard phosphate release assay. 200μl of Malachite green reagent (standard protocol) 
was added to each well and the absorbance measured at 660nm using a FLUOstar OPTIMA 
microplate reader (BMG Labtech). Absorbance values were converted to nmoles of phosphate 
and adjusted to represent total well volume corresponding to 10
5
 cells.  
2.12 Enzyme linked immunosorbent assay (ELISA)  
Cytokine (IL-6, TNF-α and IL-10) levels in culture supernatants were detected by ELISA. 
ELISA plates were coated overnight at 4
oC with 0.8μg/ml of capture antibody (R&D systems) 
diluted in PBS. Plates were washed 3 times with PBS/ 0.05% v/v Tween 20 and then blocked 
with PBS/ 0.1% w/v BSA for 2hrs at RT. After 3 more washes, samples and standards were 
added in triplicates and incubated overnight at 4 
o
C.  
Standards were diluted at a range of 125-8000pg/ml in PBS/ 1% w/v BSA, including a 
blank of diluting buffer only. Plates were washed 4 times and incubated with 0.5μg/ml 
biotinylated detection antibody (R&D systems) diluted in PBS/ 1% w/v BSA for 2 hours at room 
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temperature. Plates were washed 6 times and streptavidin-HRP (R&D systems) diluted 1:1000 in 
PBS/ 1% w/v BSA added for 30 minutes at RT. The 6 washes were repeated and plates incubated 
for 20-30 minutes in the dark with substrate solution (0.11M acetate buffer pH5.5 with 0.1 mg/ml 
tetra-methylbenzidine in DMSO and 0.003% v/v H2O2). The reaction was stopped with 1.8M 
H2SO4 at 1:5 of the final volume per well. Levels of cytokines were determined by measuring the 
absorbance at 450nm using a FLUOstar OPTIMA microplate reader (BMG Labtech).  
2.13 Arginase I activity assay 
BMMΦ harvested on day 7 of culture were plated at 105/ well in a 96 well plate in 
standard RPMI medium and allowed to adjust and adhere for 1-2hrs. Either LPS or IL4 were then 
added to a final concentration of 10ng/ml or 5ng/ml, respectively. Cells were incubated at 37
o
C 
for a specified length of time, as stated where appropriate, and then washed with 200μl PBS prior 
to the assay. 100μl of 0.1% v/v Triton + protease inhibitors (1 tablet per 10ml Triton of Complete 
Mini, Roche) were used to lyse the cells by incubating the plate at RT for 30 minutes, shaking. 
Then 100μl of 25mM Tris-HCl pH 7.5 were added per well and 100μl of lysate transferred to 
1.5ml eppendorf tube. 10μl of 10mM MnCl2 were added to the lysate and incubated at 56
o
C to 
activate the enzyme. Then 100μl of 0.5M L-arginine pH 9.7 were added and the samples 
incubated at 37
o
C for 65 minutes. Urea standards were prepared from a 10mg/ml urea stock and 
were ranging from 160 to 1.25 μg/ml in buffer containing 0.1% v/v Triton, 25mM Tris-HCl, 
10mM MnCl2 and acid mix (H2SO4: H3PO4: H2O, 1:3:7) at the same final concentrations as the 
samples. The reaction was stopped by adding 800μl of acid mix. Finally, 40μl of ISPF (α-
isonitrosopropiophenone) were added and incubated for 30 minutes at 95
 o
C. Samples and 
standards were kept in the dark for 10 minutes prior to transferring 200μl to a flat bottom 96-well 
plate and measuring absorbance at 540nm.   
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2.14 Nitric oxide (NO) assay 
Activation status of BMMΦ was determined by monitoring NO release using Griess 
reagent. The Griess reagent was composed of two separate reagents (A and B) combined in a 1:1 
ratio; Griess reagent  A - 1% w/v sulphanilamide, 5% v/v phosphoric acid (H3PO4) and Griess 
reagent B – 0.1% w/v N-(1-Napthyl)ethylenediamine dihydrochloride (NEDD) kept at 4oC in the 
dark. Sodium Nitrite (NaNO2) (Sigma) was used to produce a standard curve. 100 l of Griess 
reagent was added to 100 l of sample supernatants in a 96-well plate. The absorbance at 550nm 
was measured using a [FLUOstar OPTIMA plate reader (BMG)] and nitrite concentration was 
calculated from the standard curve obtained from NaNO2 in RPMI-1640. 
 
2.15 Endotoxin detection 
The presence of endotoxin was tested in protein solutions by using the QCL-1000 
Chromogenic Limulus Amoebocyte Lysate Endpoint Assay (Lonza) according to the 
manufacturer‟s instructions. Briefly, an equal volume of sample and LAL reagent were incubated 
for 10 minutes at 37
o
C prior to addition the chromogenic substrate. The reaction was stopped 
after 6 minutes with acetic acid. A standard curve of endotoxin was used to quantify levels 
reported as EU/ml. The absorbance was then measured at 410nm FLUOstar OPTIMA microplate 
reader (BMG Labtech). 
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2.16 Treatment of T.spiralis secreted proteins  
2.16.1 Heat inactivation of T.spiralis secreted proteins 
 50μg/ml samples of T.spiralis secreted proteins in 1.5ml eppendorf tubes, sealed with 
parafilm to prevent evaporation, were placed in a heat block set at 100 °C. After a 10-minute 
incubation period, the tubes were removed and allowed to cool. Prior to using the samples in 
macrophage cultures, they were centrifuged at top speed for 1 minute to spin down any liquid 
collected on the lid or sides of the tube.  
2.16.2 Chemical deglycosylation of T.spiralis secreted proteins 
Chemical deglycosylation of T.spiralis secreted glycoproteins was carried out using a 
GlycoProfile IV, Chemical Deglycosylation Kit (Sigma) according to the manufacturer‟s 
instructions. Briefly, samples were lyophilized (1mg per reaction vial) using a vacuum pump 
(Dell group). A lyophilized RNase B Glycoprotein Standard, which was supplied in the kit, was 
also included as a control of the deglycosylation reaction. The Trifluoromethanesulfonic acid 
(TFMS) was cooled to 2–8 °C and added to each pre-cooled sample reaction vial. The mixtures 
were shaken for 2–5 minutes to dissolve the glycoproteins completely and the sample reaction 
vials were incubated on ice for an additional 25 minutes with occasional shaking. A drop of 
indicator dye (0.2% Bromophenol Blue Solution) was added to the pre-cooled sample reaction 
vial and mixed gently until a red colour was obtained. Pre-cooled 60% Pyridine Solution was 
added dropwise and mixed, keeping the sample on ice, until the colour of the solution changed to 
yellow and then to light purple. Samples were transferred to Vivaspin columns and washed with 
10mM Hepes to obtain a clear solution before concentrating to 200μl and collecting for storage at 
-20 
o
C.  
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2.17 Macrophage Galactose Lectin (MGL) experiments  
2.17.1 MGL-purification of T.spiralis ES. The human MGL CRD (HHL-416 – extracellular 
domain) was expressed and purified by affinity chromatography on a galactose–Sepharose 
column by A. Quintero-Martinez and K. Drickamer (as described in Lobst and Drickamer, 1996). 
The column was rinsed with 5 x 1ml loading buffer (1.25 M NaCl, 25mM Tris-Cl, pH 7.8, 25 
mM CaCl2) prior to incubating with ES for 15minutes. The flow-through was collected prior to 5 
x 0.5ml washes with eluting buffer (1.25 M NaCl, 25 mM Tris-Cl, pH 7.8, 2.5 mM EDTA). 
Fractions were then analysed by SDS-PAGE as described above.  
 
2.17.2 SDS-PAGE with radiolabelled MGL. All the fractions obtained from the MGL column 
were resolved by SDS-PAGE and then blotted for 
125
I-labelled MGL by K. Drickamer as 
described in Coombs et al, 2005. 
 
2.17.3 Competition Binding Assays. The binding affinity to an immobilised fragment of the 
MGL receptor was determined in the presence of increasing concentrations of the competing test 
ligand 
125
I-Gal34-BSA. Assays were performed in duplicate as described by Quesenberry and 
Drickamer, 1992 and Lobst and Drickamer, 1996. Briefly, polystyrene plates were coated with 
10μg/ml MGL (HHL-416 – extracellular domain) and incubated overnight at 4 oC. Wells were 
blocked for 2 hours at 4
o
C with 5% (w/v) BSA in low salt-loading buffer (150mM NaCl, 25mM 
Tris pH7.8, 25mM CaCl2) prior to incubation of serial dilutions of ES or galactose with equal 
volumes of 
125
I-Gal34-BSA in binding buffer (0.3M NaCl, 50mM Tris pH7.8, 50mM CaCl2, 0.2% 
(w/v) BSA), for 2 hours at 4 
o
C. Wells were washed in low salt-loading buffer and then counted 
for 2 minutes/well in a Packard PRIAS γ-counter. A nonlinear, least squares fitting program 
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(SigmaPlot, Jandel Scientific) was used to obtain Ki values, corresponding to the concentration of 
monosaccharide giving 50% inhibition of glycoprotein binding (Lobst and Drickamer, 1996). 
 
2.18 CD4+ T cell Proliferation Assay  
2.18.1 Generation of spleen cell suspensions. Spleens were removed under sterile conditions 
from BALB/c mice sacrificed by cervical dislocation. Spleens were placed in a Sterilin dish with 
10ml medium [RPMI-1640 + 10% FCS, 2mM L-glutamine (Gibco), 100Uml
-1
 penicillin/ 100 g 
ml
-1 
streptomycin (Gibco)], and homogenised using pointed forceps to tear the tissue apart and 
clumps were broken up by passing through a 21G needle. The cell suspension was passed 
through a 100µm cell strainer to remove any remaining clumps and then centrifuged at 300 xg for 
5mins at 4 
o
C. The cell pellet was then incubated at RT with 1ml ice-cold ammonium chloride 
(0.83%) for 2 minutes to lyse red blood cells and washed with 20ml medium to stop lysis 
(centrifuged at 300 xg, 5mins, 4
o
C). Cells were resuspended in 10ml medium and counted.  
2.18.2 CD4+ cell isolation and proliferation assay. CD4+ cells were isolated from the spleen 
cell suspension using anti-CD4 microbeads (Miltenyi Biotech) to purify on an LC column. Cells 
were centrifuged to remove all medium and the pellet was then resuspended in buffer (PBS/0.5% 
BSA+2mM EDTA) at 90µl per 107 cells and beads added at 10µl per 107 cells. The cells were 
incubated with the beads for 15mins on ice and then washed with 2ml of the above buffer per 10
7
 
cells, centrifuged at 300 xg for 10mins. The supernatant was then removed and 500µl buffer 
added and transferred to the LC column (previously equilibrated with 3ml of the above buffer). 
The column was washed with 3x3ml of the same buffer and the flow-through collected in a 
falcon tube. The column was then removed from the magnetic field and placed on a 15ml falcon 
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and CD4+ cells collected in 5ml buffer. CD4+ cell suspension and the flow-through, collectively 
referred to as APCs (antigen presenting cells), were centrifuged and counted. CD4+ cells were 
resuspended to 5x10
6/ml and plated at 100µl per well in a 96-well round-bottom plate. They were 
placed at 37
oC while the APCs were irradiated for 7´21´´ (Irradiation facility, SAF). APCs were 
then centrifuged and resuspended at 2x10
6/ml and added to the CD4+ cells at 100µl per well and 
transferred to a flat-bottom plate pre-coated overnight with 1µg/ml anti-CD3 (Serotec). Cells 
were cultured at 37
o
C, 5% CO2 for 3 days in a final volume of 200μl with treatments in 
quadruplicate as specified in Chapter 5. Proliferation was assessed by the addition of 1μCi of 
[
3
H] – thymidine /well (10µl/well of 1:10 diluted [3H] – thymidine) at the end of day 3 of culture. 
Prior to addition of [
3
H] – thymidine, 100μl of supernatant was removed from each well for 
analysis or stored at -20
 o
C. Cells were harvested on day 4 of culture using a Tomtec harvester 96 
Mach III. The level of [
3
H] – thymidine incorporation was determined using a Trilux microbeta 
1450 liquid scintillation counter.  
3.19 Statistical Evaluation. Data values are expressed as the mean + standard error of the mean 
(SEM). Student‟s t-test was used to assess the statistical significanc, except where stated 
otherwise. Paired t-test analysis was carried out for comparisons between groups of independent 
experiments. Results were taken to be statistically significant where p<0.05. Additionally, results 
were significant where p<0.01 and where p<0.001.  
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Chapter 3 
Molecular analysis of bone marrow derived macrophage markers and 
purinergic receptors 
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3.1 Introduction  
Macrophages have several biological functions ranging from phagocytosis and antigen 
presentation to pro- and/or anti-inflammatory responses resulting from signalling through a 
variety of cytokines and co-stimulatory molecules. Microbial antigens in conjunction with 
effector T cells (T helper (Th1), Th2 and Th3) and regulatory T cells influence the heterogeneity 
and state of activation of macrophages (Noel et al, 2004). Classically activated macrophages 
(CAMΦ) are the best characterised macrophage subset and this state is induced by pro-
inflammatory microbial molecules such as LPS or a Th1 cytokine (IFN-γ) environment (Gordon 
2003). CAMΦ characteristics include nitric oxide (NO) production and increased antigen 
presentation (Noel et al, 2004). However, a balance between pro- and anti-inflammatory 
responses is essential to limit tissue damage resulting from persistent inflammation that could 
jeopardise host survival.  
In view of the fact that development of CAMΦ is inhibited by Th2 cytokines, 
macrophages arising in a Th2 environment were investigated and were found to perform a 
different activation program, resulting in a very different phenotype from CAMΦ. These 
alternatively activated macrophages (AAMΦ) develop in the presence of IL-4/IL-13 acting 
through the IL-4 receptor α chain to activate STAT6 and IRS-1 family members leading to 
macrophage survival and regulation of anti-inflammatory gene expression (Nelms et al, 1999). 
AAMΦ preferentially use arginase I instead of iNOS (inducible nitric oxide synthase) for 
metabolism of L-arginine thus skewing the pro-inflammatory phenotype of NO generation to a 
biosynthetic-repair phenotype.  
In a murine model of nematode infection Nair and colleagues have found macrophages 
that display a phenotype that may be characteristic of chronic type 2 inflammation (Nair et al, 
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2003). These nematode-elicited macrophages (NeMΦ) are uniquely characterised by the ability to 
actively suppress proliferation of a broad range of cell types, and in addition exhibit a high level 
of expression of two novel macrophage genes, Ym1 and Fizz1. Fizz1, is a resistin-like molecule 
α (RELMα) that can promote deposition of extracellular matrix (Raes et al, 2002) while Ym1 is a 
member of the chitinase family with no known chitinase activity but possible interaction with 
extracellular matrix components in wound healing (Nair et al, 2003). It has been suggested 
recently that chitin, a structural polysaccharide expressed by many parasites, can induce 
eosinophil and basophil IL-4 production and also AAMΦ polarisation when administered in vivo, 
emphasising the ability of parasite products to influence immune environment (Kreider et al, 
2007). NeMΦ show similar properties as AAMΦ derived in vitro such as the down-regulation of 
inflammatory cytokines (Nair et al, 2003; Loke et al, 2007) and the up-regulation of Fizz1 and 
Ym1 (Nair et al, 2005). Similar findings have been reported by Donnelly and colleagues in in 
vivo studies of F.hepatica infection or injection of F.hepatica derived molecules into mouse 
peritoneum which resulted in the presence of peritoneal macrophages with AAMΦ characteristics 
(Donnelly et al, 2005). Furthermore, in vitro cultures of F.hepatica secreted products with the 
RAW264.7 macrophage cell line showed induction of an AAMΦ phenotype determined by 
increased arginase I levels. 
 Overall, AAMΦ have been proposed to have several roles in parasite infection (Maizels 
et al, 2004). Firstly, they act to suppress inflammatory responses against the parasite as they are 
known to down-regulate pro-inflammatory functions of other effector cells such as T cells. In 
addition, their abundance in sites of infection makes them important effector cells which 
potentially target extracellular helminths and drive Th2 immune responses. Finally, their 
biosynthetic ability may be important in helminth-induced damage repair. With relevance to this 
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study, the activation state of macrophages is important in the case of Trichinella spiralis infection 
as a Th2 phenotype is important for parasite expulsion (Garside et al, 2000). 
The parasitic nematode, Trichinella spiralis, which infects mammalian species including 
humans, is suggested to have evolved mechanisms for dampening immune cell responses by 
down-regulating the host‟s immune system during infection (Gounaris and Selkirk, 2005). In this 
scenario, it has been postulated that in order to evade host immune responses these parasites have 
adapted to utilise enzymes such as a secreted 5′-nucleotidase (5′NT) in the same way that the host 
immune system uses the endogenous ecto-enzymes, such as ecto-nucleotidases like CD39 and 
CD73 (Zimmerman, 2000). Extensive tissue damage to the host as a consequence of parasite 
invasion, results in nucleotide release which act as warning signals to the immune system. Hence, 
suppression of immediate inflammatory responses, leading to recruitment and degranulation of 
granulocytes, is achieved by enzyme action producing end-products such as adenosine that will 
abolish these warning signals by activating receptors linked to anti-inflammatory pathways.  
Nucleotides mediate their effects by ligating purinergic receptors expressed on immune 
cells (as described in Chapter 1). Briefly, two distinct families of purinergic receptors have been 
characterised in terms of receptor coupling and the subtypes identified in terms of agonist type 
and affinity. The P1 receptor family consists of four G-protein coupled receptors that respond to 
adenosine and inosine with differential affinity. The P2 receptor family is subdivided into G-
protein P2Y receptors with ligands including ATP, ADP, UTP and UDP and the ligand gated ion 
channel P2X receptors which are ATP receptors. Downstream signalling pathways activated 
following G-protein coupling of these receptors are diverse and can result in expression of a 
range of mediators involved in inflammatory responses, such as reactive oxygen species and 
cytokines.  
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Macrophages have major roles in host protection against excessive inflammation and 
pathogen invasion. Considering the emerging role of macrophages in nematode infection the 
aims of this study were to investigate the response of different macrophage subsets to T.spiralis 
secreted products. Firstly, this study aimed to characterise macrophages in terms of the known 
alternative activation markers expressed at the molecular level. In order to elucidate the 
molecular basis for any observed alteration in macrophage function in the context of T.spiralis 
infection, purinergic receptor profiles of the different subsets of murine macrophage activation 
were investigated. In addition, CD39/CD73 expression profiles were also investigated to 
determine their potential involvement in modulation of purinergic signalling.  
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3.2 Results  
3.2.1 Flow cytometric analysis of macrophage purity 
Bone marrow derived macrophages differentiated for 7 days with M-CSF were harvested 
and cultured for 20 hours with 10ng/ml LPS (CAMΦ), 5ng/ml IL-4 (AAMΦ) or medium 
(BMMΦ).  Their purity was determined using FACS analysis to detect the macrophage markers 
F4/80 and CD11b (Figure 3.1). F4/80 is a 160kDa glycoprotein of the EGF TM7 family 
characterised as a macrophage marker by Hirsch and colleagues (Hirsch et al, 1981) and 
confirmed against the already characterised macrophage marker CD11b, also referred to as Mac-
1, which is an alpha integrin (Springer et al, 1979). Approximately 106 cells were incubated with 
APC-conjugated F4/80 and PE-conjugated CD11b antibodies. Controls were included with 
unstained cells or PE/FITC conjugated IgG. The samples were analysed on the FL2 (PE) and FL4 
(APC) channels of a FACS Calibur. Macrophage purity, as determined by double positive cells 
for both F4/80 and CD11b, was around 98% in all macrophage types as shown in Figure 3.1. 
Therefore, macrophage purity was not affected by the different activating stimuli used to generate 
the 2 activation phenotypes.  
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Figure 3.1: Flow cytometric analyses of expression of F4/80 and CD11b on bone marrow-derived 
macrophages (BMMΦ), classically activated macrophages (CAMΦ) and alternatively activated 
macrophages (AAMΦ).  Percentage purity of macrophages, as determined by the presence of the 
markers F4/80 and CD11b, is shown in the top right quadrant.   
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3.2.2 Molecular analysis of macrophage marker expression 
Alternative macrophage activation is characterised by the expression of certain markers, 
such as mannose receptor (MR), arginase I (Arg1), Fizz1 and Ym1. Therefore, the presence of 
the transcripts of these markers was used to distinguish between the macrophage types. cDNA 
was synthesised from RNA extracted from bone marrow derived macrophages (BMMΦ), 
classically activated macrophages (CAMΦ) and alternatively activated macrophages (AAMΦ) 
and was then amplified using specific primer pairs. Actin primer pairs were used as controls for 
the amplification reaction and as well as to determine if contaminating genomic DNA was 
present in the RNA used to make the cDNA (-RT control).  
The MR transcript was found in all 3 macrophage types (Figure 3.2, 3.3 and 3.4). 
Arginase I, Fizz1 and Ym1 transcripts were present in macrophages cultured with IL-4 as early as 
2 hours after IL-4 stimulation (Figure 3.4). At the 24-hour time point these transcripts appeared 
to be present at low levels in CAMΦ as well, while the Fizz1 transcript remained detectable even 
after 48 hours (Figure 3.3). Arginase I transcripts appeared in CAMΦ from the 16-hour time 
point, however, a non-specific product was also detected in RT-PCRs (Figure 3.3). This product, 
which was observed at 400-500bp, was sequenced and was found to be a result of non-specific 
primer binding to a cathepsin pre-protein. The sequence analysis is shown in the Appendix. Table 
3.1 summarises the presence of marker transcripts detected in the 3 macrophage types by RT-
PCR after 20 hours of culture, which was selected as an appropriate time point for macrophage 
stimulation due to consistent molecular expression of markers and purinergic receptors, shown in 
the following section (3.2.3).  
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Figure 3.2: Determination of the presence of transcripts of alternative activation markers in 
BMMΦ following 48 hours of culture. PCR products obtained for mannose receptor (MR), arginase I 
(Arg 1), Fizz1 and Ym1 are shown and product sizes were determined by the ladder shown annotated on 
the left (in bp). Expected sizes were obtained for all transcripts detected (see Materials and Methods, 
Table 2.1A). Actin primers were used in reactions to confirm cDNA quality (Act) and in reactions to 
determine if RNA was contaminated with DNA (-RT). 
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Figure 3.3: Determination of the presence of transcripts of alternative activation markers in CAMΦ 
following 48 hours of culture with 10ng/ml LPS. PCR products obtained for mannose receptor (MR), 
arginase I (Arg 1), Fizz1 and Ym1 are shown and product sizes were determined by the ladder shown 
annotated on the left (in bp). Expected sizes were obtained for all transcripts detected (see Materials and 
Methods, Table 2.1A) except the 500bp product in the arginase I lane which is non-specific, as explained 
in the text. Actin primers were used in reactions to confirm cDNA quality (Act) and in reactions to 
determine if RNA was contaminated with DNA (-RT). 
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Figure 3.4: Determination of the presence of markers of alternative activation transcripts in AAMΦ 
following 48 hours of culture with 5ng/ml IL-4. PCR products obtained for mannose receptor (MR), 
arginase I (Arg 1), Fizz1 and Ym1 are shown and product sizes were determined by the ladder shown 
annotated on the left (in bp). Expected sizes were obtained for all transcripts detected (see Materials and 
Methods, Table 2.1A). Actin primers were used in reactions to confirm cDNA quality (Act) and in 
reactions to determine if RNA was contaminated with DNA (-RT).  
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Table 3.1: Summary of the presence of transcripts for markers of alternative activation in the 
different bone marrow derived macrophage types after 20 hours of culture. BMMΦ were cultured in 
standard medium only, CAMΦ were cultured in standard medium with 10ng/ml LPS and AAMΦ were 
cultured in standard medium with 5ng/ml IL-4.  (-) = absent, (+) = present , (++) = present  and abundant.  
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Quantitative PCR analysis was carried out to determine any differences in the relative 
levels of marker transcripts associated with alternative activation after 20 hours of culture. The 20 
hour time point was selected for Q-PCR analysis as well as for functional assays as the molecular 
differences between the macrophage subsets were better defined at this time point. It is shown in 
Figure 3.5 that these transcripts increased only in AAMΦ while in CAMΦ only arginase I mRNA 
levels increased 35-fold relative to BMMΦ. As expected, this was not as high as the increase 
observed in AAMΦ arginase I mRNA levels (close to 900-fold). Fizz1 and Ym1 increased 10 and 
150 fold, respectively, in AAMΦ when compared to BMMΦ as opposed to CAMΦ that appeared 
to have no difference in Fizz1 and Ym1 levels relative to BMMΦ. The mannose receptor 
transcript was expressed by all 3 subsets at similar levels and was only slightly up-regulated in 
AAMΦ by 2-fold.  
In vitro generation of the alternative activation phenotype has been achieved by 
macrophage culture with IL-4 or IL-13 (Nair et al, 2003). In order to determine if marker levels 
are affected by a different combination of interleukins (IL-4 and IL-13) known to alternatively 
activate macrophages, as well as the anti-inflammatory cytokine, IL-10, Q-PCR analysis was 
carried out. Figure 3.6 shows the effect of combined cytokine treatment of macrophages 
compared to IL-4 alone. Macrophage culture in the presence of both IL-4 and IL-13 did not 
significantly affect marker up-regulation but appeared to slightly lower arginase I levels when 
compared to IL-4 alone. However, IL-10 enhanced IL-4-induced mannose receptor and arginase I 
up-regulation by 5-fold but had no effect on Fizz1 and Ym1. Taken together, these results show 
that macrophage activation states can clearly be defined in terms of expression or up-regulation 
of arginase I as well as Fizz1 and Ym1 transcript levels. In addition, anti-inflammatory cytokines 
such as IL-10 can further enhance alternative activation characteristics of AAMΦ.  
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Figure 3.5: Quantitative PCR comparison of changes in alternative activation marker mRNA levels 
between different bone marrow derived macrophage activation types. RNA isolated from BMMΦ, 
CAMΦ and AAMΦ was used to produce  cDNA used in quantitative PCR to determine changes of marker 
mRNA levels after 20 hours of cell culture with culture medium, in the presence of 10ng/ml LPS (A) or 
5ng/ml IL-4 (B), respectively. The fold changes presented are relative to unstimulated BMMΦ after 
normalising to β-actin mRNA. Results show averages of experiments carried out in triplicate + SEM (n = 
3). Asterisks indicate statistical significance compared to absence of nucleotide stimulation. *** p<0.001 
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Figure 3.6: Quantitative PCR comparison of changes in alternative activation marker mRNA levels 
between different AAMΦ types. Bone marrow derived macrophages were activated with IL-4, IL-4/IL-
10 or IL-4/IL-13 for 20 hours (5ng/ml of each cytokine) and cDNA synthesised from RNA extracted from 
these cells. Quantitative PCR was carried out to determine relative changes in mRNA levels of the 
mannose receptor (MR), arginase I, Fizz and Ym1. The fold changes presented are relative to 
macrophages treated with IL-4 only, after normalising to β-actin mRNA. Error bars represent standard 
error of the mean from one representative experiment. ns p>0.05, * p<0.05, *** p<0.001 
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3.2.3 Molecular analysis of macrophage purinergic receptor expression 
Transcriptional profiling was used to determine purinergic receptor expression in 
macrophages. The presence of mRNA encoding these receptors was detected by RT-PCR. cDNA 
was synthesised from RNA extracted from unstimulated bone marrow derived macrophages 
(BMMΦ), classically activated macrophages (CAMΦ) and alternatively activated macrophages 
(AAMΦ) and was then amplified using specific primer pairs for P1 and P2 receptors. Actin 
primer pairs were used as positive controls for the amplification reaction and as negative controls 
to determine if contaminating genomic DNA was present in the RNA used to make the cDNA (-
RT control).  
PCR products of expected sizes were identified for the adenosine receptors. A1, A2B and 
A3 mRNA was detected in all 3 macrophage subsets throughout the time course of culture 
(Figures 7, 8 and 9). A2A transcripts were not found in BMMΦ and AAMΦ, while in CAMΦ a 
time-dependent expression was observed, as mRNA levels apparently increased between 2 and 6 
hours of culture, remained detectable until the 20 hour time point and disappeared at 24 and 48 
hours (Figure 3.8). The other P1 receptor transcripts did not appear to vary when analysed by RT-
PCR. In the case of the A3 receptor, two PCR products were obtained with the primers used. 
Sequencing of these products confirmed the higher molecular weight product being the correct A3 
receptor transcript while the other product was a result of non-specific binding to ferritin (light 
chain). Sequence analysis is shown in the Appendix. There was no contamination in the (-RT) of 
BMMΦ, CAMΦ or AAMΦ as shown in Figure 3.12, 3.13 and 3.14, respectively. Table 3.2 
summarises the P1 receptor transcripts detected by RT-PCR in the 3 macrophage subsets after 20 
hours of culture.  
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 Figure 3.7: Purinergic receptor (P1R) transcripts in BMMΦ following 48 hours of culture, 
determined using RT-PCR. PCR products are shown and product sizes were determined by the ladder 
shown annotated on the left (in bp). Expected sizes were obtained for all transcripts detected (see 
Materials and Methods, Table 2.1C) except the 100bp product in the A3 lane which is non-specific as 
explained in the text. Actin primers were used in reactions to confirm cDNA quality (Act) and in reactions 
to determine if RNA was contaminated with DNA (-RT). 
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Figure 3.8: Purinergic receptor (P1R) transcripts in CAMΦ following 48 hours of culture with 
10ng/ml LPS, determined using RT-PCR. PCR products are shown and product sizes were determined 
by the ladder shown annotated on the left (in bp). Expected sizes were obtained for all transcripts detected 
(see Materials and Methods, Table 2.1C) except the 100bp product in the A3 lane which is non-specific as 
explained in the text. The A2A receptor products obtained are highlighted in the orange box as there 
appears to be a time-dependent regulation. Actin primers were used in reactions to confirm cDNA quality 
(Act) and in reactions to determine if RNA was contaminated with DNA (-RT). 
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Figure 3.9: Purinergic receptor (P1R) transcripts in AAMΦ following 48 hours of culture with 
5ng/ml IL-4, determined using RT-PCR. PCR products are shown and product sizes were determined 
by the ladder shown annotated on the left (in bp). Expected sizes were obtained for all transcripts detected 
(see Materials and Methods, Table 2.1C) except the 100bp product in the A3 lane which is non-specific as 
explained in the text. Actin primers were used in reactions to confirm cDNA quality (Act) and in reactions 
to determine if RNA was contaminated with DNA (-RT). 
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Table 3.2: Summary of the presence of purinergic receptor (P1R) transcripts in the different bone 
marrow derived macrophage types after 20 hours of culture.  BMMΦ were cultured in standard 
medium only, CAMΦ were cultured in standard medium with 10ng/ml LPS and AAMΦ were cultured in 
standard medium with 5ng/ml IL-4. (*) In CAMΦ the A2A receptor showed a time-dependent expression 
up to 20hrs and was not detectable after 20hrs. (-) = absent, (+) = present , (++) = present  and abundant. 
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Quantitative PCR analysis was carried out to detect any differences in P1 receptor levels 
between the BMMΦ, CAMΦ and AAMΦ. In Figure 3.10, the relative P1 receptor levels for the 
different macrophage subsets after 20 hours of culture are shown. A1 and A3 receptor levels 
appeared to be similar in all 3 subsets. A2A receptor levels were 200-fold higher in CAMΦ when 
compared to BMMΦ while A2B receptor levels were 25-fold higher in CAMΦ and 8-fold higher 
in AAMΦ.  
The LPS time course of P1 receptor expression analysed by quantitative RT-PCR is 
shown in Figure 3.11. A2AR transcript levels increased by 10-fold within 2 hours and reached a 
peak above 80-fold after 4 hours of culture in agreement with RT-PCR bands observed on the gel 
presented in Figure 3.8. A2AR levels decreased after 6 hours of culture to 20-fold at 16 hours and 
remained at similar levels up to 20 hours. Similar expression patterns of the A2AR have been 
detected in mouse peritoneal and human macrophages (Murphree et al, 2005).  In addition, a 15-
fold up-regulation of the A3R transcript level was also observed at 4 hours which decreased at 6 
hours and remained at a steady level (10-fold) until 24 hours.  
These data suggest that, A2A receptor expression was dependent on macrophage activation 
state and, in particular, LPS-induced classical activation. Furthermore, A2A receptor expression 
displayed a time-dependent response to LPS stimulation as opposed to the other P1 receptor 
subtypes which were expressed steadily throughout the CAMΦ culture period. 
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Figure 3.10: Quantitative PCR analyses of P1 receptor expression in the different activation 
phenotypes of bone marrow derived macrophages. Macrophages were treated with either (A) 10ng/ml 
LPS (CAMΦ) or (B) 5ng/ml IL-4 (AAMΦ) for 20 hours and mRNA levels of the P1 receptors determined 
and compared to levels detected in BMMΦ. The fold changes presented are relative to BMMΦ after 
normalising to β-actin mRNA and error bars show standard error of the mean from one representative 
experiment.  
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Figure 3.11: Quantitative PCR showing the changes in mRNA level of P1 receptor transcripts in 
CAMΦ during the 24 hour time course of culture with 10 ng/ml LPS. Fold mRNA change as well as 
standard errors are shown for (A) A1 receptor (B) A2A receptor (C) A2B receptor (D) A3 receptor relative to 
unstimulated BMMΦ, after normalising to β-actin mRNA.  
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The macrophage transcriptional profile of the other G-protein coupled purinergic 
receptors belonging to the P2Y subfamily was also characterised. P2Y receptor transcripts were 
detected at the expected sizes by RT-PCR (Figures 3.12, 3.13 and 3.14) and the profile detected 
at the 20 hour time point summarised in Table 3.3. The following receptor transcripts were 
present in all 3 types of macrophages: P2Y1, 2, 6, 12, 13, 14, although, P2Y13 and P2Y14 
mRNA was not consistently detected exhibiting time-dependent up-regulation in all macrophage 
subsets. At 48 hours the P2Y14 receptor was detected at very low levels in BMMΦ and AAMΦ. 
The transcripts detected were not due to genomic DNA contamination as no β – actin products 
were obtained in the (-RT) controls (Figures 3.12, 3.13 and 3.14). The fact that transcripts of all 
P2Y receptors responding to ADP, ATP and UDP were present at the molecular level in all 3 
macrophage subsets suggests that they can all potentially respond to extracellular nucleotide 
stimulation.  
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Figure 3.12: Purinergic receptor (P2YR) transcripts in BMMΦ following 48 hours of culture, 
determined using RT-PCR. PCR products are shown and product sizes were determined by the 
ladder shown annotated on the left (in bp). Expected sizes were obtained for all transcripts detected (see 
Materials and Methods, Table 2.1C). Actin primers were used in reactions to confirm cDNA quality (Act) 
and in reactions to determine if RNA was contaminated with DNA (-RT). 
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Figure 3.13: Purinergic receptor (P2YR) transcripts in CAMΦ following 48 hours of culture with 
10ng/ml, determined using RT-PCR. PCR products are shown and product sizes were determined by the 
ladder shown annotated on the left (in bp). Expected sizes were obtained for all transcripts detected (see 
Materials and Methods, Table 2.1C). Actin primers were used in reactions to confirm cDNA quality (Act) 
and in reactions to determine if RNA was contaminated with DNA (-RT). 
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Figure 3.14: Purinergic receptor (P2YR) transcripts in AAMΦ following 48 hours of culture with 
10ng/ml IL-4, determined using RT-PCR. PCR products are shown and product sizes were determined 
by the ladder shown annotated on the left (in bp). Expected sizes were obtained for all transcripts detected 
(see Materials and Methods, Table 2.1C). Actin primers were used in reactions to confirm cDNA quality 
(Act) and in reactions to determine if RNA was contaminated with DNA (-RT). 
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Table 3.3: Summary of the presence of purinergic receptor (P2YR) transcripts in the different bone 
marrow derived macrophage types after 20 hours of culture.  BMMΦ were cultured in standard 
medium only, CAMΦ were cultured in standard medium with 10ng/ml LPS and AAMΦ were cultured in 
standard medium with 5ng/ml IL-4. (-) = absent, (+) = present, (++) = present and abundant. 
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 3.2.4 Molecular analysis of macrophage ecto-nucleotidase expression 
 Purinergic signalling is dependent on extracellular nucleotide type and abundance. 
Therefore, ecto-nucleotidases present on immune cells that can affect both type and abundance of 
certain nucleotides are important in purinergic signalling. CD39 and CD73 are ecto-nucleotidases 
that have been detected on various immune cells, including T regulatory cells (Deaglio et al, 
2007). In this study, CD39 and CD73 transcripts were detected in all the macrophage activation 
types as shown in Figure 3.15. No-RT controls were negative for DNA contamination (Figures 
3.12, 3.13 and 3.14). Despite the fact that CD39 and CD73 transcripts were detected consistently 
throughout the time course tested, CD73 PCR products from BMMΦ and AAMΦ were not 
detected clearly at the 24 and 48 hour time point (Figure 3.15 A and C) while levels of CD73 
mRNA in CAMΦ remained the same (Figure 3.15B). The decrease observed in CD73 transcripts 
correlates with the control β-actin levels which were also low at the 48 hour time point, which 
reflects poor mRNA/cDNA quality rather than an actual down-regulation of CD73 transcript 
levels. The rest of the time points had relatively similar levels of control β-actin so any decrease 
in CD39 and CD73 band intensities could be due to less abundant transcripts. Since this cannot 
be determined by RT-PCR as it is not a quantitative technique, quantitative PCR analysis was 
carried out (Figure 3.16 A, B and C). It appears that CD39 mRNA levels increased by 30-fold in 
BMMΦ between 16 and 24 hours of culture while a 45-fold increase was detected following 24 
hours of IL-4 stimulation (AAMΦ). LPS stimulation of macrophages (CAMΦ) led to a 10-fold 
increase in CD39 transcript levels after 16 hours of culture and no further increase in the CD39 
transcript levels was detected between 16 and 24 hours (Figure 3.16A).  
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CD73 mRNA levels increased 30-fold after 24 hours of BMMΦ culture and no difference 
was detected in the case of LPS stimulation (CAMΦ) during the same time period. In the case of 
IL-4 stimulation (AAMΦ), a 60-fold increase in CD73 transcript levels was detected after 24 
hours of culture (Figure 3.16B). Absolute mRNA levels of CD39 and CD73 were compared in 
the 3 macrophage subsets after 20 hours of culture, as this was the time point selected for 
macrophage culture in subsequent functional assays (Figure 3.16C). It was observed that CAMΦ 
expressed similar levels of CD39 to BMMΦ while AAMΦ CD39 levels were 2-fold higher. 
CD73 transcripts were more abundant in BMMΦ when compared to CAMΦ and AAMΦ after 20 
hours showing that LPS and IL-4 stimulation led to reduction in CD73 transcripts expression 
(Figure 3.16C).  
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Figure 3.15:  Determination of presence of CD39 and CD73 transcripts the different macrophage 
types. RNA isolated from BMMΦ (A), CAMΦ (B) and AAMΦ (C) markers was used to produce cDNA 
used in RT-PCR to detect the presence of CD39 and CD73 transcripts. PCR products of expected sizes for 
CD39 and CD73 were detected (see Materials and Methods) in BMMΦ, CAMΦ and AAMΦ over 48 
hours of culture with standard medium, 10ng/ml LPS or 5ng/ml IL-4, respectively. Actin primers were 
used in reactions to confirm cDNA quality (Act) and in reactions to determine if RNA was contaminated 
with DNA (-RT). 
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Figure 3.16: Quantitative PCR analyses comparing CD39 and CD73 levels in bone marrow derived 
macrophages. (A) and (B) Changes in CD39 and CD73 levels, respectively, at three different time points 
of culture for each macrophage type, relative to the respective levels detected in unstimulated 
macrophages. The fold changes are presented with standard error of the mean, after normalising to β-actin. 
(C) Table showing quantitative PCR data of CD39 and CD73 levels in BMMΦ, CAMΦ and AAMΦ 
compared at 16, 20 and 24 hours, after normalising to β-actin.  
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3.2.5 Macrophage ecto-nucleotidase surface expression and functional characterisation 
Bone marrow derived macrophages were cultured for 20 hours with 10ng/ml LPS 
(CAMΦ), IL-4 (AAMΦ) or standard culture medium (BMMΦ) and harvested for flow cytometric 
analysis. The culture period selected for analysis of surface expression was selected to be 
between the 20 and 24 hour time point in order to see if the up-regulation detected at the 
molecular level affected surface expression. Cells were stained for CD39 and CD73 conjugated 
to FITC and PE, respectively, and analysed on the FL1 (FITC), FL2 (PE) of a FACS Calibur.  
Controls were included with unstained cells or PE/FITC conjugated IgG. The results obtained are 
shown in Figure 3.17. CD39 was detected in all 3 populations of macrophages as indicated by the 
shift in the trace peaks compared to the block trace representing IgG background staining (Figure 
3.17). CD73 was also detected in all 3 macrophage subsets, however, the shift obtained relative 
to background IgG for BMMΦ and CAMΦ was not as pronounced as in AAMΦ, resulting in a 
slight overlap of IgG control and anti-CD73-stained cell populations. This might be due to lower 
CD73 expression levels in these macrophage populations when compared to AAMΦ. 
In order to determine if the ecto-nucleotidases detected on macrophages were functional 
in vitro, macrophages were incubated with various nucleotides and nucleotidase activities 
determined by the presence of inorganic phosphate in culture supernatants. The results obtained 
are shown in Figure 3.18. Incubation of all macrophage activation types with either ADP or ATP 
resulted in detectable phosphate release after 35 minutes of culture while no phosphate release 
was detected in cultures with AMP (Figure 3.18A and B). These assays were carried out at a 
neutral pH (pH7.5-Figure 3.18A) as well as at a more alkaline pH (pH8.5-Figure 3.18B) in order 
to determine if the hydrolysis observed was due to alkaline phosphatase activity which is optimal 
at a higher pH. As shown in Figure 3.18A and B, increasing the pH did not significantly affect 
113 
 
nucleotide hydrolysis, therefore, alkaline phosphatases expressed on macrophages were not 
responsible for the phosphate release detected.  This was confirmed by further experiments 
carried out in the presence of an alkaline phosphatase inhibitor, Tetramisole HCl which produced 
similar results (data not shown).  
The different macrophage activation types were also incubated with nucleotides for 20 
hours (Figure 3.18C) to determine their nucleotidase activity during the time period allowed for 
macrophage culture in experiments shown in subsequent chapters. After 20 hours, AMP was also 
metabolised by all macrophage types. In addition, it appears that some ATP-γ was degraded over 
time as the presence of phosphate in the culture medium was more pronounced after 20 hours 
reflecting the slowly hydrolysable nature of this ATP analogue. β-ADP was more stable than 
ATP-γ after 20 hours of culture as no phosphate was detected in culture supernatants. Taken 
together, these experiments confirmed that macrophages have functional ecto-enzymes capable of 
hydrolysing ATP and ADP as well as AMP, albeit with different kinetics.  
The levels of phosphate present in the extracellular medium of AAMΦ stimulated by a 
different combination of interleukins (IL-4, IL-10 and IL-13) are shown in Figure 3.18D. There 
appears to be no difference between these differently stimulated AAMΦ, nor does this change the 
AMP metabolism.  
Collectively, these data suggest that the ecto-nucleotidases CD39 and CD73 were 
expressed in all macrophage subsets both at the molecular and protein levels. Furthermore, these 
ecto-nucleotidases were expressed on the surface in a functional state and were capable of 
hydrolysing extracellular nucleotides in vitro. Their activity did not seem to be affected by 
macrophage activation states despite the higher expression levels detected in AAMΦ.   
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Figure 3.17: Flow cytometric analyses showing expression of CD39 and CD73 on macrophages. 
Bone marrow derived macrophages were harvested after 22 hours of culture with activating ligands 
(10ng/ml LPS or 5ng/ml IL-4). The block trace corresponds to IgG isotype control and the line trace 
corresponds to CD39/CD73-positive cells, presented as a % of the maximum number of cells.  
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Figure 3.18: Phosphate release by macrophage ecto-nucleotidases. Nucleotides were incubated with 
bone marrow derived macrophage and the nmoles of phosphate released per 10
5
 cells calculated. 100 μM 
of AMP, ADP, β-ADP, ATP, ATP-γ and UDP were added to BMMΦ, CAMΦ and AAMΦ for 35 minutes 
at pH7.5 (A) and pH8.5 (B), respectively. (C) The same experiment carried out at pH7.5 used to detect 
phosphate release from the 3 macrophage subsets after 20hrs of macrophage culture with indicated 
nucleotides (D) Pi release at pH7.5 from indicated nucleotides after 35 minutes from macrophages 
activated with different combinations of cytokines. Results show averages of experiments carried out in 
triplicate + SEM (n = 3). Asterisks indicate statistical significance compared to absence of nucleotide 
stimulation. ns p>0.05, * p<0.05, ** p<0.01, *** p<0.001. 
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3.2.6 Molecular analysis of the effects exerted by T.spiralis secreted proteins on macrophage 
transcript expression  
  Macrophages were treated with T.spiralis secreted proteins (ES) for 20 hours and RT-
PCR was carried out in order to investigate whether they affect the expression of AAMΦ marker 
transcripts. As shown in Figure 3.19, arginase I levels appeared to be up-regulated in BMMΦ and 
CAMΦ. In addition, Fizz1 appeared clearly up-regulated in CAMΦ. There did not appear to be a 
difference in the AAMΦ as the levels were high in both cases. In order to determine if there were 
any differences in mRNA levels and to confirm the RT-PCR data, quantitative PCR was carried 
out. The Q-PCR data are presented in Figure 3.19B and confirm that arginase I levels indeed 
increased in all macrophage types. Specifically, in BMMΦ a more substantial up-regulation of 
arginase I levels was detected reaching 80-fold which is in agreement with the difference in band 
intensity observed in the Figure 3.19A. In addition, ES appeared to down-regulate Ym1 levels in 
AAMΦ by 6 fold. In order to characterise the nature of the ES component causing the changes 
observed, macrophages were cultured with ES treated to inactivate any enzyme activity (by heat 
inactivation) or ES treated to eliminate any carbohydrate components (by chemical 
deglycosylation). The effect of arginase I up-regulation observed in BMMΦ is reversed by 
deglycosylating ES while heat inactivating ES also partly reduces arginase I up-regulation 
(Figure 3.19 C). 
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Alternatively activated macrophages are the main macrophage phenotype detected in 
parasite infections (Noel et al, 2004). Therefore, the effect of ES on AAMΦ generated in 
different interleukin environments was also investigated. Figure 3.20 shows that when 
macrophages were activated by IL-4 in combination with IL-13 the effect of ES was similar to 
that observed when macrophages were activated with IL-4 alone. Interestingly, when 
macrophages were cultured with IL-4 and IL-10 Fizz1 and Ym1 expression was further up-
regulated by ES reaching 8 and 6-fold, respectively.  
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Figure 3.19: Molecular analysis of the effect of T.spiralis ES on bone marrow derived macrophage 
alternative activation markers. (A) PCR products obtained for mannose receptor (MR), arginase I (Arg 
1), Fizz1 and Ym1 are shown and product sizes determined by the ladder shown annotated on the left (in 
bp). Expected sizes were obtained for all transcripts detected (see Materials and Methods) Actin (Act) was 
used as a positive control for cDNA quality as well as a negative control (-RT) for determination of 
potential RNA contamination. (B) Table of quantitative PCR data showing mRNA changes in response to 
ES when compared to the respective macrophage type cultured in the absence of ES. (C) The effect of 
heat inactivated (HI-) and deglycosylated (Deg-) ES on BMMΦ arginase I transcript levels, compared to 
unstimulated BMMΦ. Changes are calculated after normalising to β-actin mRNA. Standard errors of the 
mean shown are from one representative experiment of n=2 and asterisks indicate significance. * p<0.05, 
*** p<0.001 
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Figure 3.20: Quantitative PCR analyses of alternative activation marker transcript levels in AAMΦ 
treated with T.spiralis ES. Bone marrow derived macrophages were activated with (A) IL-4, (B) IL-4/IL-
10 or (C) IL-4/IL-13 (5ng/ml of each cytokine) and co-cultured with T.spiralis ES for 20 hours. Mannose 
receptor (MR), arginase I, Fizz and Ym1 transcript levels were determined by q-PCR and the marker 
levels obtained by cells treated with ES were compared to activated cells cultured in the absence of ES (-). 
The fold changes are presented with standard errors after normalizing to β-actin. 
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Macrophage P1 receptor transcript levels were analysed by quantitative PCR to determine 
if treatment with ES altered P1 receptor expression at the molecular level. As shown in Figure 
3.21A, ES induced A2A receptor expression in BMMΦ as a 6-fold increase was detected, while 
A3 receptor levels were increased 2-fold. This receptor up-regulation was also visible by RT-PCR 
shown in Figure 3.21B, especially for the A2AR which was not detectable in the absence of ES. 
Deglycosylating ES reversed its effects while heat inactivation partly reduced the observed ES-
induced effect. In CAMΦ, ES did not significantly change P1 receptor levels except for a slight 
inhibition of A3 receptor transcript expression (Figure 3.21C), while in AAMΦ a small increase 
could be detected in A2AR and A3R levels (0.5- and 1-fold, respectively). As seen when BMMΦ 
were used, deglycosylating ES reduced any ES-induced effects.  
Quantitative PCR analysis was also carried out to detect changes in CD39 and CD73 
levels of macrophages cultured with ES. Figure 3.22 shows that CD39 transcript expression was 
down-regulated in BMMΦ and AAMΦ by ES, an effect reversed by deglycosylation and partly 
reduced by heat inactivation. CD73 was up-regulated by 3-fold in BMMΦ and 15-fold in AAMΦ 
which was brought down to 5-fold when ES was deglycosylated. In CAMΦ ES did not change 
CD73 transcript levels. 
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Figure 3.21: Analysis of the effect of T.spiralis ES on macrophage P1 receptor transcripts. Bone 
marrow derived macrophages cultured with medium (A and B), 10ng/ml LPS (C) or 5ng/ml IL-4 (D) were 
treated with T.spiralis ES, heat inactivated (HI-) or deglycosylated (Deg-) ES for 20 hours. RNA extracted 
was analysed by RT-PCR and quantitative PCR. (A) The effect of ES on BMMΦ P1 receptor transcript 
levels and reversal of the effect by deglycosylated ES. (B) Results from RT-PCR of P1 receptors from 
BMMΦ treated with ES. Quantitative PCR was carried out to determine the effect of ES, HI-ES and Deg-
ES on CAMΦ (C) and AAMΦ (D) P1 receptor transcript levels. The relative mRNA changes when 
compared to the respective macrophage type cultured in the absence of ES (-) were calculated after 
normalizing to β-actin. Standard errors of the mean shown are from one representative experiment of n=2 
and asterisks indicate significance. * p<0.05, ** p<0.01, *** p<0.001 
 
 
 
 
 
122 
 
 
 
Figure 3.22: Quantitative PCR analyses of T.spiralis ES effect on macrophage CD39 and CD73 
levels. Bone marrow derived macrophages cultured with medium (BMMΦ), 10ng/ml LPS (CAMΦ) or 
5ng/ml IL-4 (AAMΦ) were cocultured with ES, heat inactivated (HI-) or deglycosylated (Deg-) ES for 20 
hours. CD39 (A) and CD73 (B) levels were determined by q-PCR and compared to levels obtained by the 
respective macrophage type in the absence of ES (-). Relative mRNA changes presented with standard 
errors were calculated after normalizing to β-actin from one representative experiment of n=2.  
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The effect of ES on macrophage CD39 and CD73 surface expression was also 
investigated. Flow cytometric analyses of CD39 and CD73 expression from macrophages 
cultured for 20 hours with ES are shown in Figure 3.23 presented as scatter plots of 4 
independent experiments. CD39 surface expression did not change in either of the macrophage 
subsets (Figure 3.23A and 3.23C) as opposed to CD73 expression which increased by 10% in 
both BMMΦ and AAMΦ cultured with ES (Figure 3.23B and 23D). In CAMΦ ES did not 
change ecto-nucleotidase expression (Figure 3.23E). Having established the up-regulation of 
CD73 surface expression by ES, further experiments were carried out with heat inactivated (HI) 
and deglycosylated (Deg) ES.  Figure 3.24 shows that when BMMΦ (Figure 3.24A and 24B) and 
AAMΦ (Figure 3.24C and D) were cultured with either HI- or Deg-ES CD73 expression was 
restored to initial levels.  
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Figure 3.23: Flow cytometric analyses of the effect of T.spiralis ES on macrophage CD39 and CD73 
surface expression. Bone marrow derived macrophages cultured with medium (BMMΦ), 10ng/ml LPS 
(CAMΦ) or 5ng/ml IL-4 (AAMΦ) were cocultured with T.spiralis ES for 22 hours and then stained with 
anti-CD39 or anti-CD73 antibodies for FACS analysis. Data obtained from 4 different experiments as % 
positive cells are presented in paired and unpaired scatter plots. (A) and (B) Plots of % positive BMMΦ 
for CD39 and CD73, respectively. (C) and (D) Plots of % positive AAMΦ for CD39 and CD73, 
respectively. (E) A combined plot of % positive CAMΦ for CD39 and CD73. Statistical significance was 
determined by paired analysis between data from each individual experiment and the overall significance 
between (-) and (+ES) is shown on the plots (** p<0.01). 
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Figure 3.24: Flow cytometric analysis of T.spiralis ES effects on bone marrow derived macrophage 
CD73 surface expression.  BMMΦ (A and B) and AAMΦ (C and D) were cultured with ES, heat 
inactivates (HI-) or deglycosylated (Deg-) ES for 22 hours and then stained for CD73. (A) and (C) Traces 
of BMMΦ and AAMΦ, respectively, cultured with heat inactivated ES. (B) and (D) Traces of BMMΦ and 
AAMΦ, respectively, cultured with deglycosylated ES. The block trace represents the IgG control, red 
represents cells in the absence of ES, blue represents cells with ES and green represents cells with either 
heat inactivated or deglycosylated ES. 
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The IL-4R is essential for IL-4-dependent up-regulation of alternative activation markers. 
Therefore, the effect of ES on macrophage IL-4R was investigated. All 3 macrophage subsets 
were cultured for 20 hours with ES and stained with PE conjugated anti-IL-4R antibody. Flow 
cytometric analysis was carried out on the FL2 channel of a FACS Calibur. Figure 3.25 shows 
scatter plots of the results obtained from 4 independent experiments. In BMMΦ, ES up-regulated 
IL-4R expression by approximately 20% (Figure 3.25A) while the increase observed in AAMΦ 
was less than 10% (Figure 3.25C). CAMΦ IL-4R expression did not seem to be affected by ES 
(Figure 3.25B). Having established that the increase in BMMΦ IL-4R expression was significant 
experiments were then carried out with heat inactivated (HI) and deglycosylated (Deg) ES. As 
shown in Figure 3.26 IL-4R expression was restored to initial levels when macrophages were 
cultured with either HI- or Deg-ES.  
Together these results demonstrate that T.spiralis secreted products are capable of shifting 
macrophage activation to an anti-inflammatory mode by up-regulating arginase I transcript levels 
as well as IL-4R expression which makes cells more responsive to IL-4. In terms of purinergic 
signalling, the A2A receptor was up-regulated at the molecular level while CD73 was up-
regulated at the molecular and protein levels. Inactivation of T.spiralis secreted protein activity 
partly reduced these effects which were generally reversed by removing the glycan component by 
protein deglycosylation.  
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Figure 3.25: Flow cytometric analyses of the effect of T.spiralis ES on macrophage IL-4R surface 
expression. BMMΦ (A), CAMΦ (B) and AAMΦ(C) were cocultured with T.spiralis ES for 22 hours and 
then stained with anti- IL-4Rα antibodies for FACS analysis. Data obtained from 4 different experiments 
as % positive cells are presented in paired scatter plots. Statistical significance was determined by paired 
analysis between data from each individual experiment and the overall significance between (-) and (+ES) 
is shown on the plots (*p<0.05, ** p<0.01). 
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Figure 3.26: Flow cytometric analysis of ES effect on bone marrow derived macrophage IL-4R 
surface expression. BMMΦ were cultured with ES, heat inactivates (HI-) or deglycosylated (Deg-) ES 
for 22 hours and then stained for IL-4Rα. (A) BMMΦ treated with ES or HI-ES. (B) BMMΦ treated with 
ES or Deg-ES. The block trace represents the IgG control, red represents cells in the absence of ES, blue 
represents cells with ES and green represents cells with either heat inactivated or deglycosylated ES. 
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3.6 Discussion 
Macrophages participate in the innate and adaptive immune response to pathogens as well 
as in different stages of inflammatory processes exhibiting phenotypic plasticity in response to 
local changes in their environment. Classically activated macrophages (CAMΦ) generated in a 
Th1 (IFN-γ) environment or in the presence of LPS are pro-inflammatory while anti-
inflammatory macrophages are alternatively activated (AAMΦ) by Th2 cytokines (IL-4 and IL-
13) and are involved in parasite infections (Gordon, 2003; Kreider et al, 2007). In this way a 
balance is achieved to overcome an exuberant immune response to pathogen invasion that could 
be deleterious to the host. In addition to the cytokine environment macrophages are capable of 
responding to extracellular nucleotides by means of purinergic receptors expressed on their 
surface. Nucleotide effects are controlled by enzymes capable of metabolising them to their 
respective nucleoside by hydrolysis of terminal phosphates. Consequently, different purinergic 
receptors are engaged resulting in switches between pro- and anti-inflammatory responses. 
Enzymes secreted by parasites such as T.spiralis have similar properties to these endogenous 
enzymes suggesting a way to mimic and thus evade the immune response (Gounaris and Selkirk, 
2005). In this study, the aims were to characterise bone marrow derived macrophages in terms of 
alternative activation marker expression and, subsequently, in terms of their purinergic receptor 
profile. In addition, the effect of T.spiralis secreted products on their phenotype and activation 
was investigated.  
Macrophages were differentiated from murine bone marrow with M-CSF and a 98% 
purity of the final population was determined using FACS analysis to identify surface 
macrophage markers, F4/80 and Cd11b. After confirming that differentiation with M-CSF 
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produced a pure macrophage population, macrophages were then activated with either LPS or IL-
4 to produce CAMΦ and AAMΦ, respectively. In an attempt to confirm that we can distinguish 
between the two activation phenotypes investigated, macrophages were first characterised in 
terms of the known markers of alternative activation (Gordon, 2003).  
The mannose receptor was first reported to be up-regulated by murine peritoneal 
macrophages in an IL-4 environment by Stein and colleagues in 1992 and has since been used as 
a marker of alternative activation. In this study mannose receptor up-regulation was not as 
pronounced as expected at the molecular level as in AAMΦ mannose receptor levels were only 
two fold higher than the other subsets. The presence of IL-13 did not alter IL-4-induced mannose 
receptor levels. This may be explained by the fact that mannose receptor up-regulation may be a 
result of increased protein synthesis and activity rather than increased levels of mRNA (Stein et 
al, 1992). Furthermore, being a receptor involved in phagocytosis it is even possible that 
regulation is achieved by increased recycling to the surface. Interestingly, the presence of IL-10 
in macrophage culture with IL-4 induced mannose receptor up-regulation suggesting synergism 
with an alternative pathway for increasing its transcription. In fact, Dewals et al have reported an 
IL-4Rα-independent up-regulation of mannose receptor that appears to be achieved by IL-10R 
signalling (Dewals et al, 2010).  
 Arginase I is an inducible enzyme whose expression is up-regulated by Th2 cytokines 
and down-regulated by IFN-γ and TNF-α as confirmed in a murine model of granuloma (Hesse et 
al, 2001). A ubiquitous feature of alternative activation is the up-regulation of arginase I, which 
is always accompanied by an inhibition of inducible nitric oxide synthase (iNOS) (Munder et al, 
1998). This shift in enzyme expression enhances the AAMΦ protective effect through increased 
proline and collagen production essential in tissue repair. In this study, arginase I was the most 
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robustly up-regulated marker of alternative activation expressed at high levels in AAMΦ. 
Arginase I transcripts were also detected in CAMΦ but at comparatively lower levels. The 
observation that LPS induces up-regulation of arginase I levels was first made in mouse 
peritoneal macrophages by Ryan and colleagues (Ryan et al, 1980) and further characterised by 
later studies as a means employed by pathogens to control iNOS activity thus diverting 
macrophage responses away from killing (El Kasmi et al, 2008). Furthermore, this LPS-induced 
up-regulation was found to be via a STAT6-independent pathway used for induction of C/EBPβ 
that involved MyD88 (Sonoki et al, 1997; El Kasmi et al, 2008). Another possible by-product of 
LPS-induced signalling was detected in this study. A non-specific product was observed in 
CAMΦ arginase I RT-PCR reactions only, which on subsequent cloning, was found to encode a 
cathepsin protein. As arginase I levels increased with time this product remained detectable 
which, taken together with its absence from BMMΦ, rules out a possible preferential primer 
binding that may occur in the absence of the specific arginase I transcript. A possible explanation 
for the presence of cathepsin in CAMΦ is the TLR-induced activation of Interferon Regulatory 
Factor (IRF8) which is a hematopoietic transcription factor with target genes involved in myeloid 
cell differentiation (Savitsky et al, 2010). Interestingly, Tamura and colleagues have identified 
cathepsin as one of the targets of IRF8 that are rapidly up-regulated upon IRF8 induction 
(Tamura et al, 2005).    
AAMΦ arginase I levels were shown in this study to be further up-regulated by IL-10, 
which was also previously observed in a study investigating the effect of a sequentially changing 
cytokine environment on macrophage phenotype (Stout et al, 2005). Indeed, Lang and colleagues 
have reported that IL-10 increases IL-4R levels leading to synergistic induction of arginase I 
(Lang et al, 2002). In addition, gene profiling revealed that IL-10 induced up-regulation of 
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arginase I. These effects were induced via a STAT3 dependent pathway which taken with the up-
regulation of mannose receptor by IL-10 observed in this study might point to a STAT3-STAT6 
pathway cross-talk. In contrast to IL-10-induced effects, IL-13 appeared to slightly reduce IL-4-
induced arginase I up-regulation which may be explained by the fact that IL-13Rα, which is also 
engaged on IL-13 stimulation, has been characterised as a decoy receptor that can dampen IL-13 
responses (Wood et al, 2003).  
Fizz1 and Ym1 were first characterised as markers of alternative activation of 
macrophages recruited in nematode infections (NeMΦ) (Loke et al, 2002). Fizz1, also referred to 
as RELM-α, is a resistin-like molecule which is up-regulated in pulmonary inflammation and can 
inhibit the effects of nerve growth factor, while Ym1 is a secretory lectin of the chitinase family 
with the ability to form crystals in alveolar macrophages (Loke et al, 2002; Nair et al, 2003). In 
this study, both Fizz1 and Ym1 were shown to be significantly up-regulated in AAMΦ and 
neither IL-13 nor IL-10 made a difference in their expression levels. The presence of Fizz1 and 
Ym1 in CAMΦ was only detected at low levels which was also seen in RT-PCR analysis 
presented by Raes and colleagues (Raes et al, 2002). These workers showed that, both Fizz1 and 
Ym1 were detected faintly in LPS-treated thioglycollate-elicited and resident peritoneal 
macrophages suggesting that an up-regulation of these markers is indicative of alternative 
activation.  
In addition to manipulation of macrophage phenotype by the parasite, it is suggested that 
Trichinella spiralis secreted products can interfere with immune cell purinergic signalling by 
metabolising extracellular nucleotides (Gounaris and Selkirk, 2005). The presence of purinergic 
receptors on macrophages is an important determinant of nucleotide-induced effects (Bours et al, 
2006). Macrophages were characterised in terms of their purinergic receptor profile in order to 
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determine if macrophage phenotype can alter responsiveness to nucleotides. During a 48 hour 
course of culture the P1 receptor transcripts were shown to be present consistently in BMMΦ, 
CAMΦ and AAMΦ except for the A2A receptor which was absent in BMMΦ and AAMΦ but 
showed time-dependent levels in CAMΦ. Murphree and colleagues have also reported a time-
dependent up-regulation of the A2A receptor in response to LPS in human and mouse 
macrophages and have suggested this to be a protective pathway to limit inflammatory responses 
to bacterial infection (Murphree et al, 2005). Even after A2A receptor levels decreased in CAMΦ, 
after 20 hours of culture, they were still 200-fold higher than those observed in BMMΦ. This 
difference in P1 receptor repertoire may influence macrophage responses to nucleotides 
depending on activation status as a result of downstream intracellular pathways. The P2Y 
receptor profiles were the same for all 3 subsets showing that they can all potentially respond to 
ADP, ATP and UDP. The only P2Y receptor not detected in this study was the P2Y4 receptor 
which responds to UTP. P2Y4 was found to be expressed in spleen macrophages and J774 by 
Coutinho-Silva and colleagues indicating that macrophage localisation may play a role in the 
expression of this receptor.  Indeed, a control experiment carried out with mouse splenocytes 
showed that the primers used in this study can detect P2Y4 transcripts (Chapter 5).  
The fact that T.spiralis secreted proteins can mimic the function of ecto-nucleotidases 
expressed on immune cells may indicate that this is one of the major mechanisms of endogenous 
control of purinergic signalling in the host. Recent work by Borsellino et al, 2007 and Deaglio et 
al, 2007 has shown that T cell subsets express the extracellular nucleotidases, nucleoside 
triphosphate diphosphohydrolase/apyrase (CD39) and ecto5′-nucleotidase (CD73). This finding is 
relevant to this study in the context of T.spiralis secreted products which have been shown to 
contain a 5′-nucleotidase which functions as both of these mammalian counterparts (Gounaris et 
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al, 2004). Conventional RT-PCR analysis did not reveal major differences in CD39 and CD73 
expression between the macrophage subsets, although PCR products appeared to be less 
abundant than PCR products obtained for β-actin controls. Therefore, quantitative PCR analysis 
was carried out which revealed that the apparent increase observed in CD73 product bands in RT-
PCR with time was true as CD73 levels increased significantly between 20 and 24 hours of 
culture in all subsets and especially in AAMΦ, suggesting a potential anti-inflammatory 
mechanism. In contrast to CD73, CD39 transcript levels only increased significantly in BMMΦ 
and AAMΦ. These observations could be important when looking at nucleotide-induced effects 
as, depending on the time course of macrophage culture, the presence of these enzymes could 
significantly alter nucleotide levels.  
 Nevertheless, transcriptional profiling can only give an indication of receptor expression 
as it can only detect the first step of the expression process. In order to determine if CD39 and 
CD73 are actually expressed on the surface of macrophages, FACS analysis was carried out on 
unstimulated and activated macrophages. It was shown that, both CD39 and CD73 were also 
present at the protein level, with CD39 being robustly expressed in all macrophage subsets. CD73 
surface expression was actually higher in AAMΦ, a result that correlates with the increased 
transcript levels detected in AAMΦ. Aiming to dissect functionality of these ecto-enzymes, 
nucleotidase assays were carried out concurrently, and it was found to support the surface 
expression analysis. In these assays, ATP and ADP metabolism was evidenced by phosphate 
released into the extracellular medium, showing that the surface CD39 detected is indeed 
functional. AMP was only metabolised successfully after prolonged culture with the ecto-
nucleotidases a result that can be attributed to delayed expression of CD73 or slower degradation 
kinetics of this enzyme. In view of this, it would appear that CD73 is the rate-limiting enzyme in 
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this pathway thus a possible point for regulation. In addition, the presence of these functional 
ecto-nucleotidases introduces a factor to be taken into account when investigating the effects of 
nucleotides on macrophage purinergic signalling as they would be responsible for conversion of 
ATP/ADP to AMP to adenosine.  
Having established the basal expression profiles of markers, purinergic receptors and 
ecto-nucleotidases in macrophages, the effect of T.spiralis secreted proteins (ES) was then 
investigated. It is now well established that helminth infections induce an anti-inflammatory 
macrophage phenotype driven by Th2 cytokines (Noel et al, 2004). T.spiralis infection was also 
reported to give rise to macrophage responses that were not characterised by the classical 
activation pathway (Dzik et al, 2004). In addition to Th2 cytokine-induced alternative activation 
of macrophages, Donnelly and colleagues have reported induction of alternative activation by 
F.hepatica secreted products (Donnelly et al, 2005). In particular, Flynn and Mulcahy have 
suggested that F.hepatica-induced effects are due to glycans binding to TLRs (Flynn and 
Mulcahy, 2008). Furthermore, carbohydrates present on S.mansoni egg antigen (SEA) have been 
reported to cause a Th1 to Th2 switch via LNFPIII (lacto-N-fucopentaose) binding to surface 
TLRs (Okano et al, 2001). In view of these findings, the effect of T.spiralis ES on transcript and 
surface expression levels was investigated. Arginase I levels were increased in all macrophage 
subsets and more significantly in BMMΦ, probably because AAMΦ already have high basal 
levels of arginase I. However, Ym1 levels of AAMΦ were down-regulated by ES and were only 
up-regulated in the presence of IL-10 suggesting that a synergism of cytokine effects possibly 
operates in vivo to achieve the observed nematode-elicited macrophage characteristics. Indeed, 
Atochina and colleagues have reported that the up-regulation of Ym1 together with arginase I is 
initiated by LNFPIII in vivo (Atochina et al, 2008).  It is worth noting that when taken together, 
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the effect of ES on different combinations of cytokine treatment of macrophages is additive in 
that different markers are up-regulated for every combination supporting the view of potential 
synergism in vivo. In an attempt to gain some insight into the mechanism of action of T.spiralis 
secreted proteins, chemical deglycosylation was carried out to remove glycan residues, or the 
enzyme activity eliminated by boiling. ES-induced effects were generally reversed by 
deglycosylation of proteins and only reduced by heat inactivation. This may be explained by the 
fact that boiling could have the same effect as removal of glycans because protein denaturation 
induces conformational changes that would reposition conjugated glycans to become dynamically 
unfavourable for binding macrophage surface receptors. Hence, the reason for retaining some 
effect after boiling is that the glycans are still present and can still bind albeit with lower 
efficiency.  
T.spiralis ES induced a pronounced increase in BMMΦ A2A receptor levels but had no 
effect on the existing CAMΦ receptor expression. AAMΦ also had up-regulated levels of this 
receptor but they could only be detected by the more sensitive quantitative PCR approach. Ecto-
nucleotidase expression was also affected by ES and was detectable at the molecular and protein 
expression levels. In particular, CD73 transcript levels were up-regulated in AAMΦ and less so 
in BMMΦ while CD39 levels were reduced, an effect only observed at the transcript level as 
surface expression was not altered significantly. Taken together with the A2A receptor up-
regulation the increase in CD73 levels suggests a higher responsiveness to adenosine. The 
importance of the glycan component in ES-induced effects was observed again as transcript 
levels and surface expression of CD73, and A2A receptor were restored to initial levels following 
deglycosylation of ES. T.spiralis ES had no effect on CAMΦ levels of ecto-nucleotidases and P1 
receptors which may be due to some TLR interference of ES glycan binding or signalling.  
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Taking into account that alternative activation is at least partly dependent on the 
expression of the IL-4R, the capacity of ES to increase levels of this receptor was investigated. 
Indeed, ES but not deglycosylated ES, significantly increased the IL-4Rα surface expression on 
BMMΦ indicating a skewing of macrophage responsiveness to Th2 cytokines, and in particular 
IL-4 and IL-13. This effect was again more significant in BMMΦ suggesting that in the time 
frame allowed in this study changes in expression of proteins investigated occurred more readily 
in the naïve macrophage subset. It is possible that increasing culture periods could ultimately lead 
to macrophage switching as it has been reported in monocyte derived macrophages cultured for 4 
days with a variety of cytokines (Porcheray et al, 2005). Similarly in bone marrow derived 
macrophages cultured for sequential 24 hour periods in different cytokine environments 
„reversible adaptation‟ of the macrophage phenotype was achieved (Stout et al, 2005).  
In conclusion, macrophage activation phenotypes were found to vary in more aspects than 
the markers investigated giving each the potential to respond appropriately in the different stages 
of infection. Specifically, A2A receptor expression was found to be a distinguishing feature of 
classical activation and was only up-regulated on treatment of unstimulated macrophages with 
T.spiralis secreted proteins. CD73 which is responsible for the extracellular generation of 
adenosine was also up-regulated by T.spiralis, pointing to a possible mechanism of increasing the 
macrophage anti-inflammatory response as a result of adenosine-induced purinergic signalling. 
Furthermore, T.spiralis proteins can potentially skew macrophage activation by causing up-
regulation of the IL-4 receptor thus making them more responsive to Th2 cytokines. Finally, the 
component responsible for T.spiralis-induced effects is most likely the carbohydrate portion of its 
secreted glycoproteins. Therefore, this parasitic nematode does not differ from other organisms of 
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its family in this direct mode of host cell manipulation as many helminths have been reported to 
interfere with immune cell signalling via similar structures present on their secreted products. 
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Chapter 4 
Effect of purinergic signalling on macrophage effector functions in vitro  
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4.1 Introduction  
Purinergic receptors control immune cell responses due to their ubiquitous expression on cells 
of the hematopoietic lineage, especially on antigen presenting cells (APC). APCs, including 
macrophages, B cells and dendritic cells, are the first line of defence against infection and present 
foreign antigen to naïve T lymphocytes using the Major Histocompatibility Complex (MHC) 
thereby initiating specific lymphocyte-effector pathways (Banchereau et al, 2000).  
 Distinct macrophage subsets have been found, the best characterised being the classically 
activated macrophages induced by pro-inflammatory microbial molecules, such as LPS, and in a 
Th1 cytokine environment by IFN-γ (Gordon, 2003). Classically activated macrophages (CAMΦ) 
have the ability to produce nitric oxide (NO), have a high capacity of antigen presentation and 
show increased expression of MHCII and CD86 (Noel et al, 2004). Their essential role in 
protection against intracellular pathogens is also a consequence of increased oxidative burst and 
NO release. In addition, their ability to secrete NO and pro-inflammatory cytokines (TNF-α, IL-
1, IL-6) enhances their anti-proliferative and cytotoxic activities. However, if these pro-
inflammatory effector functions are not controlled by the host the balance might shift to a more 
toxic environment that could be deleterious to the host. In an attempt to control excessive 
inflammation, macrophages can have an anti-inflammatory function when they develop in the 
presence of IL-4/IL-13 and are known as alternatively activated macrophages (AAMΦ) (Nelms et 
al, 1999). AAMΦ differ from CAMΦ in that they use an alternative pathway for metabolism of 
L-arginine thus preventing nitric oxide generation from iNOS. In addition, they do not secrete 
pro-inflammatory cytokines but produce IL-10 in vivo which is an anti-inflammatory cytokine 
(Gordon, 2003).  
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Studies have shown that nematode elicited macrophages (NeMΦ) have characteristics of 
alternative activation as they down-regulate inflammatory cytokines (Donnelly et al, 2005, Loke 
et al, 2007; Nair et al, 2003) and they up-regulate alternative activation markers such as arginase 
I, Fizz1 and Ym1 (Flynn et al, 2007; Nair et al, 2005). Inoculation of mice with the enzyme 
peroxiredoxin (Prx), which is an excretory/secretory product of F.hepatica, created a population 
of macrophages with suppressed iNOS mNRA levels and elevated TGF-β levels (Flynn et al, 
2007). With relevance to T.spiralis, which is an intestinal nematode, parasite invasion can cause 
damage to the intestinal epithelium of the host which leads to initiation of inflammatory 
reactions. Nucleotides released by host immune cells at sites of inflammation are danger signals 
that trigger purinergic signalling, which is an essential means of immune cell communication. 
The importance of host purinergic signalling in dealing with T.spiralis-induced damage is 
emphasised by the fact that T.spiralis secreted proteins have nucleotide metabolising ability and 
can thus potentially interfere with this process. In this study, purinergic signalling was 
investigated in different macrophage types in order to determine if macrophages activated in 
different stages of inflammation and infection altered their responses to nucleotides.  
The purinergic receptors investigated in this study are G-protein coupled receptors 
(GPCRs) and depending on the G-protein subunit associated with each receptor the downstream 
events that ensue following receptor ligation have different outcomes on macrophage effector 
functions. Specifically, stimulatory G-protein signalling results in cAMP generation or 
Phospholipase C (PLC) activation, while inhibitory G-protein signalling prevents cAMP 
accumulation. In addition, Toll-like receptor (TLR) ligation on classically activated macrophages 
ultimately leads to activation of NF-κB, the major transcription factor involved in pro-
inflammatory gene transcription. NF-κB is found in the cytosol of unstimulated cells and upon 
142 
 
stimulation it translocates to the nucleus following phosphorylation and degradation of its 
inhibitory binding protein, IκB (Rothwarf and Karin, 1999). Pathways leading to NF-κB 
activation are overlapping and redundant and may be subject to interference by other pathways 
originating from G-protein activation at the cell surface. For example, PI3 kinase, which is 
known to be involved in pro-inflammatory responses, mainly due to the fact that NF-κB is one of 
its downstream targets, can be activated both by TLR signalling and GPCR signalling (Dos 
Santos et al, 2007). Therefore, cross-talk between these pathways can lead to unique activation 
profiles of macrophages that encounter extracellular nucleotides.  
Macrophages are known to express purinergic receptors, as shown in Chapter 3, which are 
important, among other surface proteins, in host protection against excessive inflammation and 
pathogen invasion. Firstly, this study aimed to functionally characterise bone marrow derived 
macrophages in terms of known effector functions like nitric oxide release, arginase I activity and 
cytokine release. Then, the effect of purinergic receptor activation on these functions was 
investigated by treating the different macrophage types with nucleotides such as AMP, ADP and 
ATP as well as adenosine, the product resulting from adenine nucleotide hydrolysis. Finally, 
functional purinergic receptors involved in macrophage responses to nucleotides were identified 
by using a variety of selective purinergic receptor antagonists and agonists. Furthermore, an 
attempt was made at characterising intracellular signal transduction pathways triggered by 
purinergic receptor activation. 
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4.2 Results 
4.2.1 Effect of extracellular nucleotides on murine macrophage effector functions  
Nitric oxide release vs arginase I activity  
Nitric oxide (NO) is a key effector molecule of CAMΦ only as it is released in response 
to stimulation by IFN-γ or microbial products like LPS. NO release was assayed to determine the 
effect of nucleotides on bone marrow derived macrophages (BMMΦ), CAMΦ and AAMΦ. In 
order to determine the effect of nucleotides on NO release and arginase I activity, macrophages 
were stimulated with a range of LPS or interleukin-4 (IL-4) concentrations to obtain an optimal 
concentration for further experiments. Firstly, the optimal concentration of LPS required to 
trigger robust NO release by macrophages was investigated (Figure 4.1A). The first concentration 
that produced significant levels of NO release was 0.5ng/ml LPS while 10ng/ml produced a 
robust response, which was selected for classically activating macrophages in all further 
experiments. In order to determine an optimal concentration of IL-4 for alternatively activating 
macrophages, a range of IL-4 concentrations was used to activate macrophages and the resulting 
phenotype assayed by arginase I activity (Figure 4.1B). The arginase I activity assay was carried 
out as described by Corraliza and colleagues (Corraliza et al, 1994).  Arginase I activity appeared 
to be robustly and consistently up-regulated at 5ng/ml of IL-4 so this concentration was selected 
for further AAMΦ experiments.  Characteristic of alternative macrophage stimulation is an 
up-regulation of arginase I activity leading to a shift of L-arginine metabolism from iNOS to 
arginase. The arginase I activity of macrophages was assayed to determine differences in L-
arginine metabolism and a possible shift of phenotype. In Figure 4.1D a comparison of arginase I 
activity between macrophage activation subsets is shown. CAMΦ have significantly higher levels 
of arginase I activity than BMMΦ but not as high as AAMΦ which have close to 10-fold higher. 
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L-arginine was administered exogenously to see if the low arginase I activity measured in CAMΦ 
was due to substrate depletion by iNOS. As can be seen in Figure 4.1D, arginase I activity was 
not enhanced by administering L-arginine to CAMΦ. In addition, the levels of NO released by 
CAMΦ were actually enhanced by the lower concentration of exogenous L-arginine 
administered, while five-fold more L-arginine (10mM) enhanced NO release levels to a lesser 
extent (Figure 4.1C). Exogenous L-arginine administered to AAMΦ did not enhance arginase I 
activity levels and became inhibitory at the higher concentration used (Figure 4.1D). In addition, 
a slight increase in NO release by AAMΦ was detected at the higher L-arginine concentration 
which, although not visible in the graph when compared to NO release by CAMΦ, was 
significant when compared to background levels of NO released by AAMΦ. 
Having selected optimal concentrations of LPS and IL-4, BMMΦ, CAMΦ and AAMΦ 
were incubated with nucleotides in order to determine their effect on NO release and arginase I 
activity. Stimulation by nucleotides did not cause NO release by BMMΦ and AAMΦ (Figure 
4.2A). It is shown here that, all nucleotides tested inhibited NO release from CAMΦ, except for 
the slowly hydrolysable analogue of ADP (β-ADP) and UDP (a P2Y6 ligand) (Figure 4.2B). This 
shows that ADP-induced inhibition of NO release by CAMΦ is not due to P2Y receptor 
activation so it could be a result of ADP hydrolysis to adenosine in culture which acts on P1 
receptors. In addition, P2Y6 receptor activation does not cause inhibition of NO release either. 
ATP-γ, which is a slowly-hydrolysable analogue of ATP, also inhibited NO release to some 
extent (30% decrease) but this inhibition was less pronounced than the 50% reduction in NO 
release induced by adenosine and NECA (an analogue of adenosine that is not taken up by 
nucleoside transporters). This shows that the inhibition of NO release caused by ATP may either 
be due to P2Y receptor activation or P1 receptor activation by adenosine generated in culture. 
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Only one concentration of nucleotides is shown here that was selected from a titration carried out 
for all nucleotides (shown in Appendix, Figures A.5 and A.6).  
In order to investigate if inhibition induced by purinergic receptor activation required the 
involvement of a specific TLR, different TLR ligands were used to activate macrophages. The 
effect of nucleotides on CAMΦ resulting from TLR4 (Ultrapure LPS) and TLR2 (Pam3C) 
activation, respectively, is shown in Figure 4.2C and D. It appears that TLR activation of any 
kind resulted in the same inhibition of NO release following purinergic receptor activation.  
 
 
 
146 
 
 
Figure 4.1: Bone marrow-derived macrophage characterisation in terms of nitric oxide (NO) release 
and arginase I activity. (A) The effect of a range of LPS concentrations on nitric oxide (NO) release by 
bone marrow-derived macrophage (BMMΦ). Levels of NO are expressed in μM nitrite measured in the 
supernatants of BMMΦ stimulated with different concentrations of LPS for 20 hours. (B) The effect of a 
range of IL-4 concentrations on arginase I activity of bone marrow-derived macrophage (BMMΦ). 
Macrophages were stimulated with increasing IL-4 concentrations for 20 hours to determine the optimal 
concentration required to obtain a robust response. Arginase I activity is expressed as μmol Urea/min per 
5 x 10
4
 cells. Arrows indicate the concentration of LPS and IL-4 selected for subsequent experiments. (C) 
A comparison of the levels of NO released by different BMMΦ activation subsets. Macrophages were 
classically or alternatively activated macrophages with 10ng/ml LPS or 5ng/ml IL-4, respectively and co-
stimulated with exogenous L-arginine at 2mM and 10mM for 20 hours. Levels of NO release are 
expressed in μM nitrite. (D) A comparison of the levels of arginase I activity in the BMMΦ activation 
subsets. Data presented are an average of triplicates + SEM from one representative experiment of n = 3. 
(*) is compared to untreated BMMΦ. ** p< 0.01, *** p< 0.001. (†) is compared to the untreated control of 
the respective macrophage type. † p< 0.05, †† p< 0.01, ††† p< 0.001, ns - not significant (p> 0.05). 
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Figure 4.2: The effect of nucleotides on NO release by bone marrow-derived macrophages. Bone 
marrow-derived macrophages (BMMΦ), classically activated macrophages (CAMΦ) and alternatively 
activated macrophages (AAMΦ) were treated with 100μM adenosine (Ado), NECA, nucleotides or the 
slowly-hydrolysable analogues of ADP and ATP (β-ADP and ATP-γ, respectively) for 20 hours. 10μM of 
the adenosine transporter inhibitor, Dipyridamole, was co-administered with adenosine, AMP, ADP and 
ATP. Levels of NO release, expressed in μM nitrite, were measured in supernatants from (A) untreated 
BMMΦ and AAMΦ, (B) CAMΦ activated with 10ng/ml LPS, (C) CAMΦ activated through TLR4 with 
10ng/ml ultrapure LPS and (D) CAMΦ activated through TLR2 with 10ng/ml Pam3C. Data presented are 
an average of triplicates + SEM from one representative xperiment of n > 3 and asterisks indicate 
statistical significance compared to the untreated control.* p< 0.05, ** p< 0.01, *** p< 0.001. 
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The effect of purinergic receptor activation by nucleotides on macrophage arginase I 
activity was investigated to determine if the inhibition of NO release was accompanied by an 
enhancement of arginase I activity, considering that it is the alternative pathway of L-arginine 
metabolism. The effects of purinergic signalling on CAMΦ arginase I activity are shown in 
Figure 4.3A. Adenosine increased arginase I activity while its analogue, NECA, caused an even 
higher increase as it cannot be taken up by cells or be metabolised. It should be noted that 
Dipyridamole, a nucleoside transporter inhibitor used in other assays to prevent adenosine 
uptake, was not used in arginase I activity assays as it was found to interfere with this assay. β-
ADP stimulation did not increase arginase I activity while stimulation with ATP-γ caused a slight 
increase, possibly due to slow hydrolysis to adenosine over time (Figure 4.3A). 
 The up-regulatory effect of adenosine stimulation on CAMΦ arginase I activity was 
restricted to LPS-activated macrophages, as IFN-γ-activated macrophages did not respond to 
adenosine stimulation in the same way, despite the fact that stimulation of macrophages with 
IFN-γ also results in classical activation (Figure 4.3B). Therefore, it appears that TLR activation 
is necessary for up-regulation of CAMΦ arginase I activity by P1R activation. CAMΦ were 
stimulated with adenosine, NECA and ADP at three different concentrations and the optimal 
concentration for the increase observed was 150μM, while NECA produced a similar increase at 
100μM (Figure 4.3C). In CAMΦ, NECA always induced higher levels of arginase I activity than 
adenosine and ADP, which induced similar levels at 100μM and 150μM. 
AAMΦ arginase I activity was also affected by nucleotides although to a lesser extent due 
to the higher basal levels (Figure 4.4A). Adenosine/NECA induced the highest increase while 
AMP, ADP, ATP, UDP induced a slight but significant increase. β-ADP stimulation did not lead 
to an increase in arginase I activity while stimulation with ATP-γ produced a slight increase. 
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AAMΦ were stimulated with adenosine, NECA and ADP at three different concentrations to 
determine if there was any concentration dependence (Figure 4.4B). NECA produced a higher 
increase at 100μM, while the increase was comparatively lower for all the concentrations of ADP 
tested. Adenosine induced a more gradual increase in arginase I activity than NECA in AAMΦ.  
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Figure 4.3: The effect of nucleotides on classically activated macrophage (CAMΦ) arginase I 
activity. Macrophages were classically activated either with 10ng/ml LPS or IFN-γ and incubated with 
nucleotides for 20 hours before measuring arginase I activity. (A) The levels of arginase I activity 
measured after incubation of LPS-activated CAMΦ with 100μM adenosine, NECA, AMP, ADP, ATP or 
the slowly hydrolysable analogues of ADP and ATP (β-ADP and ATP-γ, respectively). (B) A comparison 
of arginase I activity in IFN-γ and LPS - activated macrophages. (C) The effect of 3 different 
concentrations of adenosine, NECA and ADP on CAMΦ arginase I activity is shown after 20 hours of 
culture. 10μM of the adenosine transporter inhibitor, Dipyridamole, was co-administered with adenosine, 
AMP, ADP and ATP. Arginase I activity is expressed as μmol Urea/ min per 5 x 104 cells. Data presented 
are an average of triplicates + SEM from one representative experiment of n > 3 and asterisks indicate 
statistical significance. (*) is compared to untreated BMMΦ.* p< 0.05, ** p< 0.01, *** p< 0.001, ns - not 
significant (p> 0.05). (†) compares to basal arginase I activity in CAMΦ activated with LPS. †† p< 0.01, 
ns - not significant (p> 0.05). 
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Figure 4.4: The effect of nucleotides on alternatively activated macrophage (AAMΦ) arginase I 
activity. Macrophages were alternatively activated with 5ng/ml IL-4 and incubated with nucleotides for 
20 hours before measuring arginase I activity. (A) The levels of arginase I activity measured after 
incubation of AAMΦ with 100μM adenosine, NECA, AMP, ADP, ATP or the slowly hydrolysable 
analogues of ADP and ATP (β-ADP and ATP-γ, respectively). (B) The effect of 3 concentrations of 
adenosine, NECA and ADP on AAMΦ arginase I activity after 20 hours of culture. Arginase I activity is 
expressed as μmol Urea/ min per 5 x 104 cells. Data presented are an average of triplicates + SEM from 
one representative experiment of n > 3 and asterisks indicate statistical significance compared to the 
untreated control. * p< 0.05, ** p< 0.01, *** p< 0.001. 
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Cytokine release 
Cytokine release is another major effector function of macrophages which differs 
depending on macrophage activation state. Pro-inflammatory cytokines such as IL-6 and TNF-α 
are produced by CAMΦ in a Th1 environment or in response to LPS. LPS also induces IL-10 
production by CAMΦ, while BMMΦ and AAMΦ do not produce any cytokines in vitro. In the 
presence of adenosine or nucleotides, IL-6 and TNF-α release from CAMΦ were reduced while 
IL-10 release was up-regulated (Figure 4.7).  
Firstly, the optimal concentration of LPS that induced cytokine release was investigated 
by titrating the LPS concentration (Figure 4.5). It appears that 0.5-1ng/ml LPS produced 
submaximal cytokine release, while stimulation with concentrations above 1ng/ml resulted in a 
plateau for IL-6 and IL-10. Hence, 10ng/ml LPS was used a suitable concentration for triggering 
optimal cytokine release for further experiments. The effects adenosine and nucleotides exerted 
on the different macrophage subsets were then assayed after having determined an optimal 
concentration (Appendix, Figures 7-10). Stimulation with exogenous nucleotides had no effect on 
cytokine release from BMMΦ and AAMΦ and the low background levels of IL-6 that were 
observed were not significant (Figure 4.6).  
Pro-inflammatory cytokine release from CAMΦ in response to purinergic receptor 
stimulation by nucleotides was similar to the inhibitory pattern observed for NO release (Figure 
4.7A and B). On the other hand, purinergic receptor stimulation led to an enhancement in the 
levels of IL-10 released by CAMΦ (Figure 4.7C). Stimulation with the slowly hydrolysable 
analogue of ADP, β-ADP had no effect on cytokine release levels, therefore, the fact that ADP 
stimulation had an effect on cytokine levels was probably a result of hydrolysis to adenosine. 
153 
 
ATP and ATP-γ stimulation had similar inhibitory effect on cytokine release, although ATP-γ-
induced effects were always less pronounced. The response to adenosine and nucleotides was 
further investigated pharmacologically to dissect which purinergic receptors are involved.  
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Figure 4.5: The effect of LPS concentration on cytokine release from bone marrow-derived 
macrophage (BMMΦ). Levels of cytokine release measured in the supernatants of BMMΦ stimulated 
with different concentrations of LPS for 20 hours are expressed in pg/ml. (A) The effect of LPS on TNF-α 
release, (B) The effect of LPS on IL-6 release and (C) The effect of LPS on IL-10 release. Data presented 
are an average of triplicates + SEM from one representative experiment of n > 3. 
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Figure 4.6: The effect of nucleotides on cytokine release from BMMΦ and AAMΦ. Macrophages 
were alternatively activated with 5ng/ml IL-4 or cultured with standard medium and incubated with 
nucleotides for 20 hours. The levels of cytokine release after stimulation of  BMMΦ and AAMΦ with 
100μM adenosine, NECA, AMP, ADP, ATP or the slowly hydrolysable analogues of ADP and ATP (β-
ADP and ATP-γ, respectively) were measured after 20 hours of culture. 10μM of the adenosine 
transporter inhibitor, Dipyridamole, was co-administered with adenosine, AMP, ADP and ATP. (A) The 
effect on TNF-α release, (B) The effect on IL-6 release and (C) The effect on IL-10 release. Data 
presented are an average of triplicates + SEM from one representative experiment of n > 3. 
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Figure 4.7: The effect of nucleotides on cytokine release from CAMΦ. Macrophages were classically 
activated with 10ng/ml LPS and incubated with nucleotides for 20 hours. The levels of cytokine release 
measured after incubation of CAMΦ with 100μM adenosine, NECA, AMP, ADP, ATP or the slowly 
hydrolysable analogues of ADP and ATP (β-ADP, ATP-γ, respectively). 10μM of the adenosine 
transporter inhibitor, Dipyridamole, was co-administered with adenosine, AMP, ADP and ATP. (A) The 
effect on TNF-α release, (B) The effect on IL-6 release and (C) The effect on IL-10 release. Data 
presented are an average of triplicates + SEM from one representative experiment of n > 3. ** p< 0.01, 
*** p< 0.001. 
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4.2.2 Characterisation of the receptors involved in murine macrophage purinergic 
signalling  
Nitric oxide release vs arginase I activity  
In order to confirm and further characterise the effects induced by adenosine administered 
directly or resulting from hydrolysis of adenine nucleotides on nitric oxide release and arginase I 
activity, P1 receptor (P1R) agonists and antagonists were used. The concentration of agonists and 
antagonists used (Materials and Methods, 2.4) was selected from a range of concentrations tested 
(data not shown). Considering that adenosine acts on all P1 receptors with varying affinities, 
agonists that act on specific P1 receptors were used in order to see if adenosine-induced effects 
could be mimicked by stimulation of one particular receptor. As can be seen in Figure 4.8A, A2A 
receptor (A2AR) activation is also capable of inhibiting NO release from CAMΦ which is also 
supported by the fact that NECA, which has a higher affinity for the A2 receptors, is also a potent 
inhibitor of NO release. An A2B receptor (A2BR) agonist has been used by Eckle et al, 2007 but is 
restricted to use by Bayer Healthcare and was not available for use in this study.  
 In addition to using P1R antagonists to characterise the receptor via which adenosine 
inhibited NO release and enhanced arginase I activity, they were also used to determine if AMP, 
ADP and ATP also inhibited NO release via P1R stimulation as a result of adenosine generation 
in culture. The results obtained and presented in Figures 8 and 9 show that antagonising A2B 
receptor activation reverses the effects induced by adenosine, and its stable analogue NECA, on 
NO release and arginase I activity. Specifically, it is shown in Figure 4.8B and C that, the A2BR 
antagonist MRS1754 significantly inhibited both adenosine and NECA-induced effects restoring 
the levels of NO release to levels detected when CAMΦ were cultured alone (-). Therefore, 
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adenosine mediated its effects via A2BR activation and it appears that purinergic receptor 
activation by nucleotides also involved the A2B receptor. Specifically, it can be seen in Figure 
4.8D, E and F that AMP, ADP and ATP-induced inhibition of NO release was also reversed by 
A2BR antagonism. Furthermore, the fact that no AMP purinergic receptor has been reported 
suggests that ADP and ATP-induced effects are not due to AMP generation and that AMP-
induced effects are due to its hydrolysis to adenosine.  
In terms of arginase I activity, the use of P1R agonists showed that the up-regulation 
induced by adenosine was mimicked by A2R activation by NECA as well as by A2AR-activation 
specifically by CGS21680 (Figure 4.9A). Similarly to NO release, P1R antagonism showed that 
up-regulation of arginase I activity induced by adenosine was also inhibited by targeting the 
A2BR. This was observed in both CAMΦ and AAMΦ as can be seen in Figure 4.9B.  
Further confirmation that nucleotide-induced effects were mediated via P1 receptor 
activation was obtained from experiments with P2Y receptor (P2YR) antagonists. As is shown in 
Figure 4.10, the inhibition in NO release observed when CAMΦ were stimulated with ADP and 
ATP was not reversed by the P2YR antagonists, Suramin (A) or PPADS (B). Furthermore, the 
slowly hydrolysable nucleotides -ADP and ATP-γ, which were also used as controls to ensure 
P2YR activation, induced the same effects on NO release both in the presence and absence of 
P2YR antagonists. In fact, the slight decrease in NO release observed with ATP-γ was not 
reversed by P2YR antagonists, so it was not due to P2YR ligation by ATP, or ADP that could be 
generated from ATP degradation. 
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Figure 4.8: Pharmacological characterisation of P1R-mediated effects on NO release from CAMΦ. 
Macrophages were cultured with 10ng/ml LPS in the presence or absence of P1 receptor agonists (A) or 
antagonists (B-F). (A) The effect of the following agonists: 100 μM of adenosine + 10μM Dipyridamole 
(DP), NECA (A2R), CPA (A1R), CGS21680 (A2AR) or IB-MECA (A3R). Antagonists were used to 
reverse effects elicited by (B) adenosine, (C) NECA, (D) AMP, (E) ADP, (F) ATP. Antagonists: DPCPX 
(A1R), ZM241385 (A2AR), MRS1753 (A2BR) or MRS1523 (A3R). Levels of NO release are expressed as 
µM nitrite and the data presented are an average of triplicates + SEM from one representative experiment 
of n > 3 and asterisks indicate statistical significance compared to the untreated control. * p< 0.05, *** p< 
0.001. (†) is compared to the effect induced by the respective nucleoside/nucleotide. †† p< 0.01, ††† p< 
0.001. 
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Figure 4.9: Pharmacological characterisation of P1R-mediated effects on CAMΦ and AAMΦ 
arginase I activity. Macrophages were cultured with 5ng/ml IL-4 in the presence or absence of P1 
receptor agonists (A) or antagonists (B). Agonists: 100μM of adenosine + 10μM Dipyridamole (DP), 
NECA, CPA (A1R agonist), CGS21680 (A2AR agonist) or IB-MECA (A3R agonist). Antagonists: DPCPX 
(A1R antagonist), ZM241385 (A2AR antagonist), MRS1753 (A2BR antagonist) or MRS1523 (A3R 
antagonist). Arginase I activity is expressed as μmol Urea/ min per 5 x 104 cells. The data presented are an 
average of triplicates + SEM from one representative experiment of n = 3 and asterisks/daggers indicate 
statistical significance compared to the untreated control. ** p< 0.01, *** p< 0.001. (†) is compared to the 
respective untreated control. †† p< 0.01, ††† p< 0.001. 
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Figure 4.10: Pharmacological characterisation of P2YR-mediated effects on NO release from 
CAMΦ. Macrophages were activated with 10ng/ml LPS and incubated with 100μM nucleotides in the 
presence or absence of 2 different non-selective P2Y receptor antagonists for 20 hours. (A) The effect of 
Suramin on ADP- and ATP-induced inhibition of NO release by CAMΦ (B) The effect of PPADS 
(Pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid) on ADP- and  ATP-induced  inhibition of NO 
release by CAMΦ. The data presented are an average of triplicates + SEM from one representative 
experiment of n = 3 and asterisks indicate statistical significance compared to the untreated control. ** p< 
0.01, *** p< 0.001, ns - not significant (p> 0.05). 
162 
 
Cytokine release  
Cytokine responses following activation of purinergic signalling were also characterised 
pharmacologically. P1 receptor antagonists were used to antagonise adenosine/NECA-induced 
effects as well as the effects induced by nucleotides that could potentially be converted to 
adenosine in culture. The results presented in Figure 4.11 show that TNF-α release was inhibited 
by adenosine via both A2A and A2B receptors, as antagonism of both receptors by ZM241385 and 
MRS1754, respectively, led to partial reversal of adenosine inhibition. Levels of IL-6 release 
appeared to be affected in the same way as TNF-α release by adenosine stimulation as a similar 
pattern of antagonism was observed (Figure 4.11A and B). In addition to characterising the P1R 
involved in adenosine-induced inhibition of TNF-α and IL-6 release from CAMΦ, AMP, ADP 
and ATP were also used to stimulate cells in the presence of P1R antagonists. As can be seen in 
Figure 4.11 C, D and E, the inhibition of TNF-α release by AMP, ADP and ATP was partially 
reversed both by A2A and A2B receptor antagonists. Similarly, the levels of IL-6 release were 
partially restored to CAMΦ background levels when AMP, ADP and ATP were used to stimulate 
cells in the presence of A2A and A2B receptor antagonists (Figure 4.12 C, D and E). As was 
observed with both TNF-α and IL-6 release, antagonism of adenosine/NECA and AMP resulted 
in more efficient reversal of inhibition when compared to the reversal achieved with ADP and 
ATP. In order to confirm that both A2A and A2B receptors have an additive effect in adenosine-
induced inhibition of IL-6 and TNF-α release which cannot be properly reversed by inhibiting 
one of the two receptors, experiments were carried out using a combination of both A2A and A2B 
receptor antagonists (Figure 4.13). Indeed, when a cocktail of A2 receptor antagonists was used 
the adenosine and NECA-induced inhibition of IL-6 and TNF-α release was completely reversed 
and levels were restored to basal levels detected when CAMΦ were cultured in medium (-).  
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In the case of IL-10 release, which was enhanced in response to adenosine, 
pharmacological characterisation showed that only one P1R was involved. As it is shown in 
Figure 4.14A, only the A2B receptor antagonist (MRS1754) reversed the adenosine-induced 
enhancement of IL-10 release by CAMΦ. This was also the case for NECA, AMP, ADP and 
ATP as can be seen in Figure 4.14 B, C D and E, suggesting that the active ligand is adenosine 
resulting from nucleotide hydrolysis in culture. Furthermore, the A2BR antagonist caused 
complete restoration of IL-10 release levels to basal levels when incubated with all the 
nucleotides tested. This observation may be due to the fact that only one receptor was involved, 
therefore, adenosine stimulation of this particular receptor could be blocked by a specific P1R 
antagonist.   
Taken together these data show that, similar to the observations made when investigating 
NO release and arginase I activity in this study, the cytokine responses triggered in the presence 
of AMP, ADP and ATP were reversed in a way that points to adenosine as the active ligand in 
activation of purinergic signalling.  
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Figure 4.11: Pharmacological characterisation of P1R-mediated effects on TNF-α release from 
CAMΦ. Macrophages were cultured with 10ng/ml LPS in the presence or absence of P1 receptor 
antagonists (A-E). Antagonists were used to reverse effects elicited by (A) adenosine, (B) NECA, (C) 
AMP, (D) ADP, (E) ATP. DPCPX (A1R antagonist), ZM241385 (A2AR antagonist), MRS1753 (A2BR 
antagonist) or MRS1523 (A3R antagonist). Levels of TNF-α release are expressed as pg/ml and the data 
presented are an average of triplicates + SEM from one representative experiment of n > 3 and asterisks 
indicate statistical significance compared to the untreated control. *** p< 0.001. (†) is compared to the 
effect induced by the respective nucleoside/nucleotide. † p< 0.05, †† p< 0.01, ††† p< 0.001. 
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Figure 4.12: Pharmacological characterisation of P1R-mediated effects on IL-6 release from 
CAMΦ. Macrophages were cultured with 10ng/ml LPS in the presence or absence of P1 receptor 
antagonists (A-E). Antagonists were used to reverse effects elicited by (A) adenosine, (B) NECA, (C) 
AMP, (D) ADP, (E) ATP. DPCPX (A1R antagonist), ZM241385 (A2AR antagonist), MRS1753 (A2BR 
antagonist) or MRS1523 (A3R antagonist). Levels of IL-6 release are expressed as pg/ml and the data 
presented are an average of triplicates + SEM from one representative experiment of n > 3 and asterisks 
indicate statistical significance compared to the untreated control. *** p< 0.001. (†) is compared to the 
effect induced by the respective nucleoside/nucleotide. †† p< 0.01, ††† p< 0.001. 
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Figure 4.13: Pharmacological characterisation of P1R-mediated effects on TNF-α and IL-6 release 
from CAMΦ. Macrophages were cultured with 10ng/ml LPS in the presence or absence of P1 receptor 
antagonists (A-D). Antagonists, ZM241385 (A2AR antagonist) and MRS1753 (A2BR antagonist), were 
used to reverse effects elicited by (A, C) adenosine, (B, D) NECA. The levels of TNF-α (A, B) and IL-6 
(C, D) release are expressed as pg/ml and the data presented are an average of triplicates + SEM from one 
representative experiment and asterisks indicate statistical significance compared to the untreated control. 
*** p< 0.001. (†) is compared to the effect induced by adenosine or NECA alone. †† p< 0.01, ††† p< 
0.001. 
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Figure 4.14: Pharmacological characterisation of P1R-mediated effects on bone marrow derived 
macrophage IL-10 release. Macrophages were cultured with 10ng/ml LPS in the presence or absence of 
P1 receptor antagonists (A-E). Antagonists were used to reverse effects elicited by (A) adenosine, (B) 
NECA, (C) AMP, (D) ADP, (E) ATP. DPCPX (A1R antagonist), ZM241385 (A2AR antagonist), 
MRS1753 (A2BR antagonist) or MRS1523 (A3R antagonist). The levels of IL-10 release are expressed as 
pg/ml and the data presented are an average of triplicates + SEM from one representative experiment of n 
> 3 and asterisks indicate statistical significance compared to the untreated control. *** p< 0.001. (†) is 
compared to the effect induced by the respective nucleoside/ nucleotide. † p< 0.05, †† p< 0.01, ††† p< 
0.001, ns - not significant (p> 0.05). 
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Despite the fact that purinergic receptor-induced cytokine responses were blocked by P1R 
antagonists, P2Y receptor involvement could not be ruled out. Therefore, P2YR antagonists were 
used to determine if ADP and ATP-induced the cytokine responses observed by direct action on 
their respective P2YR, before being degraded to adenosine. As it is shown in Figure 4.15A and 
B, the ADP and ATP-induced inhibition of TNF-α and IL-6 release from CAMΦ was not 
reversed by the P2YR antagonist, Suramin. The same result was obtained with a second P2YR 
antagonist, PPADS which is shown in Figure 4.16A and B. These P2YR antagonists were 
ineffective at reversing the ADP and ATP-induced enhancement of IL-10 release (Figure 4.15C 
and 16C). The slowly hydrolysable analogue of ADP (β-ADP) did not affect cytokine release 
from CAMΦ, which shows that ATP-induced cytokine responses were not due to generation of 
ADP. Furthermore, the fact that the slowly hydrolysable analogue of ATP (ATP-γ) induced 
similar responses to ATP that were not reversed by the P2YR antagonists shows that, ATP-
induced responses were not due to P2YR activation either.  
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Figure 4.15: Pharmacological characterisation of P2YR-mediated effects on cytokine release from 
CAMΦ. Macrophages were cultured with 10ng/ml LPS with 100μM nucleotides in the presence or 
absence of a non-selective P2Y receptor antagonist for 20 hours. The effect of Suramin on ADP- and 
ATP-induced effects on cytokine release by CAMΦ was investigated for (A) TNF-α, (B) IL-6 and (C) IL-
10 release. The data presented are an average of triplicates + SEM from one representative experiment of 
n = 3 and asterisks indicate statistical significance compared to the respective untreated control.** p< 
0.01, *** p< 0.001, ns - not significant (p> 0.05). 
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Figure 4.16: Pharmacological characterisation of P2YR-mediated effects on cytokine release from 
CAMΦ. Macrophages were cultured with 10ng/ml LPS with 100μM nucleotides in the presence or 
absence of a non-selective P2Y receptor antagonist for 20 hours. The effect of PPADS 
(Pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid) on ADP- and ATP-induced  effects on (A) TNF-α, 
(B) IL-6 and (C) IL-10 release by CAMΦ was investigated. The data presented are an average of 
triplicates + SEM from one representative experiment of n = 3 and asterisks indicate statistical 
significance compared to the respective untreated control. ** p< 0.01, *** p< 0.001, ns - not significant 
(p> 0.05). 
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4.2.3 Downstream effectors of purinergic signalling in murine macrophages 
 Purinergic receptors are G-protein coupled so they mediate their effects by engaging 
different G subunits, namely Gs, Gi or Gq. Gs and Gi subunits act via adenylyl cyclase activation 
or inhibition, respectively, and thus control levels of cAMP. Gq subunits act via phospholipase C 
(PLC) and/or PI3 kinase activation. Ultimately these pathways converge to signal transcriptional 
activation in the nucleus either via NF-κB or p38/MAPK pathways. Inhibitors acting at certain 
points in the pathways mentioned were used in order to dissect how nucleotides mediate their 
effects. 
Involvement of cAMP in purinergic signalling 
In order to determine if the effects downstream of adenosine stimulation were Gs/i – 
mediated, macrophages were first incubated with an analogue of cAMP, Rp-cAMP. Unlike 
cAMP, Rp-cAMP is resistant to metabolism by phosphodiesterase (PDE) and can bind protein 
kinase A to prevent its activation by cAMP. The effect exerted by Rp-cAMP on P1R-induced 
inhibition of NO release from CAMΦ is shown in Figure 4.17A, B, C. Inhibition of NO release 
induced by adenosine and NECA was partly restored at the higher concentration of Rp-cAMP 
used (50μM). Similarly, when ultrapure LPS was used to classically activate macrophages via 
TLR4, adenosine-induced inhibition of NO release was partly restored by 25μM Rp-cAMP while 
at 50μM Rp-cAMP, NO release levels were almost completely restored. Rp-cAMP had no effect 
on BMMΦ and AAMΦ NO release.  
Arginase I activity has been shown so far to change reciprocally to NO release, therefore, 
arginase I activity following inhibition of cAMP accumulation was also investigated.  As it is 
shown in Figure 4.18A, the increase in CAMΦ arginase I activity induced by adenosine/NECA 
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was inhibited by 50μM Rp-cAMP by approximately 75%, while 25μM Rp-cAMP only caused a 
20% inhibition. In addition, Rp-cAMP also inhibited basal arginase I activity in CAMΦ. TLR4-
activated CAMΦ, stimulated with ultrapure LPS, whose arginase I activity was enhanced by 
adenosine/NECA, also required cAMP elevation for this response, as Rp-cAMP reversed 
adenosine and NECA induced up-regulation of arginase I activity by 50% at the higher 
concentration used (Figure 4.18B).   
The effect of inhibiting cAMP elevation on arginase I activity was also investigated in 
AAMΦ. The results shown in Figure 4.18C, confirm that up-regulation of arginase I activity 
requires cAMP accumulation as Rp-cAMP administration to AAMΦ resulted in a 10 to 20% 
reduction in basal arginase I activity levels. Furthermore, the increase in arginase I activity 
induced by adenosine and NECA was restored to background levels in AAMΦ by both 
concentrations of Rp-cAMP tested (Figure 4.18C).  
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Figure 4.17: The effect of cAMP inhibition on adenosine-induced inhibition of NO release from 
macrophages. Macrophages were classically activated with 10ng/ml LPS (A) or 10ng/ml ultrapure LPS 
(B) or alternatively activated with 5ng/ml IL-4 (C). The inhibiting cAMP elevation with 2different 
concentrations of Rp-cAMP on the adenosine-induced inhibition of NO release after 20 hours of culture 
was investigated. Levels of NO release are expressed as μM nitrite and the data presented are an average 
of triplicates + SEM from one representative experiment of n > 3 and asterisks indicate significance 
compared to untreated control.* p< 0.05, *** p< 0.001. (†) is compared to the effect induced by adenosine 
or NECA alone. †† p< 0.01, ††† p< 0.001, ns - not significant (p> 0.05). 
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Figure 4.18: The effect of cAMP inhibition on adenosine-induced enhancement of macrophage 
arginase I activity. Macrophages were classically activated with 10ng/ml LPS (A) or 10ng/ml ultrapure 
LPS (B) or alternatively activated with 5ng/ml IL-4 (C). The effect of inhibiting cAMP elevation with 2 
different concentrations of Rp-cAMP on the adenosine-induced enhancement of arginase I activity after 
20 hours of culture was investigated. Arginase I activity is expressed as μmol Urea/ min per 5 x 104 cells 
and the data presented are an average of triplicates + SEM from one representative experiment of n > 3 
and asterisks indicate significance com pared to the respective untreated control. ** p< 0.01, *** p< 
0.001. 
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Compounds which elevate cAMP levels were then used to see if elevating cAMP levels 
exogenously was enough to mimic the adenosine-induced responses. Forskolin is an adenylate 
cyclase activator (Schneyer et al, 1983) which causes increased cAMP production while rolipram 
is a selective Phosphodiesterase (PDE) IV inhibitor which prevents cAMP turnover (Greten et al, 
1995; Griswold et al, 1993). In CAMΦ, arginase I activity was increased by treatment with 
forskolin or rolipram (Figure 4.19A) which was accompanied by a decrease in NO release at 
10μM (Figure 4.19B). The concentration of DMSO used to solubilise these compounds was 
tested on cells to determine their DMSO tolerance. The final concentration of DMSO in 50μM 
forskolin was toxic to the cells and caused inhibition of NO release so forskolin was used at 
10μM in further experiments. The final concentration of DMSO in rolipram was much lower than 
in forskolin and since rolipram was effective at both concentrations tested, 5μM was selected for 
subsequent experiments. A comparison of NO release in different CAMΦ (LPS, Pam3C for 
TLR2 and ultrapure LPS for TLR4) was carried out (Figure 4.19C). It appears that, 10μM 
forskolin and 5μM rolipram had the same inhibitory effect in all types of CAMΦ. LPS-activated 
CAMΦ generally produced higher levels of NO which might be due to the presence of more than 
one TLR ligand, leading to activation of more TLRs resulting in an additive response.  
In order to further investigate cAMP involvement, cAMP elevators were also combined 
with adenosine and NECA. The levels of NO released from CAMΦ stimulated with adenosine or 
NECA combined with forskolin or rolipram were measured and the results are shown in Figure 
4.20. Forskolin and rolipram caused a 10% decrease in NO release from CAMΦ, while the 
inhibition induced by adenosine and NECA was enhanced by elevating cAMP levels. 
Specifically, as shown in Figure 4.20A, forskolin increased adenosine and NECA-induced 
inhibition of NO release by 10%, while rolipram caused a further 50% decrease (Figure 4.20B). 
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Figure 4.19: The effect of cAMP elevators on NO release by macrophages and arginase I activity. 
Macrophages were cultured in standard medium or classically activated with 10ng/ml LPS, ultrapure LPS 
(UP-LPS) or Pam3C for 20 hours. (A) The effect of 2 concentrations of forskolin and rolipram on BMMΦ 
arginase I activity, expressed as μmol Urea/ min per 5 x 104 cells. (B) The effect of forskolin and rolipram 
on CAMΦ (LPS) NO release, expressed as μM nitrite. DMSO controls corresponding to the final 
concentration of DMSO used to solubilise compounds were also included. The final concentration of 
DMSO in forskolin was the same as the forskolin concentration while 5μM rolipram corresponds had a 
final concentration of 10μM DMSO. (C) The effect of 10μM forskolin and 5μM rolipram on the levels of 
NO released by CAMΦ (LPS, Pam3C and ultrapure LPS – activated). The data presented are an average 
of triplicates + SEM from one representative experiment of n = 3 and asterisks indicate significance 
compared to the respective untreated control. *** p< 0.001. 
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Figure 4.20: The effect of cAMP elevators on adenosine/NECA-induced inhibition of NO release by 
CAMΦ. Macrophages were classically activated with 10ng/ml LPS and the effect of 2 cAMP elevators on 
adenosine – induced inhibition of NO release investigated after 20 hours of culture. (A) The effect of 
10μM forskolin on the inhibition of NO release by CAMΦ induced by 100μM adenosine or 100μM 
NECA, expressed as μM nitrite. (B) The effect of 5μM rolipram on the inhibition of NO release by 
CAMΦ induced by 100μM adenosine or 100μM NECA, expressed as μM nitrite. The data presented are 
an average of triplicates + SEM from one representative experiment of n = 3 and asterisks indicate 
significance. *** p< 0.001. 
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Finally, the dependence of cytokine release on cAMP elevation was also investigated in 
CAMΦ and the results obtained are shown in Figure 4.21. cAMP elevation by forskolin and 
rolipram caused a reduction in the levels of IL-6 (Figure 4.21A) and TNF-α (Figure 4.21B), while 
the opposite was true for the levels of IL-10 (Figure 4.21C). The concentration of DMSO used to 
solubilise these compounds was tested on cells to determine their DMSO tolerance. The final 
concentration of DMSO in 50μM forskolin was again toxic to the cells as IL-6 and TNF-α release 
levels were reduced by DMSO alone. The levels of IL-10 release were not affected by the DMSO 
levels in these compounds. Having selected 10μM forskolin and 5μM rolipram as optimal 
concentrations for inducing a measurable difference in cytokine levels, CAMΦ were stimulated 
with adenosine or NECA in the presence of forskolin or rolipram. Both these compounds caused 
a 50% reduction in the levels of TNF-α (Figure 4.22A) and IL-6 (Figure 4.22B) released by 
CAMΦ that were stimulated with either adenosine or NECA. The decrease in the levels of these 
cytokines induced in CAMΦ stimulated with adenosine/NECA was more pronounced than the 
reduction detected in basal CAMΦ levels showing that, exogenous elevation of cAMP levels led 
to an additive response. As shown in Figure 4.22C, IL-10 release was enhanced following cAMP 
elevation as stimulation with both forskolin and rolipram resulted in the levels of IL-10 released 
by CAMΦ being 10% higher. 
In general, it was observed that when cAMP elevators were used to stimulate 
macrophages, effector functions such as NO and cytokine release were affected in the same way 
as when adenosine was present in culture. The effect of adenosine on cAMP levels was further 
analysed at the molecular level to see if the shift caused between iNOS and arginase I metabolism 
of L-arginine was due to transcriptional up-regulation of arginase I or due to a shift in 
metabolism of L-arginine by iNOS.  
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Figure 4.21: The effect of cAMP elevators on cytokine release from CAMΦ. Macrophages were 
classically activated with 10ng/ml LPS and the effect of 2 cAMP elevators on cytokine release 
investigated after 20 hours of culture. The effect of 2 concentrations of forskolin and rolipram on TNF-α 
(A) IL-6 (B) and IL-10 (C) release from CAMΦ is shown expressed in pg/ml. DMSO controls 
corresponding to the final concentration of DMSO used to solubilise compounds were also included. The 
final concentration of DMSO in forskolin was the same as the forskolin concentration while 5μM rolipram 
corresponds had a final concentration of 10μM DMSO. The data presented are an average of triplicates + 
SEM from one representative experiment of n = 3 and asterisks indicate significance. ** p< 0.01, *** p< 
0.001, ns - not significant (p> 0.05). 
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Figure 4.22: The effect of cAMP elevators on cytokine release from CAMΦ following stimulation 
with adenosine/NECA. Macrophages were classically activated with 10ng/ml LPS and the effect of 2 
cAMP elevators on adenosine-induced inhibition of cytokine release investigated. The effect of 10μM 
forskolin and 5μM rolipram on TNF-α (A), IL-6 (B) and IL-10 (C) release by CAMΦ stimulated with 
100μM adenosine or 100μM NECA is shown expressed in pg/ml.  The data presented are an average of 
triplicates + SEM from one representative experiment of n = 3 and asterisks indicate significance. ** p< 
0.01, *** p< 0.001. 
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Quantitative PCR (Q-PCR) was carried out to determine arginase I mRNA levels 
following macrophage stimulation with the two cAMP elevators used previously in functional 
assays. Arginase I transcript levels were up-regulated in all 3 macrophage types following 
stimulation with forskolin or rolipram (Figure 4.23). In particular, it is shown in Figure 4.23A 
that, forskolin led to a 5-fold increase in arginase I mRNA levels in BMMΦ and CAMΦ, while in 
AAMΦ only a 3-fold increase was detected. Rolipram stimulation of BMMΦ and AAMΦ led to a 
2-fold and 3-fold increase in arginase I mRNA levels, respectively, while CAMΦ arginase I 
mRNA levels were up-regulated by 15-fold (Figure 4.23B).  
In order to see if adenosine stimulation of macrophages caused a similar up-regulation in 
arginase I transcripts, RT-PCR analysis was carried out on mRNA extracted from cells stimulated 
with the adenosine analogue, NECA, to ensure sustained P1R stimulation. In addition to arginase 
I mRNA, the presence of transcripts of markers of alternative activation in response to NECA 
was also investigated. The RT-PCR analysis is shown in Figure 4.24. Arginase I transcripts were 
detected in CAMΦ stimulated with NECA. The presence of the non-specific arginase I PCR 
product in the un-stimulated CAMΦ reaction, which is absent from the NECA-stimulated 
CAMΦ, suggests that, the levels of arginase I mRNA were probably increased by NECA-
stimulation because binding of arginase I primers to non-specific cDNA was prevented by the 
higher abundance of specific arginase I cDNA. A comparison was carried out between P1R 
stimulation with NECA and P2YR stimulation with β-ADP to determine if the latter also leads to 
up-regulation of marker transcripts. Interestingly, β-ADP stimulation of CAMΦ led to inhibition 
of arginase I transcript expression. Neither NECA nor β-ADP stimulation of BMMΦ induced any 
detectable increase in the transcript levels of the markers of alternative activation tested. In 
AAMΦ, the high basal levels of all markers of alternative activation made it hard to distinguish 
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between the different stimulants used. For this reason as well as to clarify if arginase I transcripts 
were indeed up-regulated in CAMΦ, Q-PCR was also carried out on the same mRNA samples 
used for RT-PCR.  
It is evident from the Q-PCR analysis shown in Figure 4.25 that, stimulation of BMMΦ, 
CAMΦ and to a lesser extent, AAMΦ, led to up-regulation of arginase I transcript levels. In 
addition, it can be seen that, although not detected by RT-PCR, arginase I transcript levels were 
also up-regulated significantly in BMMΦ (Figure 4.25A). However, the increase in arginase I 
transcript levels induced by NECA in CAMΦ (Figure 4.25B) was almost 2-fold more than the 
increase induced in BMMΦ, which may explain why this increase was only detected by the more 
sensitive Q-PCR technique. In AAMΦ, arginase I transcript levels only increased by 5-fold 
following NECA stimulation possibly due to the fact that, arginase I transcripts are already 
abundantly expressed in this macrophage type (Figure 4.25C).  
In the case of β-ADP, the results shown in Figure 4.26 did not reveal any significant 
changes in the levels of markers of alternative activation expressed by BMMΦ (Figure 4.26A) 
and CAMΦ (Figure 4.26B). An increase in Fizz1 and Ym1 levels was apparent in AAMΦ 
stimulated with β-ADP corresponding to 4 and 10-fold, respectively (Figure 4.26C). In all the 
macrophage types, arginase I transcript levels were not affected by P2YR stimulation with β-
ADP. 
.  
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Figure 4.23: The effect of cAMP elevators on BMMΦ arginase I transcript levels.  Macrophages were 
cultured in standard medium and treated with either 10μM forskolin (A) or 5μM rolipram (B) for 20 
hours. The fold changes presented are relative to untreated BMMΦ after normalising to β-actin mRNA 
and error bars show standard error of the mean from one experiment carried out in triplicate. Asterisks 
indicate significance. ** p< 0.01, *** p< 0.001. 
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Figure 4.24: Detection of transcripts of markers of alternative activation following NECA or β-ADP 
stimulation. Macrophages were stimulated with 100μM NECA or 100μM β-ADP for 20 hours and 
mRNA levels of mannose receptor (MR), arginase I (Arg1), Fizz1 and Ym1 were detected using RT-PCR. 
PCR products of expected sizes, determined by the ladder shown annotated on the left in bp, were 
obtained (see Materials and Methods, Table 2.1A). Actin primers were used in reactions to confirm cDNA 
quality (Act) and in reactions to determine if RNA was contaminated with DNA (-RT). 
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Figure 4.25: Changes in mRNA levels of AAMΦ markers in response to NECA. RNA isolated from 
BMMΦ (A), macrophages activated with 10ng/ml LPS-CAMΦ (B) and macrophages activated with 
5ng/ml IL-4-AAMΦ (C) stimulated with 100μM NECA for 16 or 20 hours was used to produce cDNA for 
quantitative PCR to determine changes in mRNA levels of mannose receptor, arginase, Fizz1 and Ym1. 
The fold changes presented are relative to the respective macrophage type cultured without NECA, after 
normalising to β-actin mRNA. * p< 0.05, ** p< 0.01. 
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Figure 4.26: Changes in mRNA levels of AAMΦ markers in response to β-ADP. RNA RNA isolated 
from BMMΦ (A), macrophages activated with 10ng/ml LPS-CAMΦ (B) and macrophages activated with 
5ng/ml IL-4-AAMΦ (C) stimulated with 100μM β-ADP for 16 or 20 hours was used to produce cDNA for 
quantitative PCR to determine changes in mRNA levels of mannose receptor, arginase, Fizz1 and Ym1. 
The fold changes presented are relative to the respective macrophage type cultured without β-ADP, after 
normalising to β-actin mRNA. ** p< 0.01, *** p< 0.001, ns - not significant (p> 0.05). 
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Involvement of PLC in purinergic signalling 
Gq involvement was investigated by inhibiting phospholipase C (PLC) in macrophages 
treated with adenosine and NECA. This was achieved by using U73122 which is a PLC, and 
PLA2 inhibitor, that prevents G-protein coupling to PLC and generation of the second messengers 
IP3 and DAG (Grinberg et al, 2009). In Figure 4.27 a comparison is shown of the effect of 
inhibiting cAMP (Rp-cAMP) or PLC (U73122) signalling on inhibition of NO release by 
adenosine/NECA and nucleotides. An inactive analogue of U73122 (U73433) was also available 
and was used to confirm that any responses inhibited by the PLC inhibitor were only due to 
blocking PLC activity and not due to intrinsic compound-induced effects. Inhibition of PLC 
activity (Figure 4.27A) did not reverse the nucleotide-induced inhibition of NO release which 
was only achieved when Rp-cAMP was used in macrophage cultures (Figure 4.27B). Taken 
together with the fact that PLC inhibition appeared to enhance the AMP-induced inhibition of 
NO release (Figure 4.27A), it is evident that elevation of cAMP was necessary for inhibition of 
NO release by CAMΦ following P1R stimulation. 
A comparison between cAMP and PLC activation was also carried out to determine 
which pathway was involved in nucleotide-induced cytokine responses by CAMΦ. As it is shown 
in Figure 4.28A and B, the levels of TNF-α and IL-6 inhibited by stimulation of CAMΦ with 
adenosine, NECA, AMP, ADP or ATP were restored to basal levels only by blocking cAMP 
accumulation. In addition, IL-10 levels that were enhanced by stimulation of CAMΦ with 
nucleotides were reduced to initial levels when Rp-cAMP was used to inhibit cAMP signalling. 
CAMΦ stimulated with adenosine, NECA, AMP or ADP were pre-incubated with the PLC 
inhibitor U73122 to determine if PLC activation was involved in the effects induced by these 
compounds on cytokine release. It should be noted that the slowly hydrolysable analogue of ADP 
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(β-ADP) was used in these experiments to determine if PLC activation via the P2Y receptors was 
responsible for ADP and ATP-induced effects. Inhibition of PLC activity did not reverse the 
nucleotide-induced reduction of TNF-α and IL-6 release from CAMΦ as shown in Figure 4.29A 
and B. Similarly, the levels of IL-10 release, which were up-regulated in response to nucleotide 
stimulation, remained higher than the basal levels even when PLC activity was blocked (Figure 
4.29C). 
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Figure 4.27: The effect of cAMP and PLC inhibition on adenosine-induced inhibition of NO release 
from CAMΦ. Macrophages were classically activated with 10ng/ml LPS and treated with 100μM 
adenosine/NECA or nucleotides for 20 hours. Cells were pre-incubated either with the cAMP inhibitor, 
Rp-cAMP, or with the PLC inhibitor U73122 or the mock inhibitor U73343 and then stimulated with 
adenosine, NECA or the nucleotides shown. (A) The effect of inhibiting cAMP elevation with 50μM Rp-
cAMP on the adenosine and nucleotide – induced inhibition of NO release by CAMΦ is expressed in μM 
nitrite. (B) The effect of inhibiting PLC with 10μM P U73122 on the adenosine and nucleotide – induced 
inhibition of NO release by CAMΦ is expressed in μM nitrite. The data presented are an average of 
triplicates + SEM from one representative experiment of n = 3 and asterisks indicate significance 
compared to untreated control. *** p< 0.001. (†) is compared to the effect induced by the respective 
nucleoside/nucleotide. † p< 0.05, †† p< 0.01, ††† p< 0.001, ns - not significant (p> 0.05). 
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Figure 4.28: The effect of cAMP inhibition on adenosine-induced inhibition of cytokine release by 
CAMΦ. Macrophages were classically activated with 10ng/ml LPS and treated with 100μM 
adenosine/NECA or nucleotides for 20 hours. Cells were pre-incubated with the cAMP inhibitor, Rp-
cAMP and then stimulated with adenosine, NECA or the nucleotides shown. The effect of inhibiting 
cAMP elevation with 50μM Rp-cAMP on the adenosine and nucleotide – induced changes in TNF-α (A), 
IL-6 (B) and IL-10 (C) release by CAMΦ is shown expressed in pg/ml. The data presented are an average 
of triplicates + SEM from one representative experiment of n = 3 and asterisks indicate significance 
compared to untreated control. ** p< 0.01, *** p< 0.001. 
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Figure 4.29: The effect of PLC inhibition on adenosine-induced inhibition of cytokine release by 
CAMΦ. Macrophages were classically activated with 10ng/ml LPS and treated with 100μM adenosine, 
NECA or 100μM of the nucleotides shown for 20 hours. The effect of inhibiting PLC with 10μM U73122 
on the adenosine and nucleotide – induced changes in TNF-α (A), IL-6 (B) and IL-10 (C) release by 
CAMΦ is shown expressed in pg/ml. U73343 is an inactive analogue of U73122 used at the same 
concentration. The data presented are an average of triplicates + SEM from one representative experiment 
of n = 3 and asterisks indicate significance compared to the respective untreated control. * p< 0.05, ** p< 
0.01, *** p< 0.001, ns - not significant (p> 0.05). 
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Involvement of PI3 kinase in purinergic signalling  
Macrophage PI3 kinase (PI3K) activity was inhibited by a known PI3K inhibitor, 
LY294002 (Koga et al, 2009), and the resulting NO and cytokine release by CAMΦ were 
assayed. Before testing the effect of this inhibitor on adenosine/NECA-induced inhibition it was 
observed that basal NO release by CAMΦ was inhibited even at the lowest concentration of 
LY29002 used (10μM) (Figure 4.30). Furthermore, when LY294002 was combined with 
adenosine or NECA, a further inhibition was observed proportional to the inhibition seen in the 
control (-). 
Similar to the inhibitory effect of LY294002 on NO release by CAMΦ, the basal levels of 
TNF-α, IL-6 and IL-10 release were all inhibited by 20% to 50% when PI3K activity was 
blocked (Figure 4.31). In fact, even in the presence of adenosine or NECA, IL-10 release levels 
were reduced by the same amount by both concentrations of LY29004 used to block PI3K 
activity (Figure 4.31C). As can be seen in Figure 4.31A and B, the adenosine/NECA-induced 
inhibition of TNF-α and IL-6 release was enhanced by both concentrations of LY29004 used.  
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Figure 4.30: The effect of PI3 kinase inhibition on adenosine-induced inhibition of NO release by 
CAMΦ. Macrophages were classically activated with 10ng/ml LPS and treated with 100μM adenosine or 
NECA for 20 hours. The effect of inhibiting PI3 kinase activity with 2 different concentrations of 
LY294002 was investigated by measuring the nitrite levels in cell supernatants. Levels of NO release are 
expressed as µM nitrite and the data presented are an average of triplicates + SEM from one representative 
experiment of n > 3 and asterisks indicate significance compared to the respective untreated control. *** 
p< 0.001. 
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Figure 4.31: The effect of PI3 kinase inhibition on adenosine-induced inhibition of cytokine release 
by CAMΦ. Macrophages were classically activated with 10ng/ml LPS and treated with 100μM adenosine 
or NECA for 20 hours. The effect of inhibiting PI3 kinase activity with 2 different concentrations of 
LY294002 was investigated by measuring the cytokine levels in cell supernatants. Levels of cytokine 
release are expressed in pg/ml and the data presented are an average of triplicates + SEM from one 
representative experiment of n > 3 and asterisks indicate significance compared to the respective untreated 
control.** p< 0.01, *** p< 0.001. 
195 
 
The effects of IL-10R signalling  
Having established that P1 receptor stimulation led to an increase in the levels of IL-10 
released by CAMΦ (Figure 4.7C), the effect of IL-10R signalling was investigated. CAMΦ were 
pre-incubated with an anti-IL-10 antibody prior to adenosine/NECA or AMP stimulation in order 
to block the action of IL-10 released in response to P1R activation. Firstly, a range of anti-IL-10 
concentrations was used to determine if there were any concentration-dependent effects on the 
basal levels of TNF-α and IL-6 release by CAMΦ. As it is shown in Figure 4.32A and B, 
administering IL-10 exogenously inhibited both TNF-α and IL-6 release from CAMΦ by 10% 
and 90%, respectively. As the concentration of anti-IL-10 was increased to 2.5μg/ml, the levels 
of TNF-α and IL-6 released from CAMΦ increased (Figure 4.32A and B). The positive control 
testing the effect of anti-IL-10 on IL-10 release showed that, after 1.5μg/ml IL-10 release was 
completely neutralised (Figure 4.32C). In fact, this corresponds to the concentration after which 
both TNF-α and IL-6 release reached maximal levels.  
Having selected 2.5μg/ml as the optimal concentration of anti-IL-10 required to neutralise 
extracellular IL-10, anti-IL-10 was added to cultures of CAMΦ stimulated with adenosine, 
NECA or AMP to determine if eliminating IL-10 released by these cells relieved inhibition of 
TNF-α and IL-6 release. The inhibition induced by adenosine on IL-6 release by CAMΦ was 
almost completely reversed by neutralising IL-10, but only a partial restoration of TNF-α levels 
was achieved (Figure 4.32 D and E). In the case of NECA-induced inhibition of TNF-α and IL-6 
release, almost 100% reversal was detected when extracellular IL-10 was neutralised. Finally,   
the inhibition of TNF-α and IL-6 release from CAMΦ that was detected by stimulation with 
AMP was 50% less when IL-10 accumulation was prevented.  
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Figure 4.32:  The effect of extracellular IL-10 neutralisation on cytokine release from CAMΦ. 
Macrophages were classically activated with 10ng/ml LPS and cultured for 20 hours with 100μM 
adenosine, NECA or AMP. Supernatants were then assayed for TNF-α (A and D), IL-6 (B and E) and IL-
10 (C) and levels are expressed in pg/ml. The effect of a range of α-IL-10 concentrations on (A) TNF-α, 
(B) IL-6 and (C) IL-10 release from CAMΦ. (D) The effect of neutralising IL-10 with 2.5µg/ml α-IL-10 
on the inhibition of TNF-α release from CAMΦ induced by 100μM adenosine. (E) The effect of 
neutralising IL-10 with 2.5µg/ml α-IL-10 on the inhibition of IL-6 release from CAMΦ induced by 
100μM adenosine. The data presented are an average of triplicates + SEM from one representative 
experiment of n = 3 and asterisks indicate significance compared to the respective untreated control (-). ** 
p< 0.01, *** p< 0.001. 
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Involvement of MEK1/2 and NF-kB in purinergic signalling  
The effect of purinergic receptor stimulation on downstream signalling was further 
investigated by looking at the involvement of two pathways, namely, the MAP Kinase Kinase 
(MEK1/2) and NF-κB pathways. CAMΦ were pre-incubated with known inhibitors of MEK1/2 
(Bay11-7082) and NF-κB pathways (U0126) (Gringhuis et al, 2007). In CAMΦ, basal NO 
release was inhibited by Bay 11-7082 as opposed to U0126 which slightly enhanced NO release 
upon TLR stimulation with Pam3C and Ultrapure LPS (Figure 4.33A). Inhibition of these two 
pathways was also tested in terms of P1R stimulation by the analogue of adenosine, NECA. As it 
is shown in Figure 4.33B, the NECA-induced inhibition of NO release by CAMΦ was almost 
completely reversed by U0126.  
In terms of cytokine release, it is shown in Figure 4.34 that Bay 11-7082 and U0126 
inhibited all cytokines released by LPS, Pam3C and ultrapure LPS-activated CAMΦ. TLR2 
(Pam3C)-activated CAMΦ produced higher levels of TNF-α and lower IL-10 levels than LPS 
and ultrapure LPS-activated CAMΦ, whereas TLR4 (ultrapure LPS)-activated CAMΦ released 
comparable cytokine levels to LPS-activated CAMΦ (Figure 4.34A, B and C). Despite the fact 
that activation via different TLRs led to different basal levels of cytokine release, inhibition of 
both the NF-κB and MEK1/2 pathways resulted in equal inhibition of cytokine release by all the 
CAMΦ types. 
Since the NF-κB inhibitor was toxic to macrophages and inhibited basal levels of CAMΦ 
NO and cytokine release, NF-κB involvement could not be confirmed. The fact that the MEK1/2 
inhibitor reversed some effects could point to MEK1/2 involvement but it cannot be concluded 
that the effects observed are solely dependent on this pathway. 
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Figure 4.33: The effect of NF-κB and MEK1/2 inhibition on NO release by CAMΦ and inhibition of 
NO release by CAMΦ stimulated with NECA. (A) Macrophages were classically activated with 
10ng/ml LPS, Pam3C or ultrapure LPS (UP-LPS) for 20 hours and the effect of 5μM Bay 11-7082 (NF-
κB selective inhibitor) and 5μM U0126 (MEK1/2 inhibitor) on NO release was investigated. (B) The 
effect of inhibiting NF-κB and MEK1/2 on NO release by LPS-activated macrophages stimulated with 
100μM NECA for 20 hours. Levels of NO release are expressed as μM nitrite. The data presented are an 
average of triplicates + SEM from one representative experiment of n = 3 and asterisks indicate 
significance compared to the respective untreated control.  *** p< 0.001. (†) is compared to the respective 
control cultured in the absence of inhibitors. † p< 0.05, ††† p< 0.001. 
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Figure 4.34: The effect of NF-κB and MEK1/2 inhibition on cytokine release from CAMΦ. 
Macrophages were classically activated with 10ng/ml LPS, Pam3C or ultrapure LPS (UP-LPS) for 20 
hours and the effect of 5μM Bay 11-7082 (NF-κB selective inhibitor) and 5μM U0126 (MEK1/2 inhibitor) 
on cytokine release investigated. Supernatants were assayed for TNF-α (A), IL-6 (B) and IL-10 (C) 
release, expressed in pg/ml. The data presented are an average of triplicates + SEM from one 
representative experiment of n = 3 and asterisks indicate significance compared to the respective untreated 
control. ** p< 0.01, *** p< 0.001. 
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4.3 Discussion  
The phenotype of activated macrophages is characterised by a number of effector 
functions as well as expression of specific proteins. These effector functions are generally either 
pro- or anti- inflammatory and the balance between these two states is achieved by the ability of 
macrophages to switch from the pro-inflammatory classical activation mode to the anti-
inflammatory alternative activation mode. The state of macrophage activation can dictate how 
they respond to danger signals they may encounter in their local environment. Nucleotides, which 
are found at high concentrations intracellularly, are released from damaged or lysed cells at sites 
of inflammation and are therefore considered to be ubiquitous danger signals for cells that 
possess purinergic receptors. Having established that murine bone marrow derived macrophages 
(BMMΦ) express purinergic receptors at the molecular level (Chapter 3), purinergic signalling in 
BMMΦ was investigated. Furthermore, the different macrophage activation states, known as 
classical and alternative, were characterised in terms of effector functions and the impact of 
purinergic signalling on these functions studied for each macrophage activation phenotype.  
Characterisation of macrophage activation phenotype was carried out for the two 
activation states used in this study in terms of their effector functions. In order to generate 
optimal conditions for classical and alternative activation, macrophages were activated with TLR 
ligands or IL-4, respectively, and nitric oxide (NO) release was assayed and compared to arginase 
I activity. The reason for selecting NO release and arginase I activity to distinguish between the 
two macrophage activation phenotypes is that, in the absence of microbial stimulation or in the 
presence of Th2 cytokines, L-arginine metabolism proceeds via the arginase I pathway which 
generates polyamines used for biosynthesis and repair as opposed to the cytotoxic NO produced 
by the inducible NO synthase (iNOS) pathway (Munder et al, 1998; Hesse et al, 2001). In an 
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attempt to investigate the possible switch of L-arginine metabolism from iNOS to arginase I that 
could cause a phenotype shift, both macrophage subsets were assayed for NO release and 
arginase I activity to see if there was a pattern of reciprocal activation of the two enzymes. LPS 
was used to induce classical activation of macrophages producing a robust response between 
0.5ng/ml and 10ng/ml with the latter concentration significantly eliciting NO release. Alternative 
activation was achieved using 5ng/ml IL-4, as determined by arginase I activity levels which 
were optimal at this concentration. IL-13, the other Th2 cytokine capable of inducing alternative 
activation, was also found to optimally induce arginase I activity in the macrophage cell line, 
J774A.1, when used at this concentration (Chang et al, 2000), while IL-4 used at 8ng/ml 
produced submaximal arginase I activity levels in peritoneal macrophages (Waddington et al, 
1998).  
Increasing LPS concentration increased NO release by BMMΦ while arginase I activity 
followed a similar pattern of induction with increasing IL-4 concentrations, confirming 
previously published work showing reciprocal activation of iNOS and arginase I depending on 
the macrophage local cytokine environment (Modolell et al, 1995). In this study, CAMΦ were 
found to have arginase I activity that was significantly higher than that observed in BMMΦ. 
However, AAMΦ arginase I activity was 10-fold higher than the arginase I activity detected in 
CAMΦ. Interestingly, TLR activation by LPS has been shown to be responsible for arginase I up-
regulation in peritoneal macrophages and has been proposed to be a means of controlling NO 
levels in chronic bacterial infections (Ryan et al, 1980; Sonoki et al, 1997; Sosroseno et al, 
2006). In addition, no increase in arginase I activity was observed with IFN-γ in this study 
showing that, it is an LPS-dependent effect rather than a Th1-dependent response and also 
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confirming published observations showing that this effect is due to a MyD88-dependent 
pathway, as IFN-γ acts via a different pathway (El Kasmi et al, 2008). 
The balance between iNOS and arginase I can be achieved by altering enzyme availability 
(by means of protein expression), enzyme activity or by indirect control resulting from substrate 
availability. In order to account for limiting L-arginine being the cause of lower arginase I 
activity in CAMΦ in this study, L-arginine was administered exogenously. This did not appear to 
alter CAMΦ arginase I activity levels significantly while in the case of AAMΦ exogenous L-
arginine led to decreased arginase I activity levels. In fact, exogenous L-arginine appeared to 
enhance NO release levels in both CAMΦ and AAMΦ, the increase in CAMΦ NO release being 
more significant, suggesting that L-arginine supplementation resulted in a shift to its use by 
iNOS, so it can be considered both as a substrate and regulator of this pathway. It has been shown 
in a study using IL-13 to induce arginase I activity in peritoneal macrophages that extracellular 
arginine depletion had the same effect on macrophage iNOS activity as IL-13 itself and that 
administration of exogenous L-arginine could reverse the IL-13-induced inhibition of iNOS 
expression (El-Gayar et al, 2003). These observations point to iNOS regulation by Th2 cytokines 
being a result of lack of substrate, depleted as a result of arginase I up-regulation, as well as 
inhibition of iNOS synthesis. Therefore, interaction between these two pathways is important in 
pathophysiologic conditions as a counteracting mechanism in case of NO over-production.  
Cytokine release is another important macrophage function that can determine the 
outcome of immune responses. In this study, cytokine release from bone marrow derived 
macrophages was only detected when cells were cultured in the presence of TLR ligands such as 
LPS and Pam3C. Specifically, titrating LPS revealed a concentration-dependent increase in the 
release of all cytokines tested, namely TNF-α, IL-6 and IL-10. Similar to NO release, 1-10ng/ml 
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LPS were sufficient to produce a robust response. Having selected an LPS concentration for 
optimally inducing classical activation of macrophages as determined by their effector functions, 
the effect of purinergic receptor activation on these effector functions was investigated. Taking 
into account that BMMΦ and AAMΦ do not release cytokines in vitro, the only way of assaying 
the effect of purinergic signalling on AAMΦ was by means of arginase I activity. 
Purinergic receptor activation was investigated in both murine macrophages activation 
subsets by exogenously administering various nucleotides and testing the resulting macrophage 
responses in terms of effector functions such as NO release, arginase I activity and cytokine 
release. Firstly, the effect of purinergic receptor activation on the switch between classical and 
alternative macrophage activation was investigated by assaying CAMΦ NO release versus 
arginase I activity. NO release was only affected in CAMΦ as the other macrophage subsets do 
not produce NO in the presence or absence of nucleotides. In general, adenosine inhibited NO 
release from CAMΦ as did all adenine nucleotides and UDP which is known to be a ligand for 
P2Y6 expressed by monocytes (Cox et al, 2005). pharmacological characterisation of purinergic 
receptor stimulation suggested that the active ligand was adenosine. Indeed, taking into account 
data obtained in this study and presented in Chapter 3, macrophages have functional, surface-
expressed enzymes capable of degrading nucleotides. Therefore, it can be expected that 
nucleotides encountered by macrophages in culture for more than a few hours are degraded by 
CD39 and CD73 to adenosine. This can be confirmed by the fact that AMP also had an inhibitory 
effect on NO release, despite the fact that there is no known receptor for this ligand, suggesting 
that CD73 was able to metabolise AMP to adenosine. Inhibition of NO release by a slowly 
hydrolysable analogue was only observed when ATP-γ was used as the slowly hydrolysable β-
ADP did not have an inhibitory effect. This could be due to the fact that these two compounds are 
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not the same structurally so that, ATP-γ is made in a way that is more susceptible to hydrolysis in 
culture either by cell ecto-nucleotidases or by degradation due to low stability in the culture 
conditions used.  
The adenosine-induced inhibition of NO release was further investigated to see if it was 
accompanied by an enhancement of arginase I activity, taking into account that it is the 
alternative pathway of L-arginine metabolism. Indeed, stimulation by adenosine or nucleotides 
led to an increase of arginase I activity in both CAMΦ and AAMΦ while NECA caused an even 
higher increase probably due to the fact that it is an adenosine analogue that cannot be taken up 
by cells or metabolised. The slowly hydrolysable ADP analogue did not increase arginase I 
activity while ATP-γ caused a slight increase probably due to slow hydrolysis to adenosine over 
time. When comparing adenosine, NECA and ADP-induced up-regulation of arginase I activity, 
NECA appeared to induce a more pronounced increase in arginase I activity levels, while ADP-
induced arginase I activity followed a similar pattern to adenosine suggesting that purinergic 
activation by ADP was via adenosine. In AAMΦ, arginase I basal levels were always too high to 
allow significant up-regulation by adenosine and nucleotides, however, the slight increase 
detected in every case was significant. β-ADP did not increase arginase I activity as opposed to 
the slight increase observed with the stable ATP analogue. When investigating arginase I activity 
levels in response to stimulation with increasing concentrations of adenosine, NECA and ADP, 
adenosine appeared to be more efficient in up-regulating arginase I activity in AAMΦ as it 
produced a more steady increase than NECA. This might be due to the fact that, as presented in 
Chapter 3, AAMΦ do not express A2A receptors (A2AR) so the use of an A2 receptor agonist like 
NECA does not greatly differ to P1R stimulation by adenosine. In addition, CAMΦ responses to 
P1R activation that led to arginase I up-regulation may involve other downstream pathways 
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whose effects are amplified by an A2 receptor-specific ligand like NECA since CAMΦ have been 
shown to express both A2 receptors during the incubation period used in this study (Chapter 3). In 
fact, the effect observed in CAMΦ with adenosine was restricted to macrophages activated with 
LPS as IFN-γ, which is an endogenous trigger of classical activation, had no such effect. This 
apparent TLR synergy was also investigated for NO release by stimulating macrophages with 
different TLR ligands and, indeed, TLR activation of any kind resulted in adenosine-induced 
inhibition of NO release. In addition, the adenosine receptor – TLR synergy does not appear to be 
specific to a particular TLR as adenosine receptor activation had the same effect with both TLR2 
and TLR4 ligands suggesting that it is a MyD88-dependent effect since both these TLRs act 
through this downstream pathway.  
In view of the fact that only CAMΦ produce detectable cytokine levels in vitro, the 
effects of purinergic receptor activation on cytokine release were only investigated in this 
macrophage subset. Similar to NO release, TNF-α and IL-6 release were inhibited by adenosine 
and nucleotides while slowly hydrolysable nucleotides did not affect cytokine levels. The anti-
inflammatory cytokine IL-10 was positively regulated by direct P1 receptor activation showing 
that in the presence of adenosine pro-inflammatory macrophage functions are inhibited. The 
slowly hydrolysable β-ADP had no effect on cytokine levels suggesting that the effects observed 
with ADP were a result of adenosine generation. The other slowly hydrolysable nucleotide used, 
ATP-γ, had a similar effect to ATP which, as explained earlier, was probably a result of its 
intrinsic instability in culture. Furthermore, this effect was not due to degradation to ADP since 
experiments with β-ADP did not mirror ATP-γ-induced effects.  
Since the immunomodulatory effects of nucleotides on macrophage effector functions are 
mediated by ligation of specific purinergic receptors these effects were further investigated 
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pharmacologically, in order to identify the specific receptor involved. P1 receptors were targeted 
on macrophages with specific antagonists and the effects induced by adenosine on NO release 
and arginase I activity were only reversed by the A2B receptor (A2BR) antagonist MRS1754. In 
addition, the inhibitory effect elicited on CAMΦ NO release by nucleotides was also reversed by 
antagonising the A2BR. The effect of adenosine on arginase I activity in both CAMΦ and AAMΦ 
was shown to be the opposite to that observed for NO release and, as expected, targeting the 
A2BR in both CAMΦ and AAMΦ led to inhibition of adenosine-induced up-regulation of 
arginase I activity. When looking at the effect of P1R agonists, A2AR activation using CGS21680 
also resulted in up-regulation of arginase I activity in CAMΦ and AAMΦ. Unfortunately, the 
A2BR agonist used in published work by Eckle and colleagues (Eckle et al, 2007) was not 
available for use in this study so the involvement of the A2BR could only be shown using the P1R 
antagonists. In addition, despite the fact that the A2AR agonist had an up-regulatory effect on 
arginase I activity, the A2AR antagonist was not found to significantly inhibit adenosine-induced 
effects, suggesting that the A2AR is either dispensable and may only be activated in conjunction 
to the A2BR, or that the A2AR agonist acts non-specifically on the A2BR. Similarly in dendritic 
cells it has been reported that NECA-induced inhibition of NO release is accompanied by an 
increase in arginase I expression and this effect is A2BR mediated (Ben Addi et al, 2008). In the 
same study, it is suggested that NECA-induced effects on dendritic cell effector functions occur 
in the presence of LPS stimulation due to TLR synergism with the A2AR. This LPS/NECA 
synergy has also been reported to cause VEGF up-regulation in murine macrophages, an 
important component of angiogenesis and wound healing both of which are major functions 
attributed to AAMΦ (Ramanathan et al, 2009). In fact, Pinhal-Enfield and colleagues showed 
that this up-regulation of VEGF can result from synergy between the A2AR and the TLRs 2,4,7,9 
(Pinhal-Enfield et al, 2003). 
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P1R antagonists also confirmed the fact that the inhibitory effect of nucleotides on 
CAMΦ NO release was due to their degradation to adenosine as AMP, ADP and ATP-induced 
effects were only reversed by the A2BR antagonist, MRS1754. Furthermore, confirmation of P1R 
involvement in effects observed after stimulation by ADP and ATP was obtained by the fact that, 
the P2Y inhibitors suramin and PPADS had no effect on the changes observed with ADP and 
ATP, as well as their slowly hydrolysable forms. In addition, this showed that ATP-γ-induced 
inhibition of NO release was not due to the intermediate breakdown product, ADP. Since AMP 
has no known receptor, CAMΦ responses to nucleotides are mainly due hydrolysis to adenosine 
and this is also suggested by the observation that reversal of AMP-induced effects is achieved in 
a similar mode to adenosine. The existence of AMP receptors is debatable as their presence has 
been reported in neuronal systems but this has not been confirmed for cells of the immune system 
(Ross et al, 1998), while a recently de-orphanised GPCR was mistakenly characterised as a 
purinergic receptor (P2Y15) responding to AMP and adenosine (Abbracchio et al, 2005). Based 
on the results obtained in this study and discussed above, responses to AMP stimulation were 
most likely due to adenosine generation.  
The mode of regulation of cytokine release by purinergic signalling was found to be due 
to CAMΦ P1 receptor activation by adenosine similar to regulation of NO release and arginase I 
activity. However, the release of the pro-inflammatory cytokines, TNF-α and IL-6, was not 
affected in the same way as IL-10 in that, both the A2A and A2B receptors were involved in 
inhibition of TNF-α and IL-6 as opposed to IL-10 whose levels were up-regulated by adenosine 
ligation of the A2BR alone. Indeed, this has also been reported by Nemeth and colleagues who 
also showed that the adenosine-induced increase of IL-10 expression levels in murine 
macrophages was a result of post transcriptional control following A2BR activation (Nemeth et al, 
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2005). All nucleotides appeared to act via their degradation product, adenosine, as antagonism at 
the A2 receptors was successful at reversing their effects on cytokine release. Reversal was 
generally better for IL-10 and this was confirmed to be due to the fact that only one receptor is 
responsible for adenosine-induced up-regulation. Indeed, when a cocktail of A2R antagonists was 
used, TNF-α and IL-6 release was fully restored, suggesting that inhibition of these cytokines is a 
result of an additive effect of A2R receptor activation and it can be achieved by activating either 
one of these two receptors. These data are in agreement with published work by Hasko and 
colleagues who reported that, inhibition of TNF-α release by adenosine from murine peritoneal 
macrophages was not only dependent on the A2AR (Hasko, Kuhel et al, 2000). This was 
confirmed by another study carried out on murine peritoneal macrophages which further showed 
that the other receptor responsible for adenosine-induced suppression of TNF-α was the A2BR 
(Kreckler et al, 2006).  
All macrophage effector functions tested in this study were influenced by purinergic 
signalling via P1 receptor activation due to generation of adenosine in culture. As was the case 
for NO release, antagonism at P2 receptors with suramin and PPADS showed that ADP/ATP-
induced effects on cytokine release were not P2YR-mediated for the culture period in this study. 
It is possible that initial encounters to nucleotides trigger responses via the P2Y receptors but 
these responses are short-lived due to CD39 expression on murine macrophages that effectively 
reduces ADP and ATP concentrations in the local macrophage environment. Furthermore, CD73 
which is also expressed on murine macrophages, completes conversion of AMP to adenosine 
leading to increased P1R stimulation that masks any initial effects induced by P2YR activation. 
Having established that adenosine was the active ligand in macrophage responses to 
adenine nucleotides and following pharmacological confirmation of A2R involvement, 
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downstream signalling events were analysed taking into account that the A2 receptors act via 
coupling to Gs, Gi and Gq subunits (Fredholm et al, 2000). Hence, regulation of cAMP levels 
was investigated to determine if Gs/Gi are involved while PLC and PI3 kinase activation were 
investigated to determine Gq involvement (Ralevic and Burnstock, 1998). Signalling cascades 
activated downstream of these G proteins result in activation of known pathways of 
transcriptional control within the nucleus two of which were investigated in this study, namely 
the NF-κB or MEK pathways.  
Ligation of receptors coupled to Gs results in adenylyl cyclase activation and subsequent 
cAMP accumulation leading to Protein Kinase A (PKA) activation (Ralevic and Burnstock, 
1998). Rp-cAMP is a PKA inhibitor used to inhibit cAMP-induced effects in vtiro (Zang and 
Hintze, 2001; Zhao et al, 2006). In this study administration of Rp-cAMP to CAMΦ partly 
restored the adenosine-induced suppression of NO release, especially when CAMΦ were 
activated via TLR4. Inhibition of cAMP did not affect basal NO release levels significantly nor 
was it enough to induce NO release by BMMΦ and AAMΦ. Conversely, basal CAMΦ arginase I 
activity was inhibited by Rp-cAMP while in AAMΦ the increased levels caused by adenosine 
were restored to basal activity typical of AAMΦ. These data suggested that adenosine-induced 
effects via the A2BR were due to cAMP elevation as a result of Gs coupling. In an attempt to 
determine if cAMP elevation alone was responsible for these effects and in order to confirm Gs 
coupling, cAMP elevation was achieved superficially by administration of forskolin and rolipram 
which are known to increase cAMP levels by different mechanisms. Both forskolin and rolipram 
led to inhibition of NO release by CAMΦ activated by the different TLR ligands used, while 
adenosine-induced inhibition of NO release was additive when macrophages were co-cultured 
with adenosine and cAMP elevators. Control of NO release by cAMP has been shown to be time 
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and concentration-dependent. Specifically, Greten and colleagues have reported that NO release 
by RAW 264.7 macrophages increased in response to rolipram for up to one hour and then was 
inhibited for the rest of the culture period (Greten et al, 1995). Mullet and colleagues showed that 
NO release by a murine macrophage cell line was enhanced by cAMP elevation but that at high 
concentrations cAMP became inhibitory leading them to suggest that, NO release was biphasic in 
response to cAMP levels and that regulation could be autocrine as a result of cAMP-induced 
cytokine release (Mullet et al, 1997).  
In this study, cAMP elevation was found to be sufficient to induce arginase I activity even 
in BMMΦ suggesting that the increase caused by adenosine was mainly due to Gs coupling and 
subsequent cAMP accumulation. It should be noted though that for this to happen in vitro some 
kind of co-stimulation is necessary, such as TLR (CAMΦ) or IL-4R (AAMΦ) activation, since 
P1R ligation alone had no effect on BMMΦ arginase I activity. This increase in arginase I 
activity could be a result of transcriptional or translational control. From molecular analysis using 
both RT-PCR and quantitative PCR (Q-PCR) approaches, it was apparent that the increase in 
arginase I activity achieved by cAMP elevation, either by adenosine or by chemical means, was 
accompanied by an increase in arginase I transcript levels. This is in agreement with work 
published by Nebes and Morris who showed that liver arginase I was up-regulated by cAMP-
induced increase of arginase I mRNA levels (Nebes and Morris, 1998). Furthermore, Haffner and 
colleagues have shown that in RAW 264.7 macrophages arginase I up-regulation was PKA-
HDAC dependent (Haffner et al, 2007). The fact that BMMΦ arginase I transcript levels were 
found to be increased in this study by the adenosine analogue, NECA, despite an apparent lack of 
enhancement in activity, may suggest that there is some form of post-transcriptional control as 
well, possibly affecting mRNA stability. The Q-PCR analysis also confirmed the fact that ADP 
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does not cause an increase in arginase I expression and that any up-regulation detected when 
macrophages were cultured in the presence of ADP or ATP was due to adenosine generation. In 
addition, the data obtained from the molecular analysis showed that the shift between iNOS and 
arginase I metabolism of L-arginine was due to increasing arginase I levels and not just an 
alteration in enzyme preference. Interestingly, it has been reported that the inhibition in NO 
release caused by IL-13 is via up-regulation of arginase I through cAMP/PKA-mediated de novo 
synthesis of arginase I mRNA and protein (Chang et al, 2000).  
Similar to NO release, TNF-α and IL-6 release by CAMΦ was found to be suppressed by 
cAMP elevation in agreement with published work by Greten and colleagues who showed that, 
similar concentrations of rolipram to the ones used in this study were enough to inhibit TNF-α 
release (Greten et al, 1995). In addition, adenosine-induced effects were reversed by cAMP 
inhibition with Rp-cAMP and enhanced with cAMP elevators. IL-10 release was enhanced by 
cAMP elevation showing that the same pathway downstream of P1R activation led to differential 
regulation of pro-inflammatory and anti-inflammatory cytokine expression. Similarly, cAMP 
elevating agents were found to inhibit TNF-α and IL-12 from RAW 264.7 cells and bone marrow 
derived dendritic cells, while IL-10 release was increased by up-regulation of c-fos mRNA that 
led to reduced transcription of TNF-α genes (Koga et al, 2009). The fact that Rp-cAMP reversed 
adenosine-induced effects shows that cAMP-induced effects are mediated via activation of PKA 
instead of Epac, another kinase downstream of cAMP, which is confirmed by published work by 
Kreckler and colleagues who showed that, NECA inhibited TNF-α release by murine LPS-
stimulated macrophages through cAMP activation of PKA and not Epac (Kreckler et al, 2009). 
The requirement for TLR-P1R crosstalk is highlighted by another study which showed that, the 
reciprocal regulation of IL-10/TNF-α in RAW 264.7 macrophages was PKA-dependent and that 
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LPS-induced phosphorylation of CREB downstream of PKA only becomes inhibitory in terms of 
TNF-α expression in the presence of a G-protein coupled receptor (GPCR) ligand (Avni et al, 
2010). Furthermore, simultaneous stimulation with LPS and a GPCR ligand capable of activating 
the PKA-CREB pathway was shown in the same study to be essential for up-regulation of IL-10 
expression.  
Another pathway coupled to G proteins and particularly to Gq subunits is the PLC-
mediated generation of second messengers such as IP3 and DAG that ultimately leads to Ca
2+
 
mobilization. Inhibition of PLC activation did not reverse nucleotide-induced effects on any of 
the effector functions tested in this study. Specifically, adenosine and nucleotide-induced 
inhibition of NO release was only reversed effectively by cAMP inhibition by Rp-cAMP as no 
such reversal was achieved by PLC inhibition, showing that even nucleotide-induced effects were 
due to adenosine-induced elevation of cAMP. Furthermore, the fact that PLC inhibition enhanced 
the AMP-induced inhibition of NO release may suggest that blocking Gq coupling of the A2BR 
shifts coupling to Gs. Likewise with cytokine release PLC inhibition was not sufficient to reverse 
adenosine-induced changes in cytokine levels detected in CAMΦ supernatants. These data further 
confirm that TNF-α and IL-6 release, shown in this study to be controlled by both A2A and A2B 
receptor activation by adenosine, is via cAMP and not by A2BR coupling to the PLC pathway. 
Furthermore, IL-10 up-regulation by adenosine activation of A2B receptors is also cAMP-
dependent and is not a result of PLC activation. Despite the fact that A2A receptors are not known 
to couple to PLC, Grinberg and colleagues have reported that the VEGF up-regulation in murine 
peritoneal macrophages and RAW 246.7 cells is a PLC-induced effect resulting from A2AR 
activation (Grinberg et al, 2009). 
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Gq subunits may also couple to PI3 kinase. In this study, blocking PI3 kinase activation 
with LY294002 led to inhibition of basal CAMΦ NO, TNF-α and IL-6 release. Similar 
observations were made by Zang and Hintze who showed that LY294002 inhibited NO release 
by endothelial cells (Zang and Hintze, 2001). The adenosine-induced inhibition was not reversed 
by LY294002 but was further enhanced. Basal IL-10 release levels were also affected by 
LY294002 which appeared to cause the same reduction even in the presence of adenosine. 
Therefore, no conclusions can be drawn regarding PI3 kinase involvement in purinergic 
signalling. 
An indirect mode of control for the adenosine-induced effects observed in this study was 
also investigated based on the observation that adenosine caused a significant increase in IL-10 
release by CAMΦ. IL-10 has been reported to deactivate macrophages in the sense that, IL-10R 
signalling prevents activation of other pathways and in doing so makes macrophages refractory to 
further activation (Porcheray et al, 2005). In this study, when extracellular IL-10 levels were 
completely neutralised TNF-α and IL-6 release by CAMΦ was evidently increased. Fiorentino 
and colleagues also showed that IL-6 release from peritoneal macrophages is inhibited by IL-10, 
by neutralising extracellular endogenously-produced IL-10 (Fiorentino, Zlotnik et al, 1991). 
Interestingly, adenosine, NECA and AMP-induced inhibition of TNF-α and IL-6 release was not 
completely reversed suggesting that, this is also a direct effect of cAMP elevation as well as an 
indirect response to the cAMP-induced increase in IL-10 release. Indeed, this autocrine 
mechanism of IL-10 control has been suggested in a study using human monocytes showing that 
IL-10 produced by LPS-activated monocytes occurs later than the other cytokines thus allowing 
control of pro-inflammatory cytokine production (de Waal Malefyt et al, 1991). This further 
explained their observation that exogenously administered IL-10 produced a more effective 
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inhibition on TNF-α and IL-6 production, an effect also observed in this study. IL-10 has been 
reported by many studies to be a suppressor of pro-inflammatory cytokines such as TNF-α, IL-6 
and IL-1 in murine peritoneal macrophages and macrophage cell lines (Bogdan et al, 1991; 
Fiorentino, Zlotnik et al, 1991). The mechanism via which IL-10 mediates reduction in alveolar 
macrophage cytokine levels has been shown to be dependent on inhibition of NF-κB nuclear 
localisation (Lentsch et al, 1997). According to the authors, this is achieved by increasing IκB 
mRNA levels through stabilisation thus leading to its preservation which maintains NF-κB in its 
inactive state in the cytosol.  
In order to further characterise signalling pathways downstream of G-protein activation, 
two pathways leading to activation of transcription in the nucleus were selected. NF-κB 
activation was blocked by using an inhibitor of cytokine-induced Iκ-B phosphorylation (Bay 11-
7082) while MEK1/2 activation was blocked using a specific inhibitor, U0126 (Zhao et al, 2006; 
Gringhuis et al, 2007). NF-κB inhibition led to suppression of basal CAMΦ NO release as 
opposed to MEK1/2 inhibition which appeared to improve NO release by TLR2 and TLR4-
activated CAMΦ. In addition, MEK1/2 inhibition partly relieved NECA-induced suppression of 
NO release. As for cytokine release, both inhibitors had similar effects on all cytokines tested 
suggesting that, pathways downstream of cytokine receptors converge to these two pathways or 
that there is some means of cross-talk operating somewhere between the cell surface and the 
nucleus. The fact that the p38/MSK1 pathway (which is downstream of the MEK1/2 activation) 
is important for LPS-induced TNF-α expression has been recently reported by Avni and 
colleagues (Avni et al, 2010). Since NF-κB inhibition suppressed LPS activation of macrophages 
even prior to nucleotide addition and inhibited all macrophage effector functions, it could not be 
determined if purinergic signalling has an inhibitory effect on NF-κB. However, it could be 
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suggested that purinergic receptor activation does not have an activatory effect on NF-κB either, 
as P1R activation was not capable of outcompeting the inhibitor to allow NF-κB translocation to 
the nucleus. However, it should be noted that in order to confirm this a titration of P1R activation 
would have to be carried out. Nevertheless, Majumdar and Agarwal have shown that TNF-α 
inhibition by adenosine is in fact due to A2AR-induced NF-κB inhibition (Majumdar and 
Agarwal, 2003). MEK1/2 inhibition led to some reversal of adenosine/NECA-induced effects and 
this could lead to the assumption that, MEK1/2 activation is part of the downstream signalling 
events, however, it may not be the only pathway responsible for purinergic signalling-induced 
effects.  
In conclusion, this study has shown that both murine macrophage activation states can be 
influenced by purinergic signalling at least in terms of the effector functions tested here. In 
particular, adenosine activation of A2B receptors is responsible for shifting macrophage L-
arginine metabolism from iNOS to arginase I effectively suppressing NO release. In addition to 
pro-inflammatory NO release adenosine also inhibits pro-inflammatory cytokine release, such as 
TNF-α and IL-6, by activation of both A2A and A2B receptors. Furthermore, production of the 
anti-inflammatory cytokine IL-10 is enhanced by adenosine activation of the A2BR. It can be 
concluded that adenosine, present in culture either by direct addition or through generation by 
nucleotide hydrolysis, mediates these effects via cAMP elevation through the A2BR. These data 
point to a versatility of macrophage activation in response to exogenous danger signals such as 
nucleotides that allows resolution of inflammation without having to recruit naïve macrophages.  
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Chapter 5 
Effects of Trichinella Spiralis secreted proteins on macrophage effector 
functions in vitro  
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5.1 Introduction  
Helminth parasites are known to colonise a variety of organs and tissues in the host, such as 
the gastrointestinal tract and the lymphatics, and they employ a range of immunomodulatory 
mechanisms in order to evade host detection and achieve successful colonisation. In the case of 
the parasitic nematode, Trichinella spiralis, invasion during the gastrointestinal phase of 
infection results in tissue damage generating molecular signals capable of activating the immune 
system. Extracellular nucleotides are major molecular signals encountered by cells of the 
hematopoietic lineage which are capable of controlling immune responses as a result of 
ubiquitous purinergic receptor expression. So far, this study has shown that bone marrow derived 
macrophages (BMMΦ) possess functional purinergic receptors and are thus subject to regulation 
by nucleotides (Chapter 3 and 4). T.spiralis appears to take advantage of this feature of immune 
cells as nucleotide metabolising enzymes have been characterised in its secretory products (ES) 
which effectively convert pro-inflammatory signals (ATP and ADP) to anti-inflammatory 
adenosine, thus allowing for parasite survival (Gounaris, 2002). In view of this, the effect of 
T.spiralis ES on BMMΦ purinergic signalling was investigated and is presented in this chapter.  
In addition to their role in immune regulation by means of their purinergic receptor 
expression, macrophages are also an important component of the innate immune response due to 
their ability, as antigen presenting cells (APCs), to recognize a broad spectrum of molecular 
patterns known as pathogen-associated molecular patterns (PAMPs). APCs are known to express 
pattern recognition receptors (PRRs) that, upon ligation by PAMPs, induce inflammatory 
cytokine production. PAMPs have been widely characterised for viruses, bacteria and lower 
eukaryotes and shown to include lipopolysaccharides and peptidoglycans. Toll-like receptors 
(TLRs) are type I transmembrane PRRs that are sensors of these molecular patterns and function 
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in linking innate and adaptive immune responses (Venugopal et al, 2008). The responses elicited 
by different pathogens vary depending on TLR engagement and may even involve interaction of 
multiple TLRs. These responses are predominantly pro-inflammatory in nature resulting from the 
generation of classically activated macrophages (CAMΦ). Recently, components of higher 
eukaryotes such as helminths have been identified as potential PAMPs that are recognized by 
host PRRs including TLRs and C-type lectins. In particular, glycoproteins and 
glycophospholipids have been shown to induce a Th2 phenotype in APCs via TLR ligation. 
Indeed, this is a unique mode of host manipulation made even more significant when considering 
that different stages of parasite development within the host are accompanied by changes in the 
glycan combinations expressed (Van der kleij et al, 2002).  
Immune cell responses triggered by PAMPs may be exploited by parasites to act in their 
favour. Specifically, helminth parasites are capable of triggering highly polarised immune 
responses due to increased numbers of CD4+ Th2 cells, eosinophils, mast cells and basophils 
(Loke et al, 2007). These cells coordinate an effective response ultimately leading to parasite 
expulsion in addition to their role in the regulation of associated pathologic inflammation. 
Functional modulation of macrophages, as well as other APCs, is a fundamental event involved 
in establishing immune regulation by parasites supported by the fact that, alternatively activated 
macrophages (AAMΦ) were consistently shown to be recruited in Th2 responses to nematode 
infections (Kreider et al, 2007). In particular, arginase I which is a major marker of alternative 
activation that can be up-regulated by IL4, IL-10 or TGF-β, has also been shown to be up-
regulated either by parasites directly or by their secreted products (Stempin et al, 2009). 
Alternative activation of macrophages is important in limiting collateral tissue damage that 
generally results from an excessive Th1 response and, additionally, it is advantageous for parasite 
survival and proliferation. With relevance to this study, T.spiralis ES glycans have been reported 
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to bind the macrophage mannose receptor (MR), an event partly responsible for triggering NO 
release by these cells (Gruden-Movsesijan and Milosavljevic Lj, 2006). The same authors 
showed that, T.spiralis ES carbohydrates can potentially activate another arm of the innate 
immune response via mannose-binding lectin (MBL) ligation leading to complement component 
deposition on larvae which is suggested to act in a protective manner (Gruden-Movsesijan et al, 
2003).  
Macrophages are emerging as an important immune cell type involved in nematode 
infection so this study aimed to delineate the effector responses of different macrophage subsets 
to T.spiralis secreted products. Having established that macrophage effector functions such as 
arginase I activity, nitric oxide (NO) and cytokine release are affected by administration of 
extracellular nucleotides and considering that T.spiralis secretory proteins contain nucleotide 
metabolising activity, the effect of combining the two was investigated. Finally, T.spiralis ES-
induced effects were characterised in terms of downstream pathway activation and an attempt 
was made at determining which component of ES was responsible for macrophage responses 
elicited.  
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5.2 Results 
The objectives of experiments presented in this chapter were to determine how the 
parasitic nematode, T.spiralis, interferes with host macrophage effector functions. Macrophage 
responses to T.spiralis secreted products were investigated as well as the effect of these products 
on extracellular nucleotide-induced responses, bearing in mind that T.spiralis proteins are known 
to metabolise nucleotides (Gounaris, 2002). This was confirmed in this study prior to using 
T.spiralis ES in stimulation of macrophages by carrying out phosphate release assays of ES with 
AMP, ADP and ATP (results shown in the appendix, Figure A.3).  
5.2.1 Effect of T.spiralis secreted proteins on murine macrophage effector functions 
The effect of T.spiralis secreted proteins (ES) on macrophage functions was first 
investigated. ES triggered cytokine release from BMMΦ and AAMΦ but did not seem to affect 
the existing levels produced by CAMΦ (Figure 5.3 and 5.4). This effect was concentration-
dependent. In order to dissect the origin of this stimulation, ES was subjected to heating to 
inactivate any enzyme activity as well as to deglycosylation to remove carbohydrates. In order to 
test if the effect observed was due to mannose-type carbohydrates acting on the mannose receptor 
of macrophages, D-mannose was used to stimulate cells. In addition, the effect of other 
carbohydrates on macrophage C-type lectin activation was also investigated to determine the 
source of ES-induced effects. 
Effects of ES on nitric oxide release 
Bone marrow derived macrophages (BMMΦ) were classically (CAMΦ) or alternatively 
(AAMΦ) activated and cultured for 20 hours with a range of ES concentrations. The effect of 
titrating the concentration of ES used to stimulate macrophages on NO release is shown in Figure 
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5.1. A concentration dependent NO release was detected in BMMΦ and AAMΦ that gradually 
increased up to 75μg/ml for both BMMΦ and AAMΦ but at 100μg/ml BMMΦ released higher 
levels of NO. However, when compared to CAMΦ the increase in NO released from BMMΦ 
elicited by ES was only 20% of the NO released following LPS stimulation. Activation of 
macrophages to produce CAMΦ and AAMΦ was tested at two different concentrations of LPS 
and IL-4, respectively, to examine if the concentration of the activating stimulus affected the 
macrophage response to ES. There appeared to be no difference in the response elicited by ES.  
However, the fact that NO release was triggered by ES could also suggest the presence of 
endotoxin/LPS in ES, as NO release is typical of classically (LPS) activated macrophages. 
Therefore, ES was tested for endotoxin using the Limulus Amoebocyte Lysate assay and a 
positive result was obtained for the presence of endotoxin (data not shown). The data were 
inconclusive due to the fact that the levels detected were too high for the sterile preparation of ES 
material used. In addition, when examined in the context of the final concentration of this 
detected „endotoxin‟ that would end up in the cell culture, the response observed was a lot higher 
than would be expected by the corresponding concentration of LPS cultured with cells (data of 
LPS titration on BMMΦ shown in Chapter 4, Figure 4.1A). In addition, previous work carried 
out in this lab involving ES treatment of other immune cells like mucosal mast cells (Holly 
Afferson PhD thesis) and dendritic cells did not suggest ES contamination by LPS. It should be 
noted that the basis of the endotoxin detection assay involves activation of a pro-enzyme in the 
presence of endotoxin, which could explain why ES may be capable of activating this enzyme, 
since it has been found to contain certain proteases, such as serine proteases (Nagano et al, 2003). 
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Effects of ES on arginase I activity  
 Macrophages whose supernatants were used to measure NO release were also assayed for 
arginase I activity levels post ES treatment. As shown in Figure 5.2, arginase I activity was 
increased in BMMΦ and CAMΦ (A and B, respectively) when in response to stimulation with ES 
with the effect being more significant at the concentration of 100μg/ml. The increase observed 
never reached basal AAMΦ levels which were approximately 10-fold higher. Furthermore, the 
slight increase observed in AAMΦ arginase I activity by ES was not as high when compared to 
untreated AAMΦ (Figure 5.2C). Therefore, ES only affected arginase I activity levels in BMMΦ 
and CAMΦ. 
Effects of ES on cytokine production  
Supernatants from ES-treated macrophages assayed for NO release were also used to 
measure cytokine levels. In BMMΦ and AAMΦ, cytokine release was significant after 
stimulation with 25μg/ml ES while 50μg/ml produced a submaximal response and was selected 
for further experiments (Figure 5.3). In BMMΦ, 100μg/ml ES stimulated production of higher 
levels of TNF-α than in AAMΦ, while AAMΦ activated with 20ng/ml IL-4 appeared be limited 
in their production of IL-6 following stimulation with ES. ES induced higher levels of TNF-α 
release from BMMΦ at 75 and 100μg/ml when compared to AAMΦ, while the levels of IL-10 
produced by both BMMΦ and AAMΦ were comparable for all the concentrations of ES tested. In 
fact, the levels of IL-10 released by BMMΦ cultured with 100μg/ml ES were only 70% of the 
levels induced by LPS in CAMΦ (Figure 5.4). The levels of TNF-α and IL-6 released by BMMΦ 
stimulated with 100μg/ml ES were the same as the levels released following stimulation of 
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CAMΦ with ES. It should be noted that, cytokine release by CAMΦ activated LPS was not 
affected by any of the ES concentrations tested. At the concentration of ES selected for further 
experiments (50μg/ml), cytokine release levels elicited in BMMΦ were only 50% of the levels 
released following macrophage stimulation with LPS (CAMΦ).  
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Figure 5.1: The effect of T.spiralis ES on nitric oxide (NO) release by bone marrow derived 
macrophages. Macrophages cultured with standard medium (BMMΦ), 10 or 50ng/ml LPS (CAMΦ), or 5 
or 20ng/ml IL4 (AAMΦ) were treated with T.spiralis ES at a range of concentrations (5-100μg/ml) for 
20hrs. Nitrite levels were measured in supernatants and are presented in µM. (A) The effect of ES on 
BMMΦ and AAMΦ NO release and (B) The effect of ES on BMMΦ and CAMΦ NO release. The data 
presented are an average of triplicates + SEM from one representative experiment of n = 3. 
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Figure 5.2: The effect of T.spiralis ES on bone marrow derived macrophage arginase I activity. 
Macrophages cultured with standard medium (BMMΦ), 10 ng/ml LPS (CAMΦ), or 5 ng/ml IL4 (AAMΦ) 
were treated with T.spiralis ES at a range of concentrations (5-100μg/ml) for 20hrs. Arginase I activity 
levels were measured and are presented in µmol urea per minute per 5 x 104 cells. The effect of ES on 
BMMΦ (A) on CAMΦ (B) and on AAMΦ (C) arginase I activity. The data presented are an average of 
triplicates + SEM from one representative experiment of n = 2 and asterisks indicate significance 
compared to the respective untreated control. * p< 0.05, ** p< 0.01, *** p< 0.001, ns - not significant (p> 
0.05). 
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Figure 5.3: The effect of T.spiralis ES on cytokine release by bone marrow derived macrophages. 
Macrophages cultured with standard medium (BMMΦ), 5 or 20ng/ml IL4 (AAMΦ) were treated with 
T.spiralis ES at a range of concentrations (5-100μg/ml) for 20hrs. The levels of TNF-α, IL-6 and IL-10 
released from BMMΦ and AAMΦ are shown in (A), (B) and (C), respectively. The data presented are an 
average of triplicates + SEM from one representative experiment of n = 3. 
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Figure 5.4: The effect of T.spiralis ES on cytokine release by classically activated macrophages 
(CAMΦ). Macrophages cultured with standard medium (BMMΦ), 10 or 50ng/ml LPS (CAMΦ) were 
treated with T.spiralis ES at a range of concentrations (5-100μg/ml) for 20hrs. The levels of TNF-α, IL-6 
and IL-10 released by BMMΦ and CAMΦ are shown in (A), (B) and (C) respectively. The data presented 
are an average of triplicates + SEM from one representative experiment of n = 3. 
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5.2.2 Effect of T. spiralis secreted proteins on murine macrophage purinergic signalling 
Taking into account that T.spiralis secreted proteins (ES) have nucleotide metabolising 
activity (Gounaris, 2002), the effect of ES on nucleotide-induced macrophage effector functions 
was investigated. Macrophages were treated with nucleotides in the presence of T.spiralis ES and 
were assayed for NO and cytokine release and arginase I activity. ES was used at a concentration 
of 50µg/ml.  
 
Effect of ES on nucleotide-induced NO release 
After verifying the effect of nucleotides on NO release from CAMΦ, T.spiralis ES was 
included in macrophage treatment with nucleotides. In addition, having established that ES 
treatment of macrophages resulted in detectable NO release, BMMΦ and AAMΦ were also 
treated with ES combined with nucleotides. As shown in Figure 5.5, the ES-induced NO release 
detected in BMMΦ and AAMΦ (A and C, respectively) was abolished by adenosine or adenine 
nucleotides. This suggests that ES enzymes converted nucleotides to adenosine which, in turn, 
reversed the increase in NO release induced by ES components. In CAMΦ (Figure 5.5B), 
adenine nucleotides inhibited NO release further and NO release reached levels similar to those 
induced by adenosine/NECA when incubated with ES. This was probably due to the additive 
effect of hydrolysis by ES enzymes and macrophage CD39 and CD73 resulting in generation of 
adenosine. The effect of incubating UDP in the presence of ES was also investigated since ES 
enzymes can also hydrolyse UDP. UDP did not affect NO release by any of the macrophage 
types which was also the case when UDP was co-administered with ES.  
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Figure 5.5: The effect of T.spiralis ES on NO released by bone marrow derived macrophages 
following purinergic receptor activation. Macrophages were cultured with standard medium (BMMΦ), 
classically or alternatively activated with 10ng/ml LPS or 5ng/ml IL-4, respectively, and treated for 20 
hours with 100μM adenosine, NECA, AMP, ADP, ATP or the slowly hydrolysable analogues of 
adenosine, ADP and ATP (β-ADP and ATP-γ, respectively). The effect of nucleotides, in the presence of 
50μg/ml ES, on NO released from BMMΦ (A), CAMΦ (B) and AAMΦ (C).The levels of NO release are 
expressed in μM. The data presented are an average of triplicates + SEM from one representative 
experiment of n > 3 and asterisks indicate significance compared to the respective untreated control (-ES). 
** p< 0.01, *** p< 0.001. 
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Effect of ES on nucleotide-induced arginase I activity  
Macrophage arginase I activity in response to nucleotides has also been investigated in 
this study (Chapter 4), therefore, the effect of ES on nucleotide-induced arginase I activity was 
assayed. Arginase I activity was only assayed in CAMΦ and AAMΦ since BMMΦ were not 
found to have significant arginase I activity levels (Chapter 4, Figure 4.1). The effect of ES on 
nucleotide-induced arginase I activity is shown in Figure 5.6. In CAMΦ, the adenosine/NECA-
induced increase in arginase I activity was not affected by ES, while ES only caused a slight 
increase on its own, similar to the increase observed in Figure 5.2. This increase in arginase I 
activity in response to ES alone can be attributed to an increase in arginase I transcripts, as 
determined by Q-PCR presented in Chapter 3. When CAMΦ were stimulated with nucleotides in 
the presence of ES, a 10-fold increase was detected in arginase I activity which is of similar 
magnitude to the increase induced by adenosine/NECA. Therefore, ES enzymes catalyzed the 
hydrolysis of adenine nucleotides to adenosine in culture. Similarly in AAMΦ, when adenine 
nucleotides were co-administered with ES, the increase in arginase I activity produced was 
comparable to the adenosine/NECA-induced increase. It should be noted that, because of the high 
basal levels of arginase I activity in AAMΦ, the fold increase was not as high as in CAMΦ. The 
effect of UDP on arginase I activity levels was also tested as it is a P2YR agonist that can be 
hydrolysed by ES enzymes. As it can be seen in Figure 5.6, UDP caused an increase in CAMΦ 
arginase I activity and a decrease in AAMΦ arginase I activity, which was not affected when 
UDP was added in the presence of ES. The observation that UDP had different effects on 
arginase I activity in the two macrophage types could be due to different levels of expression of 
the P2Y6R (which responds to UDP) or different coupling to intracellular signalling pathways by 
CAMΦ and AAMΦ. 
231 
 
 
Figure 5.6:  The effect of T.spiralis ES on arginase I activity of purinergic receptor activated bone 
marrow derived macrophage. Macrophages were classically or alternatively activated with 10ng/ml LPS 
(A) or 5ng/ml IL-4 (B), respectively, and treated for 20 hours with 100μM adenosine, NECA, AMP, ADP, 
ATP or the slowly hydrolysable analogues of adenosine, ADP and ATP (β-ADP and ATP-γ, respectively). 
The effect of nucleotides in the presence of 50μg/ml ES on CAMΦ (A) and AAMΦ (B) arginase I activity 
is expressed as μmol Urea/ min for every 5 x 104 cells. The data presented are an average of triplicates + 
SEM from one representative experiment of n > 3 and asterisks indicate significance compared to the 
respective untreated control. * p< 0.05, ** p< 0.01, *** p< 0.001, ns - not significant (p> 0.05).  
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Effect of ES on nucleotide-induced cytokine production  
Having determined macrophage cytokine release levels in response to nucleotides and 
T.spiralis ES separately, the effect of combining nucleotides with ES was then investigated. As 
shown in Figures 5.7, 5.8, 5.9 the effect of ES on nucleotide-induced cytokine release in BMMΦ 
and AAMΦ was similar to the pattern observed with NO release. Specifically, the ES-induced 
release of TNF-α and IL-6 from BMMΦ and AAMΦ was inhibited by adenosine/NECA and the 
same was true for adenine nucleotides, probably due to the fact they were hydrolysed to 
adenosine by ES enzymes. The ES-induced release of IL-10 was further enhanced by 
adenosine/NECA as well as by adenine nucleotides converted to adenosine in culture. In BMMΦ 
and AAMΦ, β-ADP did not affect the ES-induced cytokine release while ATP-γ-induced effects 
were not consistent. Specifically, TNF-α and IL-6 released from BMMΦ stimulated with ES was 
not affected by ATP-γ but the release of these cytokines from AAMΦ was inhibited by ATP-γ 
(Figure 5.7 and 5.8). The ES-induced IL-10 release from both BMMΦ and AAMΦ was slightly 
enhanced by ATP-γ (Figure 5.9).  
In CAMΦ, the effects of ES were only tested with respect to nucleotide hydrolysis as ES 
on its own did not affect background cytokine levels. Indeed, nucleotides such as AMP, ADP and 
ATP that could be hydrolysed by ES enzymes affected cytokine release by CAMΦ in a similar 
manner to adenosine/NECA. In cases where nucleotides (such as AMP, ADP and ATP) produced 
an effect on cytokine release even in the absence of ES, this effect was enhanced by co-
stimulation with ES due to the additive effect of hydrolysis by enzymes present in ES as well as 
macrophage CD39 and CD73 (discussed in Chapter 3). The slowly hydrolysable analogues of 
ADP and ATP (β-ADP and ATP-γ) had similar effects when used to stimulate CAMΦ both in the 
presence and absence of ES, therefore, ES enzymes were not capable of hydrolysing these 
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nucleotides in this form. β-ADP did not affect release of any of the cytokines tested while ATP-γ 
inhibited TNF-α and IL-6 release and slightly increased IL-10 release.  
In addition to testing the effect of ES with adenine nucleotides, UDP was also included as 
it is a P2YR agonist that is also potentially hydrolysed by ES enzymes. The ES-induced cytokine 
release from BMMΦ and AAMΦ was not affected by UDP, while hydrolysis of UDP by ES 
enzymes did not change CAMΦ responses to this nucleotide.  
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Figure 5.7: The effect of T.spiralis ES on TNF-α released from purinergic receptor activated bone 
marrow derived macrophages. Macrophages were cultured with standard medium (BMMΦ), classically 
or alternatively activated with 10ng/ml LPS or 5ng/ml IL-4, respectively, and treated for 20 hours with 
adenosine, NECA, nucleotides or their slowly hydrolysable analogues. The effect of nucleotides in the 
presence of 50μg/ml ES on TNF-α released from BMMΦ (A), CAMΦ (B) and AAMΦ (C).The levels of 
TNF-α release are expressed in pg/ml. The data presented are an average of triplicates + SEM from one 
representative experiment of n > 3 and asterisks indicate significance compared to the respective untreated 
control. ** p< 0.01, *** p< 0.001, ns - not significant (p> 0.05).  
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Figure 5.8: The effect of T.spiralis ES on IL-6 released from purinergic receptor activated bone 
marrow derived macrophages. Macrophages were cultured with standard medium (BMMΦ), classically 
or alternatively activated with 10ng/ml LPS or 5ng/ml IL-4, respectively, and treated for 20 hours with 
adenosine, NECA, nucleotides or their slowly hydrolysable analogues. The effect of nucleotides in the 
presence of 50μg/ml ES on IL-6 released from BMMΦ (A), CAMΦ (B) and AAMΦ (C). The levels of IL-
6 release are expressed in pg/ml. The data presented are an average of triplicates + SEM from one 
representative experiment of n > 3 and asterisks indicate significance compared to the respective untreated 
control. ** p< 0.01, *** p< 0.001, ns - not significant (p> 0.05).  
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Figure 5.9: The effect of T.spiralis ES on IL-10 released from purinergic receptor activated bone 
marrow derived macrophages. Macrophages were cultured with standard medium (BMMΦ), classically 
or alternatively activated with 10ng/ml LPS or 5ng/ml IL-4, respectively, and treated for 20 hours with 
adenosine, nucleotides or their slowly hydrolysable analogues. The effect of nucleotides in the presence of 
50μg/ml ES on IL-10 released from BMMΦ (A), CAMΦ (B) and AAMΦ (C). The levels of IL-10 release 
are expressed in pg/ml. The data presented are an average of triplicates + SEM from one representative 
experiment of n > 3 and asterisks indicate significance compared to the respective untreated control. ** p< 
0.01, *** p< 0.001, ns - not significant (p> 0.05).  
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Effect of ES on nucleotides mediated by 5`NT 
It is known that one of the enzymes present in T.spiralis ES has unique catalytic 
properties in that it can convert ADP to AMP and AMP to adenosine (Gounaris et al, 2004). This 
enzyme was recombinantly expressed and was available for in vitro use in order to examine 
whether this enzyme was responsible for the ES-induced effects on macrophage responses to 
nucleotides. Expression and purification of 5`NT was carried out and its activity confirmed in 
vitro prior to treatment of macrophages (Appendix, Figures A.1 and A.2). As shown in Figure 
5.10, the changes in nucleotide-induced effects observed when ES was present in culture of 
CAMΦ were due to the action of 5`NT. Experiments were only carried out with CAMΦ because 
the other macrophage subsets do not produce NO in the absence of ES. NO release and arginase I 
activity were assayed when nucleotides were incubated with 5`NT instead of ES (Figure 5.10). 
The results obtained followed the same pattern as that detected with ES, except for the ATP-
induced effects which were not as pronounced with 5`NT due to the fact that this enzyme is not 
responsible for catalysing hydrolysis of ATP by ES. The rest of the nucleotides incubated with 
5`NT had similar effects to adenosine, which was an inhibition of NO release from CAMΦ 
accompanied by an increase in arginase I activity. 5`NT itself did not affect basal NO release or 
arginase I activity levels.  
When ES was replaced by recombinant 5`NT in cultures of CAMΦ with nucleotides, the 
levels of TNF-α and IL-6 release were inhibited further when AMP and ADP were present in 
culture while the levels of IL-10 were enhanced. This was also observed when ES was co-
administered with these nucleotides showing that the 5`NT activity of ES was responsible for the 
nucleotide hydrolysis to adenosine. The only difference was observed with ATP which was 
degraded by ES (Figure 5.7-9) but it is not a substrate for 5`NT-mediated hydrolysis. 
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Figure 5.10: The effect of recombinant 5`NT on the levels of NO release and arginase I activity in 
purinegic receptor activated CAMΦ. Macrophages were classically activated with 10ng/ml LPS (A) 
and treated for 20 hours with adenosine, nucleotides or their slowly hydrolysable analogues. The effect of 
nucleotides in the presence of 15μg/ml 5`NT on NO release by CAMΦ (A), expressed in μM nitrite, and 
arginase I activity (B), expressed as μmol Urea/ min for every 5 x 104 cells, is shown. The data presented 
are an average of triplicates + SEM from one representative experiment of n > 3 and asterisks indicate 
significance compared to the respective untreated control. * p< 0.05, ** p< 0.01, *** p< 0.001. 
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Figure 5.11: The effect of recombinant 5`NT on cytokine released from purinergic receptor 
activated CAMΦ. Macrophages were classically activated with 10ng/ml LPS and treated for 20 hours 
with adenosine, nucleotides or their slowly hydrolysable analogues. The effect of nucleotides in the 
presence of 15μg/ml 5`NT on the levels of TNF-α (A), IL-6 (B) and IL-10 (C) released by CAMΦ. 
Cytokine levels are expressed in pg/ml. The data presented are an average of triplicates + SEM from one 
representative experiment of n > 3 and asterisks indicate significance compared to the respective untreated 
control. *** p< 0.001, ns - not significant (p> 0.05). 
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5.2.3 Characterisation of T.spiralis ES-induced effects  
Involvement of downstream signalling pathways 
In order to characterise the pathways involved in mediating T.spiralis ES-induced effects, 
macrophages cultured with ES were pre-incubated with compounds known to interfere with or 
activate some of the known intracellular signalling pathways. Taking into account that adenosine 
inhibited ES-induced effects and knowing that adenosine mediated its effects via cAMP elevation 
(as discussed in Chapter 4), ES-treated macrophages were pre-incubated with forskolin to 
determine if the adenosine-induced effects could be mimicked just by raising cAMP levels. The 
effect of forskolin on ES-induced NO release is shown in Figure 5.12. In BMMΦ, cAMP 
elevation with two different concentrations of forskolin inhibited the ES-induced NO release. The 
effect of forskolin could not be tested at a higher concentration due to the fact that DMSO used to 
solubilise this compound was toxic to the cells. 
TNF-α and IL-6 release from BMMΦ triggered by ES was also partly reversed by cAMP 
elevation (Figure 5.13A, B). On the other hand, cAMP elevation enhanced the ES-induced IL-10 
release by BMMΦ. In the case of cytokine release, DMSO-induced toxicity was observed at the 
lower concentration of forskolin used. However, it was evident that the forskolin-induced 
inhibition of TNF-α and IL-6 release were due to cAMP elevation and not to DMSO-induced 
toxicity as the inhibition observed in the presence of forskolin was much more pronounced. In 
addition, no DMSO-induced effects were observed in the case of IL-10 release.  
 Taken together, these data indicate that cAMP elevation can interfere with the ES-induced 
release of NO and cytokines from BMMΦ. This could either be a direct cAMP effect or might be 
due to interference with PLC signalling.  
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Figure 5.12: The effect of cAMP elevation on T.spiralis ES-induced NO release from BMMΦ. 
Macrophages were cultured with standard medium for 20 hours and treated with 50μg/ml T.spiralis ES. 
Prior to ES addition cells were incubated with the cAMP elevator, forskolin. DMSO controls 
corresponding to the final concentration of DMSO for forskolin were also included. DMSO 10 and 50 
correspond to the 10μM and 50μM forskolin used. The data presented are an average of triplicates + SEM 
from one representative experiment of n = 3 and asterisks indicate significance compared to the untreated 
control (-).  *** p< 0.001, ns - not significant (p> 0.05). 
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Figure 5.13: The effect of cAMP elevation on T.spiralis ES – induced cytokine release from BMMΦ. 
Macrophages were cultured with standard medium for 20 hours and treated with 50μg/ml T.spiralis ES. 
Prior to ES addition cells were incubated with the cAMP elevator, forskolin. DMSO controls 
corresponding to the final concentration of DMSO for forskolin were also included. DMSO 10 and 50 
correspond to the 10μM and 50μM forskolin used. Supernatants were assayed for TNF-α (A), IL-6 (B) 
and IL-10 (C) release, and the levels of cytokines are expressed in pg/ml. The data presented are an 
average of triplicates + SEM from one representative experiment of n = 3 and asterisks indicate 
significance compared to the untreated control (-).  * p< 0.05, *** p< 0.001, ns - not significant (p> 0.05). 
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The involvement of PLC in macrophage effector functions induced by ES was also 
investigated. As shown in Figure 5.14A, the ES-induced increase in NO release by BMMΦ was 
completely reversed by the PLC inhibitor U73122 while the mock inhibitor had no effect, as 
expected. Downstream pathways were also blocked at different points using Bay 11-7082, U0126 
and LY294002 to inhibit NF-κB, MEK1/2 and PI3 kinase, respectively (Figure 5.14B). Inhibiting 
NF-κB and MEK1/2 also inhibited the ES-induced effect but not as dramatically as PLC 
inhibition. However, blocking PI3 kinase resulted in a 50% inhibition of ES-induced NO release.  
The effect of blocking downstream pathways on ES-induced cytokine release was also 
investigated. As shown in Figure 5.15, the PLC inhibitor did not have the same effect on all the 
cytokines tested. Specifically, U73122 reversed the ES-induced TNF-α and IL-10 release but so 
did the mock PLC inhibitor showing that the effect was non-specific. However, it should be 
noted that, the inhibition of TNF-α release observed with U73122 was more pronounced than that 
caused by the inactive analogue. In the case of IL-6 release, only the PLC inhibitor blocked the 
ES-induced increase. These data show that only the IL-6 release induced by ES was affected by 
inhibiting activation of the PLC pathway since the data obtained for TNF-α and IL-10 release 
were inconclusive. 
The NF-κB, MEK1/2 and PI3 kinase pathways were also blocked to determine if ES-
induced cytokine release was dependent on their activation (Figure 5.16). As shown in Figure 
5.16A, Bay 11-7082, U0126 and LY294002 increased basal TNF-α release. When the inhibitors 
were co-administered with ES, the ES-induced increase was reduced by 20% when NF-κB and 
MEK1/2 were inhibited and by 50% when PI3 kinase was blocked. In the case of IL-6 release 
only LY294002 increased BMMΦ basal levels while all inhibitors reversed the ES-induced IL-6 
release by approximately 70% (Figure 5.16B). Finally, basal IL-10 release levels were increased 
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by all 3 inhibitors, however, when BMMΦ were co-cultured with ES and the respective inhibitor, 
Bay 11-7082, U0126 and LY294002, ES-induced effects were reduced by 50% in all cases.  
In general, the NO and cytokine release triggered by ES varied according to the ES batch 
used so only one representative experiment is shown. In addition, ES was used at a concentration 
that triggered a submaximal response, especially when inhibitors were tested to avoid saturation 
effects that would lead to inefficient antagonism.  
Taken together these data show that ES-induced effects were mediated by an increase in 
PLC levels and/or a decrease in cAMP levels. In addition, ES-induced NO and cytokine release 
required NF-κB and MEK1/2 activation at some point in the signalling cascade, however, the 
lack of dependence on one particular pathway points to overlap as these pathways converge 
before activating nuclear transcription factors. PI3 kinase involvement is also a possibility, 
however, it should be taken into account that the inhibitor used also blocked background NO and 
cytokine release by CAMΦ, which may suggest toxicity or that PI3 kinase is a ubiquitous enzyme 
in macrophage signalling cascades.  
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Figure 5.14: The effect of PLC, NF-κB, MEK and PI3 kinase inhibition on T.spiralis ES-induced NO 
release from BMMΦ. Macrophages were cultured in standard medium for 20 hours and treated with 
50μg/ml T.spiralis ES. Prior to ES addition cells were incubated with different inhibitors for 15 minutes at 
37˚C. (A) The effect of PLC inhibition with 10μM U73122 on ES-induced effects. U73343 is a mock PLC 
inhibitor. (B) The effect of 5μM Bay11-7082 (NF-κB), 5μM U0126 (MEK1/2) and 10μM LY294002 (PI3 
kinase) on ES – induced NO release from BMMΦ. The data presented are an average of triplicates + SEM 
from one representative experiment of n = 3 and asterisks indicate significance compared to the respective 
untreated control.* p< 0.05, *** p< 0.001. 
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Figure 5.15: The effect of PLC inhibition on T.spiralis ES-induced cytokine release from BMMΦ. 
Macrophages were pre-incubated with 10μM of the PLC inhibitor U73122 or the mock inhibitor U73343 
and then cultured in standard medium for 20 hours with 50μg/ml T.spiralis ES. Cell supernatants were 
then assayed for TNF-α (A), IL-6 (B) and IL-10 (C) release, expressed in pg/ml. The data presented are an 
average of triplicates + SEM from one representative experiment of n = 3 and asterisks indicate 
significance compared to the respective untreated control.*** p< 0.001. 
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Figure 5.16: The effect of NF-κB, MEK and PI3 kinase inhibition on T.spiralis ES-induced cytokine 
release from BMMΦ. Macrophages were pre-incubated with 5μM Bay 11-7082 (NF-κB), 5μM U0126 
(MEK1/2) or 10μM LY294002 (PI3 kinase) and then cultured in standard medium for 20 hours with 
50μg/ml T.spiralis ES. Cell supernatants were then assayed for the presence of TNF-α (A), IL-6 (B) and 
IL-10 (C). Cytokine levels are expressed in pg/ml. The data presented are an average of triplicates + SEM 
from one representative experiment of n = 3 and asterisks indicate significance compared to the respective 
untreated control.* p< 0.05, ** p< 0.01, *** p< 0.001, ns - not significant (p> 0.05). 
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Effect of heat inactivation of ES 
In an attempt to characterise which component of ES was responsible for the induction of 
macrophage effector functions, ES was subjected to different treatments to alter or eliminate 
certain structural characteristics. Firstly, ES was heat-inactivated by incubating at 100˚C for 10 
minutes in order to inhibit any enzymatic activity prior to macrophage stimulation. The effect of 
heat inactivating ES on arginase I activity and NO release is shown in Figure 5.17. In BMMΦ the 
increase in NO release and arginase I activity was reduced by heat inactivation. No effect was 
observed in CAMΦ and AAMΦ NO release or arginase I activity.  
Cytokine release was also assayed and as it is shown in Figure 5.18, heat inactivation 
partly but significantly reduced TNF-α release from BMMΦ and AAMΦ by 20-30%. Likewise, 
IL-6 release was also reduced in BMMΦ and AAMΦ by 50% and 20%, respectively.  There was 
no significant change in CAMΦ TNF-α and IL-6 release levels. Interestingly, IL-10 release by 
BMMΦ and AAMΦ was almost completely reversed by heat inactivating ES. In this particular 
set of experiments the batch of ES used appeared to increase CAMΦ IL-10 release as well, 
however, this increase was also reversed by heat inactivation.   
Glycan involvement in ES-induced effects 
To further characterise the ES-induced effects, the involvement of glycans conjugated 
onto ES proteins was investigated. ES was chemically deglycosylated by the TFMS method 
which eliminates all O- and N-linked glycans whilst preserving the core proteins. These proteins 
were recovered and used to stimulate BMMΦ. As shown in Figure 5.19, deglycosylating ES 
completely inhibited the NO release triggered in BMMΦ while in AAMΦ, where stimulation 
with ES caused a smaller increase, the reduction was less pronounced but still significant. 
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Similarly, the increase in cytokine release elicited by ES in BMMΦ and AAMΦ was also 
reversed by deglycosylation, as can be seen in Figure 5.20. As with NO release, the ES-induced 
effects on cytokine release were more pronounced in BMMΦ which made the reversal more 
apparent than in AAMΦ. Nevertheless, AAMΦ cytokine release levels up-regulated by ES were 
also significantly reduced when the deglycosylated protein was administered instead.  
Taken together these results suggest that the glycan components of T.spiralis ES are 
responsible for macrophage activation. The fact that heat inactivation also partly reversed ES-
induced effects may point to the importance of correct positioning of glycans, which is directly 
related to protein structural integrity.  
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Figure 5.17: The effect of heat inactivating T.spiralis ES on arginase I activity and NO released from 
bone marrow derived macrophages. Macrophages cultured with standard medium (BMMΦ), 10ng/ml 
LPS (CAMΦ) or 5ng/ml IL4 (AAMΦ) were treated with 50 μ g/ml T.spiralis ES that was boiled at 100˚C 
for 10 minutes (HI-ES). (A) and (B) The effect on the levels of arginase I activity in the 3 macrophage 
types expressed as μmol Urea/ min for every 5 x 104 cells. (C) and (D) The effect on nitric oxide released 
by the 3 macrophage types expressed in µM nitrite. The data presented are an average of triplicates + 
SEM from one representative experiment of n = 3 and asterisks indicate significance compared to the 
respective untreated control. *** p< 0.001. (†) is compared to the respective macrophage type treated with 
ES only. ††† p< 0.001, ns - not significant (p> 0.05). 
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Figure 5.18: The effect of heat inactivating T.spiralis ES on cytokine release by bone marrow 
derived macrophages. Macrophages cultured with standard medium (BMMΦ), 10ng/ml LPS (CAMΦ) or 
5ng/ml IL4 (AAMΦ) were treated with 50 μ g/ml T.spiralis ES that was boiled at 100˚C for 10 minutes 
(HI-ES). Cell supernatants were assayed for the presence of TNF-α (A), IL-6 (B) and IL-10 (C). Cytokine 
levels are expressed in pg/ml. The data presented are an average of triplicates + SEM from one 
representative experiment of n = 3 and asterisks indicate significance compared to the respective untreated 
control. *** p< 0.001, ns - not significant (p> 0.05). (†) is compared to the respective macrophage type 
treated with ES only. ††† p< 0.001. 
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Figure 5.19: The effect of deglycosylating T.spiralis ES on induction of NO release from BMMΦ and 
AAMΦ. Macrophages were cultured in standard medium (BMMΦ) or 5ng/ml IL-4 (AAMΦ) for 20 hours 
and treated with 50μg/ml T.spiralis ES or deglycosylated ES (Deg.ES). Cell supernatants were assayed for 
the presence of NO. NO levels are expressed as μM nitrite. The data presented are an average of triplicates 
+ SEM from one representative experiment of n > 3 and asterisks indicate significance compared to the 
respective untreated control. *** p< 0.001. (†) is compared to the respective macrophage type treated with 
ES only. †† p< 0.01, ††† p< 0.001. 
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Figure 5.20: The effect of deglycosylating T.spiralis ES on induction of cytokine release from 
BMMΦ and AAMΦ. Macrophages were cultured in standard medium (BMMΦ) or 5ng/ml IL-4 
(AAMΦ) for 20 hours and treated with 50μg/ml T.spiralis ES or deglycosylated ES (Deg.ES). Cell 
supernatants were assayed for the presence of TNF-α (A), IL-6 (B) and IL-10 (C). Cytokine levels are 
expressed in pg/ml. The data presented are an average of triplicates + SEM from one representative 
experiment of n > 3 and asterisks indicate significance compared to the respective untreated control. *** 
p< 0.001. (†) is compared to the respective macrophage type treated with ES only. ††† p< 0.001. 
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Investigation of macrophage glycan receptor activation 
Having established that the glycan component of T.spiralis ES was responsible for the 
activation of BMMΦ by ES, the involvement of specific macrophage receptors of the C-type 
lectin class was investigated. This was achieved by pre-incubating macrophages with 
carbohydrates known to bind C-type lectins prior to treatment with T.spiralis ES.  
Firstly, BMMΦ, CAMΦ and AAMΦ were incubated with D-mannose to see if ES-
induced effects could be mimicked by mannose receptor activation. As shown in Figure 5.21, D-
mannose had no effect on macrophage arginase I activity and NO release. Cytokine release in 
response to D-mannose was also assayed but no increase was detected throughout the D-mannose 
concentration range tested (Figure 5.22).  
Macrophage cytokine and NO release were then measured in response to ES after 
blocking surface lectins for one hour with specific carbohydrates, such as, D-mannose (mannose 
receptor), mannan (DC-SIGN and mannose receptor), laminarin (Dectin-1), EGTA (all c-type 
lectins) and GalNAc (Macrophage Galactose binding Lectin-MGL). The effect of blocking 
lectins was only investigated in BMMΦ and AAMΦ which generally showed a greater 
responsiveness to ES. EGTA completely abolished NO release triggered by ES while GalNAc 
also significantly inhibited NO release (Figure 5.23). D-mannose and laminarin had no effect on 
NO release but mannan seemed to enhance the ES-induced NO production. Cytokine release was 
similarly affected by blocking macrophage surface lectins. As shown in Figure 5.24, blocking the 
effects induced by ES with GalNAc and EGTA inhibited release of all the cytokines measured. 
The effects induced by mannan and laminarin on NO release were not as significant in the case of 
IL-6 and IL-10 release and were not detected in the case on TNF-α release. Taken together, these 
data point to the involvement of MGL in the ES-induced NO and cytokine release by BMMΦ.  
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Figure 5.21: The effect of D-Mannose on arginase I activity and NO released by bone marrow 
derived macrophages. Macrophages cultured with standard medium (BMMΦ), 10ng/ml LPS (CAMΦ), 
or 5ng/ml IL4 (AAMΦ) were treated with D-Mannose at a range of concentrations (0.05-1mM) for 20hrs. 
Arginase I activity (A) and nitric oxide release (B) levels were determined. Arginase I activity is 
expressed as μmol Urea/ min for every 5 x 104 cells and nitrite levels detected are presented in µM. The 
data presented are an average of triplicates + SEM from one representative experiment of n = 3 and 
asterisks indicate significance compared to the respective untreated control. ns - not significant (p> 0.05). 
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Figure 5.22: The effect of D-Mannose on cytokine release from bone marrow derived macrophages. 
Macrophages cultured with standard medium (BMMΦ), 10 ng/ml LPS (CAMΦ), or 5 ng/ml IL4 (AAMΦ) 
were treated with D-Mannose at a range of concentrations (0.05-1mM) for 20hrs. Supernatants were 
collected and ELISA carried out to determine TNF-α (A), IL-6 (B) and IL-10 (C) levels. The data 
presented are an average of triplicates + SEM from one representative experiment of n = 3 and asterisks 
indicate significance compared to the respective untreated control.  ns - not significant (p> 0.05). 
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Figure 5.23: The effect of blocking BMMΦ surface lectins on T.spiralis ES – induced NO release. 
Macrophages were cultured with standard medium for 20 hours and treated with 50μg/ml T.spiralis ES. 
Prior to ES addition cells were incubated with the following carbohydrates: 100μg/ml mannan (blocking 
DC-SIGN and MR), 200μg/ml laminarin (blocking Dectin-1), 10mM EGTA (blocking all c-type lectins) 
and 100mM GalNAc (blocking MGL). Cell supernatants were assayed for NO release, expressed as μM 
nitrite. The data presented are an average of triplicates + SEM from one representative experiment of n > 
3 and asterisks indicate significance compared to the respective untreated control. *** p< 0.001, ns - not 
significant (p> 0.05). 
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Figure 5.24: The effect of blocking BMMΦ surface lectins on T.spiralis ES – induced cytokine 
release. Macrophages were cultured with standard medium for 20 hours and treated with 50μg/ml 
T.spiralis ES. Prior to ES addition cells were incubated with the following carbohydrates: 100μg/ml 
mannan (blocking DC-SIGN and MR), 200μg/ml laminarin (blocking Dectin-1), 10mM EGTA (blocking 
all c-type lectins) and 100mM GalNAc (blocking MGL). Cell supernatants were assayed for the presence 
of TNF-α (A), IL-6 (B) and IL-10 (C). Cytokine levels are expressed in pg/ml. The data presented are an 
average of triplicates + SEM from one representative experiment of n > 3 and asterisks indicate 
significance compared to the respective untreated control. * p< 0.05, *** p< 0.001. 
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Macrophage Galactose Lectin (MGL) involvement  
Having concluded from macrophage functional assays that MGL is responsible for 
T.spiralis ES-induced effects, MGL-binding fractions in ES were purified. The human 
macrophage galactose lectin CRD was expressed and purified by affinity chromatography on a 
galactose–Sepharose column (by A. Quintero-Martinez, K. Drickamer as described in Lobst and 
Drickamer, 1996) and incubated with ES in loading buffer containing Ca
2+
 ions required for 
MGL stability. Unbound or weakly-bound fractions were collected by washing with loading 
buffer and bound ES proteins eluted by removal of Ca
2+
 ions (elution buffer – Ca2+). BMMΦ 
were then cultured with the fractions obtained and NO and cytokine release assayed. The effect 
of MGL-purified fractions of ES on NO release by BMMΦ is shown in Figure 5.25. As shown in 
Figure 5.25A, the flow-through (F), the first fraction collected after application of ES, retained 
some activity that was comparable to the levels measured with ES and the MGL-bound ES 
fraction. In order to determine if the residual activity was due to low affinity fractions of 
GalNAc-conjugated proteins present in the flow-through, macrophages were blocked with 
GalNAc prior to their treatment with the different fractions (Figure 5.25B). As expected, the 
activity of all fractions tested was significantly inhibited by blocking macrophage MGL with 
GalNAc. This also confirmed that the bound fraction was specific for MGL on macrophages 
since GalNAc completely inhibited the Bound-ES-induced NO release.  
Cytokine release in response to MGL-purified fractions was also measured in macrophage 
supernatants. A similar pattern to NO release was observed for all cytokines tested (Figure 5.26). 
Specifically, the activity detected in the first two fractions that were collected from the column 
gradually decreased with each wash so that no activity was detected in the last wash. The 
cytokine release triggered by the flow-through (F) and Bound fractions was inhibited by pre-
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treatment of macrophages with GalNAc and in the case of IL-10 the effect was completely 
reversed (Figure 5.27).  
In an attempt to identify ES proteins that were eluted from the MGL column, SDS-PAGE 
analysis was carried out. SDS-PAGE gels used to resolve the different ES fractions that resulted 
from MGL-purification are shown in Figure 5.28. Protein bands that were detected in the bound-
ES fraction were very faint and corresponded to 120, 50, 45, 20 kDa. A band at 37kDa was 
unique for the bound-ES fraction and could be due to leaching of MGL from the column during 
the elution step. The rest of the bands detected in the bound-ES fraction were also observed in the 
flow-through (F) and wash (W1 and W2) fractions as well. This could indicate the presence of 
active ES components in F and W which would also explain the persisting activity in these 
fractions.  
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Figure 5.25: The effect of MGL-purified T.spiralis ES fractions on NO release from BMMΦ. 
Macrophages were cultured in standard medium and treated with 50μg/ml T.spiralis ES. Cells were also 
incubated with separated ES fractions obtained from applying ES to an MGL-conjugated column. (A) The 
effect of incubating BMMΦ with the following fractions: R (column rinse), F1 and F2 (flow through 1 and 
2), W 1, 2, 3 and 4 (Column washes with loading buffer) and Bound ES (eluted products). (B) The effect 
of incubating purified fractions with 100mM GalNAc. NO release was assayed in cell supernatants and 
expressed as μM nitrite. The data presented are an average of triplicates + SEM from one experiment of n 
> 3 and asterisks indicate significance compared to the respective untreated control.* p< 0.05, *** p< 
0.001. (†) is compared to the respective fraction not treated with GalNAc. ††† p< 0.001. 
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Figure 5.26: The effect of MGL-purified T.spiralis ES fractions on cytokine release from BMMΦ. 
Macrophages were cultured in standard medium and treated with 50μg/ml T.spiralis ES. Cells were also 
incubated with separated ES fractions obtained from applying ES to an MGL-conjugated column. The 
effect of incubating BMMΦ with the following fractions: R (column rinse), F1 and F2 (flow through 1 and 
2), W 1, 2, 3 and 4 (Column washes with loading buffer) and Bound ES (eluted products) was investigated 
and cell supernatants were assayed for the presence of TNF-α (A), IL-6 (B) and IL-10 (C). Cytokine levels 
are expressed in pg/ml. The data presented are an average of triplicates + SEM from one representative 
experiment of n > 3 and asterisks indicate significance compared to the respective untreated control.* p< 
0.05, ** p< 0.01, *** p< 0.001. 
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Figure 5.27: The effect of MGL-purified T.spiralis ES fractions on NO release from BMMΦ. 
Macrophages were cultured in standard medium and treated with 50μg/ml T.spiralis ES. Cells were also 
incubated with separated ES fractions obtained from applying ES to an MGL-conjugated column. The 
effect of incubating purified fractions with 100mM GalNAc was investigated and cell supernatants were 
assayed for the presence of TNF-α (A), IL-6 (B) and IL-10 (C). Cytokine levels are expressed in pg/ml. 
The data presented are an average of triplicates + SEM from one representative experiment of n > 3 and 
asterisks indicate significance compared to the respective untreated control.*** p< 0.001. (†) is compared 
to the respective fraction not treated with GalNAc. †† p< 0.01, ††† p< 0.001. 
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Figure 5.28: SDS-PAGE analysis of MGL-purified T.spiralis ES proteins.  T.spiralis secretory 
proteins were applied to an MGL-conjugated column and the fractions obtained after elution were 
analysed by SDS-PAGE. (A) SDS-PAGE of all the fractions obtained: F (Flow through), W1,2 and 3 
(column washes with loading buffer) and Bound (fraction eluted from the column). (B) SDS-PAGE of 
Bound and Flow through fractions as well as ES for band comparison. Product sizes were determined by 
the protein ladder annotated with sizes in kDa.  
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In conjunction to MGL-specific purification of ES proteins, competition assays were 
carried out to determine the specificity and affinity of ES components to immobilised MGL (as 
described by Quesenberry and Drickamer, 1992 and Lobst and Drickamer, 1996). The binding 
affinity of ES components to an immobilised fragment of the MGL receptor was determined by 
competition of increasing concentrations of ES with radioiodinated galactose-BSA (Figure 5.29). 
The results obtained revealed a high affinity of ES proteins for MGL that was comparable to the 
galactose control. 
In order to confirm that the activity detected in MGL-purified ES fractions was due to 
GalNAc residues, all the fractions obtained from the MGL column were resolved by SDS-PAGE 
and then blotted for 
125
I-labelled MGL (Figure 5.30). This was carried out by K. Drickamer as 
described in Coombs et al, 2005. Indeed, 
125
I-MGL was found to bind to all the fractions with 
varying affinity. Flow-through and Wash fractions appeared to be more enriched in GalNAc 
residues that bound 
125
I-MGL as band intensity was higher in lanes loaded with these fractions. 
125
I-MGL binding was also detected in the Eluted (or Bound-ES) fractions confirming the 
presence of GalNAc residues on glycoproteins retained by the MGL-column.  
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Figure 5.29: Binding competition assays to characterise T.spiralis glycoprotein binding to 
recombinant MGL. MGL extracellular domain was immobilised on wells and probed with 
125
I-
Galactose-BSA in the presence of varying concentrations of ligands. (A) Competition with varying 
concentrations of the MGL ligand Galactose. (B) Competition with varying concentrations of T.spiralis 
secretory proteins. (Kurt Drickamer) 
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Figure 5.30: SDS-PAGE and blot analysis of T.spiralis ES fractionated on human MGL. 
T.spiralis secretory products were applied to an MGL-conjugated column and the fractions obtained after 
elution were analysed by SDS-PAGE and blotted with 
125
I-MGL. Fractions resolved are annotated on the 
blot. Elutions 1,2,3/4 and 5correspond to the „Bound‟ fractions. Product sizes were determined by the 
protein ladder annotated with sizes in kDa (right). (Kurt Drickamer, Adrián Quintero-Martínez) 
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5.3 Discussion  
Macrophages are important innate immune cells known to express a wide range of surface 
receptors capable of interacting with natural and altered-self host components as well as a range 
of microorganisms. Following recognition the signalling that ensues contributes to macrophage 
activation which can directly or indirectly affect host defence effector mechanisms to pathogens 
by linking innate and adaptive immunity. In general, the sequence of events triggered by 
pathogen invasion is considered an inflammatory response aiming to kill or expel the invading 
organism. However, helminth parasites have evolved to survive in hostile host environments by 
evading these responses and this has been shown to involve recruitment of AAMΦs which are 
stimulated optimally in the context of a Th2 cytokine environment (Kreider et al, 2007). This 
chapter focused on the effects induced by the parasitic nematode Trichinella spiralis on 
macrophage effector functions. In particular, the parasite secreted proteins (ES) were used to 
stimulate macrophages and the effects on nitric oxide release, arginase I activity and cytokine 
release investigated. In addition, bearing in mind that T.spiralis ES contains nucleotide 
metabolising activity, the impact on macrophage purinergic signalling was also investigated.  
T.spiralis ES induced a concentration-dependent NO release from BMMΦ and AAMΦ 
that was lower than the release observed from CAMΦ. This is consistent with studies carried out 
with F.hepatica secretory products which similarly showed that the levels of NO released from 
monocyte-derived macrophages were not as high as the levels released from LPS-stimulated 
macrophages (Flynn and Mulcahy, 2008). In order to investigate if the concentration of the 
activating stimulus affected the macrophage response to ES, ES-induced effects were measured at 
two different concentrations of LPS or IL4 in CAMΦ and AAMΦ, respectively. No difference in 
the response elicited by ES was observed. In fact, the minimal effect of ES on CAMΦ NO release 
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was found to be insignificant. Interestingly, in studies carried out with the macrophage cell line 
RAW264.7, T.spiralis ES was found to inhibit LPS-induced NOS2 via mRNA down-regulation, 
however, the authors have not shown a correlation with NO release levels (Bian et al, 2005).  
Arginase I activity was also increased in BMMΦ and CAMΦ by high ES concentrations 
but this effect was a lot more significant at the concentration of 100μg/ml which is higher than 
ES concentrations encountered in vivo. Nevertheless, arginase I activity levels were never as high 
as basal AAMΦ levels. Furthermore, basal AAMΦ arginase I activity was not significantly 
affected by ES which might be due to the fact that arginase I activity levels are maximal and 
further enhancement in activity is either not possible or not detectable by the in vitro assays used. 
A number of studies on the effects of parasite products have shown that arginase I up-regulation 
is a common characteristic of macrophage manipulation by parasites. In guinea pig alveolar 
macrophages arginase I levels were found to be increased by T.spiralis as well as T.cruzi 
infection but no effect on NO release was detected (Dzik et al, 2004). Cuervo and colleagues also 
showed that T.cruzi infection caused arginase I up-regulation in heart-infiltrating macrophages 
(Cuervo et al, 2008). Increases in both arginase I and YmI have been reported in mouse 
peritoneal macrophages treated with LNFPIII from schistosome egg antigen (SEA) which did not 
seem to be dependent on the presence of IL-4 or IL-13 (Atochina et al, 2008). In addition, 
Omega-1 from SEA was also found to be a potent Th2 inducer in a study with human monocyte-
derived dendritic cells (Everts et al, 2009).  
Both NO release levels and arginase I activity levels were found to be increased by 
T.spiralis ES in this study which can be attributed to the fact that, the immune response switches 
from a Th1 pro-inflammatory response to a Th2 protective response, as NO can act as an effector 
against parasites. The increase in arginase I ultimately leads to depletion of L-arginine which, 
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being an iNOS substrate, may eventually shift macrophage phenotype away from classical 
activation by disabling iNOS activity. It is known that a Th2 response is required to expel 
gastrointestinal nematodes (Jenkins and Allen, 2009). Specifically, in the case of T.spiralis 
infection it has been reported that the Th2 response and, in particular IL-4, is necessary for 
parasite expulsion (Garside et al, 2000). In fact, mice deficient in IL-4R or lacking IL-13 showed 
a reduction in parasite expulsion (Scales et al, 2007). Therefore, it is conceivable that Th1 
responses synergise with Th2 responses to kill parasites.  
The involvement of the Th2 arm of the immune response has also been reported in 
N.brasiliensis infection where AAMΦ recruitment was detected in mouse lungs as early as 4 days 
post-infection and, although initially dependent on Th2 cytokines IL-4 and IL-13, appeared to be 
influenced by additional factors developing in the pulmonary environment by parasite infection 
(Reece et al, 2006; Siracusa et al, 2008). AAMΦs have also been detected in Brugia malayi 
infection and this was found to result from the synergy of B.malayi-generated MIF and IL-4 
(Prieto-Lafuente et al, 2009). The macrophage inhibitory factor (MIF) has been shown to 
synergise with LPS to upregulate IL-6 and TNF-α production as well, which is another example 
of parasite products inducing both pro- and anti-inflammatory responses in the host (Vermeire et 
al, 2008). Similarly in this study, T.spiralis ES was found to elicit a significant cytokine release 
from BMMΦ and AAMΦ at the concentration selected for in vitro experiments. The TNF-α 
levels induced in BMMΦ were not detected in AAMΦ activated with high levels of IL4 
suggesting that the presence of IL-4 limited pro-inflammatory cytokine induction by ES. This 
induction of Th1 cytokines by T.spiralis ES even in the AAMΦ subset is in agreement with 
published work by Ishikawa and colleagues that reports a role for the Th1 lymphocyte subset in 
early phases of T.spiralis infection (Ishikawa et al, 1998). In addition, T.spiralis ES has been 
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shown to induce IL-6 release in peritoneal macrophages in vitro (Gruden-Movsesijan and 
Milosavljevic, 2006). In the current study, IL-10 release was also induced by T.spiralis ES in 
BMMΦ and AAMΦ and were similar to CAMΦ background levels, an effect that was not 
observed with TNF-α and IL-6 levels which never reached CAMΦ levels. Consistent with this, 
Van der Kleij and colleagues have reported that LDN-DF (difucosylated LacDiNac) from 
schistosome eggs induced IL-6, TNF-α and IL-10 production by PBMCs (Van der Kleij et al, 
2002). Similar to NO release, basal CAMΦ cytokine levels were not affected by ES at either 
concentration of LPS used. The observation that parasite products can induce both Th1 and Th2 
responses was also made by Dissanayake and colleagues in studies using T.crassiceps glycans 
(Dissanayake et al, 2004). The authors suggested a two step mechanism for induction of the Th2 
response by T.crassiceps whereby glycans are recognized by macrophage TLR4 resulting in IL6 
release which subsequently aids in producing a Th2 cytokine environment, possibly by blocking 
Th1 cells and promoting differentiation of IL-4 producing T cells.  
In addition to the ability of T.spiralis secreted products to generate both Th1 and Th2 
responses, its secreted proteins can potentially manipulate host danger signals to evade any 
response aimed to eliminate the parasite. Specifically, it is known that the enzymatic activity of 
T.spiralis secreted proteins can interfere with purinergic signalling by altering extracellular 
nucleotide type and concentration. In Chapter 4 the effects of nucleotides on CAMΦ effector 
functions were established showing a general trend where the presence of adenosine, either by 
administration or by degradation of adenine nucleotides by macrophage ecto-nucleotidases, 
resulted in enhancement of anti-inflammatory functions such as arginase I activity and IL-10 
release and inhibition of pro-inflammatory cytokine and NO release. In the presence of ES the 
effects of nucleotides on CAMΦ NO and cytokine release were more pronounced as the 
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combination of ES enzymes with macrophage ecto-nucleotidases resulted in more efficient 
conversion to adenosine. Since ES had no effect on CAMΦ basal cytokine levels, the effects of 
nucleotide metabolising enzymes were clear as the only differences in purinergic responses were 
solely due to manipulation of the extracellular nucleotide pool. In this chapter ES was found to 
induce NO and cytokine release in BMMΦ and AAMΦ so the effect of nucleotides on this 
induction was also investigated. Interestingly, the presence of adenosine reversed ES-induced 
NO, IL-6 and TNF-α release detected in BMMΦ and AAMΦ while enhancing IL-10 release, 
which further supports its anti-inflammatory role in the context of parasite infection. 
Furthermore, arginase I activity was also enhanced by hydrolysis of nucleotides to adenosine by 
ES enzymes producing an additive increase in arginase I activity in BMMΦ and CAMΦ. 
Therefore, ES-induced effects leading to a pro-inflammatory phenotype were inhibited by 
generation of adenosine in the presence of ES while anti-inflammatory responses were enhanced.  
The generation of adenosine by T.spiralis ES enzymes has been attributed to a 
nucleotidase that has unique catalytic properties in that it can convert ADP to AMP and AMP to 
adenosine (Gounaris et al, 2004). This enzyme, 5`-nucleotidase (5`NT), has been recombinantly 
expressed in our lab so it was used to determine if nucleotide manipulation by T.spiralis was 
indeed due to 5`NT.  Since BMMΦ and AAMΦ displayed effector functions that were only 
induced in the presence of ES, 5`NT-induced effects were only investigated in CAMΦ and 
indeed the manipulation of nucleotide-induced effects observed with ES was mirrored by the 
action of the recombinant 5`NT. The only difference was observed when ATP was present due to 
the fact that this nucleotide is not metabolised by 5`NT in ES, but it is possible that other 
enzymes in ES are capable of metabolising ATP directly. Arginase I activity in CAMΦ and 
AAMΦ was enhanced by incubating nucleotides with 5`NT in a similar manner to ES, once again 
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confirming that when nucleotides are in culture with T.spiralis ES, macrophage effector functions 
are dictated by generation of adenosine. 
Adenosine mediates its anti-inflammatory effects predominantly by downstream signalling 
involving cAMP elevation as shown in the previous chapter (Chapter 4). Combining this result 
with the observation that adenosine inhibited ES-induced effects, studies were carried out to 
determine if cAMP was involved in ES-induced effects and this was then extended to determine 
involvement of other intracellular signalling pathways. Interestingly, cAMP elevation by 
exogenous agents like forskolin had similar effects to adenosine in that NO, IL-6 and TNF-α 
release elicited by ES were inhibited while IL-10 release was further enhanced. Therefore, cAMP 
elevation induced by adenosine is probably the major event responsible for dampening the ES-
induced responses. Taking into account that this could also be a result of indirect effects on PLC 
signalling, this was the downstream pathway investigated next. Inhibition of PLC also inhibited 
ES-induced NO, IL-6 and TNF-α release, although the reversal obtained for TNF-α release was 
not as clear as that obtained for NO and IL-6 release. On the other hand, IL-10 release was not 
affected by PLC inhibition indicating that cAMP is a major signalling component upstream of IL-
10 release. As opposed to IL-10, TNF-α and IL6 production was found to be more reliant on the 
PLC pathway in bacterial ligand-induced APC activation via TLR2 and 4 (Aki et al, 2008).  
The involvement of other signalling components such as PI3 kinase and the MEK1/2 
pathway were also determined as well as the effect of inhibiting NF-κB. ES-induced NO release 
was more dramatically inhibited by blocking PI3 kinase activity when compared to blocking 
MEK1/2 and NF-κB. This could be attributed to the fact that PI3 kinase is higher up in the 
signalling cascade so blocking the pathway at an initial stage abolishes effects more efficiently 
than when blocking PLC activation and cAMP generation. Conversely, inhibition of MEK1/2 
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may not have profound effects as other MAP kinases may be used as alternative pathways for 
signals to reach the nucleus due to the redundancy of intracellular signalling pathways.  
A study with T.crassiceps glycans has shown that LewisX galactose residues increased 
IFN-γ via NF-κB induction following TLR activation of mouse peritoneal macrophages 
(Dissanayake and Shahin, 2007). Despite the similarity in APC activation observed by parasite 
glycans to LPS activation, it is generally accepted that the pathways downstream are altered by 
glycans so that they no longer follow the canonical TLR signalling, resulting in the generation of 
APCs with an immature phenotype that produce decreased levels of pro-inflammatory cytokines 
(Harn et al, 2009). Specifically, a phosphorylcholine-containing glycoprotein ES-62 from the 
nematode A.viteae that induces a Th2 polarised immune response has been shown to act via 
TLR4 and in doing so it interferes with APC activation by a variety of TLR ligands (Goodridge 
et al, 2005). LNFPIII was shown to activate bone marrow derived dendritic cells to a Th2 
inducing phenotype via a TLR4-dependent mechanism (Thomas et al, 2003). When comparing 
LPS with LNFPIII (SEA) signalling, the LPS-induced activation of NF-κB via MAPK/JNK/p38 
is replaced by ERK activation and NF-κB activation is not accompanied by IκB degradation 
(Harn et al, 2009). DC-SIGN activation, a major event in SEA manipulation of DCs, was shown 
to act via Raf-1 kinase to activate NF-κB (Gringhuis et al, 2007). Binding of H.pylori LewisX, 
another DC-SIGN ligand, on gastric DCs has been shown to block Th1 development (Bergman et 
al, 2004). Recently, van Stijn and colleagues reported that DC-SIGN acts as co-receptor for 
TLR4 in SEA-induced effects which may explain the mode of manipulation of TLR signalling 
(Van Stijn et al, 2010). However, SEA-induced effects have also been shown to be independent 
of TLR activation (Kane et al, 2008). This may indicate that the TLR pathway is not necessary 
for SEA-induced effects but, if active, SEA interactions act to inactivate it in order to promote a 
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Th2 phenotype. Finally, S.mansoni larvae were shown to inhibit cytokine production by 
macrophages via a TLR4 and MyD88-dependent mechanism and this was suggested to be due to 
the presence of mannose receptor ligands found in SEA (Jenkins et al, 2005). With relevance to 
T.spiralis secreted products in this study, the fact that macrophage phenotype was shifted to an 
alternative mode of activation by ES suggested the possibility that macrophages could respond to 
ES via mannose receptor ligation since this is a marker of alternative activation. However, the 
effects of T.spiralis secreted proteins on macrophage effector functions were not found to be due 
to mannose structures in ES, as treatment of macrophages with D-mannose did not appear to 
activate them in terms of any of the effector functions tested. In fact, another study has shown 
that NO release induced by T.spiralis in peritoneal macrophages was only partly due to the MR 
(Gruden-Movsesijan and Milosavljevic, 2006). Similarly, deSchoolmeester and colleagues have 
reported that cytokine released from BMMΦ in response to T.muris ES was also partly due to 
MR binding (deSchoolmeester et al, 2009).  
T.spiralis ES is known to contain heavily glycosylated proteins and analysis of these 
glycoproteins has revealed N- and O-linked structures of oligosaccharides, including mannose 
(Reason et al, 1994; Gruden-Movsesijan et al, 2002). Having eliminated mannose as a possible 
trigger of ES-induced effects, the hypothesis that other glycans may be involved in macrophage 
activation was investigated. In addition, in order to test the possibility that ES glycoproteins 
mediated their effects via the protein component, any enzyme activity was deactivated prior to 
macrophage stimulation by heat denaturation. In general, heat-inactivation partly restored some 
of the effector functions induced by ES, however, this was inconsistent for NO, TNF-α and IL-6 
release while arginase I activity did not seem to be significantly affected. On the other hand, IL-
10 release seemed to be more consistently reversed by heat inactivation of ES suggesting once 
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again that the mechanism of IL-10 regulation is not the same as for NO, TNF-α and IL-6. The 
fact that heat-inactivation had a partial effect on ES-induced responses suggests that the protein 
component is important but not essential. This points to a structural role for the protein part as 
denaturation probably led to protein unfolding that interfered with glycan positioning, an 
explanation also supported by the fact that some ES activity was retained after heating probably 
as a result of less efficient glycan binding. In order to further confirm that the glycan component 
of ES was responsible for activating macrophages, secreted products were chemically 
deglycosylated to remove N- and O-linked carbohydrates. As expected, ES-induced effects were 
completely reversed when the glycans were no longer present. Interestingly, in a study published 
by Flynn and Mulcahy using F.hepatica ES, the increase in arginase I induced in human PBMC-
derived macrophages was also only abolished by removal of glycans by oxidation (Flynn and 
Mulcahy, 2008).  
Glycans mediate their effects following recognition by APCs via C-type lectin receptors 
(van Vliet et al, 2008, Geijtenbeek and Gringhuis, 2009). In S.mansoni-treated immature human 
monocyte derived DCs, SEA was found to be localized in compartments for MHC II presentation 
following internalization through the C-type lectins DC-SIGN, MGL (macrophage galactose 
lectin) and the mannose receptor and was suggested to be important in regulation of TLR-induced 
DC activation (van Liempt et al, 2007). This was determined by van Liempt and colleagues by 
blocking DC surface lectins with carbohydrates known to bind and activate specific lectins. A 
variation of this experiment was carried out in this study in an attempt to block T.spiralis ES-
induced effects and to determine the receptor via which these effects were elicited. Confirmation 
of C-type lectin involvement was first obtained by the fact that EGTA abolished all responses 
triggered by ES, since EGTA is a Ca
2+
 chelator that effectively removes calcium ions from the 
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extracellular milieu thus destabilising lectins which require this ion for structural integrity 
(Drickamer, 1999). Mannan appeared to enhance ES-induced effects instead of blocking them 
which may suggest synergy of DC-SIGN or MR with the lectin actually involved in ES glycan 
binding. This may be explained by published work referred to earlier in this section reporting 
partial involvement of the MR in T.spiralis-induced NO and cytokine release (Gruden-
Movsesijan and Milosavljevic, 2006). Only GalNAc significantly inhibited all ES-induced effects 
on macrophage effector functions pointing to the involvement of the macrophage galactose lectin 
(MGL) in recognition of ES glycoproteins. The fact that ES responses were not completely 
abolished by blocking MGL may be a result of involvement of more than one C-type lectin in 
glycan recognition or may be due to lectin redundancy allowing for recognition to occur even if 
MGL is not available for binding. Indeed, Saunders and colleagues have reported that SIGNR1 (a 
mouse paralogue of DC-SIGN) binding to SEA was redundant since in the knockout was still 
capable of SEA recognition (Saunders et al, 2009). Interestingly, MGL has been characterised by 
Raes and colleagues as a novel marker of alternative macrophage activation by parasites which 
becomes relevant in the context of T.spiralis-induced macrophage alternative activation in this 
study (Raes et al, 2005). Therefore, AAMΦ would be expected to respond better to ES glycans 
due to the fact that they already have higher MGL levels as a result of IL4-induced up-regulation. 
However, this was not so clear and may be due to insufficient levels of IL-4 to induce MGL up-
regulation in vitro. In addition, the lack of Th2-independent signals in systems of in vitro studies 
that activate macrophages with IL-4 and IL-13 produces characteristics that are less pronounced 
than those elicited during a natural infection.  
Characterisation of MGL as the lectin responsible for ES glycan activation of 
macrophages was extended by purifying ES fractions on a MGL-conjugated column provided by 
278 
 
Prof. K. Drickamer and using these fractions to detect those positive for NO and cytokine release 
from macrophages. Indeed, bound fractions were capable of activating macrophage responses, 
however, some activity was still present in unbound fractions. This could be due to low affinity 
binding of GalNAc to the column-conjugated MGL or a result of recognition of other ES glycans 
by other lectins. In fact, when trying to block this activity by pre-incubation of active fractions 
with GalNAc, activity was not always completely inhibited suggesting that other glycans may be 
involved. However, this could also be attributed to the fact that MGL immobilised on a column is 
not as efficient at binding all GalNAc-positive glycoproteins due to steric hindrance which is 
avoided in vivo due to mobility of lectins on the macrophage surface. In addition, MGL activation 
on macrophages may be additive so that GalNAc from neighbouring glycoproteins can come 
together to cluster MGL molecules to produce robust responses. Indeed, studies have shown that 
binding of multiple glycan branches to multiple recognition domains of receptor oligomers 
enhances interactions as a result of membrane receptor geometry (Coombs et al, 2009). The 
importance of multivalency of glycan recognition can be seen by the fact that incubation of 
macrophages with carbohydrates was not sufficient to activate them, an observation also made by 
van der Kleij and colleagues who reported that free synthetic oligosaccharides were unable to 
stimulate monocytes to produce cytokines (Van der Kleij et al, 2005). Another factor that needs 
to be taken into account is that, the MGL available for in vitro studies carried out was of human 
origin that may explain differences in specificities leading to inefficient isolation of GalNAc-
containing residues that the mouse MGL would respond to (Coombs et al, 2006). It is known that 
there are differences between structure and specificity of mouse and human C-type lectins. In 
fact, murine cells are known to express MGL-1 and MGL-2 whose glycan specificities have been 
characterised and are different (Singh et al, 2009). Furthermore, carbohydrate profiling of human 
MGL binding specificity showed that it more closely resembled MGL-2 (Van Vliet et al, 2005). 
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In addition, Singh and colleagues suggest that cellular MGL has better affinity for its ligands than 
soluble MGL, suggesting that the efficiency of purification of MGL-specific glycoproteins may 
not have been good enough in the current study (Singh et al, 2009). When MGL was immobilised 
on plates and used in competition assays to determine the specificity and affinity of ES, the 
affinity was found to be comparable to galactose, which is the natural ligand of MGL used in in 
vitro competition assays (K.Drickamer personal communication) (Powelsland et al, 2010).  
The glycoproteins obtained from MGL purification were analysed by SDS-PAGE but 
there were no specific bands that only came up in the MGL-eluted fractions except for the 37kDa, 
which was probably a result of some conjugated MGL being pulled down with the bound 
glycoprotein on elution. The SDS-PAGE analysis was further used to confirm the presence of 
GalNAc-positive fractions by blotting for 
125
I-labelled MGL (K. Drickamer) and 
125
I-MGL did 
indeed bind to all the fractions with flow-through and wash fractions binding 
125
I-MGL with 
higher affinity. The fact that GalNAc residues appear to be recognized by MGL suggests that 
T.spiralis glycoproteins have exposed GalNAc perhaps from tetra-antennary complex chains that 
lack terminal sugars. These sugars have been characterised to decorate all T.spiralis 
glycoproteins, namely tyvelose (Reason et al, 1994). The fact that MGL-column purification did 
not produce clear GalNAc eluted fractions may also be explained by the existence of this unique 
T.spiralis capping sugar. It is conceivable that it is in fact tyvelose that is recognized by 
macrophage MGL and that no GalNAc residues are actually exposed. Therefore, effects elicited 
by ES tyvelose are blocked by GalNAc because of competition for receptor binding but when the 
receptor is incubated with ES on a column the interactions resulting under these conditions are 
not strong enough to purify all active glycoproteins.  
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Parasites have evolved to modulate the host immune response to ensure long-term 
survival and they do so in many ways. Macrophages are an important link between the innate and 
acquired immune response as they are capable of detecting the presence of invading pathogens on 
the basis of the composition of carbohydrate moieties expressed. T.spiralis secreted proteins used 
in this study were found to induce pro-and anti-inflammatory cytokine responses in macrophages 
which indicates a role for these structures in stimulating innate immunity, besides the effects 
resulting from manipulation of purinergic signalling. Therefore, T.spiralis has developed multiple 
mechanisms of evading host defences to invasion protecting itself long enough to allow 
establishment of a long-term infection.  
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Chapter 6 
Purinergic signalling and the effect of T.spiralis secreted proteins on  
T cell effector functions in vitro  
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6.1 Introduction  
 T cell effector functions ranging from pro- to anti- inflammatory to regulatory are 
dependent on the mode of activation following T cell receptor (TCR) ligation as a result of 
costimulation, source of antigen and local cytokine environment. Naïve CD4+ T cell activation 
leads to proliferation and differentiation into T helper (Th) cells which are subcategorized into 
Th1 and Th2 based on their cytokine profile and immunomodulatory effects (O‟Garra, 1998). 
Th1 cells, which arise in the presence of IL-12, IL-18 and IFN-γ, are generally involved in pro-
inflammatory cell-mediated reactions as they produce IFN-γ and TNF-β. On the other hand, Th2 
cells develop in the presence of IL-4 and produce IL-4, IL-5, IL-10 and IL-13. It is evident that 
differentiation into Th1 or Th2 will determine the outcome of an immune response as the 
resulting cytokine environment gives rise to pro-inflammatory or anti-inflammatory immune cell 
activation, respectively. In addition to the cytokine influence on T cell differentiation another 
important factor is costimulation achieved through antigen presentation by APCs. TCR activation 
in response to antigen recognition requires specific costimulatory molecules such as CD28 
expressed on APCs, in the absence of which TCR activation leads to T cell anergy (Schwartz, 
2003).  
Regulatory T (Treg) cells are emerging as an important regulator of T cell differentiation 
and proliferation as well as activation of other immune cells such as APCs. Regulation is either 
contact-dependent or is due to modulation of the local cytokine environment. Another means of 
control used by Treg cells is an indirect mechanism involving metabolism of extracellular 
nucleotides (Bynoe and Viret, 2008). Recent characterisation of T cell activation markers 
revealed that, the surface expression of CD73, which is responsible for catabolism of AMP to 
adenosine, is a novel marker of Treg. activation as it is up-regulated in CD4+CD25+Foxp3+ 
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Treg. cells (Deaglio et al, 2007). In addition, it has been reported that Foxp3 in human spleen and 
lymph CD4+ T cells drives expression of CD39, an ecto-nucleotidase responsible for conversion 
of ATP to ADP and ADP to AMP (Borsellino et al, 2007; Eckle et al, 2007). The up-regulated 
expression of these ecto-nucleotidases on Treg. cells means that these cells have the capacity to 
hydrolyse extracellular levels of ATP thus dampening its pro-inflammatory effects. In addition to 
the action of CD39 which leads to removal of ATP, CD73 activity leads to generation of 
adenosine which is known to have anti-inflammatory effects (Lappas et al, 2005; Kobie et al, 
2006).  
Helminth infections are known to induce “modified” Th2 responses as a means of 
improving their survival (Hewitson et al, 2009). In the case of the intestinal parasite Trichuris 
muris, increased recruitment of Foxp3+ T cells was detected in the gut of infected mice and was 
found to be important for protection of the host from parasite driven pathology as well as for 
providing more efficient parasite expulsion (D‟Elia et al, 2009). Trichinella spiralis infection 
also involves an intestinal phase and persistence of the parasite during this phase is essential for 
successful establishment in the host. In addition, T.spiralis secreted products (ES) are known to 
possess nucleotide metabolising activity and thus have the capacity to manipulate host purinergic 
signalling by generation of extracellular adenosine, much like the mode of action of Treg. ecto-
nucleotidases (Gounaris, 2002).  
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The aims of this study were to investigate purinergic signalling in CD4+ T cells in terms 
of purinergic receptor expression as well as the effects of extracellular nucleotides on T cell 
proliferation and cytokine release. The expression of ecto-nucleotidases CD39/CD73 was 
investigated as the presence of these enzymes on T cells would also influence the outcome of 
purinergic receptor stimulation. Finally, the direct effects of T.spiralis ES on T cell effector 
functions were investigated prior to determining ES-induced effects on T cell purinergic 
signalling. 
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6.2 Results 
CD4+ T cells were isolated from Balb/c mouse spleens and the remaining cells, mostly 
antigen presenting cells (APCs), were irradiated to prevent effector functions like proliferation 
and cytokine release. T cell proliferation was measured following culture of the isolated CD4+ 
cell population with the irradiated APCs in the presence of anti-CD3 to trigger TCR activation. 
The effects induced by extracellular nucleotides on proliferation and cytokine release by T cells 
were investigated. Molecular characterisation of CD4+ T cells was carried out in terms of 
purinergic receptor expression and ecto-nucleotidase expression as they both influence purinergic 
signalling. The effects of T.spiralis secreted products (ES) on expression of these two classes of 
surface expressed proteins was investigated as well as the resulting T cell proliferation and 
cytokine release in the presence of these products. Finally, an attempt was made at characterising 
downstream pathways responsible for the effects observed with nucleotides and T.spiralis ES.  
6.2.1 T cell purinergic signalling  
Molecular characterisation of purinergic receptor expression  
In order to investigate the effects of purinergic signalling on T cell responses, the 
purinergic receptor profile of resting splenic CD4+ T cells used in this study was determined by 
RT-PCR analysis (Figure 6.1). In general, CD4+ T cells express all purinergic receptor 
transcripts at the molecular level except for the P2Y4R. All P1 receptor transcripts were detected. 
In order to confirm that the primers used for the RT-PCR analysis of purinergic receptors were 
capable of detecting transcripts correctly, mRNA extracted from the original splenocyte 
population was used as a positive control. Indeed, purinergic receptor transcripts of expected 
sizes were detected with all primers used and PCR products were of similar intensity.  
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Figure 6.1: Purinergic receptor (PR) transcripts in murine CD4+ T cells and spleen determined 
using RT-PCR. A) The PR transcripts detected in resting CD4+ T cells purified from mouse spleen and 
B) PR transcripts from mouse whole spleen. PCR products are shown and product sizes were determined 
by the ladder shown annotated on the left (in bp). Expected sizes were obtained for all transcripts detected 
(see Materials and Methods, Table 2.1C). Actin primers were used in reactions to confirm cDNA quality 
(Act) and in reactions to determine if RNA was contaminated with DNA (-RT). 
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Effect of purinergic signalling on T cell proliferation in vitro 
Purinergic signalling-induced effects were first investigated on T cell proliferation in 
vitro. CD4+ T cells isolated from mouse spleen were stimulated with 50μM nucleotides (as 
determined from trial experiments not shown) and then transferred to anti-CD3 coated plates and 
co-cultured with irradiated APCs from the same spleen for 4 days. Proliferation was measured by 
3
H-thymidine incorporation during the final 16 hours of culture and the results obtained presented 
in Figure 6.2. T cell proliferation was inhibited by all nucleotides. Considering the similarity in 
nucleotide responses to adenosine it is possible that nucleotide-induced effects were due to their 
breakdown to adenosine. The fact that, in some cases, nucleotide stimulation resulted in lower 
levels of proliferation than adenosine was probably due to adenosine uptake by nucleoside 
transporters, since the nucleoside transporter inhibitor, dipyridamole, was not used in T cell 
experiments due to interference with this assay (data not shown). For this reason, NECA which is 
an analogue of adenosine that is not taken up by cells, was used to confirm the involvement of 
P1R activation. 
In order to confirm if the inhibitory effect on proliferation was indeed due to generation of 
adenosine and P1 receptor activation, P1R agonists were used to examine if these effects were 
indeed due to P1R activation. P1R agonists also inhibited proliferation except for IB-MECA 
which acts on A3 receptors (A3R) (Figure 6.3A). Inhibition obtained with the A1 receptor agonist 
CPA was not as significant as that obtained with adenosine, NECA and the A2B receptor (A2BR) 
agonist (CGS21680), which points to A2A and A2B receptor involvement (Figure 6.3A). In fact, 
P1 receptor antagonism showed that the A2AR and A2BR antagonists, ZM241385 and MRS1754 
respectively, reversed adenosine-induced effects almost completely (Figure 6.3B). Similarly, the 
50% inhibition in proliferation induced by AMP was completely reversed by the A2A and A2B 
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receptor antagonists (Figure 6.4A) as was the 20% inhibition induced by ADP (Figure 6.4B). 
These data confirm that nucleotide-induced effects on T cell proliferation were in fact due to P1 
receptor activation by adenosine generated from their degradation. 
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Figure 6.2: The effect of nucleotides on T cell proliferation. CD4+ cells isolated from mouse spleen 
were cultured with irradiated APCs from the same original splenocyte population in the presence of anti-
CD3 to induce cell proliferation, measured by means of 
3
H-thymidine incorporation. The effect of 50μM 
adenosine, AMP, ADP, ATP, their slowly hydrolysable analogues, inosine and UDP on T cell 
proliferation was measured after 4 days of culture. Data presented are an average of triplicates + SEM 
from one representative experiment of n > 3. * p< 0.05, *** p< 0.001, ns - not significant (p> 0.05) 
compared to the untreated control. 
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Figure 6.3: Pharmacological characterisation of P1R-mediated effects on T cell proliferation. CD4+ 
cells isolated from mouse spleen were cultured with irradiated APCs from the same original splenocyte 
population in the presence of anti-CD3 to induce cell proliferation, measured by means of 
3
H-thymidine 
incorporation cultured in the presence or absence of P1 receptor agonists (A) or antagonists (B) for 4 days. 
The following agonists and antagonists (10μM) were added 15 minutes prior to adenosine addition: 50 μM 
of adenosine, CPA (A1R agonist), CGS21680 (A2AR agonist), NECA or IB-MECA (A3R agonist), DPCPX 
(A1R antagonist), ZM241385 (A2AR antagonist), MRS1753 (A2BR antagonist) or MRS1523 (A3R 
antagonist). The data presented are an average of triplicates + SEM from one representative experiment of 
n = 3 and asterisks/daggers indicate statistical significance compared to the untreated control.* p< 0.05, 
*** p< 0.001. (†) is compared to treatment with adenosine only. ††† p< 0.001, ns - not significant (p> 
0.05). 
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Figure 6.4: Pharmacological characterisation of P1R-mediated effects on T cell proliferation. CD4+ 
cells isolated from mouse spleen were cultured with irradiated APCs from the same original splenocyte 
population in the presence of anti-CD3 to induce cell proliferation, measured by means of 
3
H-thymidine 
incorporation in the presence of P1R antagonists, after 4 days of culture. The following antagonists 
(10μM) were added 15 minutes prior to addition of 50μM (A) AMP or (B) ADP: DPCPX (A1R 
antagonist), ZM241385 (A2AR antagonist), MRS1753 (A2BR antagonist) or MRS1523 (A3R antagonist). 
The data presented are an average of triplicates + SEM from one representative experiment of n = 3 and 
asterisks/daggers indicate statistical significance compared to the untreated control. ** p< 0.01, *** p< 
0.001. (†) is compared to treatment with AMP or ADP only. ††† p< 0.001, ns - not significant (p> 0.05). 
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In an attempt to determine if adenosine-induced effects were a result of coupling to Gs 
protein subunits and activation of adenylate cyclase leading to cAMP elevation, known cAMP 
elevators were administered exogenously to see if they mimicked adenosine-induced effects. 
Indeed, cAMP elevation also led to inhibition of proliferation and this effect was additive when 
NECA was combined with rolipram (Figure 6.5A). Investigation of signalling downstream of 
adenosine-induced activation of P1 receptors showed that only the MEK1/2 inhibitor (U0126) 
reversed adenosine-induced effects. The PLC and NF-κB inhibitors (U73122 and Bay 11-7082) 
blocked proliferation completely as did the MEK1/2 inhibitor while the PLC mock inhibitor 
(U73343) had no effect showing that, the inhibition in proliferation observed with the PLC 
inhibitor was in fact due to inactivation of PLC and not a compound interference effect (Figure 
6.5B). 
Collectively, these data show that CD4+ T cells express most of the purinergic receptors 
and all the P1 receptors which respond to adenosine, either administered or generated in culture 
by degradation of adenine nucleotides. Furthermore, these data confirm that the effects of AMP 
and ADP are due to P1R stimulation as P1R antagonists, and specifically of the A2AR and A2BR, 
reversed these effects. Finally, exogenous cAMP elevation was sufficient to mimic adenosine-
induced effects showing that adenosine mediates its effects mainly by cAMP elevation. In 
addition, inhibition of MEK1/2 was also effective in reversing adenosine-induced effects, 
however, it cannot be concluded that other pathways are not involved since the inhibitors used to 
test involvement of other pathways produced background effects on proliferation. 
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Figure 6.5: The effect of downstream signalling pathways on P1R-mediated effects on T cell 
proliferation. CD4+ cells isolated from mouse spleen were cultured with irradiated APCs from the same 
original splenocyte population in the presence of anti-CD3 to induce cell proliferation, measured by means 
of 
3
H-thymidine incorporation. (A) The effect of the cAMP elevators forskolin (10μM) and rolipram 
(5μM) on T cell proliferation compared to and combined with P1R agonists adenosine and NECA. (B) 
The effect of PLC, NF-κB and MEK inhibition on P1R-mediated inhibition of T cell proliferation. The 
effect of 10μM U73122 (PLC inhibitor), 5μM Bay 11-7082 (NF-κB selective inhibitor) and 5μM U0126 
(MEK1/2 inhibitor) on adenosine-induced inhibition of T cell proliferation was measured after 4 days of 
culture. Cells were pre-incubated with the all inhibitors for 15 minutes prior to adenosine addition. The 
data presented are an average of triplicates + SEM from one representative experiment of n = 3 and 
asterisks indicate significance compared to the respective untreated control.  ** p< 0.01, *** p< 0.001. (†) 
is compared to treatment with 50μM (A) NECA or (B) adenosine, only. ††† p< 0.001.  
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Effect of purinergic signalling on cytokine release from T cells 
Cytokine release is another important effector function that can determine the outcome of 
an immune response as it can influence activation of APCs amongst other immune cells. 
Cytokine release from T cells was similarly affected by nucleotides as in this case all nucleotides 
inhibited IL-4, IL-10 and IFN-γ release (Figure 6.6). In general, adenosine and NECA inhibited 
IL-4 and IFN-γ by 50% while in the case of IL-10 inhibition was more pronounced. The 
similarity of nucleotide-induced effects on cytokine release to adenosine again suggests that 
nucleotides were hydrolysed and generation of adenosine led to P1R stimulation. As explained 
previously, the fact that adenosine-induced inhibition of cytokine release was higher with 
nucleotides than with adenosine was due to adenosine uptake into cells. UDP appeared to inhibit 
IL-4 and IFN-γ release only (Figure 6.6). 
Confirmation of P1R effects on cytokine release was obtained by using P1R agonists 
which also inhibited cytokine release in general (Figure 6.7). Specifically, IL-4 release was 
inhibited by all agonists used except for the A1R and A3R agonists (CPA and IB-MECA, 
respectively). IL-10 release was inhibited by all agonists but more significantly by the A2BR 
agonist (CGS21680), NECA and adenosine. IFN-γ release was inhibited by adenosine, NECA 
and CGS21680 but not by IB-MECA (Figure 6.7). Therefore, activation of the A2AR and A2BR 
resulted in inhibition of all cytokines tested. This was further confirmed by the fact that P1R 
antagonists acting on A2AR (ZM241385) and A2BR (MRS1754) reversed adenosine-induced 
inhibition of cytokine release (Figure 6.8). In order to confirm the hypothesis that AMP and ADP 
inhibit cytokine release from T cells by P1R activation as a result of their conversion to 
adenosine, AMP and ADP were co-administered with P1R antagonists. As it is shown in Figure 
6.9, the AMP-induced inhibition of cytokine release from T cells is restored by A2AR and A2BR 
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antagonists. A similar restoration of cytokine release was observed when ADP was co-
administered with either the A2AR or the A2BR antagonist (Figure 6.10).  
Collectively these data show that, A2AR and A2BR activation is responsible for adenosine-
induced inhibition of cytokine release from T cells. Adenine nucleotides inhibit cytokine release 
from T cells and this is also due to A2AR and A2BR activation by adenosine generated in culture 
from hydrolysis of these nucleotides. In addition to P1R activation, P2Y6R activation by UDP 
also results in inhibition of IL-4 and IFN-γ release from T cells. 
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Figure 6.6: The effect of nucleotides on cytokine release from T cells. CD4+ cells isolated from mouse 
spleen were cultured with irradiated APCs from the same original splenocyte population in the presence of 
anti-CD3 and cytokine release measured after 4 days of culture. The effect of 50μM adenosine, AMP, 
ADP, inosine and UDP or the slowly-hydrolysable analogues of adenosine, ADP and ATP (NECA, β-
ADP, ATP-γ, respectively, on (A) IL-4 release, (B) IL-10 release and (C) IFN-γ release. Cytokine levels 
are expressed in pg/ml. Data presented are an average of triplicates + SEM from one representative 
experiment of n > 3. * p< 0.05, ** p< 0.01, *** p< 0.001, ns - not significant (p> 0.05) compared to the 
untreated control. 
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Figure 6.7: Pharmacological characterisation of P1R-mediated effects on cytokine release from T 
cells. CD4+ cells isolated from mouse spleen were cultured with irradiated APCs from the same original 
splenocyte population in the presence of anti-CD3 and cytokine release measured after 4 days of culture. 
The effect of 50μM of the following P1R agonists on (A) IL-4 release, (B) IL-10 release and (C) IFN-γ 
release: 50 μM of adenosine, CPA (A1R agonist), CGS21680 (A2AR agonist), NECA or IB-MECA (A3R 
agonist). Cytokine levels are expressed in pg/ml. The data presented are an average of triplicates + SEM 
from one representative experiment of n = 3 and asterisks indicate statistical significance compared to the 
untreated control.* p< 0.05, ** p< 0.01, *** p< 0.001, ns - not significant (p> 0.05). 
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Figure 6.8: Pharmacological characterisation of P1R-mediated effects on cytokine release from T 
cells. CD4+ cells isolated from mouse spleen were cultured with irradiated APCs from the same original 
splenocyte population in the presence of anti-CD3 and cytokine release measured after 4 days of culture. 
The effect of 50μM adenosine in the presence of P1R antagonists (10μM) on (A) IL-4 release, (B) IL-10 
release and (C) IFN-γ release. Cytokine levels are expressed in pg/ml. The following antagonists were 
added 15 minutes prior to adenosine addition: DPCPX (A1R antagonist), ZM241385 (A2AR antagonist), 
MRS1753 (A2BR antagonist) or MRS1523 (A3R antagonist). The data presented are an average of 
triplicates + SEM from one representative experiment of n = 3 and asterisks/daggers indicate statistical 
significance compared to the untreated control.* p< 0.05, *** p< 0.001. (†) is compared to treatment with 
adenosine only. †† p< 0.01, ††† p< 0.001, ns - not significant (p> 0.05). 
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Figure 6.9: Pharmacological characterisation of P1R-mediated effects on cytokine release from T 
cells. CD4+ cells isolated from mouse spleen were cultured with irradiated APCs from the same original 
splenocyte population in the presence of anti-CD3 and cytokine release measured after 4 days of culture. 
The effect of 50μM AMP in the presence of P1R antagonists on (A) IL-4 release, (B) IL-10 release and 
(C) IFN-γ release. Cytokine levels are expressed in pg/ml. The following antagonists (10μM) were added 
15 minutes prior to adenosine addition: DPCPX (A1R antagonist), ZM241385 (A2AR antagonist), 
MRS1753 (A2BR antagonist) or MRS1523 (A3R antagonist). The data presented are an average of 
triplicates + SEM from one representative experiment of n = 3 and asterisks/daggers indicate statistical 
significance compared to the untreated control. *** p< 0.001. (†) is compared to treatment with AMP 
only. †† p< 0.01, ††† p< 0.001, ns - not significant (p> 0.05). 
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Figure 6.10: Pharmacological characterisation of P1R-mediated effects on cytokine release from T 
cells. CD4+ cells isolated from mouse spleen were cultured with irradiated APCs from the same original 
splenocyte population in the presence of anti-CD3 and cytokine release measured after 4 days of culture. 
The effect of 50μM ADP in the presence of P1R antagonists was measured on (A) IL-4 release, (B) IL-10 
release and (C) IFN-γ release. Cytokine levels are expressed in pg/ml. The following antagonists (10μM) 
were added 15 minutes prior to adenosine addition: DPCPX (A1R antagonist), ZM241385 (A2AR 
antagonist), MRS1753 (A2BR antagonist) or MRS1523 (A3R antagonist). The data presented are an 
average of triplicates + SEM from one representative experiment of n = 3 and asterisks/daggers indicate 
statistical significance compared to the untreated control.* p< 0.05, *** p< 0.001. (†) is compared to 
treatment with ADP only. †† p< 0.01, ††† p< 0.001, ns - not significant (p> 0.05). 
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The involvement of downstream pathways in adenosine-induced inhibition of cytokine 
release was also investigated. Similar to T cell proliferation, cAMP elevation also mimicked the 
pattern of cytokine release obtained with adenosine as it inhibited all cytokine release. The 
combination of NECA and rolipram had an additive effect of inhibition for IL-4 and IFN-γ 
release while IL-10 levels were similar for all cAMP elevators (Figure 6.11). When components 
of other downstream pathways were inhibited it was evident that most of these components were 
essential for basal levels of cytokine release. Specifically, all inhibitors used inhibited IL-4 
release except for the PLC mock (U73343) while the NF-κB and PLC inhibitors (Bay 11-7082 
and U73122) blocked IL-10 and IFN-γ release. Adenosine-induced inhibition of IL-4 release was 
only slightly reversed by inhibition of PLC while in the case of IL-10 there was no significant 
reversal by any of the inhibitors tested. IFN-γ release was restored more significantly by the PLC 
inhibitor while the NF-κB and MEK1/2 inhibitors partly reversed adenosine inhibition.  
Taken together, these results show that P1 receptor activation and, in particular the A2AR 
and A2BR, was responsible for adenosine-induced inhibition of cytokine release by CD4+ T cells. 
This inhibition was mainly due to receptor coupling to Gs leading to accumulation of cAMP. In 
addition, blocking MEK1/2 and PLC activation also reversed adenosine-induced inhibition of IL-
4 and IFN-γ release although these effects were not very clear due to inhibitor interference with 
basal cytokine levels.  
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Figure 6.11: The effect of cAMP elevators on P1R-mediated effects on cytokine release from T cells. 
CD4+ cells isolated from mouse spleen were cultured with irradiated APCs from the same original 
splenocyte population in the presence of anti-CD3 and cytokine release measured after 4 days of culture. 
The effect of the cAMP elevators forskolin (10μM) and rolipram (5μM) on cytokine release from T cells 
compared to and combined with P1R agonists 50μM adenosine and 50μM NECA. A) IL-4 release, (B) IL-
10 release and (C) IFN-γ release are shown expressed in pg/ml. The cAMP elevators were added 15 
minutes prior to adenosine/NECA addition.  The data presented are an average of triplicates + SEM from 
one experiment of n = 3 and asterisks indicate significance. *** p< 0.001. (†) is compared to treatment 
with NECA only. †† p< 0.01, ††† p< 0.001, ns - not significant (p> 0.05). 
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Figure 6.12: The effect of downstream signalling pathways on P1R-mediated effects on cytokine 
release from T cells. CD4+ cells isolated from mouse spleen were cultured with irradiated APCs from the 
same original splenocyte population in the presence of anti-CD3 and cytokine release measured after 4 
days of culture. The effect of 10μM U73122 (PLC inhibitor), 5μM Bay 11-7082 (NF-κB selective 
inhibitor) and 5μM U0126 (MEK1/2 inhibitor) on adenosine-induced inhibition of cytokine release from T 
cells was measured after 4 days of culture. Cells were pre-incubated with the all inhibitors for 15 minutes 
prior to adenosine addition. The effect on the release of the following cytokines was measured: (A) IL-4, 
(B) IL-10, and (C) IFN-γ and expressed in pg/ml.  The data presented are an average of triplicates + SEM 
from one representative experiment of n = 3 and asterisks indicate significance compared to the respective 
untreated control.  ** p< 0.01, *** p< 0.001. (†) is compared to treatment with 50μM adenosine only. † 
p< 0.05, †† p< 0.01, ††† p< 0.001, ns - not significant (p> 0.05). 
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6.2.2 T cell ecto-nucleotidases  
Characterisation of ecto-nucleotidase expression and function 
Most immune cells are known to express ecto-nucleotidases on their surface and, 
specifically in T cells, these proteins have been shown to act as markers of their activation. 
Hence, in this study, CD39/CD73 expression was analysed by RT-PCR and both ecto-
nucleotidases were found to be present on CD4+ T cells while both CD39 and CD73 PCR 
products were detected (Figure 6.13A). In order to determine if these ecto-nucleotidases were in 
fact functionally expressed, CD4+ T cells were cultured for 24 hours in the presence of 
nucleotides and levels of inorganic phosphate measured in culture supernatants. Phosphate was 
released from all nucleotides tested and the levels of phosphate detected were in the order ATP > 
ADP > AMP (Figure 6.13B). 
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Figure 6.13: Determination of the presence and function of CD39 and CD73 in CD4+ T cells. (A) 
RNA isolated from resting CD4+ T cells purified from mouse spleen was used to produce cDNA used in 
RT-PCR to detect the presence of CD39 and CD73 transcripts. PCR products of expected sizes for CD39 
and CD73 were detected (see Materials and Methods, Table 2.1B) in untreated T cells. Actin primers were 
used in reactions to confirm cDNA quality (Act) and in reactions to determine if RNA was contaminated 
with DNA (-RT). (B) Nucleotides were incubated with spleen derived CD4+ T cells and the nmoles of 
phosphate released per 10
5
 cells calculated. 50 μM of AMP, ADP, β-ADP, ATP, ATP-γ and UDP were 
added to T cells for 24 hours. Results show averages of experiments carried out in triplicate + SEM (n = 
2). 
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Effect of T.spiralis ES on ecto-nucleotidase expression  
The effect of T.spiralis secreted proteins (ES) on ecto-nucleotidase expression on T cells 
was investigated in order to examine if they interfere with T cell activation. The RT-PCR 
analysis presented in Figure 6.14 showed that ES appeared to reduce CD73 transcripts while heat 
inactivated ES (HI-ES) and deglycosylated ES (Deg-ES) did not. CD39 transcripts appeared to be 
the same for all T cell treatments (Figure 6.14). Since RT-PCR is qualitative a quantitative 
approach was used in order to determine if this apparent difference in transcript levels was real. 
 The reduction in CD73 levels was confirmed by Q-PCR, however, a similar reduction 
was also detected in CD39 levels. The ES-induced inhibition of CD39 and CD73 transcript levels 
was reversed partly by heat inactivation of ES (HI-ES) while complete reversal was obtained by 
deglycosylation of ES (Deg-ES) (Figure 6.15A). In order to investigate if this increase in 
transcript levels resulted in up-regulation of CD39 and CD73 protein expression, FACS analysis 
was carried out. CD39 protein levels were not affected by ES as all conditions tested produced 
overlapping traces (Figure 6.15B). In contrast, ES inhibited CD73 expression to levels that were 
no longer detectable by FACS as the trace obtained was similar to the isotype control. CD73 
expression was restored to basal CD4+ T cell levels by HI-ES and Deg-ES (Figure 6.15C).  
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Figure 6.14: Determination of the presence of CD39 and CD73 transcripts in CD4+ T cells and 
effect of T.spiralis ES. RNA isolated from CD4+ T cells purified from mouse spleen was used to produce 
cDNA used in RT-PCR to detect the presence of CD39 and CD73 transcripts. PCR products of expected 
sizes for CD39 and CD73 were detected (see Materials and Methods, Table 2.1B) in untreated T cells or T 
cells treated with ES or heat-inactivated (HI-) ES. Actin primers were used in reactions to confirm cDNA 
quality (Act) and in reactions to determine if RNA was contaminated with DNA (-RT). 
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Figure 6.15: Flow cytometric analyses showing expression of CD39 and CD73 on CD4+ T cells. 
CD4+ T cells were isolated from mouse spleen and cultured for 24 hours in culture medium only or in the 
presence of 50μg/ml T.spiralis ES, HI-ES or deglycosylated (Deg-) ES. (A) The effect on CD39 and 
CD73 transcript levels. (B) The effect on CD39 expression. (C) The effect on CD73 expression. In the 
flow cytometric analysis of ES-induced effects, the block trace corresponds to IgG isotype control and the 
line trace corresponds to CD39/CD73-positive cells, presented as a % of the maximum number of cells. In 
the quantitative PCR analyses of ES-induced effects on T cell CD39 and CD73 expression, relative 
mRNA changes presented with standard errors were calculated after normalizing to β-actin from one 
representative experiment of n=2. 
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6.2.3 Effects of T.spiralis ES on T cell effector functions 
Effect of ES on T cell proliferation in vitro 
The effect of T.spiralis ES on anti-CD3-activated CD4+ T cell proliferation in the 
presence of irradiated APCs was then investigated. ES induced an inhibition of T cell 
proliferation which reached 40% after 4 days of culture (Figure 6.16A). This inhibition was 
enhanced when ES was co-administered with ATP due to generation of adenosine in culture by 
ecto-nucleotidases on T cells, as ATP alone caused the same inhibition of proliferation as when it 
was combined with ES. The activity of T cell ectonucleotidases in culture was confirmed by 
carrying out phosphate release assays, the results of which are shown in Figure 6.13B. In order to 
investigate if inhibition of T cell proliferation is a common characteristic of parasite infection, 
Brugia malayi microfilarial and adult ES which was available in our lab, was used. As opposed to 
the T.spiralis ES-induced inhibition of proliferation, Brugia malayi ES from both microfilaria 
and adults seemed to increase proliferation by 10-20% (Figure 6.16B and C). ATP inhbited the 
increase in proliferation induced by B.malayi ES which was probably due to generation of 
adenosine by T cell CD39 and CD73, as well as by B.malayi ES enzymes which are also capable 
of catalysing ATP hydrolysis, as shown in the Appendix, Figure A.3 B and C.   
Taking into account that T.spiralis ES contains nucleotide metabolising enzymes and that 
it was found previously in this section that adenosine inhibits proliferation, P1R antagonists were 
used to see if ES-induced effects were due to generation of adenosine from nucleotides 
potentially released during culture. However, ES-induced effects on proliferation were not due to 
P1R activation as none of the P1R antagonists were capable of reversing the ES-induced 
inhibition (Figure 6.17). 
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Figure 6.16: The effect of T.spiralis ES on T cell proliferation; comparison with B.malayi ES. CD4+ 
cells isolated from mouse spleen were cultured with irradiated APCs from the same original splenocyte 
population in the presence of anti-CD3 to induce cell proliferation, measured by means of 
3
H-thymidine 
incorporation, after 4 days of culture. CD4+ T cells were pre-incubated with 50μg/ml T.spiralis ES and 
10μg/ml of B.malayi ES for 1 hour prior to co-culture with iAPCs for 3 days before 3H-thymidine 
addition. The data presented are an average of triplicates + SEM from one representative experiment of n 
≥ 2 and asterisks indicate statistical significance compared to the untreated control. ** p< 0.01, *** p< 
0.001. . (†) is compared to treatment with ES only. ††† p< 0.001. 
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Figure 6.17: Pharmacological characterisation of T.spiralis ES-mediated effects on T cell 
proliferation. CD4+ cells isolated from mouse spleen were cultured with irradiated APCs from the same 
original splenocyte population in the presence of anti-CD3 to induce cell proliferation, measured by means 
of 
3
H-thymidine incorporation, after 4 days of culture. Antagonists (10μM) DPCPX (A1R antagonist), 
ZM241385 (A2AR antagonist), MRS1753 (A2BR antagonist) or MRS1523 (A3R antagonist) were added 15 
minutes prior to addition of 50μg/ml ES. The data presented are an average of triplicates + SEM from one 
representative experiment of n = 3 and asterisks indicate statistical significance compared to the untreated 
control. *** p< 0.001. 
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In order to further analyse ES-induced inhibition of T cell proliferation, downstream 
pathways were blocked with specific inhibitors. All inhibitors blocked basal levels of 
proliferation, except for the PLC mock inhibitor (U73343) suggesting that the inhibition induced 
by the PLC inhibitor was not due to compound effects. The MEK1/2 inhibitor (U0126) also 
reduced basal levels of proliferation but it induced complete reversal of the ES-induced inhibition 
suggesting that activation MEK1/2 is necessary for inhibiting T cell proliferation (Figure 6.18). 
Having established in the previous chapter (Chapter 5) that ES-induced effects on 
macrophages were mediated via activation MGL, the effect of blocking MGL using GalNAc was 
also investigated on T cell proliferation. In fact, GalNAc partly reversed inhibition of 
proliferation by ES despite the fact that GalNAc administered in the absence of ES inhibited 
proliferation. Glycan involvement was further supported by the fact that both HI-ES and Deg-ES 
reversed the inhibition completely. EGTA which blocks all C-type lectins also inhibited 
proliferation due to interference with the T cell receptor (Figure 6.19). 
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Figure 6.18: The effect of downstream signalling pathways on T.spiralis ES-mediated effects on T 
cell proliferation. CD4+ cells isolated from mouse spleen were cultured with irradiated APCs from the 
same original splenocyte population in the presence of anti-CD3 to induce cell proliferation, measured by 
means of 
3
H-thymidine incorporation, after 4 days of culture. The effect of 10μM U73122 (PLC inhibitor), 
5μM Bay 11-7082 (NF-κB selective inhibitor) and 5μM U0126 (MEK1/2 inhibitor) on ES-induced 
inhibition of T cell proliferation was measured after 4 days of culture. Cells were pre-incubated with the 
all inhibitors for 15 minutes prior to addition of 50μg/ml ES. The data presented are an average of 
triplicates + SEM from one representative experiment of n = 3 and asterisks indicate significance 
compared to the respective untreated control. ** p< 0.01, *** p< 0.001. (†) is compared to treatment with 
ES only. †† p< 0.01, ††† p< 0.001. 
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Figure 6.19: The effect of blocking T cell surface lectins on T.spiralis ES-mediated inhibition of 
proliferation. CD4+ cells isolated from mouse spleen were cultured with irradiated APCs from the same 
original splenocyte population in the presence of anti-CD3 to induce cell proliferation, measured by means 
of 
3
H-thymidine incorporation, after 4 days of culture. Prior to addition of 50μg/ml ES, cells were 
incubated with 100mM GalNAc (blocking MGL). Cells were also treated with either heat-inactivated ES 
or deglycosylated ES. The data presented are an average of triplicates + SEM from one representative 
experiment of n > 3 and asterisks/daggers indicate significance compared to the respective untreated 
control. *** p< 0.001. (†) is compared to treatment with ES only. †† p< 0.01, ††† p< 0.001. 
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Effect of ES on cytokine release from T cells  
Cytokine release from CD4+ T cell was also affected by T.spiralis ES. Similar to its 
effects on proliferation, ES inhibited IL-10 and IFN-γ release by 30-40%. However, IL-4 release 
was increased in the presence of ES by about 20% (Figure 6.20). Inhibitors were used to 
investigate involvement of downstream pathways. IL-4 release was inhibited by all the inhibitors 
used (Figure 6.20A). The ES-induced increase in IL-4 release was inhibited by all inhibitors, 
however, since these compounds also inhibited basal IL-4 release it may not be a specific 
inhibition of the ES-induced increase.  IL-10 release was inhibited slightly by the NF-κB and 
PLC inhibitors (Bay 11-7082 and U73122). ES inhibited IL-10 release and this inhibition was 
reversed by both the NF-κB and MEK1/2 (U0126) inhibitors (Figure 6.20B). Since the MEK1/2 
inhibitor did not affect basal IL-10 release from T cells, the fact that the ES-induced inhibition of 
IL-10 release was reversed by blocking MEK1/2 activation implies that this pathway is activated 
by ES proteins. IFN-γ release was inhibited by the NF-κB and PLC inhibitors (Figure 6.20). ES 
inhibited IFN-γ release and the NF-κB inhibitor (Bay 11-7082) reversed this inhibition. Blocking 
MEK1/2 with U0126 led to a similar reversal of ES-induced inhibition which suggests that 
activation of the MEK1/2 pathway is also required for inhibition of IFN-γ release by ES as 
U0126 did not affect basal levels (Figure 6.20C). As was the case for all cytokines tested, the 
PLC mock did not affect basal release levels showing that the inhibition induced by the PLC 
inhibitor was actually due to interference with PLC activation and not a compound effect. 
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Figure 6.20: The effect of downstream signalling pathways on T.spiralis ES-mediated effects on 
cytokine release from T cells. CD4+ cells isolated from mouse spleen were cultured with irradiated 
APCs from the same original splenocyte population in the presence of anti-CD3 and cytokine release 
measured after 4 days of culture. The effect of 10μM U73122 (PLC inhibitor), 5μM Bay 11-7082 (NF-κB 
selective inhibitor) and 5μM U0126 (MEK1/2 inhibitor) on ES-induced inhibition of T cell (A) IL-4 
release, (B) IL-10 release and (C) IFN-γ release. Cytokine levels are expressed in pg/ml. Cells were pre-
incubated with the all inhibitors for 15 minutes prior to addition of 50μg/ml ES.  The data presented are an 
average of triplicates + SEM from one representative experiment of n = 3 and asterisks indicate 
significance compared to the respective untreated control. *** p< 0.001. (†) is compared to treatment with 
ES only. †† p< 0.01, ††† p< 0.001, ns - not significant (p> 0.05). 
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Since heat inactivation and deglycosylation of ES reversed the ES-induced effects on 
cytokine release from CD4+ T cells, shown in Figure 6.21 A, B and C, the involvement of ES 
glycans was also investigated. The increase in IL-4 release induced by ES was inhibited by 
GalNAc, while GalNAc administered in the absence of ES had no effect on IL-4 release from T 
cells (Figure 6.21A). The ES-induced inhibition of IL-10 was reversed by GalNAc and this was 
specific to ES-induced effects as basal levels were not affected (Figure 6.21B). IFN-γ release was 
inhibited both by ES and GalNAc which, when administered together, produced an additive 
inhibitory effect (Figure 6.21C). Similar to T cell proliferation, EGTA blocked all cytokine 
release suggesting that interference with the TCR affects all T cell effector functions (Figure 
6.21). 
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Figure 6.21: The effect of blocking T cell surface lectins on T.spiralis ES-mediated inhibition of 
cytokine release. CD4+ cells isolated from mouse spleen were cultured with irradiated APCs from the 
same original splenocyte population in the presence of anti-CD3 and cytokine release measured after 4 
days of culture. Prior to addition of 50μg/ml ES, cells were incubated with 100mM GalNAc (blocking 
MGL). Cells were also treated with either heat-inactivated ES or deglycosylated ES. (A) IL-4 release, (B) 
IL-10 release and (C) IFN-γ release are shown expressed in pg/ml. The data presented are an average of 
triplicates + SEM from one representative experiment of n > 3 and asterisks indicate significance 
compared to the respective untreated control. *** p< 0.001, ns - not significant (p> 0.05). (†) is compared 
to treatment with ES only. †† p< 0.01, ††† p< 0.001. 
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ES-induced effects on purinergic signalling 
In order to determine if T.spiralis ES interfered with purinergic signalling at the 
purinergic receptor expression level in addition to ecto-nucleotidase expression, P1R analysis by 
RT-PCR was carried out. ES seemed to reduce A2AR and A3R transcript levels and this was 
reversed by heat inactivating or deglycosylating ES (Figure 6.22). Q-PCR analysis confirmed the 
apparent inhibitory effect of ES on A2AR mRNA levels but no effect was observed on A1R and 
A3R mRNA levels. Furthermore, A2BR levels were up-regulated by ES by approximately 2-fold. 
All ES effects were reversed by heat inactivation and deglycosylation (Figure 6.22). 
Taking into account that ES contains nucleotide metabolising enzymes, and in particular 
5`NT, the effect of ES on nucleotide-induced effects was also investigated. However, since ES 
induces an increase in IL-4 release and inhibition of IL-10 and IFN-γ release as well as inhibition 
of T cell proliferation when administered to cells, it would not be possible to distinguish between 
these effects and any effects induced by ES administered with nucleotides. Since the major 
enzyme responsible for nucleotide hydrolysis by T.spiralis ES is 5`NT, a recombinantly 
expressed 5`NT was used. Recombinant 5`NT on its own had no effect on basal T cell 
proliferation, however, when combined with nucleotides it enhanced the AMP and ADP-induced 
inhibition of proliferation (Figure 6.23). Furthermore, 5`NT had no effect on adenosine or ATP-
induced inhibition of proliferation which was expected as only AMP, ADP and UDP are 5`NT 
substrates (phosphate release from nucleotides by 5`NT is shown in the Appendix, Figure A.2). 
As a result of UDP hydrolysis by 5`NT, the UDP-induced inhibition of proliferation was no 
longer observed. 5`NT had no effect on basal IL-4, IL-10 and IFN-γ release by T cells but led to 
increased inhibition of cytokine release by nucleotides like AMP and ADP. ATP-induced effects 
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were not affected while the UDP-induced inhibition of IL-4 and IFN-γ release was reversed as a 
result of 5`NT-mediated hydrolysis of UDP (Figure 6.24).  
Collectively, these data show that T.spiralis ES inhibits CD4+ T cell expression of CD39 
at the molecular level and CD73 expression at both the molecular and protein levels. In addition, 
ES inhibits A2AR transcript expression and enhances A2BR expression. Furthermore, ES inhibits 
T cell proliferation as well as IL-10 and IFN-γ release while it enhances IL-4 release. These 
effects are generally counteracted by blocking or removing ES glycans and by interference with 
MGL binding and MEK1/2 activation. In addition to modulating CD4+ T cell effector functions 
directly, ES can influence T cell responses to nucleotides via 5`NT-mediated hydrolysis.  
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Figure 6.22: Analysis of the effect of T.spiralis ES on CD4+T cell P1 receptor transcripts. RNA 
isolated from CD4+ T cells purified from mouse spleen was used to produce cDNA used in RT-PCR to 
detect the presence of P1R transcripts in the presence of 50μg/ml T.spiralis ES or HI-ES. (A) PR 
transcripts detected in CD4+ T cells purified from mouse spleen by RT-PCR. (B) Quantitative PCR 
analyses of P1R mRNA levels and the fold changes presented are relative to untreated T cells after 
normalising to β-actin mRNA. Standard errors of the mean shown are from one representative experiment 
of n=2. ** p< 0.01, *** p< 0.001. 
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Figure 6.23: The effect of recombinant 5`NT on nucleotide-mediated effects on CD4+T cell 
proliferation. CD4+ cells isolated from mouse spleen were cultured with irradiated APCs from the same 
original splenocyte population in the presence of anti-CD3 to induce cell proliferation, measured by means 
of 
3
H-thymidine incorporation. The effect of 50μM adenosine/nucleotides in the presence of 15μg/ml 
5`NT on T cell proliferation was measured after 4 days of culture. The data presented are an average of 
triplicates + SEM from one representative experiment of n > 3 and asterisks indicate significance 
compared to the respective untreated control. *** p< 0.001. (†) is compared to treatment with the 
respective nucleotide. †† p< 0.01, ††† p< 0.001, ns - not significant (p> 0.05). 
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Figure 6.24: The effect of recombinant 5`NT on purinergic signalling-induced cytokine release from 
T cells. CD4+ cells isolated from mouse spleen were cultured with irradiated APCs from the same 
original splenocyte population in the presence of anti-CD3 and cytokine release measured after 4 days of 
culture. The effect of (50μM) adenosine/nucleotides in the presence of 15μg/ml 5`NT on (A) IL-4 release, 
(B) IL-10 release and (C) IFN-γ release are shown expressed in pg/ml. The data presented are an average 
of triplicates + SEM from one representative experiment of n > 3 and asterisks indicate significance 
compared to the respective untreated control. ** p< 0.01, *** p< 0.001. (†) is compared to treatment with 
the respective nucleotide. † p< 0.05, †† p< 0.01, ††† p< 0.001. 
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6.3 Discussion 
T cell differentiation from naïve cells, unlike other immune cells, is known to give rise to 
at least 3 major subsets, T helper 1 (Th1), T helper 2 (Th2) and regulatory T cells (Treg). The 
phenotype of T cell differentiation is important as the resulting cytokine environment influences 
the development and recruitment of other immune cells like APCs. The presence of ecto-
nucleotidases on T cells has been documented as a marker of their activation, and provides a 
basis of immunosuppression as a result of generation of adenosine from nucleotides the latter 
being considered as inducers of pro-inflammatory responses (Bynoe and Viret, 2008). Purinergic 
signalling is important in APC effector functions and adenosine in particular has been shown in 
this study to induce an anti-inflammatory phenotype in murine bone marrow derived 
macrophages (Chapter 4). Therefore, this study further aimed to determine if purinergic 
signalling had any direct effects on T cell effector functions as well. In addition, considering that 
T.spiralis ES is known to interfere with macrophage purinergic signalling-induced effector 
functions as was shown in this study (Chapter 5), the effect of ES on T cells was also 
investigated. The results obtained and presented in the previous section are discussed below. 
Purinergic signalling is dependent on purinergic receptor expression and on the 
availability of extracellular nucleotides. Immune cells can control both these parameters by 
regulating receptor expression, as well as the surface expression of ecto-nucleotidases which can 
alter nucleotide type and concentration. Analysis of CD4+ T cell purinergic receptor expression 
at the molecular level in this study showed that T cells express all P1 receptors and all of the 
known P2Y receptors except P2Y4. P1 receptor expression by murine splenic T cells has also 
been reported by Huang and colleagues (Huang et al, 1997). Having established that CD4+ T 
cells express purinergic receptors their functionality was then investigated. T cell proliferation 
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was inhibited by adenosine as well as by nucleotides due to their degradation to adenosine. P1 
receptor agonists were used to confirm that inhibition of proliferation is achieved by P1 receptor 
stimulation, a fact also confirmed by the lack of inhibition in the case of the slowly-hydrolysable 
analogue of ADP (β-ADP). This is in agreement with published work by Kobie and colleagues 
which reported that adenosine inhibits proliferation of murine splenic CD4+ T cells while Ohta 
and colleagues have shown that increasing concentration of the adenosine analogue NECA 
inhibited cytotoxic T lymphocyte proliferation in vitro (Kobie et al, 2006; Ohta et al, 2009). In 
addition, Duhant and colleagues reported that extracellular adenine nucleotides inhibit CD4+ T 
cell proliferation in response to CD3 and CD28 ligation (Duhant et al, 2002). Furthermore, P1 
receptor antagonism confirmed that inhibition of T cell proliferation obtained with adenosine, 
AMP and ADP was in fact due to A2AR and A2BR activation (Figures 6.3 and 6.4). This 
inhibition was most likely due to cAMP elevation resulting from A2R coupling to Gs as cAMP 
elevation by administration of cAMP elevators mimicked the adenosine-induced effects. 
Similarly, in a study with mouse splenocytes, it was found that inhibition of TCR-activated 
effector functions by extracellular adenosine was mimicked by an increase in cAMP when using 
dbcAMP and a PDE inhibitor (Huang et al, 1997). When investigating downstream pathway 
involvement, the only pathway that seemed to interfere with adenosine-induced inhibition of T 
cell proliferation was the MEK1/2 pathway, as blocking MEK1/2 led to restoration of basal 
levels of proliferation (Figure 6.5). It is probable that other pathways are also involved, however, 
it was not possible to draw any conclusions in this study. The reason for this is that inhibition of 
the PLC and NF-κB pathways interfered with basal T cell proliferation which shows that these 
pathways are necessary and non-redundant.  
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 Cytokine release from CD4+ T cells was similarly affected by nucleotides and in 
particular by generation of extracellular adenosine. P1 receptor stimulation with specific agonists 
as well as use of specific P1 receptor antagonists to reverse adenosine-induced effects showed 
that, inhibition of cytokine release was again due to A2AR and A2BR stimulation. Therefore, 
nucleotides probably act via their breakdown product adenosine. Many studies have reported 
similar effects of adenosine on T cells, specifically, studies using murine splenic T cells which 
generally attribute these effects to A2AR activation (Alam et al, 2009; Erdmann et al, 2005; Kobie 
et al, 2006; Ohta et al, 2009). In this study it was observed that, in some experiments, nucleotides 
had more pronounced effects than adenosine. This could be due to adenosine uptake by cells 
which would mean that after the first 24 hours in culture adenosine may no longer be available, 
while nucleotides provide a more sustained source of extracellular adenosine. Another 
explanation may be that adenosine is degraded by the action of adenosine deaminase (ADA) 
which is known to be expressed on T cells (Martin et al, 1995).  
Th1 and Th2 cytokines were inhibited by adenine nucleotides an observation also made 
by Duhant and colleagues who reported the inhibition of both Th1 and Th2 cytokines in response 
to CD3 and CD28 ligation (Duhant et al, 2002). Furthermore, Csoka and colleagues have 
reported that A2AR activation down-regulates both IFN-γ and IL-4 mRNA (Csoka et al, 2008). 
Recently, Yang and colleagues have shown that adenosine inhibits T cell activation and release of 
IL-2 and IFN-γ and that these effects were due to cAMP elevation via Gs coupling of P1 
receptors (Yang et al, 2010). This is in agreement with results presented in this study showing 
that cAMP elevation, even when produced by administration of cAMP elevators like rolipram 
and forskolin, mimicked adenosine-induced inhibition of cytokine release (Figure 6.11). Lappas 
and colleagues have also shown that the adenosine-induced inhibition of TCR-activated T cell 
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IFN-γ release was due to cAMP elevation as they were able to mimic and enhance adenosine-
induced effects when rolipram was co-administered (Lappas et al, 2005). Furthermore, 
Raskovalova and colleagues have reported that adenosine-induced inhibition of T lymphocyte 
cytokine production via A2AR stimulation involves cAMP-PKA (Protein kinase A) signalling 
(Raskovalova et al, 2007). 
 Interestingly, blocking PLC which is activated by P1 receptor coupling to Gq also 
appeared to reverse adenosine-induced inhibition of IL-4 and IFN-γ release, despite background 
effects produced by the inhibitor used. As was observed with T cell proliferation, MEK1/2 
inhibition also reversed adenosine-induced effects on cytokine release. Duhant and colleagues 
have reported that inhibition of TCR signalling by adenine nucleotides was not a result of Ca
2+
 
mobilization which rules out this downstream pathway originating from PLC activation (Duhant 
et al, 2005). In addition, they showed that ERK2 and p38 MAPK were involved which may 
explain the inhibition of cytokine release shown in this study.  
 In addition to regulation of purinergic receptor expression and stimulation, purinergic 
signalling is also regulated by the availability of extracellular nucleotides. So far, the results 
presented in this study have shown that extracellular nucleotide-induced effects are mediated by 
generation of adenosine by degradation of adenine nucleotides. This is achieved by ecto-
nucleotidases, CD39 and CD73, which are expressed on immune cells and are known to be 
expressed on lymphocytes, and are considered as the main system of termination of ADP/ATP 
purinergic effects (Yegutkin et al, 2002). Kobie and colleagues have suggested that CD4+ T cells 
suppress effector functions due to the presence of CD73 which converts AMP to adenosine 
(Kobie et al, 2006). Interestingly, this system of inactivation of purinergic signalling is also used 
by T.spiralis which has been shown to secrete an enzyme with activity similar to CD39 and 
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CD73 called 5`-nucleotidase (5`NT) (Gounaris, 2002). Therefore, it was of interest to determine 
if T.spiralis secreted products (ES) potentially interfere with T cell effector functions and 
expression of ecto-nucleotidases. In fact, it was found that, ES affects expression of both CD39 
and CD73 with more pronounced effects observed in CD73 molecular and surface expression 
(Figure 6.13). CD73 has been reported to be a marker of T regulatory cell differentiation so this 
decrease in CD73 may reflect a reduction in Treg cells, at least within the first 24 hours of T cells 
encountering T.spiralis, since PCR experiments were carried out using mRNA obtained from 24 
hour cultures of CD4+ T cells with ES. In conjunction with the inhibitory effect of ES on IFN-γ 
release and upregulatory effect on IL-4 release, this may suggest that the initial response 
triggered by T.spiralis is a Th2 response, which would be beneficial for parasite persistence in 
the gut prior to expulsion. In agreement with this, it has been reported that depletion of Treg cells 
in T.spiralis infection results in exaggerated Th2 responses (Beiting et al, 2007). This subversion 
of the T cell response to a less damaging phenotype has also been suggested as a means of 
facilitation of Trichuris muris survival in the gut (D‟Elia et al, 2009). Recently, Dvoroznakova 
and colleagues showed that T.spiralis induced a Th2 response during the intestinal phase and T 
cell proliferation at both the intestinal and muscle phases (Dvoroznakova et al, 2010). However, 
in this study, T.spiralis ES inhibited CD4+ T cell proliferation in vitro and this was not due to 
exogenously generated adenosine, since P1 receptor antagonists were not able to reverse ES-
induced effects (Figure 6.16 and 6.17). On the other hand, B.malayi ES had the opposite effects 
on CD4+ T cell proliferation as both microfilarial and adult ES induced an increase in CD3-
activated T cell proliferation. It has been reported that B.malayi infection of mice induces a Treg 
response, while injection of both microfilaria and adults have been shown to induce up-regulation 
of Treg markers thus skewing CD4+ T cell phenotype to a regulatory mode (McSorley et al, 
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2008). Interestingly, this study has shown that ATP had an inhibitory effect on B.malayi-induced 
T cell proliferation (Figure 6.16). 
The only inhibitor that was capable of reversing the inhibitory effects of ES on 
proliferation, IFN-γ and IL-10 release was the MEK1/2 inhibitor. Having established from 
Chapter 5 that T.spiralis ES mediates its direct effects on macrophages via MGL activation by ES 
glycans, the effects on CD4+ T cells were also investigated following glycan removal. Indeed, all 
ES-induced effects were reversed by removing glycans by deglycosylation or by structural 
destabilisation by heating. In addition, blocking MGL using GalNAc also reversed ES-induced 
effects. Despite the fact that GalNAc was preincubated with T cells and then added to the 
irradiated APC population, it may be possible that some effects could be a result of blocking 
MGL on APCs. In fact, van Vliet and colleagues have reported that T cell regulation by APCs 
can occur via interaction of MGL with T cell CD45 (van Vliet et al, 2006).  
T.spiralis ES-induced effects were also analysed in terms of purinergic receptor 
expression and it was found that CD4+ T cell A2AR transcript expression was inhibited while 
A2BR expression was enhanced. In order to further investigate ES-induced effects on purinergic 
signalling, the recombinant 5`NT from T.spiralis expressed in our lab was used since ES had 
direct effects on T cell effector functions and the results obtained when combining ES with 
nucleotides would not be entirely due to purinergic signalling. As expected, when 5`NT was co-
administered with nucleotides the resulting effector functions were typical of adenosine-induced 
responses. T cell proliferation and cytokine release inhibited by nucleotides were inhibited further 
as a result of combined action of ecto-nucleotidases on cells and T.spiralis 5`NT, while 5`NT on 
its own had no effect on T cell functions.  
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In conclusion, this study has shown that purinergic signalling induced in CD4+ T cells by 
adenosine ligation of A2 receptors inhibits proliferation as well as Th1 and Th2 responses. This 
points to the hypothesis that extracellular adenosine acts as an agent of induction of peripheral 
tolerance by skewing T cell responses to a regulatory phenotype. Furthermore, Treg cells are 
known to protect the host from intestinal pathology resulting from parasites like T.spiralis 
indicating another beneficial consequence of T.spiralis-induced adenosine generation. 
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7. Discussion 
Cell-mediated immunity is critical in host defence against extracellular pathogens. In 
particular, macrophages are known to participate in a variety of biological processes aimed at 
fighting infection as well as remodelling and repair. This functional diversity suggests that 
changes in their local environment can have an impact on their differentiation and activation. For 
example, classically activated macrophages (CAMΦ), linked with Th1 responses, are generally 
involved in combat against bacterial infections while Th2 responses to parasitic infections are 
associated with alternative activation of macrophages (AAMΦ). Pathogen invasion also results in 
tissue damage that introduces additional danger signals in their extracellular environment. Hence, 
immune cells are sensitive to any changes in extracellular nucleotide levels due to purinergic 
receptor surface expression and activation. Nucleotide-induced effects are controlled by enzymes 
capable of metabolising them to their respective nucleoside by hydrolysis of terminal phosphates. 
Consequently, different purinergic receptors are engaged resulting in switches between pro- and 
anti-inflammatory responses. Enzymes secreted by parasites such as T.spiralis have similar 
properties to these endogenous enzymes suggesting a way to mimic host regulation of purinergic 
signalling in order to evade the immune response (Gounaris and Selkirk, 2005). In this study, the 
aims were to characterise murine bone marrow derived macrophages (BMMΦ) and murine 
spleen derived T cells, in terms of their purinergic receptor profile and functionality. In addition, 
this study aimed to investigate nucleotide-induced responses in macrophages and T cells as well 
as the effect of T.spiralis secreted products on their phenotype and activation.  
In this study, the purinergic receptor profile of BMMΦ that were differentiated in vitro 
was shown to include G-protein coupled purinergic receptors except for the A2AR and P2Y4R, 
although the A2AR mRNA expression was up-regulated in response to LPS (CAMΦ), an 
333 
 
observation that has also been made by Murphree and colleagues in human and mouse 
macrophages (Murphree et al, 2005). Interestingly, the A2AR has been shown to be involved in 
the macrophage switch from an inflammatory to an angiogenic, anti-inflammatory phenotype in 
the presence of LPS stimulation (Grinberg et al, 2009). Furthermore, the switch to a wound 
healing phenotype has been shown to result from synergy of the A2AR with MyD88 recruited 
following LPS stimulation (Macedo et al, 2007). Stimulation of BMMΦ with IL-4 (AAMΦ) did 
not change the purinergic receptor profile detected in the absence of IL-4, except for a slightly 
up-regulated A2BR expression which was also achieved by LPS stimulation, showing that only 
A2AR induction in macrophages is LPS-specific (Chapter 3). This is in agreement with 
quantitative studies in RAW 264.7 macrophages showing that LPS stimulation up-regulated both 
the A2AR and A2BR (Streitova et al, 2010). Furthermore, it has been shown that, TLR4 
stimulation of human lung macrophages induces up-regulated expression of the A2AR as a means 
of controlling inflammation, due to its down-regulatory properties on pro-inflammatory cytokine 
production and inhibition of inflammatory cell recruitment (Buenestado et al, 2010). Similarly, it 
has been shown that glucocorticoids can up-regulate the A3R, stimulation of which leads to 
activation of ERK which is responsible for protection of monocytes, suggesting a mechanism for 
down-regulation of inflammation (Barczyk et al, 2010). In addition, Xaus and colleagues have 
shown that IFN-γ up-regulates the A2BR in bone marrow derived macrophages by de novo 
synthesis, while Khoa and colleagues have shown that the inflammatory cytokines IL-1 and TNF-
α regulate A2AR function by inducing its expression at both the mRNA and protein levels (Xaus 
et al, 1999; Khoa et al, 2001). Therefore, these data show that Th1 cytokines like IFN-γ and IL-1 
that promote classical activation of macrophages, as does TNF-α, have similar effects as LPS 
stimulation of TLR4.  
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The modulation of P1R expression becomes more important when considering that 
extracellular nucleotides can act on these receptors, following metabolism by ecto-nucleotidases 
to adenosine, which is a known regulator of innate immune responses (Kumar and Sharma, 
2009). In the current study, all nucleotides that could be degraded to adenosine had an inhibitory 
effect on macrophage pro-inflammatory functions such as nitric oxide (NO), TNF-α and IL-6 
release, while they enhanced IL-10 release and arginase I activity. This is in agreement with 
published work on RAW 264.7 macrophages showing that, adenosine-induced effects are 
generally anti-inflammatory due to P1R activation as binding of P1R agonists such as adenosine 
or its metabolite inosine was found to negatively regulate pro-inflammatory NO production 
(Hasko et al, 1996; Min et al, 2000). These adenosine-induced effects were pharmacologically 
characterised as A2R-specific and cAMP-mediated (Chapter 4). In fact, activation of the A2BR 
enhanced IL-10 release while pro-inflammatory TNF-α and IL-6 release was inhibited by 
activation of both A2A and A2B receptors. In support of this finding, it has been reported that the 
A2AR is responsible for adenosine-induced inhibition of TNF-α production in murine peritoneal 
macrophages (Ezeamuzie and Khan, 2007). In addition, adenosine receptor agonists have been 
shown to differentially regulate IL-10, TNF-α and NO production in RAW 264.7 macrophages 
(Hasko et al, 1996; Hu et al, 1998). Adenosine was also shown to inhibit TNF-α release by a 
human macrophage cell line via the A3R (McWhinney et al, 1996; Sajjadi et al, 1996). In fact, 
A3R activation in RAW 264.7 macrophages inhibits LPS-induced TNF-α by Ca
2+
-dependent 
activation of NF-κB and ERK (Martin et al, 2006). The P1 receptors have also been shown to be 
involved in inhibition of the LPS-induced respiratory burst in human monocytes (Thiele et al, 
2004).  
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Taking into account that ecto-nucleotidases were found to be present and functional on all 
macrophage activation subsets, nucleotide hydrolysis was probably combined with P1R 
stimulation in this study. Specifically, it has been reported that ecto-nucleotidase generation of 
adenosine and activation of the A2BR are coordinated in hypoxic conditions (Eltzschig et al, 
2003). Therefore, ATP and ADP-induced effects can depend on their conversion to AMP and 
adenosine, as was the case in the current study, and has also been reported previously by Moody 
and colleagues (Moody et al, 1984). However, ATP can also affect macrophage activation by 
stimulation of P2 receptors. It is known that ATP causes stimulation of the respiratory burst by 
rat alveolar macrophages as a result of P2R activation leading to Ca
2+
 mobilization (Murphy et 
al, 1993). In addition, extracellular ATP has been shown to enhance mRNA levels of iNOS and 
TNF-α in LPS-treated RAW 264.7 macrophages (Tonetti et al, 1995). This was later found to be 
due to the P2XR (Sperlagh et al, 1998). Nevertheless, P2YR agonists were also shown to inhibit 
iNOS expression by macrophages via Ca
2+
 signalling (Denlinger et al, 1996). However, as shown 
in Chapter 4, ATP effects on macrophage effector functions were found to be predominantly due 
to its conversion to adenosine, although it is possible that P2YR stimulation was masked by P1R 
signalling.  
 Macrophage activation phenotypes, characterised by the presence of known markers of 
alternative activation, can potentially respond differently to purinergic stimulation as a result of 
the variations in their P1R profile detected in this study. On the other hand, this study has shown 
that A2R activation causes up-regulation of one of these markers of alternative activation. 
Specifically, arginase I was up-regulated by A2R-dependent mechanisms and its activity 
enhanced by A2BR activation, thus shifting macrophage L-arginine metabolism from iNOS to 
arginase, which effectively suppresses NO release. As presented in Chapter 3, BMMΦ and 
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AAMΦ were not found to express the A2AR at the molecular level. Therefore, the fact that the 
A2AR agonist had an effect on AAMΦ arginase I activity points to agonist activation of other P1 
receptors, most likely the A2BR, possibly due to non-specific binding. In fact, cross-talk between 
Gs and Gq coupled pathways following A2BR activation in human mast cells has been shown to 
regulate IL-4 release (Ryzhov et al, 2006). This may be an indirect means of controlling the 
macrophage activation phenotype by producing a cytokine environment that promotes alternative 
activation. 
Arginase I expression is known to be controlled by the presence of Th2 polarising 
cytokines and, in particular, by the Th1/Th2 balance (Munder et al, 1999). Interestingly, CAMΦ 
were also found to express arginase I although the levels detected were not comparable to levels 
obtained following IL-4R stimulation in AAMΦ (Chapter 3). In support of this finding, arginase I 
mRNA and protein have been shown to be up-regulated in rodent peritoneal macrophages 
stimulated by LPS (Louis et al, 1998). The ability of macrophages to express both enzymes of the 
L-arginine metabolic cascade allows them to respond to changes in their local environment that 
can control their activation phenotype. For example, Rutschman and colleagues have reported 
that NO production is regulated by substrate depletion of iNOS as a result of IL-4R activation 
which up-regulates arginase I activity (Rutschman et al, 2001). In addition to IL-4-dependent 
regulation of arginase I activity, the current study showed that IL-10 induced up-regulation of 
arginase I in synergy with IL-4/IL-13 (Chapter 3). Considering that the arginase I mRNA appears 
at a later time point of CAMΦ culture, its up-regulation may also be due to autocrine stimulation 
effects of the IL-10 produced by CAMΦ. In fact, Hesse and colleagues have reported arginase I 
activity in macrophages stimulated with IFN-γ/TNF-α which is attributed to autocrine production 
of IL-10 (Hesse et al, 2001). This observation led the authors to suggest that this may be a 
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mechanism used to counterbalance NOS activity during Th1 responses. Furthermore, autocrine 
IL-10 has been shown to suppress production of pro-inflammatory mediators (Yan et al, 2001). 
This observation was also made in the current study (Chapter 4) whereby neutralisation of IL-10 
released by macrophages led to enhancement of TNF-α and IL-6 secretion.  
In the current study, cAMP was found to be the major downstream effector of P1R 
signalling implying coupling to Gs subunits (Sitkovsky et al, 2008). This is in agreement with the 
pharmacological evidence showing that adenosine and adenine nucleotide-induced effects were 
mediated by A2R stimulation (Chapter 4). In support of these findings, studies have shown that 
cAMP involvement downstream of adenosine stimulation of the A2R is responsible for 
manipulating macrophage effector functions. For example, the A2AR has been shown to inhibit 
matrix-induced inflammation by signalling involving cAMP generation (Scheibner et al, 2009). 
Furthermore, elevated levels of cAMP were found to reduce NO production in a macrophage cell 
line while in a study by Beshay and colleagues using the cAMP elevators rolipram and forskolin, 
macrophage suppression of NO production both in vitro and in vivo was shown to be a result of 
regulation of iNOS mRNA levels (Bulut et al, 1993; Beshay et al, 2001). Interestingly, cAMP is 
generated by adenylate cyclase from the intracellular pathogen M.tuberculosis to manipulate 
macrophage signalling and, in particular, TNF-α production (Agarwal et al, 2009). Studies in 
RAW264.7 macrophages have shown that the presence of cAMP affects activation of NF-κB by 
LPS, as stimulation with LPS in combination with a cAMP agonist led to enhancement of p50-
p50 dimers, which are considered to be transcriptional repressors at NF-κB-dependent promoters 
(Wall et al, 2009). This was proposed by the authors to be partly responsible for the cAMP-
mediated suppression of pro-inflammatory cytokines induced by LPS. Chen and colleagues have 
shown that LPS-induced effects involve activation of kinases such as PKC, ERK, and p38 MAPK 
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and activation of the latter is necessary for induction of iNOS in RAW264.7 by LPS-induced 
activation of NF-κB (Chen and Wang, 1999; Chen et al, 2001). The same authors have reported 
that MEK inhibition had no effect on LPS-induced signalling, which is relevant to the current 
study showing that adenosine-induced signalling can be inhibited by interference with MEK as 
opposed to LPS-induced signalling. In support of this, it has been reported that Gs coupled to the 
A2AR signals via ARNO to MEK1/2 before ERK activation of Fos-induced transcription (Zezula 
and Freissmuth, 2008).  
The ability of macrophages to switch between activation states has been reported in a 
number of studies (Porcheray et al, 2005; Mylonas et al, 2009). This allows macrophages to act 
more effectively as the first line of defence since inflammation can thus be resolved without the 
requirement to recruit new macrophages with the appropriate phenotype. Porcheray and 
colleagues reported that monocyte-derived macrophages of a specific phenotype can switch to an 
alternate phenotype quickly upon stimulation (Porcheray et al, 2005). Furthermore, Mylonas and 
colleagues showed that peritoneal macrophages obtained from B.malayi infection in an 
alternatively activated state could be switched to a classically activated state upon LPS/IFN-γ 
stimulation (Mylonas et al, 2009). Macrophage phenotype switching may play a key role in their 
involvement in infections. In fact, as the current study has shown, T.spiralis secreted proteins 
(ES) up-regulated arginase I in BMMΦ and FizzI and YmI in CAMΦ skewing their phenotype to 
an alternative activation mode. Furthermore, ES up-regulated A2AR expression in BMMΦ as well 
as CD73 expression in AAMΦ indicating a possible mechanism of macrophage switching to the 
anti-inflammatory phenotype. This is further supported by the fact that ES up-regulated the IL-4R 
making macrophages more responsive to stimulation that would result in alternative activation. 
The fact that T.spiralis ES interferes with P1R expression points to host cell manipulation of 
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purinergic signalling by making cells more responsive to adenosine-induced anti-inflammatory 
effects. In addition, any pro-inflammatory responses elicited by ES, such as NO and TNF-α 
release, were inhibited by adenosine-induced cAMP elevation (Chapter 5). As it was established 
in Chapter 3, BMMΦ and AAMΦ do not express the A2AR, therefore, adenosine-induced effects 
could be mediated via the A2BR, which confirms studies that show involvement of both receptors 
in adenosine-induced effects (Hasko et al, 2000; Csoka et al, 2010). However, it is also possible 
that adenosine acts via the A2AR which was found to be up-regulated in macrophages treated with 
T.spiralis ES (Chapter 3).  
The T.spiralis-induced skewing of macrophage activation to the AAMΦ phenotype 
observed in the current study is not surprising as AAMΦ have been proposed to have several 
roles in parasite infection (Maizels et al, 2004). Firstly, they act to suppress inflammatory 
responses to the parasite as they are known to down-regulate other effector cell pro-inflammatory 
functions. In addition, their abundance in sites of infection makes them important effector cells 
which potentially target extracellular helminths and drive Th2 immune responses. Finally, their 
biosynthetic ability may be important in helminth-induced damage repair. T.spiralis ES enhanced 
both pro-inflammatory and anti-inflammatory cytokine release as well as NO release and 
arginase I activity (Chapter 5). This is in agreement with published work showing that T.spiralis 
infection increased IL-10 and TGF-β production in mouse airway tract (Park et al, 2011). The 
ES-induced effects elicited in macrophages in the current study resulted from the direct action of 
glycans conjugated on ES proteins, and this was confirmed by the fact that removal of these 
carbohydrates abrogated ES-induced effects. Furthermore, the receptor responsible for 
recognition of glycans on macrophages was not the mannose receptor, as might be expected due 
to its ubiquitous expression on these immune cells, but the macrophage galactose lectin (MGL) 
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which was determined by blocking C-type lectins on macrophages. Evidently, T.spiralis employs 
a similar mechanism of direct host cell manipulation to other helminths which skew immune cell 
responses by interaction of carbohydrates with pattern recognition receptors (PRRs). In fact, it is 
known that N-linked glycans are present in T.spiralis ES (Reason et al, 1994; Morelle et al, 
2000). Furthermore, it has been reported that T.spiralis TSL-1 antigens are highly immunogenic 
and contain glycoproteins with GalNAc residues (Yepez-Mulia et al, 2007). In this study, 
T.spiralis ES was deglycosylated by chemical means which are known to remove 0- and N- 
linked glycans and, in this way, inhibition of ES-induced effects was achieved (Reason et al, 
1994; Edge, 2003).  
Helminth parasites, like all pathogens, are first encountered by APCs which are the first 
line of defence, however, not all APCs respond in the same way. Although macrophages and 
dendritic cells (DCs) have almost identical basal gene expression patterns, macrophages exposed 
to microfilaria are known to produce both IL-12 and IL-10 while DCs do not (Semnani and 
Nutman, 2004). The data obtained in the current study similarly showed that macrophages 
respond to parasite products from T.spiralis by producing cytokines such as IL-10, IL-6 and 
TNF-α. Many studies have shown that helminth parasites mediate their effects on APCs by direct 
interactions with PRRs, like C-type lectins and TLRs, or by regulation of their expression. For 
example, live B.malayi microfilaria can activate TLR2 directly, but not TLR4 or TLR3 
(Venugopal et al, 2009). In addition, it has been shown that filarial nematode ES-62 can activate 
TLR4 via phosphorylcholine (PC), although signalling was not found to be similar to that 
induced by TLR4 when activated by LPS (Harnett et al, 2010; Harnett and Harnett, 2010). 
S.mansoni secreted products activate DC TLR2 and TLR4 due to the presence of 
phosphatidylserine (PS) but the resulting DC activation profiles are distinct from those obtained 
following bacterial activation (Van Riet et al, 2009). In fact, it has been reported that parasites 
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use TLR4 as a co-receptor for PRRs to induce type II responses important in their expulsion as 
well as in host tissue repair (Diaz and Allen, 2007). Interestingly, it was recently reported that, 
Korean mistletoe lectin, which has been shown to bind GalNAc and galactose, activates mouse 
peritoneal macrophages via TLR4 (Park et al, 2010). Another C-type lectin expressed on 
macrophages, called mincle, was shown to be responsible for the C.albicans-induced TNF-α 
release from murine macrophages (Wells et al, 2008). Furthermore, Dissanayake and colleagues 
have reported that T.crassiceps carbohydrates induce IL-6 and IL-10 release by macrophages 
(Dissanayake et al, 2002).  
The importance of AAMΦ in parasitic infections is further emphasised by the fact that 
M.corti infections of IL-4-deficient mice were lethal due to reduction of Th2 cytokines and 
enhancement of Th1 cytokines leading to reduced generation of AAMΦ (O‟Connell et al, 2009). 
In addition, alternative activation of macrophages was shown to enhance survival in S.mansoni 
infection due to the fact that they down-regulate Th1 responses and iNOS toxic effects (Herbert 
et al, 2004). On the other hand, T.spiralis has been shown to down-regulate iNOS during the gut 
inflammatory phase, which again points to alternative activation of APCs, as they are the main 
producers of NO during inflammation (Bian et al, 2001). However, in the current study T.spiralis 
ES was found to increase NO release by macrophages. This may be an initial event when 
macrophages encounter ES that is replaced by activation of arginase I later on. In fact, arginase I 
was also up-regulated in this study although it was not consistent in all macrophage subsets, 
which may imply that it is indeed a response that develops later in the stimulation process. 
Furthermore, ES was found to increase both pro- and anti-inflammatory cytokine release. 
Interestingly, TNF-α has been reported to be involved in the development of the Th2 response 
required for expulsion of T.spiralis (Ierna et al, 2009). Nevertheless, T.spiralis effects on 
macrophages appear to depend on the presence of AAMΦ characteristics like MGL expression, 
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which has recently been characterised as a marker of AAMΦ recruited in parasite infections 
(Raes et al, 2005). 
Signalling events downstream of T.spiralis-induced effects were found to involve 
activation of all signalling pathways tested to some extent, although the cAMP/PLC and MEK1/2 
pathways appeared to be involved consistently. Specifically, the increase in NO and IL-6 release 
was inhibited by targeting PLC activation, while cAMP elevation was found to reverse ES-
induced effects in general. This could point to reciprocal control of the signalling pathways 
involved since cAMP elevation inhibited PLC activation, thus acting like an indirect PLC 
inhibitor. The involvement of MEK1/2 could be explained by the fact that MGL activation 
induces Ras-Raf signalling which is upstream of MEK1/2. It has been shown that signalling 
pathways originating from the cytoplasmic domain of proteins containing the YXXL motif, 
which is also found a C-type lectin called Dectin-1, result in transcription and release of IL-10 
(Brown, 2006; Saba et al, 2009). In the same study, the authors reported that murine 
macrophages lacking MGL-1 produced less IL-10 suggesting that intracellular signalling 
triggered by MGL activation may also require this motif. Therefore, it is possible that activation 
of MGL by T.spiralis ES triggers YXXL-mediated recruitment of factors that initiate intracellular 
signalling via the MEK-ERK pathway, which then activates transcription and release of IL-10. 
Similarly, another carbohydrate derived from S.mansoni called LNFPIII activates DC-SIGN 
which has been shown to signal via ERK (Harn et al, 2009). Another mode of activation of 
macrophages by T.spiralis ES was found in guinea pig alveolar macrophages involving PKC 
phosphorylation and this was shown to be due to PAFR activation by PC present in T.spiralis 
homogenates (Dzik et al, 2010).  Therefore, the fact that T.spiralis ES can potentially activate 
different pathways may explain the up-regulation of both pro- and anti-inflammatory mediators 
detected in this study (Chapters 3 and 4).  
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T cell responses are either due to direct activation of T cells or to APC-mediated 
stimulation either by soluble mediators or by contact-dependent mechanisms, or by a 
combination of both. It has been reported that IL-6 induces the expression of IL-4 by T cells 
leading to Th2 differentiation while at the same time induction of IFN-γ inhibits Th1 
differentiation (Diehl and Rincon, 2002). Fiorentino and colleagues have reported that IL-10 
(commonly derived from APCs) inhibits IL-12 and IFN-γ production by Th1 cells impairing 
APC function by contact dependent mechanisms (Fiorentino et al, 1991). Regulatory T cells were 
reported to induce high levels of IL-10 production by APCs as well as stimulating co-stimulatory 
molecule expression, rendering them immunosuppressive (Kryczek et al, 2006). Furthermore, 
studies have shown that IL-10 can inhibit Th1 cells in the presence of macrophages, and this may 
be an indirect effect resulting from macrophage expression of T cell stimulatory or inhibitory 
products or by MHCII regulation (de Waal Malefyt et al, 1991; Bogdan et al, 1991). On the other 
hand, Schebesch and colleagues showed that human AAMΦ inhibited CD4+ T cell proliferation 
and that this was not dependent on IL-10, NO or costimulatory molecules (Schebesch et al, 
1997). An important mechanism by which macrophages are known to modulate T cell function is 
L-arginine consumption, which has been shown to affect the CD3δ chain in T lymphocytes, and 
therefore their ability to be activated via the T cell receptor (TCR) (Rodriguez et al, 2003). Since 
AAMΦ are known to have up-regulated arginase I levels and activity, an observation also made 
in the current study, this suggests that generation of a macrophage anti-inflammatory phenotype 
will affect T cell activation. Furthermore, macrophage-expressed Fizz1 (RELM-α), which is 
another established marker of alternative activation, has also been reported to suppress T cell 
proliferation (Nair et al, 2009).  
As this study has shown, activation of purinergic signalling via the P1 receptors by 
adenosine can influence macrophage activation, skewing it to an AAMΦ phenotype with 
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characteristic up-regulation of arginase I activity. Therefore, the mechanism of T cell inhibition 
via depletion of L-arginine outlined above could be partly responsible for adenosine-induced 
effects on T cells, at least in vivo. Indeed, adenine nucleotides inhibited T cell proliferation and 
cytokine release and, although this was found to be a result of P1R activation on T cells, the 
indirect effect of adenosine on arginase I levels cannot be ruled out. However, since APCs were 
irradiated in this study, transcription and translation were minimal, therefore, the effects were 
probably due to the direct action on T cells. However, it should be taken into account that, in an 
in vivo setting, soluble mediators produced by macrophages, such as the ones tested in this study, 
will also influence T cell proliferation and cytokine production.  
It has been established in this study that, purinergic signalling effects on T cell effector 
functions were due to adenosine generated in culture by ecto-nucleotidases CD39 and CD73 
which were functionally expressed on T cells. It is now widely accepted that these ecto-
nucleotidases are better markers of Treg cell activation than CD25, which was the original 
marker of Treg activation together with Foxp3 (Zarek et al, 2008). In fact, CD73 has also been 
reported to play a co-stimulatory role in T cell activation (Resta et al, 1998). However, the major 
role of CD73 is the generation of extracellular adenosine from adenine nucleotides, like ATP, 
which are released by T cells and first metabolised by CD39 to AMP (Di Virgilio et al, 2009). In 
the current study, activation of A2 receptors by adenosine inhibited T cell proliferation as well as 
Th1 and Th2 responses. Adenosine has been shown to shift T cell differentiation to a regulatory 
phenotype by increasing TGF-β production and decreasing IL-6 production following A2AR 
activation (Zarek et al, 2008). This has been described as a means of inducing peripheral 
tolerance (Zarek et al, 2008; Sitkovsky et al, 2009). Activation of the A2AR was shown to be 
involved in suppression of pro-inflammatory cytokine production in T cell-mediated colitis while 
IL-10 and TGF-β production remained unaffected (Naganuma et al, 2006). Although A2AR 
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activation inhibited cytokine secretion by CD4+ T cells in this study, it has been shown that 
activation of the A2AR in natural killer T cells enhanced IL-4 and IL-10 secretion, suggesting that 
not all T cells respond to adenosine in the same way (Nowak et al, 2009).  
With reference to intracellular signalling events involved in T cell suppression, AAMΦ 
have been shown to inhibit T cell proliferation by STAT6-dependent mechanisms by up-
regulating PD-L2, which is a B7 family member that binds Th2 cells (Huber et al, 2010). This 
confirms previous studies showing that the inhibition of T cell proliferation by nematode-elicited 
AAMΦ is achieved by cell contact (Loke et al, 2000). With relevance to the current study, 
T.spiralis-induced effects on T cell effector functions could either be due to direct activation of 
CD4+ T cell PRRs by ES or by cytokines produced by APCs in response to ES. In addition, 
T.spiralis ES was shown to up-regulate expression of the low affinity A2BR by T cells while 
expression of the high affinity A2AR was inhibited, making cells more responsive to low levels of 
extracellular adenosine. The inhibitory effects of extracellular adenosine on T cell effector 
functions have been attributed to increases in intracellular cAMP which antagonises TCR-
signalling (Koshiba et al, 1997). A study has shown that a stable analogue of ATP also inhibits 
CD4+ T cell cytokine secretion by inhibiting TCR signalling and this was found to involve 
inhibition of  ERK and p38 MAPK downstream of cAMP activation (Duhant et al, 2005). In the 
current study, MEK1/2 and cAMP were found to be responsible for both ES and adenosine-
induced proliferation effects, in agreement with the studies discussed above.  
Taking into account that APCs are the first to encounter invading organisms, the type of 
compounds recognized by these cells will determine to a large extent the nature of T cell 
polarisation promoted by APCs. For example, AAMΦ isolated from T. crassiceps-infected mice 
were shown to inhibit naïve T cell proliferation (Reyes and Terrazas, 2007). In addition, 
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macrophages isolated from mice treated with N.brasiliensis ES were also found to suppress T cell 
proliferation in vitro (Allen and McDonald, 1998). Th1 cell recruitment in response to 
M.tuberculosis as well as the IFN-γ-dependent functions were not affected by macrophage IL-10, 
which caused macrophage alternative activation in an autocrine manner (Schreiber et al, 2009). 
However, filarial infection induced IL-10 expression by CD4+ cells that affected IFN-γ and IL-
12 levels in a malaria infection model (Metenou et al, 2009). In the case of microfilarial infection 
it was reported that inhibition of cellular proliferation was not due to macrophage derived factors 
like NO, prostaglandins and catalase (Allen et al, 1996). On the other hand, NO has been shown 
to inhibit Th1 cell expansion while low levels of NO promoted differentiation of Th1 cells by IL-
12R induction (Niedbala et al, 2006). In the current study, NO released by macrophages in 
response to T.spiralis ES could, therefore, influence T cell differentiation promoting a Th2 or 
even a Treg phenotype. In fact, Belkaid and colleagues have found that regulatory T cells are the 
main producers of IL-10 in S.mansoni infected mice and high levels of this cytokine were also 
secreted by T cells in the current study (Belkaid et al, 2006). However, Hesse and colleagues 
report that although IL-10 is important for polarizing the schistosome egg-specific Th2 response, 
it is not essential to generate alternatively activated, arginase I expressing cells, although 
synergistic effects between IL-10 and IL-4/-13 remain possible (Hesse et al, 2001). In support of 
this, Zhao and colleagues have reported that macrophages are not required for initiation of the 
cytokine response to N.brasiliensis infection and are activated as a result of increased Th2 
cytokine production (Zhao et al, 2009). Furthermore, Treg cell expansion in filarial infection was 
found to occur even in the absence of AAMΦ and a Th2 response showing that immune response 
is shifted toward Treg differentiation (McSorley et al, 2008). In fact the authors suggest that 
Tregs are the first cells to be recruited in filarial infection and AAMΦ development is a 
secondary event. This hypothesis is further supported by another study reporting that human 
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AAMΦ are activated in the presence of Tregs (Tiemessen et al, 2007). They showed that Tregs 
can produce IL-10 and IL-4/13 which, in co-cultures with macrophages enhance alternative 
activation markers, while they inhibit TNF-α and IL-6 and enhance IL-10 production. With 
relevance to the current study which showed that T.spiralis ES increased expression of the Treg 
cell marker CD73, Tregs have been found to be recruited to airways of T.spiralis infected animals 
(Park et al, 2011). Regulation of effector T cells by APCs has also been shown to be due to MGL 
from APCs binding to T cell CD45, which is a protein tyrosine phosphatase that controls TCR 
activation via Lck dephosphorylation (Van Vliet et al, 2006). Interestingly, the T.spiralis-induced 
inhibition of T cell proliferation and IL-10 and IFN-γ release showed some MGL dependence 
(Chapter 6). Similarly, a surface lectin of E.histolytica was reported to suppress T-cell 
proliferation while promoting Th2 cytokine production (Loukas and Maizels, 2000). Another 
mechanism of T cell responsiveness by parasites has been reported whereby filarial infection 
leads to reduced TLR expression by T cells leading to reduced cytokine production, such as IFN-
γ and IL-2 (Babu et al, 2006). As opposed to its effects on other T cell effector functions, 
T.spiralis ES induced an increase in IL-4 release (Chapter 6). This finding is supported by the 
fact that, although in some cases IL-4/IL-13 produced by innate cells may be sufficient to trigger 
their differentiation, Th2 cells are generally required for their optimal activation, recruitment and 
expansion. It is likely that the lack of Th2-dependent signals in other systems of study, like in 
vitro, is the reason why the IL-4 and IL-13 activated AAMΦ phenotype is considerably less 
intense in nature than the AAMΦ generated during a natural infection (NeMΦ).  
In summary, this study has shown that T.spiralis, like other parasites, has evolved to 
modulate the host immune response on different levels. Manipulation of host purinergic 
signalling by T.spiralis secreted enzymes has been hypothesised (Gounaris and Selkirk, 2005) 
and this study has confirmed that macrophages and T cells are also a part of this mode of immune 
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suppression. In addition to this indirect modulation of macrophage signalling, this study has 
shown that T.spiralis secreted proteins can also influence macrophage functions by binding to 
MGL. It is known that macrophages provide a link between innate and adaptive immune 
responses by contact-dependent and cytokine-dependent activation of T cells, therefore, the 
macrophage phenotype influences the T cell subsets that develop. T.spiralis secreted proteins 
used in this study were found to induce both Th1 and Th2 responses either by direct effects on T 
cells or by switching the macrophage activation phenotype. It is evident from this study that, 
T.spiralis can evade host immune responses by regulating the activation of immune cells in a way 
that is beneficial for its survival throughout the different stages of infection allowing it to 
establish itself successfully in the host. 
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Figure 7.1: Summary of T.spiralis ES-induced effects on BMMΦ. T.spiralis ES affects BMMΦ 
effector functions in 2 ways. Firstly, 5`-nucleotidase (5`NT) converts ADP to AMP and AMP to adenosine 
which acts on A2 receptors (A2AR or A2BR). This results in the elevation of cAMP levels in macrophages 
causing an increase in arginase activity and IL-10 release and inhibition of nitric oxide (NO) production, 
IL-6 and TNF-α release. Forskolin, an exogenous elevator of cAMP, was used in this study to confirm the 
cAMP involvement in macrophage effector functions. Secondly, ES glycoproteins also affect macrophage 
effector functions via activation of the MGL (macrophage galactose lectin) receptor which results in 
elevation of arginase activity, NO production as well as cytokine release. This was shown to proceed via 
the MAP kinase kinase (MEK1/2) pathway. In addition, ES induced an elevation in CD73 expression 
levels which further enhances extracellular adenosine generation.  
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A.1 Polyacrylamide gels 
Stacking gel  
Final concentration  Volume(ml)/5ml 
30% v/v Acrylamide mix 0.83 
1M Tris (pH 6.8) 0.63 
10% v/v SDS 0.05 
10% v/v Ammonium persulphate (APS) 0.05 
TEMED 0.0005 
dH2O 3.4 
 
Resolving gel (12%)  
Final concentration  Volume(ml)/5ml 
30% v/v Acrylamide mix 2 
1M Tris (pH 8.8) 1.3 
10% v/v SDS 0.05 
10% v/v Ammonium persulphate (APS) 0.05 
TEMED 0.002 
dH2O 1.6 
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A.2 5′NT Expression and Purification 
Recombinant 5′-NT was expressed and purified as described in Materials and Methods. The 
purified proteins were resolved on an SDS-PAGE gel to confirm presence of pure recombinant 
5′-NT. Western analysis carried out is shown in Figure 1 below. Following purification, r5′-NT 
was assayed for nucleotidase activity using a phosphate release assay as described previously. 
The specific activity when 5′-NT was incubated with AMP was calculated to be 10 μmol 
Pi/min/mg.  
 
 
Figure A.1: Recombinant 5-nucleotidase (r5′NT) expression and purification. The c-myc/6His – 
tagged T.spiralis recombinant 5′NT was expressed from transformed P.pastoris and purified by Ni-NTA 
affinity chromatography. Purified protein was visualised by Coomasie staining (A) and Western analysis 
using the ECL detection system (B). The expected size of 5′NT is 67kDa.  
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Figure A.2: 5`NT substrate specificity. AMP, ADP, UDP and ATP were incubated with 5`NT for 10 
minutes and the nmoles of phosphate released per mg of protein calculated. This was done by detecting 
changes in absorbance of a chromogenic detector of free phosphate. The specific activity of 5`NT for 
every nucleotide is plotted here.  
404 
 
Figure A.3: Parasite ES substrate specificity. AMP, ADP and ATP were incubated with ES from (A) 
T.spiralis, (B) B.malayi microfilaria and (C) B.malayi adult ES for 10 minutes and the nmoles of 
phosphate released per mg of protein calculated. This was done by measuring changes in absorbance of a 
chromogenic detector of free phosphate. The specific activity of ES proteins for every nucleotide is 
plotted here. *** p< 0.001, ns - not significant (p> 0.05) compared to the untreated control. 
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Sequencing non-specific bands  
A.3 Sequencing  
PCR products were cloned into pCR2.1-TOPO (Figure 2) for sequencing (Cogenics). The sequences 
obtained were then aligned to known transcripts using BLAST and then ClustalW was used to align to the 
primers used for the PCR reactions to determine sequence homology. 
A3 receptor clones  
Sequences producing significant alignments to Sequence 1 (260bp):  
Accession Description Max 
score 
Total 
score 
Query 
coverage 
E 
value 
Max 
ident 
NM_009631.3 Mus musculus adenosine A3 receptor 
(Adora3), transcript variant 1, mRNA 
472 472 100% 1e-
130 
99% 
 
Sequence 1  AGACCTGCATCCTCCAGGTTAATGGGAAGGCAGGGATAAGCGGCTGAGGTTGATGGTCCT  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NM_009631.3  AGACCTGCATCCTCCAGGTTAATGGGAAGGCAGGGATAAGCGGCTGAGGTTGATGGTCCT  187 
 
Sequence 1  GTAACAGGCCCTTTCTGAGAAGAGTCTCTAAGAGAGAGTCATACCGGAAGGAATGAGCAA  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NM_009631.3  GTAACAGGCCCTTTCTGAGAAGAGTCTCTAAGAGAGAGTCATACCGGAAGGAATGAGCAA  247 
 
Sequence 1 GTTGTGAGTTCTCTGGACTGTTGTGACATTCTAACTTCTGGGCAGAAGTCTGACAAGAGC  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NM_009631.3  GTTGTGAGTTCTCTGGACTGTTGTGACATTCTAACTTCTGGGCAGAAGTCTGACAAGAGC  307 
 
Sequence 1  TGGGTCCACTGGCCCATACACAACCTGCTGAAGAGCCACGGAAGCTTCCGCCTGAAGCTT  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NM_009631.3  TGGGTCCACTGGCCCATACACAACCTGCTGAAGAGCCACGGAAGCTTCCGCCTGAAGCTT  367 
 
Sequence 1  TTCTGCGACAGCATGGAA  258 
            ||||| |||||||||||| 
NM_009631.3  TTCTGAGACAGCATGGAA  385 
 
406 
 
 
A3              CAGCAGAAGCCCTGACTCTGTTTGCCTGGGGAAGTAAGAACGGTGGCCCTCTCGGATTTG 120 
F               ------------------------------------------------------------                                                                     
A3              GCTGCAGAGACCTGCATCCTCCAGGTTAATGGGAAGGCAGGGATAAGCGGCTGAGGTTGA 180 
F               -------AGACCTGCATCCTCCAGGTTAATG----------------------------- 24 
                      ************************                              
A3              TGGTCCTGTAACAGGCCCTTTCTGAGAAGAGTCTCTAAGAGAGAGTCATACCGGAAGGAA 240 
F               ------------------------------------------------------------ 
A3              TGAGCAAGTTGTGAGTTCTCTGGACTGTTGTGACATTCTAACTTCTGGGCAGAAGTCTGA 300 
R               ------------------------------------------------------------                                                                            
A3              CAAGAGCTGGGTCCACTGGCCCATACACAACCTGCTGAAGAGCCACGGAAGCTTCCGCCT 360 
R               ------------------------------------------------------------                                                                            
A3              GAAGCTTTTCTGAGACAGCATGGAAGCCGACAACACCACGGAGACGGACTGGCTGAACAT 420 
R               ---GCTTTTCTGAGACAGCATGGAAGC--------------------------------- 24 
                   ************************ 
 
Sequences producing significant alignments to Sequence 2 (100-200bp): 
Accession Description E 
value 
Max 
ident 
XM_001478411.1 PREDICTED: Mus musculus similar to ferritin light 
chain 1 (LOC634386), mRNA 
2e-40 96% 
XR_031806.1 PREDICTED: Mus musculus similar to ferritin light 
chain 2 (LOC633082), misc RNA 
2e-40 96% 
NM_010240.2 Mus musculus ferritin light chain 1 (Ftl1), mRNA 2e-40 96% 
 
407 
 
Sequence 2     CCTCCAGGTTAATGAACCTCTCAAGCCACTAGGCAGCTTTGTAACCGCCCTGGAGCCTCT  70 
               ||||||  | |||||||||||||||||||||||||||||||||||||||||||||||||| 
XM_001478411.1  CCTCCACCTGAATGAACCTCTCAAGCCACTAGGCAGCTTTGTAACCGCCCTGGAGCCTCT  938 
 
Sequence 2     GTCAAGTCTTGGACCAAGTAAAAATAAAGCTTTTCTGAGACAGCA  115 
               |||||||||||||||||||||||||||||||||| |||||||||| 
XM_001478411.1  GTCAAGTCTTGGACCAAGTAAAAATAAAGCTTTT-TGAGACAGCA  982 
 
 
A3 ns         GGGCTCCCCCCTCTGCTCTGCACCAGCCCGCCCTGGGACCTCCACCTGAATGAACCTCTC 900 
F             ----------------------------AGACCTGCATCCTCCAGGTTAATG-------- 24 
                                           * ****   ******  * ****         
A3 ns         AAGCCACTAGGCAGCTTTGTAACCGCCCTGGAGCCTCTGTCAAGTCTTGGACCAAGTAAA 960 
F             ------------------------------------------------------------                                                                          
A3 ns         AATAAAGCTTTTTGAGACAGCAAAAAAAACAAAAAAACAAAAAAAAAAAAAAAAAAAAAA 1020 
R             -----GCTTTTCTGAGACAGCATGGAAGC------------------------------- 24 
                      *** **********   **                                  
A3 ns         AAAGAGATAACTTTAT 1036 
R             ---------------- 
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Arginase I clones 
Sequences producing significant alignments to Sequence 1 (249bp): 
Accession Description E value Max ident 
NM_007482.2 Mus musculus Arginase I, liver (Arg1), mRNA 1e-124 99% 
 
 
 
 
Sequence 1   CAGATATGCAGGGAGTCACCCAGGAGAATCCTGGTACATCTGGGAACTTTCCTTTCAGTT  68 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NM_007482.2   CAGATATGCAGGGAGTCACCCAGGAGAATCCTGGTACATCTGGGAACTTTCCTTTCAGTT  531 
 
Sequence 1   CCTTCAGGAGAAAGGACACAGGTTGCCCATGCAGATTCCCAGAGCTGGTCGTCAGGGGAG  128 
             ||||||||||||||||||||||||||||||||||||||||||||||||| |||||||||| 
NM_007482.2   CCTTCAGGAGAAAGGACACAGGTTGCCCATGCAGATTCCCAGAGCTGGTTGTCAGGGGAG  471 
 
Sequence 1   TGTTGATGTCAGCGTGAGCATCCACCCAAATGACACATAGGTCAGGGTGGACCCTGGCGT  188 
               |||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||| 
NM_007482.2   TGTTGATGTCAGTGTGAGCATCCACCCAAATGACACATAGGTCAGGGTGGACCCTGGCGT  411 
   
Sequence 1   GGCCAGAGATGCTTCCAACTGCCAGACTGTGGTCTCCACCCAGCACCACACTGACTCTTC  248 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NM_007482.2   GGCCAGAGATGCTTCCAACTGCCAGACTGTGGTCTCCACCCAGCACCACACTGACTCTTC  351 
 
Sequence 1   CATTCTTCTG  258 
               |||||||||| 
NM_007482.2   CATTCTTCTG  341 
 
 
 
 
 
409 
 
Arg1            CTTTGTTGATGTCCCTAATGACAGCTCCTTTCAAATTGTGAAGAACCCACGGTCTGTGGG 300 
F               ------------------------------------------------------------                                                                            
Arg1            GAAAGCCAATGAAGAGCTGGCTGGTGTGGTGGCAGAGGTCCAGAAGAATGGAAGAGTCAG 360 
F               ----------------------------------------CAGAAGAATGGAAGAGTCAG 20 
                                                        ******************** 
Arg1            TGTGGTGCTGGGTGGAGACCACAGTCTGGCAGTTGGAAGCATCTCTGGCCACGCCAGGGT 420 
F               ------------------------------------------------------------                                                                             
Arg1            CCACCCTGACCTATGTGTCATTTGGGTGGATGCTCACACTGACATCAACACTCCCCTGAC 480 
F               ------------------------------------------------------------ 
Arg1            AACCAGCTCTGGGAATCTGCATGGGCAACCTGTGTCCTTTCTCCTGAAGGAACTGAAAGG 540 
R               ------------------------------------------------------------                                                                      
Arg1            AAAGTTCCCAGATGTACCAGGATTCTCCTGGGTGACTCCCTGCATATCTGCCAAAGACAT 600 
R               ------------------------------GGTGACTCCCTGCATATCTG---------- 20 
                                              ********************         Arg1            
CGTGTACATTGGCTTGCGAGACGTAGACCCTGGGGAACACTATATAATAAAAACTCTGGG 660 
R               ------------------------------------------------------------ 
 
Sequences producing significant alignments to Sequence 2 (400-500bp): 
Accession Description 
E 
value 
Max 
ident 
NW_001030728.1 
Mus musculus chromosome 3 genomic contig, alternate assembly 
(based on Celera assembly) 
0.0 98% 
NT_039240.7 Mus musculus chromosome 3 genomic contig, strain C57BL/6J 0.0 98% 
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Sequence 2      TATGCAGGGAGTCACCATTCTGTGTTGCTGGTCCGTTTTAATGCTGACGCCATGCTGTTT  64 
                  ||| |||||||||||||||||||||||||| ||||||||||||||||||||||||||||| 
NW_001030728.1   TATACAGGGAGTCACCATTCTGTGTTGCTGATCCGTTTTAATGCTGACGCCATGCTGTTT  1370157 
 
Sequence 2      GGCTGCTGTAGCTCAGGAATGCACTCTCAGGTTAGATATTGTGATGCCTCTTTTCCTCAT  124 
                  |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NW_001030728.1   GGCTGCTGTAGCTCAGGAATGCACTCTCAGGTTAGATATTGTGATGCCTCTTTTCCTCAT  1370097 
 
Sequence 2      TTTGTTCAAAGGGCTTTGGCTGTGGAGGGTCTCCATGGTTTCGTGCACTCTTTAGGATTA  184 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NW_001030728.1   TTTGTTCAAAGGGCTTTGGCTGTGGAGGGTCTCCATGGTTTCGTGCACTCTTTAGGATTA  1370037 
 
Sequence 2      GTCTGCCGAGTTTTGTGAAGAATCTTACTGACATTTGACTCTTCACTCTAAACAGAGGAT  244 
                  |||||||||||||||||||||||||||||||||||||||||||| ||||||||||||||| 
NW_001030728.1   GTCTGCCGAGTTTTGTGAAGAATCTTACTGACATTTGACTCTTCTCTCTAAACAGAGGAT  1369977 
 
Sequence 2      AGAGCTAAAGCTTTCACCTCTGTGCACGCATCACTTCGTGTCTCTCTAAGCACTTTTCTG  304 
                  | ||||||||||||||||||||||||||||||||||  |||||||||||||||||||||| 
NW_001030728.1   AAAGCTAAAGCTTTCACCTCTGTGCACGCATCACTTTATGTCTCTCTAAGCACTTTTCTG  1369917 
 
Sequence 2      CTCTCTGGATAAATTTATTATTAGCTCTCTCCATAGTTGGAAGTGGGATTGCTTTCTTGG  364 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
NW_001030728.1   CTCTCTGGATAAATTTATTATTAGCTCTCTCCATAGTTGGAAGTGGGATTGCTTTCTTGA  1369857 
 
Sequence 2      TTTTTAGTTTGTATAATGCACTCTTCATGGATTAAAAAACAAACAAACA  413 
                ||||||||||||||||||||||||||||||||||||||||||||||||| 
NW_001030728.1   TTTTTAGTTTGTATAATGCACTCTTCATGGATTAAAAAACAAACAAACA  1369808 
 
 
 
411 
 
Arg ns          ----TATACAGGGAGTCACCATTCTGTGTTGCTGATCCGTTTTAATGCTGACGCCATGCT 56 
R               CAGATATGCAGGGAGTCACC---------------------------------------- 20                        
                    *** ************                                         
Arg1 ns         GTTTGGCTGCTGTAGCTCAGGAATGCACTCTCAGGTTAGATATTGTGATGCCTCTTTTCC 116 
R               ------------------------------------------------------------                                                                           
Arg1 ns         TCATTTTGTTCAAAGGGCTTTGGCTGTGGAGGGTCTCCATGGTTTCGTGCACTCTTTAGG 176 
R               ------------------------------------------------------------                                                                            
Arg1 ns         ATTAGTCTGCCGAGTTTTGTGAAGAATCTTACTGACATTTGACTCTTCTCTCTAAACAGA 236 
R               ------------------------------------------------------------                                                                            
Arg1 ns         GGATAAAGCTAAAGCTTTCACCTCTGTGCACGCATCACTTTATGTCTCTCTAAGCACTTT 296 
F               ------------------------------------------------------------                                                                             
Arg1 ns         TCTGCTCTCTGGATAAATTTATTATTAGCTCTCTCCATAGTTGGAAGTGGGATTGCTTTC 356 
F               ------------------------------------------------------------                                                                           
Arg1 ns         TTGATTTTTAGTTTGTATAATGCACTCTTCATGGATTAAAAAACAAACAAACA 409 
F               --------CTGACTCTTCCATTCTTC-TG-------------------- 20 
                         **  *  * ** ***** **   
 
412 
 
 
 
Figure A.4: Map of pCR2.1-TOPO showing the cloning site used for PCR product insertion as well as 
Kanamycin gene used for selection and growth of vector-containing bacteria.  
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Figure A.5: The effect of adenosine, AMP and UDP titration on NO release from CAMΦ. 
Macrophages were classically activated with 10ng/ml LPS and the effect of titrating the concentration of 
adenosine (+10μM Dipyridamole) and its slowly hydrolysable analogue NECA, AMP and UDP on NO 
release by CAMΦ was measured after 20 hours of culture. (A)The effect of adenosine/NECA on NO 
release, (B) The effect of AMP on NO release and (C) The effect of UDP on NO release, expressed as 
nitrite in μM. Data presented are an average of triplicates + SEM from one representative experiment of n 
= 2.  
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Figure A.6: The effect of ADP and ATP titration on NO release from CAMΦ. Macrophages were 
classically activated with 10ng/ml LPS and the effect of titrating the concentration of ADP or ATP 
(+10μM Dipyridamole) and their slowly hydrolysable analogues, β-ADP and ATP-γ, on NO release by 
CAMΦ was measured after 20 hours of culture. (A) The effect of ADP/β-ADP on NO release. (B) The 
effect of ATP/ATP-γ on NO release, expressed as nitrite in μM. Data presented are an average of 
triplicates + SEM from one representative experiment of n = 2.  
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Figure A.7: The effect of adenosine/NECA titration on cytokine release from CAMΦ. Macrophages 
were classically activated with 10ng/ml LPS and the effect of titrating the concentration of adenosine 
(+10μM Dipyridamole) and its slowly hydrolysable analogue NECA on cytokine release by CAMΦ 
cytokine was meausered after 20 hours of culture. (A) The effect on IL-6 and TNF-α release. (B) The 
effect on IL-10 release. Cytokine release is expressed in pg/ml. Data presented are an average of 
triplicates + SEM from one representative experiment of n = 3.  
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Figure A.8: The effect of AMP titration on cytokine release from CAMΦ. Macrophages were 
classically activated with 10ng/ml LPS and the effect of titrating the concentration of AMP on cytokine 
release by CAMΦ was measured after 20 hours of culture. (A) The effect of AMP on IL-6 and TNF-α 
release. (B) The effect on IL-10 release. Cytokine release is expressed in pg/ml. Data presented are an 
average of triplicates + SEM from one representative experiment of n = 3.  
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Figure A.9: The effect of ADP titration on cytokine release from CAMΦ. Macrophages were 
classically activated with 10ng/ml LPS and the effect of titrating the concentration of ADP (+10μM 
Dipyridamole) and its slowly hydrolysable analogue β-ADP on cytokine release by CAMΦ was measured 
after 20 hours of culture. (A) The effect of ADP on IL-6 and TNF-α release. (B) The effect of ADP or β-
ADP on IL-10 release. (C) The effect of β-ADP on IL-6 and TNF-α release. Cytokine release is expressed 
in pg/ml. Data presented are an average of triplicates + SEM from one representative experiment of n = 2.  
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Figure A.10: The effect of ATP titration on cytokine release from CAMΦ. Macrophages were 
classically activated with 10ng/ml LPS and the effect of titrating the concentration of ATP (+10μM 
Dipyridamole) and its slowly hydrolysable analogue ADP-γ on cytokine release by CAMΦ was measured 
after 20 hours of culture. (A) The effect of ATP on IL-6 and TNF-α release. (B) The effect of ATP or 
ATP-γ on IL-10 release. (C) The effect of ATP-γ on IL-6 and TNF-α release. Cytokine release is 
expressed in pg/ml. Data presented are an average of triplicates + SEM from one representative 
experiment of n = 2. 
 
419 
 
 
Figure A.11: Schematic representation of the structure of (A) Tyvelose and  (B) GalNAc (N-
acetylgalactosamine).  
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Figure A.12: Schematic representation of the structure of adenosine (A) and its slowly hydrolysable 
analogue NECA (B), ADP (C) and β-ADP (D), ATP (E) and ATP-γ (F).  
 
